0001493152-20-015819.txt : 20200814 0001493152-20-015819.hdr.sgml : 20200814 20200814154814 ACCESSION NUMBER: 0001493152-20-015819 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200814 DATE AS OF CHANGE: 20200814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTRICITY INC. CENTRAL INDEX KEY: 0001630113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 472548273 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56074 FILM NUMBER: 201104727 BUSINESS ADDRESS: STREET 1: 75 INTERNATIONAL BLVD., SUITE 300 CITY: TORONTO STATE: A6 ZIP: M9W 6L9 BUSINESS PHONE: (416) 214-3678 MAIL ADDRESS: STREET 1: 75 INTERNATIONAL BLVD., SUITE 300 CITY: TORONTO STATE: A6 ZIP: M9W 6L9 FORMER COMPANY: FORMER CONFORMED NAME: METASOLUTIONS, INC. DATE OF NAME CHANGE: 20150107 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended June 30, 2020

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the period from ______________ to_______________

Commission file number: 000-56074

BIOTRICITY INC.

(Exact name of registrant as specified in its charter)

Nevada

30-0983531

State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

275 Shoreline Drive, Suite 150

Redwood City, California 94065

(Address of principal executive offices)

(650) 832-1626

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]

Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act).

Large accelerated filer [ ]	Accelerated filer [ ]
Non-accelerated filer [X]	Smaller reporting company [X]
Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 33,647,809 shares of Common Stock, $0.001 par value, at August 14, 2020. As at that same date, the Company also has 3,608,522 Exchangeable Shares outstanding that convert directly into common shares, which when combined with its Common Stock produce an amount equivalent to 37,256,315 outstanding voting securities.

BIOTRICITY INC.

Part I – Financial Information

Item 1 – Condensed Consolidated Financial Statements	3
Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3 – Quantitative and Qualitative Disclosures About Market Risk	27
Item 4 – Controls and Procedures	27
Part II – Other Information
Item 1 – Legal Proceedings	28
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3 – Defaults Upon Senior Securities	28
Item 4 – Mine Safety Disclosures	28
Item 5 – Other Information	28
Item 6 – Exhibits	28
Signatures	29

PART 1

FINANCIAL INFORMATION

Item 1 – Condensed Consolidated Financial Statements

Condensed Consolidated Balance Sheets at June 30, 2020 (unaudited) and March 31, 2020 (audited)	4

Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended June 30, 2020 and 2019 (unaudited)	5

Condensed Consolidated Statements of Stockholders’ Deficiency for the three months ended June 30, 2020 and 2019 (unaudited)	6

Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2020 and 2019 (unaudited)	7

Notes to the Condensed Consolidated Financial Statements	8

BIOTRICITY INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

AS AT JUNE 30, 2020 (unaudited) and MARCH 31, 2020 (audited)

(Expressed in US Dollars)

	As at June 30, 2020 (unaudited)			As at March 31, 2020 (audited)
	$			$
CURRENT ASSETS
Cash		64,875			949,848
Accounts receivable, net		663,687			486,187
Inventory		236,106			85,720
Deposits and other receivables		159,391			137,074
Total current assets		1,124,061			1,658,829

NON-CURRENT ASSETS
Deposits		-			33,000
Long-term accounts receivable		50,148			48,115
Operating lease right-of-use assets [Note 10]		214,884			264,472
TOTAL ASSETS		1,389,093			2,004,416

CURRENT LIABILITIES
Accounts payable and accrued liabilities [Note 4]		1,728,472			1,521,689
Convertible promissory notes and short term loans [Note 5]		1,871,389			2,068,302
Operating lease obligations, current [Note 10]		221,143			213,030
Total current liabilities		3,821,004			3,803,021

NON CURRENT LIABILITIES
Federally guaranteed loans [Note 6]		1,570,990			-
Derivative liabilities [Note 7]		982,340			1,144,733
Operating lease obligations, long term [Note 10]		-			57,055
TOTAL LIABILITIES		6,374,244			5,004,809

STOCKHOLDERS’ DEFICIENCY
Preferred stock, $0.001 par value, 10,000,000 authorized as at June 30 and March 31, 2020, respectively, 1 share issued and outstanding as at June 30 and March 31, 2020, respectively [Note 8]		1			1
Series A Preferred stock, $0.001 par value (20,000 shares designated as authorized as at June 30 and March 31, 2020); 8,045 and 7,830 shares issued and outstanding as at June 30 and March 31, 2020, respectively [Note 8]		8			8
Common stock, $0.001 par value, 125,000,000 authorized as at June 30 and March 31, 2020, respectively. Issued and outstanding common shares: 33,384,769 and 32,593,769 as at June 30 and March 31, 2020, respectively, and exchangeable shares of 3,788,062 as at June 30 and March 31, 2020 [Note 8]		37,173			36,382
Shares to be issued (25,000 and 178,750 shares of common stock as at June 30 and March 31, 2020, respectively) [Note 8]		22,194			169,490
Additional paid-in-capital		45,676,539			44,015,397
Accumulated other comprehensive loss		(962,308	)		(857,307	)
Accumulated deficit		(49,758,758	)		(46,364,364	)
TOTAL STOCKHOLDERS’ DEFICIENCY		(4,985,151	)		(3,000,393	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY		1,389,093			2,004,416

See accompanying notes to unaudited condensed consolidated interim financial statements

BIOTRICITY INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

FOR THE THREE MONTHS ENDED JUNE 30, 2020 AND 2019

(Expressed in US Dollars)

	Three Months Ended June 30, 2020			Three Months Ended June 30, 2019
	(unaudited)			(unaudited)
	$			$

REVENUE		451,898			327,000
Cost of revenue		191,462			150,586
Gross Profit		260,436			176,414

EXPENSES
General and administrative expenses [Notes 7, 8 and 9]		3,205,233			2,052,519
Research and development expenses		423,883			213,496
TOTAL OPERATING EXPENSES		3,629,116			2,266,015

Other income [Note 3]		(7,359	)		-
Change in fair value of derivative liabilities [Note 7]		(204,142	)		-
NET LOSS BEFORE INCOME TAXES		(3,157,179	)		(2,089,601	)

Income taxes		-			-
NET LOSS		(3,157,179	)		(2,089,601	)

Less: Preferred Stock Dividends [Note 8]		237,215			-
NET LOSS ATTRIBUTED TO COMMON STOCKHOLDERS		(3,394,394	)		(2,089,601	)

Translation adjustment		(105,001	)		(22,586	)

COMPREHENSIVE LOSS		(3,499,395	)		(2,112,187	)

LOSS PER SHARE, BASIC AND DILUTED		(0.900	)		(0.060	)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING		36,768,299			35,397,458

See accompanying notes to unaudited condensed consolidated interim financial statements

BIOTRICITY INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY

FOR THE THREE MONTHS ENDED JUNE 30, 2020 AND 2019 (UNAUDITED)

	Preferred stock				Common stock and exchangeable common shares				Shares to be Issued						Additional paid in capital			Accumulated other comprehensive (loss) income			Accumulated deficit			Total
	Shares		$		Shares		$		Shares			$			$			$			$			$
March 31, 2020		7,831		9		36,381,831		36,382		178,750			169,490			44,045,397			(857,307	)		(46,364,364	)		3,000,393

Issuance of preferred stock		215		-		-		-		-			-			215,000			-			-			215,000

Derivative liabilities adjustment		-		-		-		-		-			-			(41,749	)		-			-			(41,749	)

Issuance of shares for services		-		-		791,000		791		(153,750	)		(147,296	)		1,210,259			-			-			1,063,754

Issuance of warrants for services		-		-		-		-		-			-			45,113			-			-			45,113

Stock based compensation - ESOP		-		-		-		-		-			-			232,519			-			-			232,519
Issuance cost		-		-		-		-		-			-			-			-			-			-

Translation adjustment		-		-		-		-		-			-			-			(105,001	)		-			(105,001	)

Net loss before dividends for the period		-		-		-		-		-			-			-			-			(3,157,179	)		(3,157,179	)
Preferred stock dividends		-		-		-		-		-			-			-			-			(237,215	)		(237,215	)

June 30, 2020		8,046		9		37,172,831		37,173		25,000			22,194			45,676,539			(962,308	)		(49758,758	)		(4,985,151	)

	Preferred stock				Common stock and exchangeable common shares				Shares to be Issued				Additional paid in capital		Accumulated other comprehensive (loss) income			Accumulated deficit			Total
	Shares		$		Shares		$		Shares		$		$		$			$			$
March 31, 2019		1		1		35,361,656		35,362		62,085		91,498		33,889,916		(754,963	)		(35,039,495	)		(1,777,681	)

Issuance of shares for private placement		-		-		22,585		23		-		-		13,980		-			-			14,003

Issuance of shares for services		-		-		30,835		31		350,415		217,878		350,415		-			-			251,625

Issuance of warrants for services		-		-		-		-		-		-		19,955		-			-			19,955

Stock based compensation - ESOP		-		-		-		-		-		-		338,889		-			-			338,889

Translation adjustment		-		-		-		-		-		-		-		(22,586)			-			(22,586)

Net loss for the period		-		-		-		-		-		-		-		-			(2,089,601)			(2,089,601)

June 30, 2019		1		1		35,415,060		35,415		412,500		309,375		34,296,458		(777,549)			(37,129,096)			(3,265,396)

See accompanying notes to unaudited condensed consolidated interim financial statements

BIOTRICITY INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED JUNE 30, 2020 AND 2018

(Expressed in US Dollars)

	Three Months Ended June 30, 2020			Three Months Ended June 30, 2019
	(unaudited)			(unaudited)
	$			$

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss before dividends		(3,157,179	)		(2,089,601
Adjustments to reconcile net loss to net cash used in operations
Stock based compensation		232,519			338,889
Issuance of shares for services		1,063,754			251,625
Issuance of warrants for services		45,113			19,955
Change in fair value of derivative liabilities		(204,142	)		-

Changes in operating assets and liabilities:
Accounts receivable		(179,533	)		(178,530	)
Inventory		(150,386	)		(15,013	)
Deposits and other receivables		10,717			35,291
Accounts payable and accrued liabilities		(53,974	)		308,379
Net cash used in operating activities		(2,393,110	)		(1,328,375	)

CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common shares, net		-			14,003
Issuance of preferred shares		100,000			-
Proceeds from federally guaranteed loans		1,570,900			-
Issuance (repayment) of convertible promissory notes and short term loans		(96,913	)		1,315,799
Net cash provided by financing activities		1,573,987			1,329,802

Effect of foreign currency translation		(65,851	)		(17,324	)

Net increase (decrease) in cash during the period		(819,123	)		1,427

Cash, beginning of period		949,848			63,647

Cash, end of period		64,875			47,750

See accompanying notes to unaudited condensed consolidated interim financial statements

BIOTRICITY INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2020 (Unaudited)

(Expressed in US dollars)

1. NATURE OF OPERATIONS

Biotricity Inc. (formerly MetaSolutions, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over.

Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted in building technology that enables access to this market through the development of a tangible product.

2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the Securities and Exchange Commission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements and should be read in conjunction with Biotricity’s audited financial statements for the years ended March 31, 2020 and 2019 and their accompanying notes.

The accompanying unaudited condensed consolidated financial statements are expressed in United States dollars (“USD”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the three months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending March 31, 2021. The Company’s fiscal year-end is March 31.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Significant intercompany accounts and transactions have been eliminated.

Liquidity and Basis of Presentation

The Company is an emerging growth entity that is in the early stages of commercializing its first product and is concurrently in development mode, operating a research and development program in order to develop, obtain regulatory approval for, and commercialize other proposed products. The Company has incurred recurring losses from operations, and as at June 30, 2020, has an accumulated deficit of $49,758,758 and a working capital deficiency of $2,696,943. The Company launched its first commercial sales program as part of a limited market release, during the year ended March 31, 2019, using an experienced professional in-house sales team. A full market release ensued during the year ended March 31, 2020. Management anticipates the Company will attain profitable status and improve its liquidity through continued business development and after additional equity or debt capitalization of the Company. The Company has developed and continues to pursue sources of funding that management believes if successful would be sufficient to support the Company’s operating plan and alleviate any substantial doubt as to its ability to meet its obligations at least for a period of one year from the date of these consolidated financial statements. The Company raised $3,094,820 in promissory notes and short term loans during the year ended March 31, 2020. Starting in December 2019, the Company has issued 8,045 Series A preferred shares, issuing 6,100 of these for cash proceeds of $6,100,000 and 1,945 of these were issued on conversion of $1,945,000 of promissory notes and accrued interest. The Company has also raised government funding provided for economic support during COVID-19, including $1,570,900 raised during the three months ended June 30, 2020 (see Note 6 – Federally Guaranteed Loans).

The Company’s operating plan is predicated on a variety of assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue to raise additional financing and the state of the general economic environment in which the Company operates. There can be no assurance that these assumptions will prove to be accurate in all material respects, or that the Company will be able to successfully execute its operating plan. In the absence of additional appropriate financing, the Company may have to modify its operating plan or slow down the pace of development and commercialization of its proposed products.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of derivatives, convertible promissory notes, stock options, and assumptions used in the going concern assessment. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

Earnings (Loss) Per Share

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at June 30, 2020 and 2018.

Fair Value of Financial Instruments

ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes, and accounts payable and accrued liabilities. The Company’s cash and derivative liabilities, which are carried at fair values, are classified as a Level 1 and Level 2, respectively. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

Leases

On April 1, 2019, the Company adopted Accounting Standards Codification Topic 842, “Leases” (“ASC 842”) to replace existing lease accounting guidance. This pronouncement is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases will continue to be recognized in a manner similar to previous accounting guidance. The Company adopted ASC 842 utilizing the transition practical expedient added by the Financial Accounting Standards Board (“FASB”), which eliminates the requirement that entities apply the new lease standard to the comparative periods presented in the year of adoption.

Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in our consolidated statement of income. The Company determines the lease term by agreement with lessor. As our lease do not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion.

Government loan

For loans received from federal government that contains certain operating conditions and with terms over twelve month time, the Company records those loans as long term liabilities.

Convertible Notes Payable and Derivative Instruments

The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the new guidance effectively on April 1, 2020. The Company identified and updated existing internal controls and procedures to ensure compliance with the new guidance, but such modifications were not deemed to be material to the Company's overall system of internal control. While the adoption of this ASU did not have a material impact on the Company's consolidated financial statements, it required changes to the Company's process of estimating expected credit losses on trade receivables.

In July 2019, the FASB issued ASU 2019-07, Codification Updates to SEC Sections. This ASU amends various SEC paragraphs pursuant to the issuance of SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization. One of the changes in the ASU requires a presentation of changes in stockholders’ equity in the form of a reconciliation, either as a separate financial statement or in the notes to the financial statements, for the current and comparative year-to-date interim periods. The Company presented changes in stockholders' equity as separate financial statements for the current and comparative year-to-date interim periods beginning on April 1, 2019. The additional elements of the ASU did not have a material impact on the Company's consolidated financial statements.

In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. On June 16, 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis. That model replaces the probable, incurred loss model for those assets. Through the amendments in that Update, the Board added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. The amendments apply to all reporting entities within the scope of the affected accounting guidance. ASU 2019-11 is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements and related disclosures.

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impacts of the provisions of ASU 2019-12 on its financial condition, results of operations, and cash flows.

In March 2020, the FASB issued ASU No. 2030-20 Codification Improvements to Financial Instruments, An Amendment of the FASB Accounting Standards Codification: a)in ASU No. 2016-01, b) in Subtopic 820-10, c) for depository and lending institutions clarification in disclosure requirements, d) in Subtopic 470-50, e) in Subtopic 820-10, f) Interaction of Topic 842 and Topic 326, g) Interaction of the guidance in Topic 326 and Subtopic 860-20.The amendments in this Update represent changes to clarify or improve the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. For public business entities updates under the following paragraphs: a), b), d) and e) are effective upon issuance of this final update. The effective date for c) is for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company does not expect that the new guidance will significantly impact its consolidated financial statements.

The Company continues to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	As at June 30, 2020 $		As at March 31, 2020 $
Accounts payable		1,012,630		1,094,072
Accrued liabilities		715,842		427,617
		1,728,472		1,521,689

Accounts payable as at June 30, 2020, and March 31, 2020 include 345,929 and 379,881, respectively, due to a shareholder and executive of the Company, primarily as a result of that individual’s role as an employee. These amounts are unsecured, non-interest bearing and payable on demand.

5. CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS

As at June 30, 2020, the Company had promissory notes outstanding of $719,388 (March 31, 2020 – $916,301). The promissory notes generally have a term of 1-year term, at interest rates of between 10%, and 12% with allowance for the Company to repay early, and the possibility to convert into equity on the basis of mutual consent. During the three months ended June 30, 2020, the Company made repayment in amount of 96,914. During the three months ended June 30, 2020, $100,000 from the outstanding notes was converted to preferred stock. (Note 7, Note 8)

As at June 30, 2020, the Company had short term loan outstanding of $1,152,001 (March 31, 2020 – $1,152,001).

Management has evaluated the terms of these notes in accordance with the guidance provided by ASC 470 and ASC 815 and concluded that there is no derivative or beneficial conversion feature attached to these notes.

General and administrative expenses include interest expense on the above notes of $37,456 and $30,052 for the three months ended June 30, 2020 and 2019, respectively.

6. FEDERALLY GUARANTEED LOANS

Economic Injury Disaster Loan (“EIDL”)

In April 2020, the Company received $370,900 from the U.S. Small Business Administration (SBA) under the captioned program. The loan has a term of 30 years and an interest rate of 3.75%, without the requirement for payment in its first 12 months. The Company may prepay the loan without penalty at will.

Payment Protection Program (“PPP”) Loan

In May 2020, Biotricity received loan proceeds of $1.2 million (the “PPP Loan”) under the Paycheck Protection Program established by the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (“SBA”). The unsecured PPL Loan is evidenced by a promissory note (the “Note”), between the Company and the lending financial institution (the “Lender”). The Note has a two-year term, bears interest at the rate of 1.0% per annum, and may be prepaid at any time without payment of any premium. No payments of principal or interest are due during the six-month period beginning on the date of the Note (the “Deferral Period”). The principal and accrued interest under the Note is forgivable under certain specified circumstances if the Company uses the PPP Loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and otherwise complies with PPP requirements. In order to obtain forgiveness of the PPP Loan, the Company must submit a request and provide satisfactory documentation regarding its compliance with applicable requirements. The Company must repay any unforgiven principal amount of the Note, with interest, on a monthly basis following the Deferral Period. The Company intends to use the PPP Loan for qualifying expenses, though no assurance is provided that the Company will obtain forgiveness of the PPP Loan in whole or in part.

7. DERIVATIVE LIABILITIES

On December 19, 2019 and January 9, 2020, the Company issued 7,830 Series A preferred shares; 6,000 of these were issued for cash proceeds of $6,000,000 and 1,830 of these were issued on conversion of $1,830,000 of promissory notes that had previously been issued for cash proceeds in October 2019.

On May 22, 2020, another 215 Series A preferred shares were issued as a result of a combined transaction that included the conversion of $100,000 in promissory notes (Note 5) and $15,000 in accrued interest for 115 preferred shares, as well as a purchase of 100 preferred shares for cash proceeds of $100,000.

The Company analyzed the compound features of variable conversion and redemption embedded in this instrument, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (“EITF”) Issue No. 00–19 and EITF 07–05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value.

	Total
	$
Derivative liabilities as at March 31, 2019		-
Derivative fair value at issuance		1,083,952
Change in fair value of derivatives		60,781
Derivative liabilities as at March 31, 2020	$	1,144,733
Derivative fair value at issuance		41,749
Change in fair value of derivatives		(204,142	)
Derivative liabilities as at June 30, 2020	$	982,340

The lattice methodology was used to value the derivative components, using the following assumptions:

	Assumptions
Dividend yield		12	%
Risk-free rate for term		0.62% – 1.14	%
Volatility		117.4% – 198.3	%
Remaining terms (Years)		0.01 – 1.0
Stock price ($ per share)		$0.650 – $1.367

8. STOCKHOLDERS’ DEFICIENCY

a) Authorized stock

As at June 30, 2020, the Company is authorized to issue 125,000,000 (March 31, 2020 – 125,000,000) shares of common stock ($0.001 par value) and 10,000,000 (March 31, 2020 – 10,000,000) shares of preferred stock ($0.001 par value).

At June 30, 2020, there were 33,384,769 (March 31, 2020 – 32,593,769) shares of common stock issued and outstanding. Additionally, at June 30, 2020, there were 3,788,062 (March 31, 2020 – 3,788,062) outstanding exchangeable shares. There is currently one share of the Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement.

b) Exchange Agreement

As initially described in Note 1 above, on February 2, 2016:

	●	The Company issued approximately 1.197 shares of its common stock in exchange for each common share of iMedical held by the iMedical shareholders who in general terms, are not residents of Canada (for the purposes of the Income Tax Act (Canada). Accordingly, the Company issued 13,376,947 shares;
	●	Shareholders of iMedical who in general terms, are Canadian residents (for the purposes of the Income Tax Act (Canada)) received approximately 1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of iMedical held. Accordingly, the Company issued 9,123,031 Exchangeable Shares;
	●	Each outstanding option to purchase common shares in iMedical (whether vested or unvested) was exchanged, without any further action or consideration on the part of the holder of such option, for approximately 1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1;
	●	Each outstanding warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each warrant, with an inverse adjustment to the exercise price of the warrants to reflect the exchange ratio of approximately 1.197:1

	●	Each outstanding advisor warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each advisor warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1; and
	●	The outstanding 11% secured convertible promissory notes of iMedical were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of the Company at a 25% discount to purchase price per share in Biotricity’s next offering.

Issuance of common stock, exchangeable shares and cancellation of shares in connection with the reverse takeover transaction as explained above represents recapitalization of capital retroactively adjusting the accounting acquirer’s legal capital to reflect the legal capital of the accounting acquiree.

c) Share issuances

Share issuances during the year ended March 31, 2020

On December 19, 2019, the Company issued 6,000 shares of Series A preferred stock in a private placement for gross proceeds of $6,000,000 (Note 7). The shares are convertible into common stock of the Company at a conversion price equal to the greater of $0.001 or a 15% discount to the 5-day volume weighted price at the time of conversion. The conversion rights commence 24 months after issuance, but conversion is limited to 5% of the aggregate purchase price of the holder on a monthly basis thereafter. Alternatively, the shares are convertible into common stock at a 15% discount to any qualified future common stock financing conducted by the Company. The Company may redeem the shares after 1 year for 110% of the purchase price plus accrued dividends. The preferred stock bears a dividend rate of 12% per annum. On January 9, 2020, the Company issued a further 1,830 of Series A preferred stock with same terms on conversion of $1,830,000 of promissory notes that had previously been issued for cash proceeds in 2019 (see Note 5). During the year ended March 31, 2020, the Company accrued dividends in amount of $257,927 and made a payment in amount of $180,000.

In May and July 2019, the Company issued 47,585 shares of common stock under a registered offering outstanding in the previous fiscal year, which raised proceeds of $28,565.

During the year ended March 31, 2019, the Company issued a total of 972,950 shares of common stock and recognized its obligations to issue a total of 178,750 shares of common stock to various consultants and advisors, with a cumulative fair value of $666,129 and $169,490, respectively, or $835,619 in total; these costs were recognized as general and administrative and research and development expenses, as applicable, in the statement of operations, with corresponding credit to common stock, shares to be issued, and additional paid-in-capital, respectively.

During the year ended March 31, 2020, the Company also issued an aggregate of 525,023 shares of its common stock to investors as part of the one-for-one exchange of previously issued exchangeable shares into the Company’s Common Stock, which is a non-cash transaction. No options or warrants were exercised during this period.

Share issuances during the three months ended June 30, 2020

During the three months ended June 30, 2020, the Company issued an aggregate of 160,000 shares pursuant to obligations existing as at March 31, 2020. The Company also issued a further 631,000 shares of its common stock pursuant to obligations to issue these, the fair value of which were recognized during the three months ended June 30, 2020. Total fair value of the total 791,000 common shares, in amount of $1,063,754, was determined by using the market date price on the date of issuance. The Company recorded the fair value of the common shares issued in general and administrative expenses and research and development expenses with corresponding credit to common stock and additional paid in capital.

d) Shares to be issued

As of June 30, 2020, the Company recognized its contractual obligations to issue a total of 25,000 shares of common stock to an advisor. The fair value of these shares amounted to $22,194 and has been expensed to general and administrative and research and development expenses in the consolidated statements of operations, with a corresponding credit to additional paid-in-capital. The fair value of these shares was determined by using the market price of the common stock as at the date of issuance.

As of March 31, 2020, the Company had recognized its contractual obligations to issue a total of 178,750 shares of common stock to consultants, advisors and other service providers, (as explained in paragraph c, above). The fair value of these shares amounted to $169,490 and has been expensed to general and administrative and research and development expenses in the consolidated statements of operations, with a corresponding credit to additional paid-in-capital. The fair value of these shares was determined by using the market price of the common stock as at the date of issuance.

e) Warrant issuances and exercises

Warrant issuances during the year ended March 31, 2020

During the year ended March 31, 2020, the Company issued 1,021,430 warrants, respectively, as compensation for advisor and consultant services and certain promissory noteholders, which were fair valued at $277,053. Warrants issued to advisors and consultants were expensed in general and administrative expenses and amounted to $184,637, for the year ended March 31, 2020. Warrants issued to promissory notes holders were credited to additional paid-in capital in amount of $92,416. Their fair value has been estimated using a multi-nomial lattice model with an expected life of 2 to 3 years, risk free rates of 0.22% to 1.71%, stock price of $0.52 to $0.974 and expected volatility of 114.3% to 132.2%.

Warrant issuances during the three months ended June 30, 2020

During the three months ended June 30, 2020, the Company issued 50,000 warrants as compensation for advisor and consultant services, which were fair valued at $45,113 and expensed in general and administrative expenses, with a corresponding credit to additional paid in capital. Their fair value has been estimated using a multi-nomial lattice model with an expected life of 3 years, a risk free rate ranging from 0.259% to 0.692%, stock price in range of $0.970 to $1.367 and expected volatility of 125.4% to 131.90%

Warrant exercises

No warrants were exercised during the fiscal year ended March 31, 2020 and the three months ended June 30, 2020.

Warrant issuances, exercises and expirations or cancellations during the three months ended June 30, 2020 and preceding periods resulted in warrants outstanding at the end of those respective periods as follows:

	Broker Warrants			Consultant Warrants			Warrants Issued on Conversion of Convertible Notes			Private Placement Warrants		Total
As at March 31, 2018		384,152			669,972	*		2,734,530			1,163,722		4,952,376

Less: Exercised		(62,838	)		-			-			-		(62,838	)
Less: Expired/cancelled		-			(31,250	)		-			-		(31,250	)
Add: Issued		-			65,000			-			-		65,000
As at June 30, 2018		321,314			703,722	*		2,734,530			1,163,722		4,923,288

Less: Exercised		-			-			-			-		-
Less: Expired/cancelled		-			-			-			-
Add: Issued		-			393,333			-			-		393,333
As at September 30 2018		321,314			1,097,055	*		2,734,530			1,163,722		5,316,621

Less: Exercised		-			-			-			-		-
Less: Expired/cancelled		-			(126,250	)**		-			-		(126,250	)
Add: Issued		-			50,000			-			-		50,000
As at December 31, 2018		321,314			1,020,805	*		2,734,530			1,163,722		5,240,371

Less: Exercised		-			-			-			-		-
Less: Expired/cancelled		-			(184,916	)**		-			-		(184,916	)
Add: Issued		-			341,268			-			-		341,268
As at March 31, 2019		321,314			1,177,157	*		2,734,530			1,163,722		5,396,723

Less: Exercised		-			-			-			-		-
Less: Expired/cancelled		-			(5,000	)		-			-		(5,000	)
Add: Issued		-			83,750			-			-		83,750
As at June 30, 2019		321,314			1,255,907	*		2,734,530			1,163,722		5,475,473

Less: Exercised		-			-			-			-		-
Less: Expired/cancelled		-			(10,000	)		-			-		(10,000	)
Add: Issued		-			311,350			-			-		311,350
As at September 30, 2019		321,314			1,557,257	*		2,734,530			1,163,722		5,776,823

Less: Exercised		-			-			-			-		-
Less: Exercised		-			-			-			-		-
Less: Expired/cancelled		-			(35,000	)		-			-		(35,000	)
Add: Issued		-			568,000			-			-		568,000
As at December 31, 2019		321,314			2,090,257	*		2,734,530			1,163,722		6,309,823

Less: Exercised		-			-			-			-		-
Less: Expired/cancelled		-			(98,750	)		-			-		(98,750	)
Add: Issued		-			58,330			-			-		58,330
As at March 31, 2020		321,314			2,049,837	*		2,734,530			1,163,722		6,269,403
Less: Expired/cancelled		-			(65,000	)		(911,510	)		-		(986,510	)

Add: Issued		-			50,000			-			-		50,000
As at June 30, 2020		321,314			2,034,837	*		1,823,020			1,163,722		5,332,893

Exercise Price	$	0.78-$3.00		$	0.48-$7.59			2.00			3.00
Expiration Date		March 2022 to July 2022			April 2020 to June 2023			March 2020 to November 2022			April 2020 to July 2020

*Consultant Warrants include warrants issued to directors and officers of the Company who were not members of the Company’s options plan at the time of issuance. As at June 30, 2020, Consultant Warrants include an aggregate of 638,806 warrants provided to an officer of the Company as compensation while he was not a member of any Company options plan.

f) Stock-based compensation

2015 Equity Incentive Plan

On March 30, 2015, iMedical approved Directors, Officers and Employees Stock Option Plan, under which it authorized and issued 3,000,000 options. This plan was established to enable the Company to attract and retain the services of highly qualified and experience directors, officers, employees and consultants and to give such person an interest in the success of the Company. As of March 31, 2018, and March 31, 2017, there were no outstanding vested options and 137,500 unvested options at an exercise price of $.0001 under this plan. These options now represent the right to purchase shares of the Company’s common stock using the same exchange ratio of approximately 1.1969:1, thus there were 164,590 (35,907 had been cancelled) adjusted unvested options as at March 31, 2018. These remaining 164,590 options were exercised during the year ended March 31, 2019. No other grants will be made under this plan.

The following table summarizes the stock option activities of the Company:

	Number of options			Weighted average exercise price ($)
Granted		3,591,000			0.0001
Exercised		(3,390,503	)		0.0001
Outstanding as of December 31, 2015		200,497			0.0001
Cancelled during 2016		(35,907	)		0.0001
Outstanding as of March 31, 2018		164,590			0.0001
Exercised		(164,590	)		0.0001
Outstanding as of June 30, 2020 and March 31, 2019		-

The fair value of options at the issuance date were determined at $2,257,953 which were fully expensed during the twelve months ended December 31, 2015 based on vesting period and were included in general and administrative expenses with corresponding credit to additional paid-in-capital. During the twelve months ended December 31, 2015, 3,390,503 (2,832,500 Pre-exchange Agreement) options were exercised by those employees who met the vesting conditions; 50% of the grants either vest immediately or at the time of U.S. Food and Drug Administration (FDA) filing date and 50% will vest upon Liquidity Trigger. Liquidity Trigger means the day on which the board of directors resolve in favor of i) the Company is able to raise a certain level of financing; ii) a reverse takeover transaction that results in the Company being a reporting issuer, and iii) initial public offering that results in the Company being a reporting issuer.

2016 Equity Incentive Plan

On February 2, 2016, the Board of Directors of the Company approved 2016 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards.

The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan shall be equal to 3,750,000 shares; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 15% of the Company’s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase.

During July 2016, the Company granted an officer options to purchase an aggregate of 2,499,998 shares of common stock at an exercise price of $2.20 subject to a 3 year vesting period, with the fair value of the options being expensed over a 3 year period. Two additional employees were also granted 175,000 options to purchase shares of common stock at an exercise price of $2.24 with a 1 year vesting period, with the fair value of the options being expensed over a 1 year period. One additional employee was also granted 35,000 options to purchase shares of common stock at an exercise price of $2.24 with a 2 year vesting period, with the fair value of the options expensed over a 2 year period.

During the year ended March 31, 2018, an additional 1,437,500 stock options were granted with a weighted average remaining contractual life from 2.76 to 9.51 years.

During the year ended March 31, 2019, an additional 270,521 stock options were granted with a weighted average remaining contractual life from 2.76 to 9.51 years. During the year ended March 31, 2019, the Company recorded stock based compensation of $1,451,261 in connection with ESOP 2016 Plan under general and administrative expenses with corresponding credit to additional paid in capital.

Based on the 2016 Option Plan, the Company is authorized to issue employee options with a 10-year term. On March 31, 2020, the Company’s Board of Directors approved the amendment of certain prior options grants, issued to current employees, previously issued with a 3-year term, such that the respective options issued under these agreements would have their term extended to 10 years. The Company revalued these options use g a lattice model with an expected life of 10 years, risk free rates of 0.46% to 0.75%, stock price of $0.974 and expected volatility of 132.2%, in order to recognize the additional expense associated with the longer term and recognized a one-time charge of $1,600,515 in share-based compensation, with a corresponding adjustment to adjusted paid in capital.

During the year ended March 31, 2020, an additional 88,100 stock options were granted with a weighted average remaining contractual life from 2.76 to 9.51 years. The Company recorded stock-based compensation of $2,408,713 in connection with ESOP 2016 Plan under general and administrative expenses with corresponding credit to additional paid in capital.

During the three months ended June 30, 2020, the Company granted 1,811,847 options, including 1,400,000 options to an executive and director of the Company and an additional 367,647 options to another director. Their fair value, has been estimated using a multi-nomial lattice model with an expected life of up to 6 years, a risk free rate ranging from 0.259% to 0.692%, stock price in range of $0.970 to $1.367 and expected volatility of 125.4% to 131.90%.

The following table summarizes the stock option activities of the Company:

	Number of options			Weighted average exercise price ($)
Granted		4,147,498			3.2306
Exercised		-			-
Outstanding as of June 30 and March 31, 2018		4,147,498			3.2306
Granted		270,521			1.8096
Exercised		-			-
Outstanding as of June 30, 2019 and March 31, 2019		4,418,019			3.1436
Granted		88,100			0.7763
Expired		(112,509	)		2.723
Outstanding as of March 31, 2020		4,393,610			3.1069

Granted		1,811,847			1.0513
Exercised		-			-
Outstanding as of June 30 and March 31, 2018		6,205,457			2.5070

During the three months ended June 30, 2020, the Company recorded stock-based compensation of $232,519, in connection with the 2016 equity incentive plan (June 30, 2019 – $338,889) under general and administrative expenses with a corresponding credit to additional paid in capital.

The fair value of each option granted is estimated at the time of grant using multi-nomial lattice model using the following assumptions:

	2019		2017-2018		2016-2017		2015-2016
Exercise price ($)		2.00		1.24-7.59		2.00 – 2.58		0.0001
Risk free interest rate (%)		2.27 to 2.54		1.98-2.81		0.45 - 1.47		0.04 - 1.07
Expected term (Years)		3		3		1 - 3		10
Expected volatility (%)		112.5 -141.10		97.8-145.99		101 – 105		94
Expected dividend yield (%)		0		0		0		0
Fair value of option ($)		0.28		0.6		0.88		0.74
Expected forfeiture (attrition) rate (%)		0.00		0.00		0.00 – 5.00		5.00 - 20.00

9. RELATED PARTY TRANSACTIONS AND BALANCES

The Company’s transactions with related parties were carried out on normal commercial terms and in the course of the Company’s business. Other than those disclosed elsewhere in the financial statements, related party transactions are as follows:

	Three Months Ended June 30, 2020		Three Months Ended June 30, 2019
	$		$
Salary and allowance*		150,500		135,052
Stock based compensation**		236,044		308,755
Total		386,544		443,807

The above expenses were recorded under general and administrative expenses.

* Salary and allowance include salary, car allowance, vacation pay, bonus and other allowances paid or payable to key management of the Company.

** Stock based compensation represent the fair value of the options, warrants and equity incentive plan for directors and key management of the Company.

10. LEASE

The Company has one operating lease primarily for office and administration.

The Company adopted ASC 842 – Leases using the modified retrospective cumulative catch-up approach beginning on April 1, 2019. Under this approach, the Company did not restate its comparative amounts and recognized a right-of-use asset equal to the present value of the future lease payments. The Company elected to apply the practical expedient to only transition contracts which were previously identified as leases and elected to not recognize right-of-use assets and lease obligations for leases of low value assets.

When measuring the lease obligations, the Company discounted lease payments using its incremental borrowing rate at April 1, 2019. The weighted-average-rate applied is 10%.

	$
Operating lease right-of-use asset - initial recognition		413,236
Amortization		(198,352	)
Balance at June 30, 2020		214,884

Operating lease obligation - initial recognition		413,236
Repayment and interest accretion		(192,093	)
Balance at June 30, 2020		221,143

Current portion of operating lease obligation		221,143
Noncurrent portion of operating lease obligation		-

The operating lease expense was $55,299 for the three months ended June 30, 2020 and $173,175 for the year ended March 31, 2020 and included in the General and administrative expenses.

The following table represents the contractual undiscounted cash flows for lease obligations as at June 30, 2020.

	$
Less than one year		230,118
Beyond one year		-
Total undiscounted lease obligations		230,118

11. CONTINGENCIES

There are no claims against the company that were assessed as significant, which were outstanding as at June 30, 2020 and, consequently, no provision for such has been recognized in the consolidated financial statements.

12. SUBSEQUENT EVENTS

The Company’s management has evaluated subsequent events up to August 14, 2019, the date the condensed consolidated financial statements were issued, pursuant to the requirements of ASC 855 and has determined the following material subsequent events:

From July 24, 2020 to July 31, 2020, the Company entered into subscription agreements with accredited investors for the sale to the investors of convertible promissory notes (the “Notes”) in the aggregate principal amount of $1,253,000. The Notes will bear interest at the rate of 12% per year and will mature one year from the final closing date of the offering. The Notes will be convertible into shares of common stock, at the option of the holder, commencing six months from issuance, at a conversion price equal to 75% of the volume weighted average price of the common stock for the five trading days prior to the conversion date. The Notes will automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price will be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price will be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company may prepay the Notes upon 20 days’ written notice and payment of a 15% prepayment fee. Upon conversion of the Notes, the Company will also issue to the investors warrants (the “Warrants”) to purchase 50% of the number of shares of common stock issued upon conversion of the Notes. The Warrants will have a term of three years and an exercise price equal to 120% of the volume weighted average price of the common stock for the 20 days prior to the final closing date of the offering, subject to adjustment.

In July 2020, an exchangeable shareholder holding 179,540 exchangeable shares exchanged these for an equivalent number of common shares of the Company. Also in July 2020, the Company issued 83,500 common shares as compensation for services to be provided by a contractor.

On August 6, 2020, the Company announced that it received a 510(k) clearance from the FDA for its Bioflux Software II System, engineered to improve workflows and reduce estimated analysis time from 5 minutes to 30 seconds. Because ECG monitoring requires significant human oversight to review and interpret incoming patient data to discern actionable events for clinical intervention, highlighting the necessity of driving operational efficiency, this improvement in analysis time reduces operational costs and allows the company to improve customer service and provide improved response times to physicians and their at-risk patients.

On August 11, 2020, the Company entered into an agreement of understanding that establishes terms under which Biotricity will enter into a licensing agreement, with an exclusive right to acquire MD Matrix Inc. and its telemedicine platform, which includes capabilities for real-time streaming of medical devices. The terms of the agreement of understanding expire ninety days after its execution.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information contained herein, this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contains forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on various factors and were derived utilizing numerous important assumptions and other important factors that could cause actual results to differ materially from those in the forward-looking statements. Important assumptions and other factors that could cause actual results to differ materially from those in the forward-looking statements, include but are not limited to: (a) any fluctuations in sales and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) development risks; (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; (f) competition in the Company’s existing and potential future product lines of business; (g) the Company’s ability to obtain financing on acceptable terms if and when needed; (h) uncertainty as to the Company’s future profitability; (i) uncertainty as to the future profitability of acquired businesses or product lines; and (j) uncertainty as to any future expansion of the Company. Other factors and assumptions not identified above were also involved in the derivation of these forward-looking statements and the failure of such assumptions to be realized as well as other factors may also cause actual results to differ materially from those projected. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements, except as may be required under applicable law. Past results are no guaranty of future performance. Any such forward-looking statements speak only as of the dates they are made. When used in this Report, the words “believes,” “anticipates,” “expects,” “estimates,” “plans,” “intends,” “will” and similar expressions are intended to identify forward-looking statements.

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and footnotes thereto included in this Quarterly Report on Form 10-Q (the “Financial Statements”).

Company Overview

Biotricity Inc. (“Company”, “Biotricity”, “we”, “us” or “our”)

Biotricity Inc. (the “Company”, “Biotricity”, “we”, “us”, “our”) is a medical technology company focused on biometric data monitoring solutions. Our aim is to deliver innovative, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. We approach the diagnostic side of remote patient monitoring by applying innovation within existing business models where reimbursement is established. We believe this approach reduces the risk associated with traditional medical device development and accelerates the path to revenue. In post-diagnostic markets, we intend to apply medical grade biometrics to enable consumers to self-manage, thereby driving patient compliance and reducing healthcare costs. We intend to first focus on a segment of the diagnostic mobile cardiac telemetry market, otherwise known as MCT, while providing our chosen markets with the capability to also perform other cardiac studies.

We developed our FDA-approved Bioflux® MCT technology, comprised of a monitoring device and software components, which we made available to the market under limited release on April 6, 2018, in order to assess, establish and develop sales processes and market dynamics. The fiscal year ended March 30, 2020 marked the Company’s first year of expanded commercialization efforts, focused on sales growth and expansion. We have expanded our sales efforts to 13 states, with intention to expand further and compete in the broader US market using an insourcing business model. Our technology has a large potential total addressable market, which can include hospitals, clinics and physicians’ offices, as well as other IDTFs. We believe our solution’s insourcing model, which empowers physicians with state-of-the-art technology and charges technology service fees for its use, has the benefit of a reduced operating overhead for the Company, and enables a more efficient market penetration and distribution strategy. This, when combined with the value the Company’s solution in the diagnosis of cardiac arrhythmias, enhancement of patient outcomes, improved patient compliance, and the corresponding reduction of healthcare costs, is driving growth and increasing revenues.

We are a technology company focused on earning utilization-based recurring technology fee revenue. The Company’s ability to grow this type of revenue is predicated on the size and quality of its sales force and their ability to penetrate the market and place devices with clinically focused, repeat users of its cardiac study technology. The Company plans to grow its sales force in order to address new markets and achieve sales penetration in the markets currently served. The Company has also developed or is developing several other ancillary technologies, which will require application for further FDA clearances, which the Company anticipates applying for within the next to twelve months. Among these are:

●

advanced ECG analysis software that can analyze and synthesize patient ECG monitoring data with the purpose of distilling it down to the important information that requires clinical intervention, while reducing the amount of human intervention necessary in the process;

●

the Biotres patch solution, which will be a novel product in the field of Holter monitoring;

●

the Bioflux® 2.0, which is the next generation of our award winning Bioflux®

On August 6, 2020, the Company announced that it received a 510(k) clearance from the FDA for its Bioflux Software II System, engineered to improve workflows and reduce estimated analysis time from 5 minutes to 30 seconds. ECG monitoring requires significant human oversight to review and interpret incoming patient data to discern actionable events for clinical intervention, highlighting the necessity of driving operational efficiency. This improvement in analysis time reduces operational costs and allows the company to continue to focus on excellent customer service and industry-leading response times to physicians and their at-risk patients. Additionally, these advances mean we can focus our resources on high-level operations and sales to help drive greater revenue.

The COVID-19 pandemic has highlighted the importance of telemedicine and remote patient monitoring technologies. On August 12, 2020, the Company announced that it has negotiated the terms of an agreement to license, with the exclusive right to acquire, MD Matrix Inc. (“MDM”) and its telemedicine platform, which also provides capabilities of real-time streaming of medical devices. The terms of the agreement of understanding expire ninety days after its execution, and there cannot be any assurance that the Company will enter into a definitive agreement with MDM. Telemedicine offers patients the ability to communicate directly with their health care providers without the need of leaving their home. This telemedicine solution is intended to align with the Company’s Bioflux product and facilitate remote visits and remote prescriptions for cardiac diagnostics. This results in improved care to patients that may otherwise elect not to go to medical facilities, cost savings to healthcare service providers.

Critical Accounting Policies

The unaudited condensed consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and are expressed in United States Dollars. Significant accounting policies are summarized below:

Use of Estimates

The preparation of the unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of derivatives, convertible promissory notes, stock options and warrants, as well as assumptions used by management in its assessment of liquidity. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

Earnings (Loss) Per Share

We have adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at December 31, 2019.

Fair Value of Financial Instruments

●	Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

●	Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

●	Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes and short-term loans, accounts payable and accrued liabilities, and derivative liabilities. The Company’s cash and derivative liabilities, which are carried at fair values, are classified as a Level 1 and Level 2, respectively. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

Leases

The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the consolidated balance sheet. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in our consolidated statement of income. The Company determines the lease term by agreement with lessor. As our lease does not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.

Government loan

For loans received from federal government that contains certain operating conditions and with terms over twelve month time, the Company records those loans as long term liabilities.

Recently Issued Accounting Pronouncements

Results of Operations

The fiscal year ended March 31, 2020 was the first year of full market release of the Bioflux MCT device for commercialization, launched in limited market release in April 2018, after receiving its second and final required FDA clearance in December 2017. To commence commercialization, we ordered device inventory from our FDA-approved manufacturer and hired a small, captive sales force, with deep experience in cardiac technology sales. We expanded on our limited market release, which identified potential anchor clients who could be early adopters of our technology, by increasing our sales force and geographic footprint during fiscal 2020, and had launched sales in 13 U.S. states by March 31, 2020. The Company has experienced sequential growth month over month, every month since it commenced commercialization, with the exception of the month of April 2020 when the US implemented extra-ordinary measures to close large portions of its economy in order to stem the tide of the COVID-19 pandemic.

During the three months ended June 30, 2020, the Company earned combined device sales and technology fee income totaling $451,898, a 38.2% increase over the corresponding period in the preceding year. The Company achieved this result despite experiencing an approximately 30% decrease in its business activities during the month of April 2020, the first month of the quarter, largely as a result of pent-up demand for Biotricity’s technology and services in the months of May and June. The Company also introduced innovative sales programs designed to limit the need for in-person patient visits and provide streamlined logistics in making our technology available for patient use.

During the three months ended June 30, 2020, Biotricity incurred a net loss of $3.4 million (loss per share of 0.09 cents), such that from its inception in 2009 to this date, the Company has generated an accumulated deficit of $49,758,758. During the period of initial commercialization of the Bioflux and the build out of the Company’s expended technology eco-system, we devoted, and expect to continue to devote, significant resources in higher a high-caliber sales force. We also devoted and expect to continue to devote capital to our research and development programs and incur additional operating losses as we build the infrastructure required to support higher sales volumes.

During the three months ended June 30, 2020, the Company experienced a gross margin of 57.6%, compared to 53.9% for the corresponding period of the prior year. Management expects that the cost of devices sold, as well as cellular and other costs associated with technology fees will become lower on average as business sales volumes expand.

Three Months Ended June 30, 2020 and June 30, 2019

Operating Revenues and Expenses

Operating Expenses

Total operating expenses for the three months ended June 30, 2020 were $3.6 million compared to $2.3 million for the corresponding period of fiscal 2019, as further described below.

General and administrative expenses

Our general and administrative expenses for the three months ended June 30, 2020 increased to $3.2 million compared to $2.1 million during the three months ended June 30, 2019. This increase was primarily due to marketing and promotion costs associated with launching the Company and its products, as well as the cost of expanding our sales force and building an engineering division that is less reliant on contract consultants.

Research and development expenses

During the three months ended June 30, 2020 we incurred research and development expenses of $423,883 compared to $213,496 incurred in the three months ended June 30, 2019. The increase in research and development activity related to work related to our pursuit of FDA clearance of new products, as well as the development of existing and new products, including the engineering of future product enhancements continues.

Accretion expense

During the three months ended June 30, 2020 and 2019, we incurred no accretion expense.

Change in fair value of derivative liabilities

During the three months ended June 30, 2020, the Company recognized a gain of $204,142 in expenses related to the change in fair value of derivative liabilities, compared to no change in fair value in the prior fiscal year.

Net Loss

As a result of the foregoing, the net loss attributable to common stockholders for the three months ended June 30, 2020 was $ 3.4 million compared to a net loss of $2.1 million during the corresponding fiscal period of 2019.

Translation Adjustment

Translation adjustment for the three months ended June 30, 2020 was a loss of $105,001 compared to a loss of $22,586, for the corresponding period ended June 30, 2019. This translation adjustment represents gains and losses that result from the translation of currency in the financial statements from our functional currency of Canadian dollars to the reporting currency in U.S. dollars over the course of the reporting period.

Liquidity and Capital Resources

The Company is in commercialization mode, while continuing to pursue the development of its next generation MCT product as well as new products that are being developed.

We generally require cash to:

	●	purchase devices that will be placed in the field for pilot projects and to produce revenue,

	●	launch sales initiatives,

	●	fund our operations and working capital requirements,

	●	develop and execute our product development and market introduction plans,

	●	fund research and development efforts, and

	●	pay any expense obligations as they come due.

The Company is an emerging growth entity that is in the early stages of commercializing its first product and is concurrently in development mode, operating a research and development program in order to develop, obtain regulatory approval for, and commercialize other proposed products. As a result of its early-revenue-stage operations, the Company has incurred recurring losses from operations, and as at June 30, 2020, has an accumulated deficit of $49,758,758 and a working capital deficiency of $2,696,943. The Company launched its first commercial sales program as part of a limited market release, during the year ended March 31, 2019, using an experienced professional in-house sales team. A full market release ensued during the year ended March 31, 2020. Management anticipates the Company will continue on its revenue growth trajectory and improve its liquidity through continued business development and after additional equity or debt capitalization of the Company. The Company has developed and continues to pursue sources of funding that management believes if successful would be sufficient to support the Company’s operating plan and alleviate any substantial doubt as to its ability to meet its obligations at least for a period of one year from the date of these consolidated financial statements. The Company raised $3,094,820 in promissory notes and short term loans during the year ended March 31, 2020. Starting in December 2019, the Company has issued 8,045 Series A preferred shares, issuing 6,100 of these for cash proceeds of $6,100,000 and 1,945 of these were issued on conversion of $1,945,000 of promissory notes and accrued interest. The Company has also received government funding provided for economic support during COVID-19, including $1.6 million raised during the three months ended June 30, 2020.

As we proceed with the commercialization of the Bioflux product development, we expect to continue to devote significant resources on capital expenditures, as well as research and development costs and operations, marketing and sales expenditures.

We expect to require additional funds to further develop our business plan, including the anticipated commercialization of the Bioflux and other technologies that will form part of its eco-systems. Based on our current operating plans, we will require approximately $8million (more in order to accelerate commercialization further and faster) to grow our sales team and order devices that will be placed in the field to produce revenue. A portion of these funds will also go towards the further development of Bioflux in its next generation, in addition to including marketing, sales, regulatory and clinical costs to better introduce the product into the market place. We anticipate that we will need to raise additional funds through equity or debt offerings or otherwise in order to meet our expected future liquidity requirements.

Based on the above facts and assumptions, we believe our existing cash and cash equivalents, along with anticipated near-term equity financings, will be sufficient to meet our needs for the next twelve months. However, we will need to seek additional debt or equity capital to respond to business opportunities and challenges, including our ongoing operating expenses, protecting our intellectual property, developing or acquiring new lines of business and enhancing our operating infrastructure. The terms of our future financings may be dilutive to, or otherwise adversely affect, holders of our common stock. We may also seek additional funds through arrangements with collaborators or other third parties. There can be no assurance we will be able to raise this additional capital on acceptable terms, or at all. If we are unable to obtain additional funding on a timely basis, we may be required to modify our operating plan and otherwise curtail or slow the pace of development and commercialization of our proposed product lines.

Net Cash Used in Operating Activities

During the three months ended June 30, 2020, we used cash in operating activities of $2,393,107 compared to $1,328,375 for the three months ended June 30, 2019. These activities involved expenditures undertaken on business development, marketing and operating activities, as well as continued research and product development.

Net Cash from Financing Activities

Net cash provided by financing activities was $1,573,987 for the three months ended June 30, 2020 compared to $1,329,802 for the three months ended June 30, 2019.

Net Cash Used in Investing Activities

The Company did not use any net cash in investing activities in the three month periods ended June 30, 2020 and 2018.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for a smaller reporting company.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based closely on the definition of “disclosure controls and procedures” in Rule 13a-15(e). The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching the Company’s desired disclosure control objectives. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Therefore, even a system which is determined to be effective cannot provide absolute assurance that all control issues have been detected or prevented. Our systems of internal controls are designed to provide reasonable assurance with respect to financial statement preparation and presentation.

At the end of the period being reported upon, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that the material information required to be included in our Securities and Exchange Commission reports is accumulated and communicated to our management, including our principal executive and financial officer, as well as recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms relating to the Company.

Changes in Internal Controls

There were no changes in the Company’s internal controls over financial reporting that occurred during the three-month period ended June 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II

OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors

Not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the period of April 22 to June 22, 2020, the Company issued 791,000 common shares, valued in the aggregate amount of $1,063,754 (determined by the market date price on the date of issuance) as compensation for consultants and advisors in exchange for the provision of marketing and other general and administrative services.

The securities referenced above were offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act since, among other things, the transactions did not involve a public offering.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits

4.1 Note with U.S. Small Business Administration

31.1 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

31.2 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

32.2 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

101.1 XBRL Instance.*

101.SCH XBRL Taxonomy Extension Schema.*

101.CAL XBRL Taxonomy Extension Calculation.*

101.DEF XBRL Taxonomy Extension Definition.*

101.LAB XBRL Taxonomy Extension Labels.*

101.PREXBRL Taxonomy Extension Presentation.*

* Filed herewith.

** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, this 14^th day of August 2020.

BIOTRICITY INC.

By:	/s/ Waqaas Al-Siddiq
Name:	Waqaas Al-Siddiq
Title:	Chief Executive Officer
	(principal executive officer)

By:	/s/ John Ayanoglou
Name:	John Ayanoglou
Title:	Chief Financial Officer
	(principal financial and accounting officer)

EX-4.1 2 ex4-1.htm

Exhibit 4.1

GRAPHIC 3 ex4-1_01.jpg begin 644 ex4-1_01.jpg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ⅅ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�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ex4-1_02.jpg begin 644 ex4-1_02.jpg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ex4-1_03.jpg begin 644 ex4-1_03.jpg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end EX-31.1 6 ex31-1.htm

Exhibit 31.1

BIOTRICITY INC.

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Waqaas Al-Siddiq, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Biotricity Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2020

/s/ Waqaas Al-Siddiq

Waqaas Al-Siddiq

Chief Executive Officer

(principal executive officer)

EX-31.2 7 ex31-2.htm

EXHIBIT 31.2

BIOTRICITY INC.

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, John Ayanoglou, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Biotricity Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 14, 2020

/s/ John Ayanoglou

John Ayanoglou

(Principal Financial Officer)

EX-32.1 8 ex32-1.htm

Exhibit 32.1

BIOTRICITY INC.

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Biotricity Inc. (the “Company”) for the quarterly period ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Waqaas Al-Siddiq, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2020

/s/ Waqaas Al-Siddiq

Waqaas Al-Siddiq

Chief Executive Officer

(principal executive officer)

EX-32.2 9 ex32-2.htm

Exhibit 32.2

BIOTRICITY INC.

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Biotricity Inc. (the “Company”) for the quarterly period ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Ayanoglou, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 14, 2020

/s/ John Ayanoglou

John Ayanoglou

(Principal Financial Officer)

EX-101.INS 10 btcy-20200630.xml XBRL INSTANCE FILE 0001630113 2020-04-01 2020-06-30 0001630113 2020-03-31 0001630113 2018-03-31 0001630113 2017-03-31 0001630113 2019-01-01 2019-03-31 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember 2020-04-01 2020-06-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2020-04-01 2020-06-30 0001630113 srt:MaximumMember 2019-03-31 0001630113 BTCY:ExchangeAgreementMember BTCY:ExchangecoMember 2016-02-01 2016-02-02 0001630113 BTCY:BrokerWarrantsMember 2018-03-31 0001630113 BTCY:AdvisorAndConsultantMember 2018-04-01 2019-03-31 0001630113 BTCY:AdvisorAndConsultantMember us-gaap:WarrantMember srt:MinimumMember 2018-04-01 2019-03-31 0001630113 BTCY:AdvisorAndConsultantMember us-gaap:WarrantMember srt:MaximumMember 2018-04-01 2019-03-31 0001630113 BTCY:AdvisorAndConsultantMember us-gaap:WarrantMember srt:MinimumMember 2019-03-31 0001630113 BTCY:AdvisorAndConsultantMember us-gaap:WarrantMember srt:MaximumMember 2019-03-31 0001630113 2018-12-31 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember 2015-03-30 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember 2017-04-01 2018-03-31 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember 2018-03-31 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember 2015-01-01 2015-12-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2016-02-02 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember srt:OfficerMember 2016-07-01 2016-07-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember BTCY:TwoEmployeesMember 2016-07-01 2016-07-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember BTCY:OneEmployeeMember 2016-07-01 2016-07-31 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember 2015-04-01 2015-12-31 0001630113 BTCY:BrokerWarrantsMember 2019-03-31 0001630113 BTCY:ConsultantWarrantsMember 2019-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2019-03-31 0001630113 BTCY:PrivatePlacementWarrantsMember 2019-03-31 0001630113 BTCY:ConsultantWarrantsMember 2018-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2018-03-31 0001630113 BTCY:PrivatePlacementWarrantsMember 2018-03-31 0001630113 2016-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2016-01-30 2016-02-02 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2017-04-01 2018-03-31 0001630113 BTCY:BrokerWarrantsMember 2018-04-01 2018-06-30 0001630113 BTCY:BrokerWarrantsMember 2018-07-01 2018-09-30 0001630113 BTCY:BrokerWarrantsMember 2019-01-01 2019-03-31 0001630113 BTCY:ConsultantWarrantsMember 2018-04-01 2018-06-30 0001630113 BTCY:ConsultantWarrantsMember 2018-07-01 2018-09-30 0001630113 BTCY:ConsultantWarrantsMember 2019-01-01 2019-03-31 0001630113 BTCY:BrokerWarrantsMember 2018-06-30 0001630113 BTCY:BrokerWarrantsMember 2018-12-31 0001630113 BTCY:ConsultantWarrantsMember 2018-06-30 0001630113 BTCY:ConsultantWarrantsMember 2018-12-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2018-04-01 2018-06-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2018-07-01 2018-09-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2019-01-01 2019-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2018-06-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2018-12-31 0001630113 BTCY:PrivatePlacementWarrantsMember 2018-04-01 2018-06-30 0001630113 BTCY:PrivatePlacementWarrantsMember 2018-07-01 2018-09-30 0001630113 BTCY:PrivatePlacementWarrantsMember 2019-01-01 2019-03-31 0001630113 BTCY:PrivatePlacementWarrantsMember 2018-06-30 0001630113 BTCY:PrivatePlacementWarrantsMember 2018-12-31 0001630113 2018-04-01 2018-06-30 0001630113 2018-07-01 2018-09-30 0001630113 2018-06-30 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember 2015-04-01 2016-03-31 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember 2019-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2018-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2019-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2018-04-01 2018-06-30 0001630113 2015-04-01 2016-03-31 0001630113 2016-04-01 2017-03-31 0001630113 srt:MinimumMember 2017-04-01 2018-03-31 0001630113 srt:MaximumMember 2017-04-01 2018-03-31 0001630113 srt:MinimumMember 2016-04-01 2017-03-31 0001630113 srt:MaximumMember 2016-04-01 2017-03-31 0001630113 srt:MinimumMember 2018-04-01 2019-03-31 0001630113 srt:MaximumMember 2018-04-01 2019-03-31 0001630113 srt:MinimumMember 2017-03-31 0001630113 srt:MinimumMember 2018-03-31 0001630113 srt:MaximumMember 2018-03-31 0001630113 srt:MaximumMember 2017-03-31 0001630113 srt:MaximumMember 2016-03-31 0001630113 2020-08-14 0001630113 us-gaap:PreferredStockMember 2019-03-31 0001630113 BTCY:CommonStockAndExchangeableCommonSharesMember 2019-03-31 0001630113 BTCY:SharesToBeIssuedMember 2019-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001630113 us-gaap:RetainedEarningsMember 2019-03-31 0001630113 BTCY:PromissoryNoteMember 2020-04-01 2020-06-30 0001630113 BTCY:PromissoryNoteMember us-gaap:InterestExpenseMember 2019-04-01 2019-06-30 0001630113 BTCY:ExchangeAgreementMember 2016-02-01 2016-02-02 0001630113 BTCY:ExchangeAgreementMember us-gaap:OptionMember 2016-02-01 2016-02-02 0001630113 BTCY:ExchangeAgreementMember us-gaap:WarrantMember 2016-02-01 2016-02-02 0001630113 BTCY:ExchangeAgreementMember BTCY:AdvisorWarrantMember 2016-02-01 2016-02-02 0001630113 BTCY:ExchangeAgreementMember BTCY:ElevenPercentageSecuredConvertiblePromissoryNotesMember 2016-02-01 2016-02-02 0001630113 BTCY:ConsultantsAndAdvisorsMember 2018-04-01 2019-03-31 0001630113 BTCY:ConsultantsAndAdvisorsMember 2019-03-31 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember 2015-12-31 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember 2016-04-01 2017-03-31 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember 2017-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2017-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember srt:MinimumMember 2018-04-01 2019-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember srt:MaximumMember 2018-04-01 2019-03-31 0001630113 2020-06-30 0001630113 BTCY:PromissoryNoteMember 2020-06-30 0001630113 BTCY:PromissoryNoteMember us-gaap:InterestExpenseMember 2020-04-01 2020-06-30 0001630113 us-gaap:MeasurementInputExpectedDividendRateMember 2020-06-30 0001630113 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2020-06-30 0001630113 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2020-06-30 0001630113 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2020-06-30 0001630113 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2020-06-30 0001630113 srt:MinimumMember 2020-06-30 0001630113 srt:MaximumMember 2020-06-30 0001630113 BTCY:RegisteredOfferingMember 2019-05-01 2019-05-31 0001630113 BTCY:AdvisorAndConsultantMember 2019-04-01 2020-03-31 0001630113 BTCY:AdvisorAndConsultantMember us-gaap:WarrantMember srt:MaximumMember 2019-04-01 2020-03-31 0001630113 BTCY:AdvisorAndConsultantMember us-gaap:WarrantMember srt:MaximumMember 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2018-04-01 2019-03-31 0001630113 BTCY:BrokerWarrantsMember 2018-10-01 2018-12-31 0001630113 BTCY:ConsultantWarrantsMember 2018-10-01 2018-12-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2018-10-01 2018-12-31 0001630113 BTCY:PrivatePlacementWarrantsMember 2018-10-01 2018-12-31 0001630113 2018-10-01 2018-12-31 0001630113 BTCY:BrokerWarrantsMember 2018-09-30 0001630113 BTCY:ConsultantWarrantsMember 2018-09-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2018-09-30 0001630113 BTCY:PrivatePlacementWarrantsMember 2018-09-30 0001630113 2018-09-30 0001630113 BTCY:BrokerWarrantsMember 2020-03-31 0001630113 BTCY:ConsultantWarrantsMember 2020-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2020-03-31 0001630113 BTCY:PrivatePlacementWarrantsMember 2020-03-31 0001630113 BTCY:ConsultantWarrantsMember srt:MinimumMember 2020-06-30 0001630113 BTCY:ConsultantWarrantsMember srt:MaximumMember 2020-06-30 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember 2018-04-01 2019-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2020-03-31 0001630113 2017-04-01 2018-03-31 0001630113 srt:MinimumMember 2015-04-01 2016-03-31 0001630113 srt:MaximumMember 2015-04-01 2016-03-31 0001630113 BTCY:PromissoryNoteMember 2020-03-31 0001630113 us-gaap:PreferredStockMember 2020-03-31 0001630113 BTCY:SharesToBeIssuedMember 2020-03-31 0001630113 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001630113 us-gaap:RetainedEarningsMember 2020-03-31 0001630113 2018-04-01 2019-03-31 0001630113 2020-01-01 2020-03-31 0001630113 2019-12-31 0001630113 BTCY:PromissoryNoteMember 2019-04-01 2019-06-30 0001630113 BTCY:AdvisorAndConsultantMember us-gaap:WarrantMember srt:MinimumMember 2019-04-01 2020-03-31 0001630113 BTCY:AdvisorAndConsultantMember us-gaap:WarrantMember srt:MinimumMember 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanOneMember 2019-04-01 2020-03-31 0001630113 BTCY:BrokerWarrantsMember 2019-04-01 2019-06-30 0001630113 BTCY:BrokerWarrantsMember 2020-01-01 2020-03-31 0001630113 BTCY:ConsultantWarrantsMember 2019-04-01 2019-06-30 0001630113 BTCY:ConsultantWarrantsMember 2020-01-01 2020-03-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2019-04-01 2019-06-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2020-01-01 2020-03-31 0001630113 BTCY:PrivatePlacementWarrantsMember 2019-04-01 2019-06-30 0001630113 BTCY:PrivatePlacementWarrantsMember 2020-01-01 2020-03-31 0001630113 2019-04-01 2019-06-30 0001630113 BTCY:BrokerWarrantsMember 2019-12-31 0001630113 BTCY:ConsultantWarrantsMember 2019-12-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2019-12-31 0001630113 BTCY:PrivatePlacementWarrantsMember 2019-12-31 0001630113 us-gaap:SeriesAPreferredStockMember 2020-06-30 0001630113 BTCY:BrokerWarrantsMember 2019-06-30 0001630113 BTCY:ConsultantWarrantsMember 2019-06-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2019-06-30 0001630113 BTCY:PrivatePlacementWarrantsMember 2019-06-30 0001630113 2019-06-30 0001630113 BTCY:BrokerWarrantsMember 2019-07-01 2019-09-30 0001630113 BTCY:ConsultantWarrantsMember 2019-07-01 2019-09-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2019-07-01 2019-09-30 0001630113 BTCY:PrivatePlacementWarrantsMember 2019-07-01 2019-09-30 0001630113 2019-07-01 2019-09-30 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2019-04-01 2019-06-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2018-06-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2019-06-30 0001630113 2019-09-30 0001630113 BTCY:PromissoryNotesMember 2020-01-05 2020-01-09 0001630113 BTCY:COVIDNineteenMember 2019-04-01 2020-03-31 0001630113 BTCY:PromissoryNotesMember 2020-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2019-12-18 2019-12-19 0001630113 us-gaap:SeriesAPreferredStockMember 2020-01-08 2020-01-09 0001630113 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2020-04-01 2020-06-30 0001630113 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2020-04-01 2020-06-30 0001630113 us-gaap:SeriesAPreferredStockMember BTCY:SecuritiesPurchaseAgreementMember 2019-12-01 2019-12-19 0001630113 us-gaap:CommonStockMember BTCY:InvestorsMember 2019-04-01 2020-03-31 0001630113 us-gaap:CommonStockMember BTCY:ConsultantsAdvisorsAndOtherServiceProvidersMember 2019-04-01 2020-03-31 0001630113 BTCY:ConsultantsAndAdvisorsMember 2020-03-31 0001630113 BTCY:TwoThousandAndFifteenEquityIncentivePlanMember BTCY:PreExchangeAgreementMember 2015-01-01 2015-12-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanOneMember srt:MinimumMember 2019-04-01 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanOneMember srt:MaximumMember 2019-04-01 2020-03-31 0001630113 BTCY:PromissoryNoteAndShortTermLoansMember 2020-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001630113 BTCY:PromissoryNotesMember 2019-10-01 2019-10-31 0001630113 us-gaap:SeriesAPreferredStockMember 2019-12-19 0001630113 us-gaap:SeriesAPreferredStockMember 2020-01-09 0001630113 BTCY:RegisteredOfferingMember 2019-07-01 2019-07-31 0001630113 BTCY:IssuanceOfCommonSharesMember 2018-04-01 2019-03-31 0001630113 BTCY:IssuanceOfCommonSharesMember BTCY:VariousConsultantsAndAdvisorsMember 2018-04-01 2019-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2018-03-01 2018-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember srt:MinimumMember 2018-03-01 2018-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember srt:MaximumMember 2018-03-01 2018-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanOneMember BTCY:IssueEmployeeOptionsMember 2019-04-01 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanOneMember 2020-03-31 0001630113 2019-04-02 0001630113 BTCY:LessThanOneYearMember 2020-06-30 0001630113 BTCY:BeyondOneYearMember 2020-06-30 0001630113 us-gaap:SeriesAPreferredStockMember 2019-12-01 2019-12-31 0001630113 BTCY:PromissoryNoteMember srt:MaximumMember 2020-06-30 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanOneMember BTCY:IssueEmployeeOptionsMember srt:MinimumMember 2019-04-01 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanOneMember BTCY:IssueEmployeeOptionsMember srt:MaximumMember 2019-04-01 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanOneMember BTCY:IssueEmployeeOptionsMember 2020-03-31 0001630113 BTCY:PaymentProtectionProgramMember 2020-05-01 2020-05-31 0001630113 BTCY:PaymentProtectionProgramMember 2020-05-31 0001630113 us-gaap:SeriesAPreferredStockMember 2020-03-31 0001630113 us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0001630113 us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0001630113 us-gaap:PreferredStockMember 2020-06-30 0001630113 us-gaap:PreferredStockMember 2019-06-30 0001630113 BTCY:SharesToBeIssuedMember 2020-04-01 2020-06-30 0001630113 BTCY:SharesToBeIssuedMember 2019-04-01 2019-06-30 0001630113 BTCY:SharesToBeIssuedMember 2020-06-30 0001630113 BTCY:SharesToBeIssuedMember 2019-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001630113 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001630113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001630113 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001630113 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001630113 us-gaap:RetainedEarningsMember 2020-06-30 0001630113 us-gaap:RetainedEarningsMember 2019-06-30 0001630113 2019-03-31 0001630113 BTCY:CommonStockAndExchangeableCommonSharesMember 2019-06-30 0001630113 BTCY:CommonStockAndExchangeableCommonSharesMember 2020-06-30 0001630113 BTCY:CommonStockAndExchangeableCommonSharesMember 2020-03-31 0001630113 BTCY:CommonStockAndExchangeableCommonSharesMember 2019-04-01 2019-06-30 0001630113 BTCY:CommonStockAndExchangeableCommonSharesMember 2020-04-01 2020-06-30 0001630113 BTCY:PromissoryNotesMember 2019-12-01 2019-12-31 0001630113 us-gaap:SeriesAPreferredStockMember 2020-05-22 0001630113 2019-04-01 2020-03-31 0001630113 us-gaap:SeriesAPreferredStockMember 2020-05-21 2020-05-22 0001630113 us-gaap:PreferredStockMember 2020-05-22 0001630113 us-gaap:PreferredStockMember 2020-05-21 2020-05-22 0001630113 BTCY:IssuanceOfCommonSharesMember 2020-04-01 2020-06-30 0001630113 us-gaap:CommonStockMember BTCY:InvestorsMember 2020-04-01 2020-06-30 0001630113 BTCY:IssuanceOfCommonSharesMember BTCY:AdvisorMember 2020-04-01 2020-06-30 0001630113 BTCY:AdvisorAndConsultantMember 2020-04-01 2020-06-30 0001630113 BTCY:AdvisorAndConsultantMember us-gaap:WarrantMember srt:MaximumMember 2020-04-01 2020-06-30 0001630113 BTCY:AdvisorAndConsultantMember us-gaap:WarrantMember srt:MinimumMember 2020-04-01 2020-06-30 0001630113 srt:OfficerMember 2020-06-30 0001630113 BTCY:DirectorofCompanyMember 2020-04-01 2020-06-30 0001630113 BTCY:AnotherDirectorMember 2020-04-01 2020-06-30 0001630113 BTCY:BrokerWarrantsMember 2019-10-01 2019-12-31 0001630113 BTCY:ConsultantWarrantsMember 2019-10-01 2019-12-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2019-10-01 2019-12-31 0001630113 BTCY:PrivatePlacementWarrantsMember 2019-10-01 2019-12-31 0001630113 2019-10-01 2019-12-31 0001630113 BTCY:BrokerWarrantsMember 2020-04-01 2020-06-30 0001630113 BTCY:ConsultantWarrantsMember 2020-04-01 2020-06-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2020-04-01 2020-06-30 0001630113 BTCY:BrokerWarrantsMember srt:MinimumMember 2020-06-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2020-06-30 0001630113 BTCY:ConsultantWarrantsMember BTCY:DirectorsandOfficersMember 2020-06-29 2020-06-30 0001630113 BTCY:BrokerWarrantsMember 2019-09-30 0001630113 BTCY:ConsultantWarrantsMember 2019-09-30 0001630113 BTCY:BrokerWarrantsMember 2020-06-30 0001630113 BTCY:ConsultantWarrantsMember 2020-06-30 0001630113 BTCY:PrivatePlacementWarrantsMember 2020-06-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2020-06-30 0001630113 us-gaap:SubsequentEventMember us-gaap:SubscriptionArrangementMember BTCY:AccreditedInvestorsMember 2020-07-30 2020-07-31 0001630113 us-gaap:SubsequentEventMember us-gaap:SubscriptionArrangementMember BTCY:AccreditedInvestorsMember 2020-07-31 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember 2019-09-30 0001630113 BTCY:CaptionedProgramMember BTCY:USSmallBusinessAdministrationMember 2020-04-27 2020-04-30 0001630113 BTCY:CaptionedProgramMember BTCY:USSmallBusinessAdministrationMember 2020-04-30 0001630113 us-gaap:SubsequentEventMember 2020-07-30 2020-07-31 0001630113 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001630113 BTCY:PrivatePlacementWarrantsMember 2019-09-30 0001630113 BTCY:BrokerWarrantsMember srt:MaximumMember 2020-06-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember srt:MinimumMember 2020-06-30 0001630113 BTCY:WarrantsIssuedOnConversionOfConvertibleNotesMember srt:MaximumMember 2020-06-30 0001630113 BTCY:PrivatePlacementWarrantsMember srt:MinimumMember 2020-06-30 0001630113 BTCY:PrivatePlacementWarrantsMember srt:MaximumMember 2020-06-30 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2020-03-01 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember BTCY:BoardOfDirectorMember 2020-03-01 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember srt:MinimumMember 2020-03-01 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember srt:MaximumMember 2020-03-01 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember 2020-01-01 2020-12-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember srt:MinimumMember 2020-01-01 2020-12-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanMember srt:MaximumMember 2020-01-01 2020-12-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanOneMember BTCY:IssueEmployeeOptionsMember srt:MinimumMember 2020-03-31 0001630113 BTCY:TwoThousandAndSixteenEquityIncentivePlanOneMember BTCY:IssueEmployeeOptionsMember srt:MaximumMember 2020-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure BIOTRICITY INC. 0001630113 2020-06-30 false --03-31 false Non-accelerated Filer true Q1 2021 33647809 85720 236106 137074 159402 1658829 1124070 33000 2004416 1389102 36382 37173 169490 22194 44015397 45676541 -857307 -961518 -46364364 -49758760 2004416 1389102 486187 663687 36768299 35397458 -0.900 -0.060 3629116 2266015 423883 213496 169490 3205233 30052 37456 184637 2052519 835619 1063754 260436 176414 191462 150586 14003 -53974 308379 45113 19955 1063754 251625 232519 232519 1451261 2408713 338889 367647 1600515 2408713 13376947 47585 6000 6000 525023 47585 972950 178750 6100 22585 100 631000 160000 25000 83500 178750 -153750 350415 30835 791000 791000 1063754 251625 169490 -147296 217878 1210259 350415 31 791 -65851 -17324 -10717 -35291 150386 15013 179533 178530 -3157179 -2089601 -3499395 -2112187 949848 64875 47750 63647 Yes Yes false 451898 327000 264472 214884 213030 213030 5004809 6374244 3803021 3821003 57055 -3000393 1 35362 91498 33889916 -754963 -35039495 -4985151 9 169490 44045397 -857307 -46364364 -3265396 9 1 22194 309375 45676539 34296458 -962308 -777549 -49758758 -37129096 -1777681 35415 37173 36382 1 35361656 62085 7831 178750 8046 1 25000 412500 35415060 37172831 36381831 949848 64875 1 1 8 0.001 0.001 0.001 0.001 10000000 10000000 20000 20000 1 1 8045 8045 7830 7830 7830 215 115 1 1 8045 7830 100000 6000000 6000000 6100000 100000 2068302 1871389 14003 666129 169490 13980 23 22194 1144733 982350 0.001 0.001 125000000 125000000 32593769 33384769 -2393110 -1328375 1573987 1329802 -819123 1427 10-Q 2696943 719388 916301 3094820 1253000 1830 1830 1945 1830000 1570900 1200000 370900 427617 715842 1830000 1945000 100000 0.10 0.12 0.010 0.12 0.0375 92416 1144733 982340 41749 1083952 -204142 60781 12 0.62 1.14 1.174 1.983 0.650 1.367 0.90 1.197 shares of its common stock in exchange for each common share 1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1 1.197 shares of the common stock of Biotricity for each Warrant, with an inverse adjustment to the exercise price of the Warrants to reflect the exchange ratio of approximately 1.197:1 1.197 shares of the common stock of Biotricity for each Advisor Warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1 6000 1.197:1 1.197:1 1.197:1 The outstanding 11% secured convertible promissory notes of the Company were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of Biotricity at a 25% discount to purchase price per share in Biotricity's next offering. 0.25 28565 6000000 28565 The shares are convertible into common stock of the Company at a conversion price equal to the greater of $0.001 or a 15% discount to the 5-day volume weighted price at the time of conversion. The conversion rights commence 24 months after issuance, but conversion is limited to 5% of the aggregate purchase price of the holder on a monthly basis thereafter. Alternatively, the shares are convertible into common stock at a 15% discount to any qualified future common stock financing conducted by the Company. The Company may redeem the shares after 1 year for 110% of the purchase price plus accrued dividends. The preferred stock bears a dividend rate of 12% per annum 164590 164590 3390503 3390503 164590 2832500 50835 62838 0.81 0.48 7.59 0.78 2.00 3.00 3.00 849601 1021430 50000 467411 277053 45113 1600515 P2Y P3Y P3Y P1Y P3Y P3Y P3Y P10Y P2Y P6Y P3Y P10Y 0.0213 0.0281 0.0198 0.0281 0.0045 0.0147 0.0227 0.0254 0.0004 0.0107 0.0022 0.0046 0.0075 0.00692 0.00259 0.0046 0.0075 0.588 0.6 0.88 0.48 4.15 0.74 0.76 1.367 0.974 .970 0.974 .28 0.970 1.367 0.978 1.411 1.322 1.143 1.322 1.254 1.3190 1.3190 1.254 1.322 3000000 3750000 137500 137500 0.0001 3.2306 3.1436 0.0001 0.0001 3.2306 3.1069 3.2306 3.1069 2.5070 35907 2257953 Options were exercised by those employees who met the vesting conditions; 50% of the grants either vest immediately or at the time of U.S. Food and Drug Administration (FDA) filing date and 50% will vest upon Liquidity Trigger. Liquidity Trigger means the day on which the board of directors resolve in favour of i) the Company is able to raise a certain level of financing; ii) a reverse takeover transaction that results in the Company being a reporting issuer, and iii) initial public offering that results in the Company being a reporting issuer. The maximum number of shares of stock that may be issued under the Plan shall be equal to 3,750,000 shares; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 15% of the Company's outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase. 1811847 1811847 2499998 175000 35000 3591000 88100 88100 1811847 1437500 1400000 367647 0.7763 2.20 2.24 2.24 0.0001 1.8096 0.7763 0.259 0.692 88100 P3Y P1Y P2Y P2Y9M3D P9Y6M3D P2Y9M3D P9Y6M3D P2Y9M3D P9Y6M3D P10Y P10Y P3Y P2Y9M3D P9Y6M3D 0 6269403 4952376 384152 5240371 321314 1177157 2734530 1163722 669972 2734530 1163722 321314 321314 703722 1020805 2734530 2734530 1163722 1163722 4923288 5332893 321314 1097055 -2734530 1163722 5316621 321314 2049837 2734530 1163722 6309823 321314 2090257 2734530 1163722 321314 1255907 2734530 1163722 5475473 5776823 5396723 1823020 321314 1557257 321314 2034837 12163722 2734530 1163722 986510 62838 62838 184976 31250 184916 31250 126250 126250 95750 5000 98750 5000 10000 35000 35000 50000 341268 65000 393333 341268 65000 393333 50000 50000 58330 83750 58330 83750 311350 568000 568000 2020-04-30 2023-06-30 2022-03-31 2022-04-30 2020-03-31 2022-11-30 2020-04-30 2020-07-31 638806 164590 4147498 4393610 200497 4147498 4418019 4147498 6205457 6229866 35907 2.723 2.723 0.0001 0.0001 0.0001 0.0001 2.00 2.00 1.24 7.59 2.58 .0001 0.978 1.4599 1.01 1.05 1.125 1.4110 0.94 0 0 0.00 0.0000 0.0000 0.0500 0.0000 0.0500 0.2000 0.0000 150500 135052 236044 308755 386544 443807 The Note has a two-year term, bears interest at the rate of 1.0% per annum, and may be prepaid at any time without payment of any premium. No payments of principal or interest are due during the six-month period beginning on the date of the Note (the "Deferral Period"). 178750 25000 32593769 33384769 3788062 3788062 -204142 1521689 1521689 45113 19955 45113 19955 232519 338889 232519 338889 -105001 -22586 -105001 -22586 -3394394 -2089601 -2089601 -41749 -41749 112509 P0Y0M4D P1Y 48115 50148 -7359 215000 215000 215 257927 180000 0.10 173175 55299 198352 -192093 230118 230118 The following table summarizes the stock option activities of the Company:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of options</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted average exercise price ($)</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">3,591,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">0.0001</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(3,390,503</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.0001</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of December 31, 2015</td> <td> </td> <td> </td> <td style="text-align: right">200,497</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.0001</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cancelled during 2016</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(35,907</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.0001</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of March 31, 2018</td> <td> </td> <td> </td> <td style="text-align: right">164,590</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.0001</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(164,590</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.0001</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of June 30, 2020 and March 31, 2019</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table> The following table summarizes the stock option activities of the Company:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of options</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted average exercise price ($)</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">4,147,498</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">3.2306</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of June 30 and March 31, 2018</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">4,147,498</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">3.2306</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">270,521</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.8096</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Outstanding as of June 30, 2019 and March 31, 2019</td> <td> </td> <td> </td> <td style="text-align: right">4,418,019</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.1436</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">88,100</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.7763</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(112,509</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2.723</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of March 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right">4,393,610</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.1069</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">1,811,847</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.0513</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of June 30 and March 31, 2018</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">6,205,457</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2.5070</td> <td> </td></tr> </table> -3157179 -2089601 237215 1570990 -96913 1315799 379881 345929 1094072 1012630 P1Y P1Y P30Y 15000 638806 0.75 Use of Estimates   The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of derivatives, convertible promissory notes, stock options, and assumptions used in the going concern assessment. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known. Earnings (Loss) Per Share   The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at June 30, 2020 and 2018. Fair Value of Financial Instruments   ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:   ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.   ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.   ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.   In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.   Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes, and accounts payable and accrued liabilities. The Company’s cash and derivative liabilities, which are carried at fair values, are classified as a Level 1 and Level 2, respectively. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk. Leases   On April 1, 2019, the Company adopted Accounting Standards Codification Topic 842, “Leases” (“ASC 842”) to replace existing lease accounting guidance. This pronouncement is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases will continue to be recognized in a manner similar to previous accounting guidance. The Company adopted ASC 842 utilizing the transition practical expedient added by the Financial Accounting Standards Board (“FASB”), which eliminates the requirement that entities apply the new lease standard to the comparative periods presented in the year of adoption.   The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the consolidated balance sheet.   Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in our consolidated statement of income. The Company determines the lease term by agreement with lessor. As our lease do not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion. Government loan   For loans received from federal government that contains certain operating conditions and with terms over twelve month time, the Company records those loans as long term liabilities. Convertible Notes Payable and Derivative Instruments   The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. Recently Issued Accounting Pronouncements    In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019.  The Company adopted the new guidance effectively on April 1, 2020. The Company identified and updated existing internal controls and procedures to ensure compliance with the new guidance, but such modifications were not deemed to be material to the Company's overall system of internal control. While the adoption of this ASU did not have a material impact on the Company's consolidated financial statements, it required changes to the Company's process of estimating expected credit losses on trade receivables.    In July 2019, the FASB issued ASU 2019-07, Codification Updates to SEC Sections. This ASU amends various SEC paragraphs pursuant to the issuance of SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization. One of the changes in the ASU requires a presentation of changes in stockholders’ equity in the form of a reconciliation, either as a separate financial statement or in the notes to the financial statements, for the current and comparative year-to-date interim periods. The Company presented changes in stockholders' equity as separate financial statements for the current and comparative year-to-date interim periods beginning on April 1, 2019. The additional elements of the ASU did not have a material impact on the Company's consolidated financial statements.   In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. On June 16, 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis. That model replaces the probable, incurred loss model for those assets. Through the amendments in that Update, the Board added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. The amendments apply to all reporting entities within the scope of the affected accounting guidance. ASU 2019-11 is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements and related disclosures.   In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impacts of the provisions of ASU 2019-12 on its financial condition, results of operations, and cash flows.   In March 2020, the FASB issued ASU No. 2030-20 Codification Improvements to Financial Instruments, An Amendment of the FASB Accounting Standards Codification: a)in ASU No. 2016-01, b) in Subtopic 820-10, c) for depository and lending institutions clarification in disclosure requirements, d) in Subtopic 470-50, e) in Subtopic 820-10, f) Interaction of Topic 842 and Topic 326, g) Interaction of the guidance in Topic 326 and Subtopic 860-20.The amendments in this Update represent changes to clarify or improve the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. For public business entities updates under the following paragraphs: a), b), d) and e) are effective upon issuance of this final update. The effective date for c) is for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company does not expect that the new guidance will significantly impact its consolidated financial statements.   The Company continues to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems. 96914 100000 1152001 1152001 The loan has a term of 30 years and an interest rate of 3.75%, without the requirement for payment in its first 12 months. 791000 1063754 1570900 179540 413236 221143 1. NATURE OF OPERATIONS   Biotricity Inc. (formerly MetaSolutions, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over.   Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted in building technology that enables access to this market through the development of a tangible product. 2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the Securities and Exchange Commission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements and should be read in conjunction with Biotricity’s audited financial statements for the years ended March 31, 2020 and 2019 and their accompanying notes.   The accompanying unaudited condensed consolidated financial statements are expressed in United States dollars (“USD”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the three months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending March 31, 2021. The Company’s fiscal year-end is March 31.   The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Significant intercompany accounts and transactions have been eliminated.   Liquidity and Basis of Presentation   The Company is an emerging growth entity that is in the early stages of commercializing its first product and is concurrently in development mode, operating a research and development program in order to develop, obtain regulatory approval for, and commercialize other proposed products. The Company has incurred recurring losses from operations, and as at June 30, 2020, has an accumulated deficit of $49,758,758 and a working capital deficiency of $2,696,943. The Company launched its first commercial sales program as part of a limited market release, during the year ended March 31, 2019, using an experienced professional in-house sales team. A full market release ensued during the year ended March 31, 2020. Management anticipates the Company will attain profitable status and improve its liquidity through continued business development and after additional equity or debt capitalization of the Company. The Company has developed and continues to pursue sources of funding that management believes if successful would be sufficient to support the Company’s operating plan and alleviate any substantial doubt as to its ability to meet its obligations at least for a period of one year from the date of these consolidated financial statements. The Company raised $3,094,820 in promissory notes and short term loans during the year ended March 31, 2020. Starting in December 2019, the Company has issued 8,045 Series A preferred shares, issuing 6,100 of these for cash proceeds of $6,100,000 and 1,945 of these were issued on conversion of $1,945,000 of promissory notes and accrued interest. The Company has also raised government funding provided for economic support during COVID-19, including $1,570,900 raised during the three months ended June 30, 2020 (see Note 6 – Federally Guaranteed Loans).   The Company’s operating plan is predicated on a variety of assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue to raise additional financing and the state of the general economic environment in which the Company operates. There can be no assurance that these assumptions will prove to be accurate in all material respects, or that the Company will be able to successfully execute its operating plan. In the absence of additional appropriate financing, the Company may have to modify its operating plan or slow down the pace of development and commercialization of its proposed products. 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Use of Estimates   The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of derivatives, convertible promissory notes, stock options, and assumptions used in the going concern assessment. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.   Earnings (Loss) Per Share   The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at June 30, 2020 and 2018.   Fair Value of Financial Instruments   ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:   ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.   ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.   ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.   In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.   Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes, and accounts payable and accrued liabilities. The Company’s cash and derivative liabilities, which are carried at fair values, are classified as a Level 1 and Level 2, respectively. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.   Leases   On April 1, 2019, the Company adopted Accounting Standards Codification Topic 842, “Leases” (“ASC 842”) to replace existing lease accounting guidance. This pronouncement is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases will continue to be recognized in a manner similar to previous accounting guidance. The Company adopted ASC 842 utilizing the transition practical expedient added by the Financial Accounting Standards Board (“FASB”), which eliminates the requirement that entities apply the new lease standard to the comparative periods presented in the year of adoption.   The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the consolidated balance sheet.   Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in our consolidated statement of income. The Company determines the lease term by agreement with lessor. As our lease do not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion.   Government loan   For loans received from federal government that contains certain operating conditions and with terms over twelve month time, the Company records those loans as long term liabilities.   Convertible Notes Payable and Derivative Instruments   The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.   Recently Issued Accounting Pronouncements    In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019.  The Company adopted the new guidance effectively on April 1, 2020. The Company identified and updated existing internal controls and procedures to ensure compliance with the new guidance, but such modifications were not deemed to be material to the Company's overall system of internal control. While the adoption of this ASU did not have a material impact on the Company's consolidated financial statements, it required changes to the Company's process of estimating expected credit losses on trade receivables.   In July 2019, the FASB issued ASU 2019-07, Codification Updates to SEC Sections. This ASU amends various SEC paragraphs pursuant to the issuance of SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization. One of the changes in the ASU requires a presentation of changes in stockholders’ equity in the form of a reconciliation, either as a separate financial statement or in the notes to the financial statements, for the current and comparative year-to-date interim periods. The Company presented changes in stockholders' equity as separate financial statements for the current and comparative year-to-date interim periods beginning on April 1, 2019. The additional elements of the ASU did not have a material impact on the Company's consolidated financial statements.   In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. On June 16, 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis. That model replaces the probable, incurred loss model for those assets. Through the amendments in that Update, the Board added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. The amendments apply to all reporting entities within the scope of the affected accounting guidance. ASU 2019-11 is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements and related disclosures.   In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impacts of the provisions of ASU 2019-12 on its financial condition, results of operations, and cash flows.   In March 2020, the FASB issued ASU No. 2030-20 Codification Improvements to Financial Instruments, An Amendment of the FASB Accounting Standards Codification: a)in ASU No. 2016-01, b) in Subtopic 820-10, c) for depository and lending institutions clarification in disclosure requirements, d) in Subtopic 470-50, e) in Subtopic 820-10, f) Interaction of Topic 842 and Topic 326, g) Interaction of the guidance in Topic 326 and Subtopic 860-20.The amendments in this Update represent changes to clarify or improve the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. For public business entities updates under the following paragraphs: a), b), d) and e) are effective upon issuance of this final update. The effective date for c) is for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company does not expect that the new guidance will significantly impact its consolidated financial statements.   The Company continues to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems. 4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As at June 30, 2020 $</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As at March 31, 2020 $</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%">Accounts payable</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">1,012,630</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">1,094,072</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Accrued liabilities</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">715,842</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">427,617</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,728,472</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,521,689</td> <td> </td></tr> </table>   Accounts payable as at June 30, 2020, and March 31, 2020 include 345,929 and 379,881, respectively, due to a shareholder and executive of the Company, primarily as a result of that individual’s role as an employee. These amounts are unsecured, non-interest bearing and payable on demand. 5. CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS   As at June 30, 2020, the Company had promissory notes outstanding of $719,388 (March 31, 2020 – $916,301). The promissory notes generally have a term of 1-year term, at interest rates of between 10%, and 12% with allowance for the Company to repay early, and the possibility to convert into equity on the basis of mutual consent. During the three months ended June 30, 2020, the Company made repayment in amount of 96,914. During the three months ended June 30, 2020, $100,000 from the outstanding notes was converted to preferred stock. (Note 7, Note 8)   As at June 30, 2020, the Company had short term loan outstanding of $1,152,001 (March 31, 2020 – $1,152,001).   Management has evaluated the terms of these notes in accordance with the guidance provided by ASC 470 and ASC 815 and concluded that there is no derivative or beneficial conversion feature attached to these notes.   General and administrative expenses include interest expense on the above notes of $37,456 and $30,052 for the three months ended June 30, 2020 and 2019, respectively. 6. FEDERALLY GUARANTEED LOANS   Economic Injury Disaster Loan (“EIDL”)   In April 2020, the Company received $370,900 from the U.S. Small Business Administration (SBA) under the captioned program. The loan has a term of 30 years and an interest rate of 3.75%, without the requirement for payment in its first 12 months. The Company may prepay the loan without penalty at will.   Payment Protection Program (“PPP”) Loan   In May 2020, Biotricity received loan proceeds of $1.2 million (the “PPP Loan”) under the Paycheck Protection Program established by the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (“SBA”). The unsecured PPL Loan is evidenced by a promissory note (the “Note”), between the Company and the lending financial institution (the “Lender”). The Note has a two-year term, bears interest at the rate of 1.0% per annum, and may be prepaid at any time without payment of any premium. No payments of principal or interest are due during the six-month period beginning on the date of the Note (the “Deferral Period”). The principal and accrued interest under the Note is forgivable under certain specified circumstances if the Company uses the PPP Loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and otherwise complies with PPP requirements. In order to obtain forgiveness of the PPP Loan, the Company must submit a request and provide satisfactory documentation regarding its compliance with applicable requirements. The Company must repay any unforgiven principal amount of the Note, with interest, on a monthly basis following the Deferral Period. The Company intends to use the PPP Loan for qualifying expenses, though no assurance is provided that the Company will obtain forgiveness of the PPP Loan in whole or in part. 7. DERIVATIVE LIABILITIES   On December 19, 2019 and January 9, 2020, the Company issued 7,830 Series A preferred shares; 6,000 of these were issued for cash proceeds of $6,000,000 and 1,830 of these were issued on conversion of $1,830,000 of promissory notes that had previously been issued for cash proceeds in October 2019.   On May 22, 2020, another 215 Series A preferred shares were issued as a result of a combined transaction that included the conversion of $100,000 in promissory notes (Note 5) and $15,000 in accrued interest for 115 preferred shares, as well as a purchase of 100 preferred shares for cash proceeds of $100,000.   The Company analyzed the compound features of variable conversion and redemption embedded in this instrument, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (“EITF”) Issue No. 00–19 and EITF 07–05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">$</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative liabilities as at March 31, 2019</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%">Derivative fair value at issuance</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">1,083,952</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Change in fair value of derivatives</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">60,781</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Derivative liabilities as at March 31, 2020</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,144,733</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative fair value at issuance</td> <td> </td> <td> </td> <td style="text-align: right">41,749</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Change in fair value of derivatives</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(204,142</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative liabilities as at June 30, 2020</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">982,340</td> <td> </td></tr> </table>   The lattice methodology was used to value the derivative components, using the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Assumptions</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%">Dividend yield</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">12</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk-free rate for term</td> <td> </td> <td> </td> <td style="text-align: right">0.62% – 1.14</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Volatility</td> <td> </td> <td> </td> <td style="text-align: right">117.4% – 198.3</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Remaining terms (Years)</td> <td> </td> <td> </td> <td style="text-align: right">0.01 – 1.0</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Stock price ($ per share)</td> <td> </td> <td> </td> <td style="text-align: right">$0.650 – $1.367</td> <td> </td></tr> </table> 8. STOCKHOLDERS’ DEFICIENCY   a) Authorized stock   As at June 30, 2020, the Company is authorized to issue 125,000,000 (March 31, 2020 – 125,000,000) shares of common stock ($0.001 par value) and 10,000,000 (March 31, 2020 – 10,000,000) shares of preferred stock ($0.001 par value).   At June 30, 2020, there were 33,384,769 (March 31, 2020 – 32,593,769) shares of common stock issued and outstanding. Additionally, at June 30, 2020, there were 3,788,062 (March 31, 2020 – 3,788,062) outstanding exchangeable shares. There is currently one share of the Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement.   b) Exchange Agreement   As initially described in Note 1 above, on February 2, 2016:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">The Company issued approximately 1.197 shares of its common stock in exchange for each common share of iMedical held by the iMedical shareholders who in general terms, are not residents of Canada (for the purposes of the Income Tax Act (Canada). Accordingly, the Company issued 13,376,947 shares;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">Shareholders of iMedical who in general terms, are Canadian residents (for the purposes of the Income Tax Act (Canada)) received approximately 1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of iMedical held. Accordingly, the Company issued 9,123,031 Exchangeable Shares;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">Each outstanding option to purchase common shares in iMedical (whether vested or unvested) was exchanged, without any further action or consideration on the part of the holder of such option, for approximately 1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">Each outstanding warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each warrant, with an inverse adjustment to the exercise price of the warrants to reflect the exchange ratio of approximately 1.197:1</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"> </td> <td style="width: 24px; text-align: justify">●</td> <td style="text-align: justify">Each outstanding advisor warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each advisor warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1; and</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">●</td> <td style="text-align: justify">The outstanding 11% secured convertible promissory notes of iMedical were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of the Company at a 25% discount to purchase price per share in Biotricity’s next offering.</td></tr> </table>   Issuance of common stock, exchangeable shares and cancellation of shares in connection with the reverse takeover transaction as explained above represents recapitalization of capital retroactively adjusting the accounting acquirer’s legal capital to reflect the legal capital of the accounting acquiree.   c) Share issuances   Share issuances during the year ended March 31, 2020   On December 19, 2019, the Company issued 6,000 shares of Series A preferred stock in a private placement for gross proceeds of $6,000,000 (Note 7). The shares are convertible into common stock of the Company at a conversion price equal to the greater of $0.001 or a 15% discount to the 5-day volume weighted price at the time of conversion. The conversion rights commence 24 months after issuance, but conversion is limited to 5% of the aggregate purchase price of the holder on a monthly basis thereafter. Alternatively, the shares are convertible into common stock at a 15% discount to any qualified future common stock financing conducted by the Company. The Company may redeem the shares after 1 year for 110% of the purchase price plus accrued dividends. The preferred stock bears a dividend rate of 12% per annum. On January 9, 2020, the Company issued a further 1,830 of Series A preferred stock with same terms on conversion of $1,830,000 of promissory notes that had previously been issued for cash proceeds in 2019 (see Note 5). During the year ended March 31, 2020, the Company accrued dividends in amount of $257,927 and made a payment in amount of $180,000.   In May and July 2019, the Company issued 47,585 shares of common stock under a registered offering outstanding in the previous fiscal year, which raised proceeds of $28,565.   During the year ended March 31, 2019, the Company issued a total of 972,950 shares of common stock and recognized its obligations to issue a total of 178,750 shares of common stock to various consultants and advisors, with a cumulative fair value of $666,129 and $169,490, respectively, or $835,619 in total; these costs were recognized as general and administrative and research and development expenses, as applicable, in the statement of operations, with corresponding credit to common stock, shares to be issued, and additional paid-in-capital, respectively.   During the year ended March 31, 2020, the Company also issued an aggregate of 525,023 shares of its common stock to investors as part of the one-for-one exchange of previously issued exchangeable shares into the Company’s Common Stock, which is a non-cash transaction. No options or warrants were exercised during this period.   Share issuances during the three months ended June 30, 2020   During the three months ended June 30, 2020, the Company issued an aggregate of 160,000 shares pursuant to obligations existing as at March 31, 2020. The Company also issued a further 631,000 shares of its common stock pursuant to obligations to issue these, the fair value of which were recognized during the three months ended June 30, 2020. Total fair value of the total 791,000 common shares, in amount of $1,063,754, was determined by using the market date price on the date of issuance. The Company recorded the fair value of the common shares issued in general and administrative expenses and research and development expenses with corresponding credit to common stock and additional paid in capital.   d) Shares to be issued   As of June 30, 2020, the Company recognized its contractual obligations to issue a total of 25,000 shares of common stock to an advisor. The fair value of these shares amounted to $22,194 and has been expensed to general and administrative and research and development expenses in the consolidated statements of operations, with a corresponding credit to additional paid-in-capital. The fair value of these shares was determined by using the market price of the common stock as at the date of issuance.   As of March 31, 2020, the Company had recognized its contractual obligations to issue a total of 178,750 shares of common stock to consultants, advisors and other service providers, (as explained in paragraph c, above). The fair value of these shares amounted to $169,490 and has been expensed to general and administrative and research and development expenses in the consolidated statements of operations, with a corresponding credit to additional paid-in-capital. The fair value of these shares was determined by using the market price of the common stock as at the date of issuance.   e) Warrant issuances and exercises   Warrant issuances during the year ended March 31, 2020   During the year ended March 31, 2020, the Company issued 1,021,430 warrants, respectively, as compensation for advisor and consultant services and certain promissory noteholders, which were fair valued at $277,053. Warrants issued to advisors and consultants were expensed in general and administrative expenses and amounted to $184,637, for the year ended March 31, 2020. Warrants issued to promissory notes holders were credited to additional paid-in capital in amount of $92,416. Their fair value has been estimated using a multi-nomial lattice model with an expected life of 2 to 3 years, risk free rates of 0.22% to 1.71%, stock price of $0.52 to $0.974 and expected volatility of 114.3% to 132.2%.   Warrant issuances during the three months ended June 30, 2020   During the three months ended June 30, 2020, the Company issued 50,000 warrants as compensation for advisor and consultant services, which were fair valued at $45,113 and expensed in general and administrative expenses, with a corresponding credit to additional paid in capital. Their fair value has been estimated using a multi-nomial lattice model with an expected life of 3 years, a risk free rate ranging from 0.259% to 0.692%, stock price in range of $0.970 to $1.367 and expected volatility of 125.4% to 131.90%   Warrant exercises   No warrants were exercised during the fiscal year ended March 31, 2020 and the three months ended June 30, 2020.   Warrant issuances, exercises and expirations or cancellations during the three months ended June 30, 2020 and preceding periods resulted in warrants outstanding at the end of those respective periods as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Broker Warrants</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Consultant Warrants</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Warrants Issued on Conversion of Convertible Notes</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Private Placement Warrants</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 27%">As at March 31, 2018</td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right">384,152</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right">669,972</td> <td style="width: 3%">*</td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 12%; text-align: right">2,734,530</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right">1,163,722</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right">4,952,376</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">(62,838</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(62,838</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(31,250</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(31,250</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">65,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">65,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>As at June 30, 2018</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">703,722</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">4,923,288</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">393,333</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">393,333</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>As at September 30 2018</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,097,055</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,316,621</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(126,250</td> <td>)**</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(126,250</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">50,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">50,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>As at December 31, 2018</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,020,805</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,240,371</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(184,916</td> <td>)**</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(184,916</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">341,268</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">341,268</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>As at March 31, 2019</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,177,157</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,396,723</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(5,000</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(5,000</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">83,750</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">83,750</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>As at June 30, 2019</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,255,907</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,475,473</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(10,000</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(10,000</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">311,350</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">311,350</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>As at September  30, 2019</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,557,257</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,776,823</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(35,000</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(35,000</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">568,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">568,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>As at December 31, 2019</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,090,257</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">6,309,823</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(98,750</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(98,750</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">58,330</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">58,330</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>As at March 31, 2020</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,049,837</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">6,269,403</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(65,000</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(911,510</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(986,510</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">50,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">50,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>As at June 30, 2020</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,034,837</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,823,020</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,332,893</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercise Price</td> <td> </td> <td>$</td> <td style="text-align: right">0.78-$3.00</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.48-$7.59</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expiration Date</td> <td> </td> <td> </td> <td style="text-align: center">March 2022 to July 2022</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">April 2020 to June 2023</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">March 2020 to November 2022</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">April 2020 to July 2020</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table>   *Consultant Warrants include warrants issued to directors and officers of the Company who were not members of the Company’s options plan at the time of issuance. As at June 30, 2020, Consultant Warrants include an aggregate of 638,806 warrants provided to an officer of the Company as compensation while he was not a member of any Company options plan.   f) Stock-based compensation   2015 Equity Incentive Plan   On March 30, 2015, iMedical approved Directors, Officers and Employees Stock Option Plan, under which it authorized and issued 3,000,000 options. This plan was established to enable the Company to attract and retain the services of highly qualified and experience directors, officers, employees and consultants and to give such person an interest in the success of the Company. As of March 31, 2018, and March 31, 2017, there were no outstanding vested options and 137,500 unvested options at an exercise price of $.0001 under this plan. These options now represent the right to purchase shares of the Company’s common stock using the same exchange ratio of approximately 1.1969:1, thus there were 164,590 (35,907 had been cancelled) adjusted unvested options as at March 31, 2018. These remaining 164,590 options were exercised during the year ended March 31, 2019. No other grants will be made under this plan.   The following table summarizes the stock option activities of the Company:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of options</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted average exercise price ($)</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">3,591,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">0.0001</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(3,390,503</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.0001</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of December 31, 2015</td> <td> </td> <td> </td> <td style="text-align: right">200,497</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.0001</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cancelled during 2016</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(35,907</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.0001</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of March 31, 2018</td> <td> </td> <td> </td> <td style="text-align: right">164,590</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.0001</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(164,590</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.0001</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of June 30, 2020 and March 31, 2019</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table>   The fair value of options at the issuance date were determined at $2,257,953 which were fully expensed during the twelve months ended December 31, 2015 based on vesting period and were included in general and administrative expenses with corresponding credit to additional paid-in-capital. During the twelve months ended December 31, 2015, 3,390,503 (2,832,500 Pre-exchange Agreement) options were exercised by those employees who met the vesting conditions; 50% of the grants either vest immediately or at the time of U.S. Food and Drug Administration (FDA) filing date and 50% will vest upon Liquidity Trigger. Liquidity Trigger means the day on which the board of directors resolve in favor of i) the Company is able to raise a certain level of financing; ii) a reverse takeover transaction that results in the Company being a reporting issuer, and iii) initial public offering that results in the Company being a reporting issuer.   2016 Equity Incentive Plan   On February 2, 2016, the Board of Directors of the Company approved 2016 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards.   The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan shall be equal to 3,750,000 shares; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 15% of the Company’s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase.   During July 2016, the Company granted an officer options to purchase an aggregate of 2,499,998 shares of common stock at an exercise price of $2.20 subject to a 3 year vesting period, with the fair value of the options being expensed over a 3 year period. Two additional employees were also granted 175,000 options to purchase shares of common stock at an exercise price of $2.24 with a 1 year vesting period, with the fair value of the options being expensed over a 1 year period. One additional employee was also granted 35,000 options to purchase shares of common stock at an exercise price of $2.24 with a 2 year vesting period, with the fair value of the options expensed over a 2 year period.   During the year ended March 31, 2018, an additional 1,437,500 stock options were granted with a weighted average remaining contractual life from 2.76 to 9.51 years.   During the year ended March 31, 2019, an additional 270,521 stock options were granted with a weighted average remaining contractual life from 2.76 to 9.51 years. During the year ended March 31, 2019, the Company recorded stock based compensation of $1,451,261 in connection with ESOP 2016 Plan under general and administrative expenses with corresponding credit to additional paid in capital.   Based on the 2016 Option Plan, the Company is authorized to issue employee options with a 10-year term. On March 31, 2020, the Company’s Board of Directors approved the amendment of certain prior options grants, issued to current employees, previously issued with a 3-year term, such that the respective options issued under these agreements would have their term extended to 10 years. The Company revalued these options use g a lattice model with an expected life of 10 years, risk free rates of 0.46% to 0.75%, stock price of $0.974 and expected volatility of 132.2%, in order to recognize the additional expense associated with the longer term and recognized a one-time charge of $1,600,515 in share-based compensation, with a corresponding adjustment to adjusted paid in capital.   During the year ended March 31, 2020, an additional 88,100 stock options were granted with a weighted average remaining contractual life from 2.76 to 9.51 years. The Company recorded stock-based compensation of $2,408,713 in connection with ESOP 2016 Plan under general and administrative expenses with corresponding credit to additional paid in capital.   During the three months ended June 30, 2020, the Company granted 1,811,847 options, including 1,400,000 options to an executive and director of the Company and an additional 367,647 options to another director. Their fair value, has been estimated using a multi-nomial lattice model with an expected life of up to 6 years, a risk free rate ranging from 0.259% to 0.692%, stock price in range of $0.970 to $1.367 and expected volatility of 125.4% to 131.90%.   The following table summarizes the stock option activities of the Company:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of options</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted average exercise price ($)</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%">Granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">4,147,498</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">3.2306</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of June 30 and March 31, 2018</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">4,147,498</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">3.2306</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">270,521</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.8096</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Exercised</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Outstanding as of June 30, 2019 and March 31, 2019</td> <td> </td> <td> </td> <td style="text-align: right">4,418,019</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.1436</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">88,100</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.7763</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(112,509</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2.723</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of March 31, 2020</td> <td> </td> <td> </td> <td style="text-align: right">4,393,610</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.1069</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">1,811,847</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.0513</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding as of June 30 and March 31, 2018</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">6,205,457</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2.5070</td> <td> </td></tr> </table>   During the three months ended June 30, 2020, the Company recorded stock-based compensation of $232,519, in connection with the 2016 equity incentive plan (June 30, 2019 – $338,889) under general and administrative expenses with a corresponding credit to additional paid in capital.   The fair value of each option granted is estimated at the time of grant using multi-nomial lattice model using the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017-2018</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2016-2017</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2015-2016</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Exercise price ($)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">1.24-7.59</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2.00 – 2.58</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">0.0001</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk free interest rate (%)</td> <td> </td> <td> </td> <td style="text-align: right">2.27 to 2.54</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.98-2.81</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.45 - 1.47</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.04 - 1.07</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected term (Years)</td> <td> </td> <td> </td> <td style="text-align: right">3</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1 - 3</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected volatility (%)</td> <td> </td> <td> </td> <td style="text-align: right">112.5 -141.10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">97.8-145.99</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">101 – 105</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">94</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected dividend yield (%)</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Fair value of option ($)</td> <td> </td> <td> </td> <td style="text-align: right">0.28</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.6</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.88</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.74</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected forfeiture (attrition) rate (%)</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.00 – 5.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5.00 - 20.00</td> <td> </td></tr> </table> 9. RELATED PARTY TRANSACTIONS AND BALANCES   The Company’s transactions with related parties were carried out on normal commercial terms and in the course of the Company’s business. Other than those disclosed elsewhere in the financial statements, related party transactions are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2"> Three Months Ended June 30, 2020</td> <td> </td> <td> </td> <td colspan="2"> Three Months Ended June 30, 2019</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Salary and allowance*</td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 18%; text-align: right">150,500</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 18%; text-align: right">135,052</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock based compensation**</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">236,044</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">308,755</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">386,544</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">443,807</td> <td> </td></tr> </table>   The above expenses were recorded under general and administrative expenses.   * Salary and allowance include salary, car allowance, vacation pay, bonus and other allowances paid or payable to key management of the Company.   ** Stock based compensation represent the fair value of the options, warrants and equity incentive plan for directors and key management of the Company. 10. LEASE   The Company has one operating lease primarily for office and administration.   The Company adopted ASC 842 – Leases using the modified retrospective cumulative catch-up approach beginning on April 1, 2019. Under this approach, the Company did not restate its comparative amounts and recognized a right-of-use asset equal to the present value of the future lease payments. The Company elected to apply the practical expedient to only transition contracts which were previously identified as leases and elected to not recognize right-of-use assets and lease obligations for leases of low value assets.   When measuring the lease obligations, the Company discounted lease payments using its incremental borrowing rate at April 1, 2019. The weighted-average-rate applied is 10%.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">Operating lease right-of-use asset - initial recognition</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">413,236</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Amortization </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(198,352</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Balance at June 30, 2020</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">214,884</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating lease obligation - initial recognition</td> <td> </td> <td> </td> <td style="text-align: right">413,236</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Repayment and interest accretion</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(192,093</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Balance at June 30, 2020</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">221,143</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Current portion of operating lease obligation</td> <td> </td> <td> </td> <td style="text-align: right">221,143</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Noncurrent portion of operating lease obligation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> </table>   The operating lease expense was $55,299 for the three months ended June 30, 2020 and $173,175 for the year ended March 31, 2020 and included in the General and administrative expenses.   The following table represents the contractual undiscounted cash flows for lease obligations as at June 30, 2020.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">Less than one year</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">230,118</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Beyond one year</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total undiscounted lease obligations</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">230,118</td> <td> </td></tr> </table> 11. CONTINGENCIES   There are no claims against the company that were assessed as significant, which were outstanding as at June 30, 2020 and, consequently, no provision for such has been recognized in the consolidated financial statements.  The following table represents the contractual undiscounted cash flows for lease obligations as at June 30, 2020.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">Less than one year</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">230,118</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Beyond one year</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total undiscounted lease obligations</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">230,118</td> <td> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">Operating lease right-of-use asset - initial recognition</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 18%; text-align: right">413,236</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Amortization </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(198,352</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Balance at June 30, 2020</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">214,884</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Operating lease obligation - initial recognition</td> <td> </td> <td> </td> <td style="text-align: right">413,236</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Repayment and interest accretion</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(192,093</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Balance at June 30, 2020</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">221,143</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Current portion of operating lease obligation</td> <td> </td> <td> </td> <td style="text-align: right">221,143</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Noncurrent portion of operating lease obligation</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td></td></tr> </table> Other than those disclosed elsewhere in the financial statements, related party transactions are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2"> Three Months Ended June 30, 2020</td> <td> </td> <td> </td> <td colspan="2"> Three Months Ended June 30, 2019</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%">Salary and allowance*</td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 18%; text-align: right">150,500</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 18%; text-align: right">135,052</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Stock based compensation**</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">236,044</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">308,755</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Total</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">386,544</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">443,807</td> <td> </td></tr> </table>   The above expenses were recorded under general and administrative expenses.   * Salary and allowance include salary, car allowance, vacation pay, bonus and other allowances paid or payable to key management of the Company.   ** Stock based compensation represent the fair value of the options, warrants and equity incentive plan for directors and key management of the Company. The fair value of each option granted is estimated at the time of grant using multi-nomial lattice model using the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2019</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017-2018</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2016-2017</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2015-2016</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%">Exercise price ($)</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">1.24-7.59</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">2.00 – 2.58</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">0.0001</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk free interest rate (%)</td> <td> </td> <td> </td> <td style="text-align: right">2.27 to 2.54</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.98-2.81</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.45 - 1.47</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.04 - 1.07</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected term (Years)</td> <td> </td> <td> </td> <td style="text-align: right">3</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1 - 3</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Expected volatility (%)</td> <td> </td> <td> </td> <td style="text-align: right">112.5 -141.10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">97.8-145.99</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">101 – 105</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">94</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected dividend yield (%)</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Fair value of option ($)</td> <td> </td> <td> </td> <td style="text-align: right">0.28</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.6</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.88</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.74</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expected forfeiture (attrition) rate (%)</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.00 – 5.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5.00 - 20.00</td> <td> </td></tr> </table> Warrant issuances, exercises and expirations or cancellations during the three months ended June 30, 2020 and preceding periods resulted in warrants outstanding at the end of those respective periods as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Broker Warrants</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Consultant Warrants</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Warrants Issued on Conversion of Convertible Notes</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Private Placement Warrants</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 27%">As at March 31, 2018</td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right">384,152</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right">669,972</td> <td style="width: 3%">*</td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 12%; text-align: right">2,734,530</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right">1,163,722</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 1%"> </td> <td style="border-bottom: black 1.5pt solid; width: 11%; text-align: right">4,952,376</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">(62,838</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(62,838</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(31,250</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(31,250</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">65,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">65,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>As at June 30, 2018</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">703,722</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">4,923,288</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">393,333</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">393,333</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>As at September 30 2018</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,097,055</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,316,621</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(126,250</td> <td>)**</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(126,250</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">50,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">50,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>As at December 31, 2018</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,020,805</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,240,371</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(184,916</td> <td>)**</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(184,916</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">341,268</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">341,268</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>As at March 31, 2019</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,177,157</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,396,723</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(5,000</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(5,000</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">83,750</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">83,750</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>As at June 30, 2019</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,255,907</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,475,473</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(10,000</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(10,000</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">311,350</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">311,350</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>As at September  30, 2019</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,557,257</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,776,823</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(35,000</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(35,000</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">568,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">568,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>As at December 31, 2019</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,090,257</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">6,309,823</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(98,750</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(98,750</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">58,330</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">58,330</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>As at March 31, 2020</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,049,837</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,734,530</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">6,269,403</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Less: Expired/cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(65,000</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(911,510</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(986,510</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Add: Issued</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">50,000</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">50,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>As at June 30, 2020</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,314</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,034,837</td> <td>*</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,823,020</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,163,722</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">5,332,893</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercise Price</td> <td> </td> <td>$</td> <td style="text-align: right">0.78-$3.00</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.48-$7.59</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.00</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expiration Date</td> <td> </td> <td> </td> <td style="text-align: center">March 2022 to July 2022</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">April 2020 to June 2023</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">March 2020 to November 2022</td> <td> </td> <td> </td> <td> </td> <td style="text-align: center">April 2020 to July 2020</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table>   *Consultant Warrants include warrants issued to directors and officers of the Company who were not members of the Company’s options plan at the time of issuance. As at June 30, 2020, Consultant Warrants include an aggregate of 638,806 warrants provided to an officer of the Company as compensation while he was not a member of any Company options plan. The lattice methodology was used to value the derivative components, using the following assumptions:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Assumptions</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%">Dividend yield</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">12</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Risk-free rate for term</td> <td> </td> <td> </td> <td style="text-align: right">0.62% – 1.14</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Volatility</td> <td> </td> <td> </td> <td style="text-align: right">117.4% – 198.3</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Remaining terms (Years)</td> <td> </td> <td> </td> <td style="text-align: right">0.01 – 1.0</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Stock price ($ per share)</td> <td> </td> <td> </td> <td style="text-align: right">$0.650 – $1.367</td> <td> </td></tr> </table> The Company analyzed the compound features of variable conversion and redemption embedded in this instrument, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (“EITF”) Issue No. 00–19 and EITF 07–05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">$</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative liabilities as at March 31, 2019</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%">Derivative fair value at issuance</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">1,083,952</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Change in fair value of derivatives</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">60,781</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Derivative liabilities as at March 31, 2020</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">1,144,733</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative fair value at issuance</td> <td> </td> <td> </td> <td style="text-align: right">41,749</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Change in fair value of derivatives</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(204,142</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Derivative liabilities as at June 30, 2020</td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">982,340</td> <td> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As at June 30, 2020 $</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">As at March 31, 2020 $</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%">Accounts payable</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">1,012,630</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">1,094,072</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Accrued liabilities</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">715,842</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">427,617</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,728,472</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,521,689</td> <td></td></tr> </table> -3157179 -3157179 237215 -237215 The Notes will automatically convert into common stock (in each case, subject to the trading volume of the Company's common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company's common stock being listed on a national securities exchange, in which event the conversion price will be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company's next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price will be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company may prepay the Notes upon 20 days' written notice and payment of a 15% prepayment fee. Upon conversion of the Notes, the Company will also issue to the investors warrants (the "Warrants") to purchase 50% of the number of shares of common stock issued upon conversion of the Notes. The Warrants will have a term of three years and an exercise price equal to 120% of the volume weighted average price of the common stock for the 20 days prior to the final closing date of the offering, subject to adjustment. 12. SUBSEQUENT EVENTS   The Company’s management has evaluated subsequent events up to August 14, 2019, the date the condensed consolidated financial statements were issued, pursuant to the requirements of ASC 855 and has determined the following material subsequent events:   From July 24, 2020 to July 31, 2020, the Company entered into subscription agreements with accredited investors for the sale to the investors of convertible promissory notes (the “Notes”) in the aggregate principal amount of $1,253,000. The Notes will bear interest at the rate of 12% per year and will mature one year from the final closing date of the offering. The Notes will be convertible into shares of common stock, at the option of the holder, commencing six months from issuance, at a conversion price equal to 75% of the volume weighted average price of the common stock for the five trading days prior to the conversion date. The Notes will automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price will be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price will be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company may prepay the Notes upon 20 days’ written notice and payment of a 15% prepayment fee. Upon conversion of the Notes, the Company will also issue to the investors warrants (the “Warrants”) to purchase 50% of the number of shares of common stock issued upon conversion of the Notes. The Warrants will have a term of three years and an exercise price equal to 120% of the volume weighted average price of the common stock for the 20 days prior to the final closing date of the offering, subject to adjustment.   In July 2020, an exchangeable shareholder holding 179,540 exchangeable shares exchanged these for an equivalent number of common shares of the Company. Also in July 2020, the Company issued 83,500 common shares as compensation for services to be provided by a contractor.   On August 6, 2020, the Company announced that it received a 510(k) clearance from the FDA for its Bioflux Software II System, engineered to improve workflows and reduce estimated analysis time from 5 minutes to 30 seconds. Because ECG monitoring requires significant human oversight to review and interpret incoming patient data to discern actionable events for clinical intervention, highlighting the necessity of driving operational efficiency, this improvement in analysis time reduces operational costs and allows the company to improve customer service and provide improved response times to physicians and their at-risk patients.   On August 11, 2020, the Company entered into an agreement of understanding that establishes terms under which Biotricity will enter into a licensing agreement, with an exclusive right to acquire MD Matrix Inc. and its telemedicine platform, which includes capabilities for real-time streaming of medical devices. The terms of the agreement of understanding expire ninety days after its execution. Consultant Warrants include warrants issued to directors and officers of the Company who were not members of the Company's options plan at the time of issuance. As at June 30, 2020, Consultant Warrants include an aggregate of 638,806 warrants provided to an officer of the Company as compensation while he was not a member of any Company options plan. Salary and allowance include salary, car allowance, vacation pay, bonus and other allowances paid or payable to key management of the Company. Stock based compensation represent the fair value of the options, warrants and equity incentive plan for directors and key management of the Company. EX-101.SCH 11 btcy-20200630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficiency (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Nature of Operations link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Basis of Presentation, Measurement and Consolidation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Convertible Promissory Notes and Short Term Loans link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Federally Guaranteed Loans link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Derivative Liabilities link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders' Deficiency link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Related Party Transactions and Balances link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Lease link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Derivative Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Stockholders' Deficiency (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Related Party Transactions and Balances (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Basis of Presentation, Measurement and Consolidation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Accounts Payable and Accrued Liabilities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Convertible Promissory Notes and Short Term Loans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Federally Guaranteed Loans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Derivative Liabilities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Derivative Liabilities - Schedule of Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Derivative Liabilities - Schedule of Derivative Components Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stockholders' Deficiency (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Stockholders' Deficiency - Schedule of Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Stockholders' Deficiency - Schedule of Warrants Outstanding (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Stockholders' Deficiency (Equity) - Schedule of Stock Option Activities (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Stockholders' Deficiency (Equity) - Schedule of Fair Value of Option Granted Using Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Related Party Transactions - Schedule of Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Lease (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Leases - Schedule of Operating Leases Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Operating Lease Right-Of-Use Assets and Lease Obligations - Schedule of Contractual Undiscounted Cash Flows for Lease Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 btcy-20200630_cal.xml XBRL CALCULATION FILE EX-101.DEF 13 btcy-20200630_def.xml XBRL DEFINITION FILE EX-101.LAB 14 btcy-20200630_lab.xml XBRL LABEL FILE Plan Name [Axis] 2015 Equity Incentive Plan [Member] 2016 Equity Incentive Plan [Member] Range [Axis] Maximum [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Exchange Agreement [Member] Title of Individual [Axis] Exchangeco [Member] Equity Components [Axis] Broker Warrants [Member] Advisor and Consultant [Member] Warrant [Member] Minimum [Member] Officer [Member] Two Employees [Member] One Employee [Member] Consultant and Noteholder Warrants [Member] Warrants Issued on Conversion of Convertible Notes [Member] Private Placement Warrants [Member] Preferred Stock [Member] Common Stock and Exchangeable Common Shares [Member] Shares to be Issued [Member] Additional Paid in Capital [Member] Accumulated Other Comprehensive (Loss) Income [Member] Accumulated Deficit [Member] Debt Instrument [Axis] Promissory Notes [Member] Income Statement Location [Axis] Interest Expense [Member] Financial Instrument [Axis] Options [Member] Advisor Warrant [Member] 11% Secured Convertible Promissory Notes [Member] Consultants and Advisors [Member] Measurement Input Type [Axis] Dividend Yield [Member] Risk-Free Rate for Term [Member] Volatility [Member] Registered Offering [Member] 2016 Equity Incentive Plan One [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Promissory Notes [Member] Award Type [Axis] COVID-19 [Member] Remaining Terms (Years) [Member] Securities Purchase Agreement [Member] Common Stock [Member] Investors [Member] Consultants, Advisors and Other Service Providers [Member] Pre-Exchange Agreement [Member] Promissory Note and Short-Term Loans [Member] Scenario [Axis] Issuance of Common Shares [Member] Various Consultants and Advisors [Member] Issuance of Employee Options [Member] Lease Contractual Term [Axis] Less Than One Year [Member] Beyond One Year [Member] General and Administrative Expense [Member] Payment Protection Program [Member] Sale of Stock [Axis] Advisor [Member] Director of Company [Member] Another Director [Member] Directors and Officers [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Subscription Arrangement [Member] Accredited Investors [Member] Captioned Program Program [Member] Legal Entity [Axis] US Small Business Administration [Member] Board of Director [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] CURRENT ASSETS Cash Accounts receivable, net Inventory Deposits and other receivables Total current assets NON-CURRENT ASSETS Deposits Long-term accounts receivable Operating lease right-of-use assets [Note 10] TOTAL ASSETS CURRENT LIABILITIES Accounts payable and accrued liabilities [Note 4] Convertible promissory notes and short term loans [Note 5] Operating lease obligations, current [Note 10] Total current liabilities NON CURRENT LIABILITIES Federally guaranteed loans [Note 6] Derivative liabilities [Note 7] Operating lease obligations, long term [Note 10] TOTAL LIABILITIES STOCKHOLDERS' DEFICIENCY Preferred stock value Common stock, $0.001 par value, 125,000,000 authorized as at June 30 and March 31, 2020, respectively. Issued and outstanding common shares: 33,384,769 and 32,593,769 as at June 30 and March 31, 2020, respectively, and exchangeable shares of 3,788,062 as at June 30 and March 31, 2020 [Note 8] Shares to be issued (25,000 and 178,750 shares of common stock as at June 30 and March 31, 2020, respectively) [Note 8] Additional paid-in-capital Accumulated other comprehensive loss Accumulated deficit TOTAL STOCKHOLDERS' DEFICIENCY TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Common stock, exchangeable shares outstanding Common stock, shares to be issued Income Statement [Abstract] REVENUE Cost of revenue Gross Profit EXPENSES General and administrative expenses [Notes 7, 8 and 9] Research and development expenses TOTAL OPERATING EXPENSES Other income [Note 3] Change in fair value of derivative liabilities [Note 7] NET LOSS BEFORE INCOME TAXES Income taxes NET LOSS Less: Preferred Stock Dividends [Note 8] NET LOSS ATTRIBUTED TO COMMON STOCKHOLDERS Translation adjustment COMPREHENSIVE LOSS LOSS PER SHARE, BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Balance Balance, shares Issuance of shares for private placement Issuance of shares for private placement, shares Issuance of shares for services Issuance of shares for services, shares Issuance of warrants for services Issuance of preferred stock Issuance of preferred stock, shares Derivative liabilities adjustment Stock based compensation - ESOP Issuance cost Net loss before dividends Preferred stock dividends Net loss for the Period Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss before dividends Adjustments to reconcile net loss to net cash used in operations Stock based compensation Issuance of shares for services Issuance of warrants for services Change in fair value of derivative liabilities Changes in operating assets and liabilities: Accounts receivable Inventory Deposits and other receivables Accounts payable and accrued liabilities Net cash used in operating activities CASH FLOWS FROM FINANCING ACTIVITIES Issuance of common shares, net Issuance of preferred shares Proceeds from federally guaranteed loans Issuance (repayment) of convertible promissory notes and short term loans Net cash provided by financing activities Effect of foreign currency translation Net increase (decrease) in cash during the period Cash, beginning of period Cash, end of period Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Operations Accounting Policies [Abstract] Basis of Presentation, Measurement and Consolidation Summary of Significant Accounting Policies Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Debt Disclosure [Abstract] Convertible Promissory Notes Federally Guaranteed Loans Federally Guaranteed Loans Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Liabilities Equity [Abstract] Stockholders' Deficiency Related Party Transactions [Abstract] Related Party Transactions and Balances Leases [Abstract] Operating Lease Right-Of-Use Assets and Lease Obligations Commitments and Contingencies Disclosure [Abstract] Contingencies Subsequent Events [Abstract] Subsequent Events Use of Estimates Earnings (Loss) Per Share Fair Value of Financial Instruments Leases Government Loan Convertible Notes Payable and Derivative Instruments Recently Issued Accounting Pronouncements Schedule of Accounts Payable and Accrued Liabilities Schedule of Derivative Liabilities Schedule of Derivative Components Valuation Assumptions Schedule of Warrants Outstanding Schedule of Stock Option Activities Schedule of Fair Value of Option Granted Using Valuation Assumptions Schedule of Related Party Transactions Schedule of Operating Leases Obligations Schedule of Contractual Undiscounted Cash Flows for Lease Obligation Working capital deficit Issuance value of debt, outstanding Stock issued during the period, shares Proceeds from preferred stock Conversion of stock, shares Proceeds from convertible notes payable Funds raised Potentially dilutive shares outstanding Accounts payable Accounts payable Accrued liabilities Accounts payable and accrued liabilities Statistical Measurement [Axis] Debt face value Debt instrument term Debt interest rate Debt repayment Converted preferred stock Short term loan outstanding General and administrative expenses Loan received Description on loan Interest rate Description debt instrument term Accrued interest Derivative liabilities, beginning balance Derivative fair value at issuance Change in fair value of derivatives Derivative liabilities, ending balance Derivative liability, measurement input Derivative liability, remaining term (Years) Stock price Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Exchangeable shares outstanding Percentage of common stock issued and outstanding Common stock exchange description Number of common shares issued, shares Number of common shares issued, value Number of exchangeable shares issued Exchange ratio Conversion description Discount percentage for purchase price per shares Proceeds from private offering Number of shares issued for services General and administrative and research and development expenses Number of common stock option exercise Proceeds from warrants exercise Preferred stock, conversion method on issuance, description Conversion of stock Accrued preferred stock dividends Dividends paid Issuance of shares for services, value Consultant warrants shares Number of warrants issued Warrants exercise price Number of common stock compensation for services Number of common stock compensation for services, value Expected life Risk free rate Stock price Expected volatility Proceeds from issuance of warrants Number of options authorized to issue Number of options vested Number of options non-vested Options exercise price Number of options cancelled Fair value of options Vesting description Plan description Number of options granted Number of options granted, exercise price Options vesting period Weighted average remaining contractual life Intrinsic value of options Fair value of common share Fair value of common share, value Warrants outstanding, Beginning balance Warrants outstanding, Exercised Warrants outstanding, Expired/cancelled Warrants outstanding, Issued Warrants outstanding, Ending balance Exercise Price Expiration Date Officer compensation Number of options outstanding, Beginning balance Number of options outstanding, Granted Number of options outstanding, Expired Number of options outstanding, Exercised Number of options outstanding, Cancelled Number of options outstanding, Ending balance Weighted average exercise price, Beginning balance Weighted average exercise price, Granted Weighted average exercise price, Expired Weighted average exercise price, Exercised Weighted average exercise price, Cancelled Weighted average exercise price, Ending balance Exercise price Risk free interest rate Expected term (Years) Expected volatility Expected dividend yield Fair value of option Expected forfeiture (attrition) rate Salary and allowance Stock based compensation Total Operating lease, weighted average rate Operating lease expense Operating lease right-of-use asset - initial recognition Amortization Balance at June 30, 2020 Operating lease obligation - initial recognition Repayment and interest accretion Balance at June 30, 2020 Current portion of operating lease obligation Noncurrent portion of operating lease obligation Total undiscounted lease obligations Convertible promissory notes Pricipal amount Conversion price Convertible promissory note, description Convertible prepayment, description Issue investors warrant, description Number of exchangeable shares Accredited Individuals [Member] Accredited Investors [Member] Additional Options Granted [Member] Adjustment to derivative liabilities. Issuance of warrants for services Advisor and Consultant [Member] Advisor Warrant [Member] Advisors, Contractors and Consultants [Member] Beyond One Year [Member] Bridge Notes [Member] Bridge Notes Offering [Member] Bridge Offering [Member] Broker Warrants [Member] Brokers [Member] COVID-19 [Member] Certain Investors [Member] Common Share Offering [Member] Common Share Offering One [Member] Common Stock and Exchangeable Common Shares [Member] Common stock exchange description. Common Stock One [Member] Common stock shares to be issued. Compensation to Consultant [Member] Consultant [Member] Consultant Warrants [Member] Consultants, Advisors and Other Service Providers [Member] Consultants and Advisors [Member] Consultants and Advisors [Member] Consultants [Member] Convertible notes payable and derivative instruments [Policy Text Block] Corresponding Credit to Common Shares and Additional Paid-In-Capital [Member] Derivative liability, remaining term (years). Derivative stock price. Directors [Member] Discount percentage for purchase price per shares. 11% Secured Convertible Promissory Notes [Member] Emergency Injury Disaster Loan [Member] Employee [Member] Exchange Agreement [Member] Exchange ratio. Exchangeco [Member] Federally guaranteed loans. Final 4 Month [Member] Final 3 Month [Member] General and Administrative and Research and Development Expenses [Member] General and Administrative and Research and Development Expenses [Member] iMedical Innovations Inc [Member] Investors [Member] Investors One [Member] Issuance of Common Shares [Member] Represents the monetary amount of Issuance of warrants for services, at fair value, during the indicated time period. Issue Employee Options [Member] July 1, 2019 to June 30, 2020 [Member] July 1, 2020 to June 30, 2021 [Member] Less than One Year [Member] Long-term accounts receivable. Non-Executive Directors [Member] Number of exchangeable shares issued. On or About July 31, 2017 [Member] One Employee [Member] Repayment and interest accretion. Operating leases [Policy Text Block] Payment Protection Program [Member] Percentage of common stock issued and outstanding. Performance Based Compensation [Member]. Placement Agent [Member] Pre-Exchange Agreement [Member] Preferred stock, conversion method on issuance, description Preferred Stock One [Member] Preferred Stock Two [Member] Private Placement Warrants [Member] Promissory Note and Other Net Short-Term Funding [Member] Promissory Note and Short-Term Loans [Member] Promissory Note [Member] Promissory Notes [Member] Registered Offering [Member] Schedule of Contractual Undiscounted Cashflows for Lease Obligation [Table text block] Securities Purchase Agreement [Member] Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate. Share Issuances [Member] Represents the monetary amount of Shares to be issued, as of the indicated date. Shares to be Issued [Member] Six Employees [Member] Sole Chief Executive Officer and Sole Officer [Member] Term Sheet Offering [Member] 13th to 24th Month [Member] 25th to 36th Month [Member] Two Employees [Member] 2015 Equity Incentive Plan [Member] 2016 Equity Incentive Plan [Member] 2016 Equity Incentive Plan One [Member]. Upto 12th Month [Member] Various Consultants and Advisors [Member] Various Consultants [Member] Warrants Four [Member] Warrants Issued on Conversion of Convertible Notes [Member] Warrants [Member] Warrants One [Member] Warrants Three [Member] Warrants Two [Member] Working capital deficit. Advisor [Member] Consultant warrants shares. Director of Company [Member] Another Director [Member] Directors and Officers [Member] Conversion price. Government loan [Policy Text Block] Converted preferred stock. Short term loan outstanding. Captioned Program Program [Member] US Small Business Administration [Member] Description debt instrument term. Fair value of common share Fair value of common share, value. Proceeds from federally guaranteed loans. Federally Guaranteed Loans [Text Block] Number of exchangeable shares. Board of Director [Member] Net loss before dividends. Preferred stock dividends. Convertible promissory note, description. Convertible promissory note, description. Issue investors warrant, description PromissoryNotesMember Assets, Current Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net Income (Loss) Attributable to Parent Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Issuance of Stock and Warrants for Services or Claims Issuance of warrants for services, at fair value Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Other Receivables Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations FederallyGuaranteedLoansTextBlock Accounts Payable, Current Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-based Payment Arrangement, Expense Related Party Transaction, Expenses from Transactions with Related Party Operating Lease, Right-of-Use Asset, Amortization Expense Operating Lease, Liability EX-101.PRE 15 btcy-20200630_pre.xml XBRL PRESENTATION FILE XML 16 R1.htm IDEA: XBRL DOCUMENT v3.20.2

Document and Entity Information - shares
3 Months Ended

Jun. 30, 2020

Aug. 14, 2020

Cover [Abstract]

Entity Registrant Name BIOTRICITY INC.

Entity Central Index Key 0001630113

Document Type 10-Q

Document Period End Date Jun. 30, 2020

Amendment Flag false

Current Fiscal Year End Date --03-31

Entity Current Reporting Status Yes

Entity Interactive Data Current Yes

Entity Filer Category Non-accelerated Filer

Entity Small Business Flag true

Entity Emerging Growth Company false

Entity Shell Company false

Entity Common Stock, Shares Outstanding 33,647,809

Document Fiscal Period Focus Q1

Document Fiscal Year Focus 2021

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

XML 17 R2.htm IDEA: XBRL DOCUMENT v3.20.2

Condensed Consolidated Balance Sheets - USD ($)

Jun. 30, 2020

Mar. 31, 2020

CURRENT ASSETS

Cash $ 64,875 $ 949,848

Accounts receivable, net 663,687 486,187

Inventory 236,106 85,720

Deposits and other receivables 159,402 137,074

Total current assets 1,124,070 1,658,829

NON-CURRENT ASSETS

Deposits 33,000

Long-term accounts receivable 50,148 48,115

Operating lease right-of-use assets [Note 10] 214,884 264,472

TOTAL ASSETS 1,389,102 2,004,416

CURRENT LIABILITIES

Accounts payable and accrued liabilities [Note 4] 1,521,689 1,521,689

Convertible promissory notes and short term loans [Note 5] 1,871,389 2,068,302

Operating lease obligations, current [Note 10] 213,030 213,030

Total current liabilities 3,821,003 3,803,021

NON CURRENT LIABILITIES

Federally guaranteed loans [Note 6] 1,570,990

Derivative liabilities [Note 7] 982,350 1,144,733

Operating lease obligations, long term [Note 10] 57,055

TOTAL LIABILITIES 6,374,244 5,004,809

STOCKHOLDERS' DEFICIENCY

Preferred stock value 1 1

Common stock, $0.001 par value, 125,000,000 authorized as at June 30 and March 31, 2020, respectively. Issued and outstanding common shares: 33,384,769 and 32,593,769 as at June 30 and March 31, 2020, respectively, and exchangeable shares of 3,788,062 as at June 30 and March 31, 2020 [Note 8] 37,173 36,382

Shares to be issued (25,000 and 178,750 shares of common stock as at June 30 and March 31, 2020, respectively) [Note 8] 22,194 169,490

Additional paid-in-capital 45,676,541 44,015,397

Accumulated other comprehensive loss (961,518) (857,307)

Accumulated deficit (49,758,760) (46,364,364)

TOTAL STOCKHOLDERS' DEFICIENCY (4,985,151) (3,000,393)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY $ 1,389,102 2,004,416

Series A Preferred Stock [Member]

STOCKHOLDERS' DEFICIENCY

Preferred stock value $ 8

X

- Definition
Federally guaranteed loans.
+ References
No definition available.
+ Details

Name: BTCY_FederallyGuaranteedLoans

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Long-term accounts receivable.
+ References
No definition available.
+ Details

Name: BTCY_LongtermAccountsReceivable

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the monetary amount of Shares to be issued, as of the indicated date.
+ References
No definition available.
+ Details

Name: BTCY_SharesToBeIssued

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DepositsAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DepositsAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R3.htm IDEA: XBRL DOCUMENT v3.20.2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares

Jun. 30, 2020

Mar. 31, 2020

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, shares issued 1 1

Preferred stock, shares outstanding 1 1

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 125,000,000 125,000,000

Common stock, shares issued 33,384,769 32,593,769

Common stock, shares outstanding 33,384,769 32,593,769

Common stock, exchangeable shares outstanding 3,788,062 3,788,062

Common stock, shares to be issued 25,000 178,750

Series A Preferred Stock [Member]

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 20,000 20,000

Preferred stock, shares issued 8,045 7,830

Preferred stock, shares outstanding 8,045 7,830

X

- Definition
Common stock shares to be issued.
+ References
No definition available.
+ Details

Name: BTCY_CommonStockSharesToBeIssued

Namespace Prefix: BTCY_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.
+ References
No definition available.
+ Details

Name: us-gaap_CommonStockOtherSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R4.htm IDEA: XBRL DOCUMENT v3.20.2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Income Statement [Abstract]

REVENUE $ 451,898 $ 327,000

Cost of revenue 191,462 150,586

Gross Profit 260,436 176,414

EXPENSES

General and administrative expenses [Notes 7, 8 and 9] 3,205,233 2,052,519

Research and development expenses 423,883 213,496

TOTAL OPERATING EXPENSES 3,629,116 2,266,015

Other income [Note 3] (7,359)

Change in fair value of derivative liabilities [Note 7] (204,142)

NET LOSS BEFORE INCOME TAXES (3,157,179) (2,089,601)

Income taxes

NET LOSS (3,157,179) (2,089,601)

Less: Preferred Stock Dividends [Note 8] 237,215

NET LOSS ATTRIBUTED TO COMMON STOCKHOLDERS (3,394,394) (2,089,601)

Translation adjustment (105,001) (22,586)

COMPREHENSIVE LOSS $ (3,499,395) $ (2,112,187)

LOSS PER SHARE, BASIC AND DILUTED $ (0.900) $ (0.060)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING 36,768,299 35,397,458

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(22))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(24))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(26))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959
+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue and income classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.4)
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
+ Details

Name: us-gaap_OtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 20 R5.htm IDEA: XBRL DOCUMENT v3.20.2

Condensed Consolidated Statements of Stockholders' Deficiency (Unaudited) - USD ($)
3 Months Ended 12 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Mar. 31, 2020

Preferred Stock [Member]

Balance $ 9 $ 1 $ 1

Balance, shares 7,831 1 1

Issuance of shares for private placement

Issuance of shares for private placement, shares

Issuance of shares for services

Issuance of shares for services, shares

Issuance of warrants for services

Issuance of preferred stock

Issuance of preferred stock, shares 215

Derivative liabilities adjustment

Stock based compensation - ESOP

Issuance cost

Translation adjustment

Net loss before dividends

Preferred stock dividends

Net loss for the Period

Balance $ 9 $ 1 $ 9

Balance, shares 8,046 1 7,831

Common Stock and Exchangeable Common Shares [Member]

Balance $ 36,382 $ 35,362 $ 35,362

Balance, shares 36,381,831 35,361,656 35,361,656

Issuance of shares for private placement $ 23

Issuance of shares for private placement, shares 22,585

Issuance of shares for services $ 791 $ 31

Issuance of shares for services, shares 791,000 30,835

Issuance of warrants for services

Issuance of preferred stock

Issuance of preferred stock, shares

Derivative liabilities adjustment

Stock based compensation - ESOP

Issuance cost

Translation adjustment

Net loss before dividends

Preferred stock dividends

Net loss for the Period

Balance $ 37,173 $ 35,415 $ 36,382

Balance, shares 37,172,831 35,415,060 36,381,831

Shares to be Issued [Member]

Balance $ 169,490 $ 91,498 $ 91,498

Balance, shares 178,750 62,085 62,085

Issuance of shares for private placement

Issuance of shares for private placement, shares

Issuance of shares for services $ (147,296) $ 217,878

Issuance of shares for services, shares (153,750) 350,415

Issuance of warrants for services

Issuance of preferred stock

Issuance of preferred stock, shares

Derivative liabilities adjustment

Stock based compensation - ESOP

Issuance cost

Translation adjustment

Net loss before dividends

Preferred stock dividends

Net loss for the Period

Balance $ 22,194 $ 309,375 $ 169,490

Balance, shares 25,000 412,500 178,750

Additional Paid in Capital [Member]

Balance $ 44,045,397 $ 33,889,916 $ 33,889,916

Issuance of shares for private placement 13,980

Issuance of shares for services 1,210,259 350,415

Issuance of warrants for services 45,113 19,955

Issuance of preferred stock 215,000

Derivative liabilities adjustment (41,749)

Stock based compensation - ESOP 232,519 338,889

Issuance cost

Translation adjustment

Net loss before dividends

Preferred stock dividends

Net loss for the Period

Balance 45,676,539 34,296,458 44,045,397

Accumulated Other Comprehensive (Loss) Income [Member]

Balance (857,307) (754,963) (754,963)

Issuance of shares for private placement

Issuance of shares for services

Issuance of warrants for services

Issuance of preferred stock

Derivative liabilities adjustment

Stock based compensation - ESOP

Issuance cost

Translation adjustment (105,001) (22,586)

Net loss before dividends

Preferred stock dividends

Net loss for the Period

Balance (962,308) (777,549) (857,307)

Accumulated Deficit [Member]

Balance (46,364,364) (35,039,495) (35,039,495)

Issuance of shares for private placement

Issuance of shares for services

Issuance of warrants for services

Issuance of preferred stock

Derivative liabilities adjustment

Stock based compensation - ESOP

Issuance cost

Translation adjustment

Net loss before dividends (3,157,179)

Preferred stock dividends (237,215)

Net loss for the Period (2,089,601)

Balance (49,758,758) (37,129,096) (46,364,364)

Balance (3,000,393) (1,777,681) (1,777,681)

Issuance of shares for private placement 14,003

Issuance of shares for services 1,063,754 251,625

Issuance of warrants for services 45,113 19,955

Issuance of preferred stock 215,000

Derivative liabilities adjustment (41,749)

Stock based compensation - ESOP 232,519 338,889

Issuance cost

Translation adjustment (105,001) (22,586)

Net loss before dividends (3,157,179)

Preferred stock dividends 237,215

Net loss for the Period (3,394,394) (2,089,601)

Balance $ (4,985,151) $ (3,265,396) $ (3,000,393)

X

- Definition
Adjustment to derivative liabilities.
+ References
No definition available.
+ Details

Name: BTCY_AdjustmentToDerivativeLiabilities

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Issuance of warrants for services
+ References
No definition available.
+ Details

Name: BTCY_AdjustmentsToAdditionalPaidInCapitalIssuancofWarrantsForServices

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net loss before dividends.
+ References
No definition available.
+ Details

Name: BTCY_NetLossBeforeDividends

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Preferred stock dividends.
+ References
No definition available.
+ Details

Name: BTCY_PreferredStockDividends

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=BTCY_CommonStockAndExchangeableCommonSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=BTCY_SharesToBeIssuedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R6.htm IDEA: XBRL DOCUMENT v3.20.2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 12 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Mar. 31, 2020

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss before dividends $ (3,157,179) $ (2,089,601)

Adjustments to reconcile net loss to net cash used in operations

Stock based compensation 232,519 338,889

Issuance of shares for services 1,063,754 251,625

Issuance of warrants for services 45,113 19,955

Change in fair value of derivative liabilities (204,142)

Changes in operating assets and liabilities:

Accounts receivable (179,533) (178,530)

Inventory (150,386) (15,013)

Deposits and other receivables 10,717 35,291

Accounts payable and accrued liabilities (53,974) 308,379

Net cash used in operating activities (2,393,110) (1,328,375)

CASH FLOWS FROM FINANCING ACTIVITIES

Issuance of common shares, net 14,003

Issuance of preferred shares 100,000

Proceeds from federally guaranteed loans 1,570,900

Issuance (repayment) of convertible promissory notes and short term loans (96,913) 1,315,799

Net cash provided by financing activities 1,573,987 1,329,802

Effect of foreign currency translation (65,851) (17,324)

Net increase (decrease) in cash during the period (819,123) 1,427

Cash, beginning of period 949,848 63,647 $ 63,647

Cash, end of period $ 64,875 $ 47,750 $ 949,848

X

- Definition
Represents the monetary amount of Issuance of warrants for services, at fair value, during the indicated time period.
+ References
No definition available.
+ Details

Name: BTCY_IssuanceOfWarrantsForServicesAtFairValue

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from federally guaranteed loans.
+ References
No definition available.
+ Details

Name: BTCY_ProceedsFromFederallyGuaranteedLoans

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959
+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in receivables classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 22 R7.htm IDEA: XBRL DOCUMENT v3.20.2

Nature of Operations
3 Months Ended

Jun. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations
1. NATURE OF OPERATIONS

Biotricity Inc. (formerly MetaSolutions, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on August 29, 2012. iMedical Innovations Inc. (“iMedical”) was incorporated on July 3, 2014 under the laws of the Province of Ontario, Canada and became a wholly-owned subsidiary of Biotricity through reverse take-over.

Both the Company and iMedical are engaged in research and development activities within the remote monitoring segment of preventative care. They are focused on a realizable healthcare business model that has an existing market and commercialization pathway. As such, its efforts to date have been devoted in building technology that enables access to this market through the development of a tangible product.

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R8.htm IDEA: XBRL DOCUMENT v3.20.2

Basis of Presentation, Measurement and Consolidation
3 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation, Measurement and Consolidation
2. BASIS OF PRESENTATION, MEASUREMENT AND CONSOLIDATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the Securities and Exchange Commission (“SEC”) instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements and should be read in conjunction with Biotricity’s audited financial statements for the years ended March 31, 2020 and 2019 and their accompanying notes.

The accompanying unaudited condensed consolidated financial statements are expressed in United States dollars (“USD”). In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of financial position and results of operations for the interim periods presented have been reflected herein. Operating results for the three months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending March 31, 2021. The Company’s fiscal year-end is March 31.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Significant intercompany accounts and transactions have been eliminated.

Liquidity and Basis of Presentation

The Company is an emerging growth entity that is in the early stages of commercializing its first product and is concurrently in development mode, operating a research and development program in order to develop, obtain regulatory approval for, and commercialize other proposed products. The Company has incurred recurring losses from operations, and as at June 30, 2020, has an accumulated deficit of $49,758,758 and a working capital deficiency of $2,696,943. The Company launched its first commercial sales program as part of a limited market release, during the year ended March 31, 2019, using an experienced professional in-house sales team. A full market release ensued during the year ended March 31, 2020. Management anticipates the Company will attain profitable status and improve its liquidity through continued business development and after additional equity or debt capitalization of the Company. The Company has developed and continues to pursue sources of funding that management believes if successful would be sufficient to support the Company’s operating plan and alleviate any substantial doubt as to its ability to meet its obligations at least for a period of one year from the date of these consolidated financial statements. The Company raised $3,094,820 in promissory notes and short term loans during the year ended March 31, 2020. Starting in December 2019, the Company has issued 8,045 Series A preferred shares, issuing 6,100 of these for cash proceeds of $6,100,000 and 1,945 of these were issued on conversion of $1,945,000 of promissory notes and accrued interest. The Company has also raised government funding provided for economic support during COVID-19, including $1,570,900 raised during the three months ended June 30, 2020 (see Note 6 – Federally Guaranteed Loans).

The Company’s operating plan is predicated on a variety of assumptions including, but not limited to, the level of product demand, cost estimates, its ability to continue to raise additional financing and the state of the general economic environment in which the Company operates. There can be no assurance that these assumptions will prove to be accurate in all material respects, or that the Company will be able to successfully execute its operating plan. In the absence of additional appropriate financing, the Company may have to modify its operating plan or slow down the pace of development and commercialization of its proposed products.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R9.htm IDEA: XBRL DOCUMENT v3.20.2

Summary of Significant Accounting Policies
3 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of derivatives, convertible promissory notes, stock options, and assumptions used in the going concern assessment. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

Earnings (Loss) Per Share

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at June 30, 2020 and 2018.

Fair Value of Financial Instruments

ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes, and accounts payable and accrued liabilities. The Company’s cash and derivative liabilities, which are carried at fair values, are classified as a Level 1 and Level 2, respectively. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

Leases

On April 1, 2019, the Company adopted Accounting Standards Codification Topic 842, “Leases” (“ASC 842”) to replace existing lease accounting guidance. This pronouncement is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases will continue to be recognized in a manner similar to previous accounting guidance. The Company adopted ASC 842 utilizing the transition practical expedient added by the Financial Accounting Standards Board (“FASB”), which eliminates the requirement that entities apply the new lease standard to the comparative periods presented in the year of adoption.

The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the consolidated balance sheet.

Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in our consolidated statement of income. The Company determines the lease term by agreement with lessor. As our lease do not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion.

Government loan

For loans received from federal government that contains certain operating conditions and with terms over twelve month time, the Company records those loans as long term liabilities.

Convertible Notes Payable and Derivative Instruments

The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the new guidance effectively on April 1, 2020. The Company identified and updated existing internal controls and procedures to ensure compliance with the new guidance, but such modifications were not deemed to be material to the Company's overall system of internal control. While the adoption of this ASU did not have a material impact on the Company's consolidated financial statements, it required changes to the Company's process of estimating expected credit losses on trade receivables.

In July 2019, the FASB issued ASU 2019-07, Codification Updates to SEC Sections. This ASU amends various SEC paragraphs pursuant to the issuance of SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization. One of the changes in the ASU requires a presentation of changes in stockholders’ equity in the form of a reconciliation, either as a separate financial statement or in the notes to the financial statements, for the current and comparative year-to-date interim periods. The Company presented changes in stockholders' equity as separate financial statements for the current and comparative year-to-date interim periods beginning on April 1, 2019. The additional elements of the ASU did not have a material impact on the Company's consolidated financial statements.

In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. On June 16, 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis. That model replaces the probable, incurred loss model for those assets. Through the amendments in that Update, the Board added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. The amendments apply to all reporting entities within the scope of the affected accounting guidance. ASU 2019-11 is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements and related disclosures.

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impacts of the provisions of ASU 2019-12 on its financial condition, results of operations, and cash flows.

In March 2020, the FASB issued ASU No. 2030-20 Codification Improvements to Financial Instruments, An Amendment of the FASB Accounting Standards Codification: a)in ASU No. 2016-01, b) in Subtopic 820-10, c) for depository and lending institutions clarification in disclosure requirements, d) in Subtopic 470-50, e) in Subtopic 820-10, f) Interaction of Topic 842 and Topic 326, g) Interaction of the guidance in Topic 326 and Subtopic 860-20.The amendments in this Update represent changes to clarify or improve the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. For public business entities updates under the following paragraphs: a), b), d) and e) are effective upon issuance of this final update. The effective date for c) is for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company does not expect that the new guidance will significantly impact its consolidated financial statements.

The Company continues to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R10.htm IDEA: XBRL DOCUMENT v3.20.2

Accounts Payable and Accrued Liabilities
3 Months Ended

Jun. 30, 2020

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities
4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

As at
June 30, 2020
$ As at
March 31, 2020
$

Accounts payable 1,012,630 1,094,072

Accrued liabilities 715,842 427,617

1,728,472 1,521,689

Accounts payable as at June 30, 2020, and March 31, 2020 include 345,929 and 379,881, respectively, due to a shareholder and executive of the Company, primarily as a result of that individual’s role as an employee. These amounts are unsecured, non-interest bearing and payable on demand.

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R11.htm IDEA: XBRL DOCUMENT v3.20.2

Convertible Promissory Notes and Short Term Loans
3 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Convertible Promissory Notes
5. CONVERTIBLE PROMISSORY NOTES AND SHORT TERM LOANS

As at June 30, 2020, the Company had promissory notes outstanding of $719,388 (March 31, 2020 – $916,301). The promissory notes generally have a term of 1-year term, at interest rates of between 10%, and 12% with allowance for the Company to repay early, and the possibility to convert into equity on the basis of mutual consent. During the three months ended June 30, 2020, the Company made repayment in amount of 96,914. During the three months ended June 30, 2020, $100,000 from the outstanding notes was converted to preferred stock. (Note 7, Note 8)

As at June 30, 2020, the Company had short term loan outstanding of $1,152,001 (March 31, 2020 – $1,152,001).

Management has evaluated the terms of these notes in accordance with the guidance provided by ASC 470 and ASC 815 and concluded that there is no derivative or beneficial conversion feature attached to these notes.

General and administrative expenses include interest expense on the above notes of $37,456 and $30,052 for the three months ended June 30, 2020 and 2019, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R12.htm IDEA: XBRL DOCUMENT v3.20.2

Federally Guaranteed Loans
3 Months Ended

Jun. 30, 2020

Federally Guaranteed Loans

Federally Guaranteed Loans
6. FEDERALLY GUARANTEED LOANS

Economic Injury Disaster Loan (“EIDL”)

In April 2020, the Company received $370,900 from the U.S. Small Business Administration (SBA) under the captioned program. The loan has a term of 30 years and an interest rate of 3.75%, without the requirement for payment in its first 12 months. The Company may prepay the loan without penalty at will.

Payment Protection Program (“PPP”) Loan

In May 2020, Biotricity received loan proceeds of $1.2 million (the “PPP Loan”) under the Paycheck Protection Program established by the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (“SBA”). The unsecured PPL Loan is evidenced by a promissory note (the “Note”), between the Company and the lending financial institution (the “Lender”). The Note has a two-year term, bears interest at the rate of 1.0% per annum, and may be prepaid at any time without payment of any premium. No payments of principal or interest are due during the six-month period beginning on the date of the Note (the “Deferral Period”). The principal and accrued interest under the Note is forgivable under certain specified circumstances if the Company uses the PPP Loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and otherwise complies with PPP requirements. In order to obtain forgiveness of the PPP Loan, the Company must submit a request and provide satisfactory documentation regarding its compliance with applicable requirements. The Company must repay any unforgiven principal amount of the Note, with interest, on a monthly basis following the Deferral Period. The Company intends to use the PPP Loan for qualifying expenses, though no assurance is provided that the Company will obtain forgiveness of the PPP Loan in whole or in part.

X

- References
No definition available.
+ Details

Name: BTCY_FederalLoansAbstract

Namespace Prefix: BTCY_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Federally Guaranteed Loans [Text Block]
+ References
No definition available.
+ Details

Name: BTCY_FederallyGuaranteedLoansTextBlock

Namespace Prefix: BTCY_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R13.htm IDEA: XBRL DOCUMENT v3.20.2

Derivative Liabilities
3 Months Ended

Jun. 30, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Liabilities
7. DERIVATIVE LIABILITIES

On December 19, 2019 and January 9, 2020, the Company issued 7,830 Series A preferred shares; 6,000 of these were issued for cash proceeds of $6,000,000 and 1,830 of these were issued on conversion of $1,830,000 of promissory notes that had previously been issued for cash proceeds in October 2019.

On May 22, 2020, another 215 Series A preferred shares were issued as a result of a combined transaction that included the conversion of $100,000 in promissory notes (Note 5) and $15,000 in accrued interest for 115 preferred shares, as well as a purchase of 100 preferred shares for cash proceeds of $100,000.

The Company analyzed the compound features of variable conversion and redemption embedded in this instrument, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (“EITF”) Issue No. 00–19 and EITF 07–05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value.

Total

$

Derivative liabilities as at March 31, 2019 -

Derivative fair value at issuance 1,083,952

Change in fair value of derivatives 60,781

Derivative liabilities as at March 31, 2020 $ 1,144,733

Derivative fair value at issuance 41,749

Change in fair value of derivatives (204,142 )

Derivative liabilities as at June 30, 2020 $ 982,340

The lattice methodology was used to value the derivative components, using the following assumptions:

Assumptions

Dividend yield 12 %

Risk-free rate for term 0.62% – 1.14 %

Volatility 117.4% – 198.3 %

Remaining terms (Years) 0.01 – 1.0

Stock price ($ per share) $0.650 – $1.367

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-URI http://asc.fasb.org/topic&trid=2229140
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R14.htm IDEA: XBRL DOCUMENT v3.20.2

Stockholders' Deficiency
3 Months Ended

Jun. 30, 2020

Equity [Abstract]

Stockholders' Deficiency
8. STOCKHOLDERS’ DEFICIENCY

a) Authorized stock

As at June 30, 2020, the Company is authorized to issue 125,000,000 (March 31, 2020 – 125,000,000) shares of common stock ($0.001 par value) and 10,000,000 (March 31, 2020 – 10,000,000) shares of preferred stock ($0.001 par value).

At June 30, 2020, there were 33,384,769 (March 31, 2020 – 32,593,769) shares of common stock issued and outstanding. Additionally, at June 30, 2020, there were 3,788,062 (March 31, 2020 – 3,788,062) outstanding exchangeable shares. There is currently one share of the Special Voting Preferred Stock issued and outstanding held by one holder of record, which is the Trustee in accordance with the terms of the Trust Agreement.

b) Exchange Agreement

As initially described in Note 1 above, on February 2, 2016:

● The Company issued approximately 1.197 shares of its common stock in exchange for each common share of iMedical held by the iMedical shareholders who in general terms, are not residents of Canada (for the purposes of the Income Tax Act (Canada). Accordingly, the Company issued 13,376,947 shares;

● Shareholders of iMedical who in general terms, are Canadian residents (for the purposes of the Income Tax Act (Canada)) received approximately 1.197 Exchangeable Shares in the capital of Exchangeco in exchange for each common share of iMedical held. Accordingly, the Company issued 9,123,031 Exchangeable Shares;

● Each outstanding option to purchase common shares in iMedical (whether vested or unvested) was exchanged, without any further action or consideration on the part of the holder of such option, for approximately 1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1;

● Each outstanding warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each warrant, with an inverse adjustment to the exercise price of the warrants to reflect the exchange ratio of approximately 1.197:1

● Each outstanding advisor warrant to purchase common shares in iMedical was adjusted, in accordance with the terms thereof, such that it entitles the holder to receive approximately 1.197 shares of the common stock of the Company for each advisor warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1; and

● The outstanding 11% secured convertible promissory notes of iMedical were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of the Company at a 25% discount to purchase price per share in Biotricity’s next offering.

Issuance of common stock, exchangeable shares and cancellation of shares in connection with the reverse takeover transaction as explained above represents recapitalization of capital retroactively adjusting the accounting acquirer’s legal capital to reflect the legal capital of the accounting acquiree.

c) Share issuances

Share issuances during the year ended March 31, 2020

On December 19, 2019, the Company issued 6,000 shares of Series A preferred stock in a private placement for gross proceeds of $6,000,000 (Note 7). The shares are convertible into common stock of the Company at a conversion price equal to the greater of $0.001 or a 15% discount to the 5-day volume weighted price at the time of conversion. The conversion rights commence 24 months after issuance, but conversion is limited to 5% of the aggregate purchase price of the holder on a monthly basis thereafter. Alternatively, the shares are convertible into common stock at a 15% discount to any qualified future common stock financing conducted by the Company. The Company may redeem the shares after 1 year for 110% of the purchase price plus accrued dividends. The preferred stock bears a dividend rate of 12% per annum. On January 9, 2020, the Company issued a further 1,830 of Series A preferred stock with same terms on conversion of $1,830,000 of promissory notes that had previously been issued for cash proceeds in 2019 (see Note 5). During the year ended March 31, 2020, the Company accrued dividends in amount of $257,927 and made a payment in amount of $180,000.

In May and July 2019, the Company issued 47,585 shares of common stock under a registered offering outstanding in the previous fiscal year, which raised proceeds of $28,565.

During the year ended March 31, 2019, the Company issued a total of 972,950 shares of common stock and recognized its obligations to issue a total of 178,750 shares of common stock to various consultants and advisors, with a cumulative fair value of $666,129 and $169,490, respectively, or $835,619 in total; these costs were recognized as general and administrative and research and development expenses, as applicable, in the statement of operations, with corresponding credit to common stock, shares to be issued, and additional paid-in-capital, respectively.

During the year ended March 31, 2020, the Company also issued an aggregate of 525,023 shares of its common stock to investors as part of the one-for-one exchange of previously issued exchangeable shares into the Company’s Common Stock, which is a non-cash transaction. No options or warrants were exercised during this period.

Share issuances during the three months ended June 30, 2020

During the three months ended June 30, 2020, the Company issued an aggregate of 160,000 shares pursuant to obligations existing as at March 31, 2020. The Company also issued a further 631,000 shares of its common stock pursuant to obligations to issue these, the fair value of which were recognized during the three months ended June 30, 2020. Total fair value of the total 791,000 common shares, in amount of $1,063,754, was determined by using the market date price on the date of issuance. The Company recorded the fair value of the common shares issued in general and administrative expenses and research and development expenses with corresponding credit to common stock and additional paid in capital.

d) Shares to be issued

As of June 30, 2020, the Company recognized its contractual obligations to issue a total of 25,000 shares of common stock to an advisor. The fair value of these shares amounted to $22,194 and has been expensed to general and administrative and research and development expenses in the consolidated statements of operations, with a corresponding credit to additional paid-in-capital. The fair value of these shares was determined by using the market price of the common stock as at the date of issuance.

As of March 31, 2020, the Company had recognized its contractual obligations to issue a total of 178,750 shares of common stock to consultants, advisors and other service providers, (as explained in paragraph c, above). The fair value of these shares amounted to $169,490 and has been expensed to general and administrative and research and development expenses in the consolidated statements of operations, with a corresponding credit to additional paid-in-capital. The fair value of these shares was determined by using the market price of the common stock as at the date of issuance.

e) Warrant issuances and exercises

Warrant issuances during the year ended March 31, 2020

During the year ended March 31, 2020, the Company issued 1,021,430 warrants, respectively, as compensation for advisor and consultant services and certain promissory noteholders, which were fair valued at $277,053. Warrants issued to advisors and consultants were expensed in general and administrative expenses and amounted to $184,637, for the year ended March 31, 2020. Warrants issued to promissory notes holders were credited to additional paid-in capital in amount of $92,416. Their fair value has been estimated using a multi-nomial lattice model with an expected life of 2 to 3 years, risk free rates of 0.22% to 1.71%, stock price of $0.52 to $0.974 and expected volatility of 114.3% to 132.2%.

Warrant issuances during the three months ended June 30, 2020

During the three months ended June 30, 2020, the Company issued 50,000 warrants as compensation for advisor and consultant services, which were fair valued at $45,113 and expensed in general and administrative expenses, with a corresponding credit to additional paid in capital. Their fair value has been estimated using a multi-nomial lattice model with an expected life of 3 years, a risk free rate ranging from 0.259% to 0.692%, stock price in range of $0.970 to $1.367 and expected volatility of 125.4% to 131.90%

Warrant exercises

No warrants were exercised during the fiscal year ended March 31, 2020 and the three months ended June 30, 2020.

Warrant issuances, exercises and expirations or cancellations during the three months ended June 30, 2020 and preceding periods resulted in warrants outstanding at the end of those respective periods as follows:

Broker
Warrants Consultant
Warrants Warrants Issued on
Conversion of
Convertible Notes Private
Placement
Warrants Total

As at March 31, 2018 384,152 669,972 * 2,734,530 1,163,722 4,952,376

Less: Exercised (62,838 ) - - - (62,838 )

Less: Expired/cancelled - (31,250 ) - - (31,250 )

Add: Issued - 65,000 - - 65,000

As at June 30, 2018 321,314 703,722 * 2,734,530 1,163,722 4,923,288

Less: Exercised - - - - -

Less: Expired/cancelled - - - -

Add: Issued - 393,333 - - 393,333

As at September 30 2018 321,314 1,097,055 * 2,734,530 1,163,722 5,316,621

Less: Exercised - - - - -

Less: Expired/cancelled - (126,250 )** - - (126,250 )

Add: Issued - 50,000 - - 50,000

As at December 31, 2018 321,314 1,020,805 * 2,734,530 1,163,722 5,240,371

Less: Exercised - - - - -

Less: Expired/cancelled - (184,916 )** - - (184,916 )

Add: Issued - 341,268 - - 341,268

As at March 31, 2019 321,314 1,177,157 * 2,734,530 1,163,722 5,396,723

Less: Exercised - - - - -

Less: Expired/cancelled - (5,000 ) - - (5,000 )

Add: Issued - 83,750 - - 83,750

As at June 30, 2019 321,314 1,255,907 * 2,734,530 1,163,722 5,475,473

Less: Exercised - - - - -

Less: Expired/cancelled - (10,000 ) - - (10,000 )

Add: Issued - 311,350 - - 311,350

As at September 30, 2019 321,314 1,557,257 * 2,734,530 1,163,722 5,776,823

Less: Exercised - - - - -

Less: Exercised - - - - -

Less: Expired/cancelled - (35,000 ) - - (35,000 )

Add: Issued - 568,000 - - 568,000

As at December 31, 2019 321,314 2,090,257 * 2,734,530 1,163,722 6,309,823

Less: Exercised - - - - -

Less: Expired/cancelled - (98,750 ) - - (98,750 )

Add: Issued - 58,330 - - 58,330

As at March 31, 2020 321,314 2,049,837 * 2,734,530 1,163,722 6,269,403

Less: Expired/cancelled - (65,000 ) (911,510 ) - (986,510 )

Add: Issued - 50,000 - - 50,000

As at June 30, 2020 321,314 2,034,837 * 1,823,020 1,163,722 5,332,893

Exercise Price $ 0.78-$3.00 $ 0.48-$7.59 2.00 3.00

Expiration Date March 2022 to July 2022 April 2020 to June 2023 March 2020 to November 2022 April 2020 to July 2020

*Consultant Warrants include warrants issued to directors and officers of the Company who were not members of the Company’s options plan at the time of issuance. As at June 30, 2020, Consultant Warrants include an aggregate of 638,806 warrants provided to an officer of the Company as compensation while he was not a member of any Company options plan.

f) Stock-based compensation

2015 Equity Incentive Plan

On March 30, 2015, iMedical approved Directors, Officers and Employees Stock Option Plan, under which it authorized and issued 3,000,000 options. This plan was established to enable the Company to attract and retain the services of highly qualified and experience directors, officers, employees and consultants and to give such person an interest in the success of the Company. As of March 31, 2018, and March 31, 2017, there were no outstanding vested options and 137,500 unvested options at an exercise price of $.0001 under this plan. These options now represent the right to purchase shares of the Company’s common stock using the same exchange ratio of approximately 1.1969:1, thus there were 164,590 (35,907 had been cancelled) adjusted unvested options as at March 31, 2018. These remaining 164,590 options were exercised during the year ended March 31, 2019. No other grants will be made under this plan.

The following table summarizes the stock option activities of the Company:

Number of

options

Weighted

average exercise price ($)

Granted 3,591,000 0.0001

Exercised (3,390,503 ) 0.0001

Outstanding as of December 31, 2015 200,497 0.0001

Cancelled during 2016 (35,907 ) 0.0001

Outstanding as of March 31, 2018 164,590 0.0001

Exercised (164,590 ) 0.0001

Outstanding as of June 30, 2020 and March 31, 2019 -

The fair value of options at the issuance date were determined at $2,257,953 which were fully expensed during the twelve months ended December 31, 2015 based on vesting period and were included in general and administrative expenses with corresponding credit to additional paid-in-capital. During the twelve months ended December 31, 2015, 3,390,503 (2,832,500 Pre-exchange Agreement) options were exercised by those employees who met the vesting conditions; 50% of the grants either vest immediately or at the time of U.S. Food and Drug Administration (FDA) filing date and 50% will vest upon Liquidity Trigger. Liquidity Trigger means the day on which the board of directors resolve in favor of i) the Company is able to raise a certain level of financing; ii) a reverse takeover transaction that results in the Company being a reporting issuer, and iii) initial public offering that results in the Company being a reporting issuer.

2016 Equity Incentive Plan

On February 2, 2016, the Board of Directors of the Company approved 2016 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to advance the interests of the Company and its stockholders by providing an incentive to attract, retain and reward persons performing services for the Company and by motivating such persons to contribute to the growth and profitability of the Company. The Plan seeks to achieve this purpose by providing for awards in the form of options, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, restricted stock units, performance shares, performance units and other stock-based awards.

The Plan shall continue in effect until its termination by the board of directors or committee formed by the board; provided, however, that all awards shall be granted, if at all, on or before the day immediately preceding the tenth (10th) anniversary of the effective date. The maximum number of shares of stock that may be issued under the Plan shall be equal to 3,750,000 shares; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 15% of the Company’s outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase.

During July 2016, the Company granted an officer options to purchase an aggregate of 2,499,998 shares of common stock at an exercise price of $2.20 subject to a 3 year vesting period, with the fair value of the options being expensed over a 3 year period. Two additional employees were also granted 175,000 options to purchase shares of common stock at an exercise price of $2.24 with a 1 year vesting period, with the fair value of the options being expensed over a 1 year period. One additional employee was also granted 35,000 options to purchase shares of common stock at an exercise price of $2.24 with a 2 year vesting period, with the fair value of the options expensed over a 2 year period.

During the year ended March 31, 2018, an additional 1,437,500 stock options were granted with a weighted average remaining contractual life from 2.76 to 9.51 years.

During the year ended March 31, 2019, an additional 270,521 stock options were granted with a weighted average remaining contractual life from 2.76 to 9.51 years. During the year ended March 31, 2019, the Company recorded stock based compensation of $1,451,261 in connection with ESOP 2016 Plan under general and administrative expenses with corresponding credit to additional paid in capital.

Based on the 2016 Option Plan, the Company is authorized to issue employee options with a 10-year term. On March 31, 2020, the Company’s Board of Directors approved the amendment of certain prior options grants, issued to current employees, previously issued with a 3-year term, such that the respective options issued under these agreements would have their term extended to 10 years. The Company revalued these options use g a lattice model with an expected life of 10 years, risk free rates of 0.46% to 0.75%, stock price of $0.974 and expected volatility of 132.2%, in order to recognize the additional expense associated with the longer term and recognized a one-time charge of $1,600,515 in share-based compensation, with a corresponding adjustment to adjusted paid in capital.

During the year ended March 31, 2020, an additional 88,100 stock options were granted with a weighted average remaining contractual life from 2.76 to 9.51 years. The Company recorded stock-based compensation of $2,408,713 in connection with ESOP 2016 Plan under general and administrative expenses with corresponding credit to additional paid in capital.

During the three months ended June 30, 2020, the Company granted 1,811,847 options, including 1,400,000 options to an executive and director of the Company and an additional 367,647 options to another director. Their fair value, has been estimated using a multi-nomial lattice model with an expected life of up to 6 years, a risk free rate ranging from 0.259% to 0.692%, stock price in range of $0.970 to $1.367 and expected volatility of 125.4% to 131.90%.

The following table summarizes the stock option activities of the Company:

Number of

options

Weighted

average exercise price ($)

Granted 4,147,498 3.2306

Exercised - -

Outstanding as of June 30 and March 31, 2018 4,147,498 3.2306

Granted 270,521 1.8096

Exercised - -

Outstanding as of June 30, 2019 and March 31, 2019 4,418,019 3.1436

Granted 88,100 0.7763

Expired (112,509 ) 2.723

Outstanding as of March 31, 2020 4,393,610 3.1069

Granted 1,811,847 1.0513

Exercised - -

Outstanding as of June 30 and March 31, 2018 6,205,457 2.5070

During the three months ended June 30, 2020, the Company recorded stock-based compensation of $232,519, in connection with the 2016 equity incentive plan (June 30, 2019 – $338,889) under general and administrative expenses with a corresponding credit to additional paid in capital.

The fair value of each option granted is estimated at the time of grant using multi-nomial lattice model using the following assumptions:

2019 2017-2018 2016-2017 2015-2016

Exercise price ($) 2.00 1.24-7.59 2.00 – 2.58 0.0001

Risk free interest rate (%) 2.27 to 2.54 1.98-2.81 0.45 - 1.47 0.04 - 1.07

Expected term (Years) 3 3 1 - 3 10

Expected volatility (%) 112.5 -141.10 97.8-145.99 101 – 105 94

Expected dividend yield (%) 0 0 0 0

Fair value of option ($) 0.28 0.6 0.88 0.74

Expected forfeiture (attrition) rate (%) 0.00 0.00 0.00 – 5.00 5.00 - 20.00

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R15.htm IDEA: XBRL DOCUMENT v3.20.2

Related Party Transactions and Balances
3 Months Ended

Jun. 30, 2020

Related Party Transactions [Abstract]

Related Party Transactions and Balances
9. RELATED PARTY TRANSACTIONS AND BALANCES

The Company’s transactions with related parties were carried out on normal commercial terms and in the course of the Company’s business. Other than those disclosed elsewhere in the financial statements, related party transactions are as follows:

Three Months
Ended

June 30, 2020

Three Months
Ended

June 30, 2019

$ $

Salary and allowance* 150,500 135,052

Stock based compensation** 236,044 308,755

Total 386,544 443,807

The above expenses were recorded under general and administrative expenses.

* Salary and allowance include salary, car allowance, vacation pay, bonus and other allowances paid or payable to key management of the Company.

** Stock based compensation represent the fair value of the options, warrants and equity incentive plan for directors and key management of the Company.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R16.htm IDEA: XBRL DOCUMENT v3.20.2

Lease
3 Months Ended

Jun. 30, 2020

Leases [Abstract]

Operating Lease Right-Of-Use Assets and Lease Obligations
10. LEASE

The Company has one operating lease primarily for office and administration.

The Company adopted ASC 842 – Leases using the modified retrospective cumulative catch-up approach beginning on April 1, 2019. Under this approach, the Company did not restate its comparative amounts and recognized a right-of-use asset equal to the present value of the future lease payments. The Company elected to apply the practical expedient to only transition contracts which were previously identified as leases and elected to not recognize right-of-use assets and lease obligations for leases of low value assets.

When measuring the lease obligations, the Company discounted lease payments using its incremental borrowing rate at April 1, 2019. The weighted-average-rate applied is 10%.

$

Operating lease right-of-use asset - initial recognition 413,236

Amortization (198,352 )

Balance at June 30, 2020 214,884

Operating lease obligation - initial recognition 413,236

Repayment and interest accretion (192,093 )

Balance at June 30, 2020 221,143

Current portion of operating lease obligation 221,143

Noncurrent portion of operating lease obligation -

The operating lease expense was $55,299 for the three months ended June 30, 2020 and $173,175 for the year ended March 31, 2020 and included in the General and administrative expenses.

The following table represents the contractual undiscounted cash flows for lease obligations as at June 30, 2020.

$

Less than one year 230,118

Beyond one year -

Total undiscounted lease obligations 230,118

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=77888251
+ Details

Name: us-gaap_LesseeOperatingLeasesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R17.htm IDEA: XBRL DOCUMENT v3.20.2

Contingencies
3 Months Ended

Jun. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Contingencies
11. CONTINGENCIES

There are no claims against the company that were assessed as significant, which were outstanding as at June 30, 2020 and, consequently, no provision for such has been recognized in the consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R18.htm IDEA: XBRL DOCUMENT v3.20.2

Subsequent Events
3 Months Ended

Jun. 30, 2020

Subsequent Events [Abstract]

Subsequent Events
12. SUBSEQUENT EVENTS

The Company’s management has evaluated subsequent events up to August 14, 2019, the date the condensed consolidated financial statements were issued, pursuant to the requirements of ASC 855 and has determined the following material subsequent events:

From July 24, 2020 to July 31, 2020, the Company entered into subscription agreements with accredited investors for the sale to the investors of convertible promissory notes (the “Notes”) in the aggregate principal amount of $1,253,000. The Notes will bear interest at the rate of 12% per year and will mature one year from the final closing date of the offering. The Notes will be convertible into shares of common stock, at the option of the holder, commencing six months from issuance, at a conversion price equal to 75% of the volume weighted average price of the common stock for the five trading days prior to the conversion date. The Notes will automatically convert into common stock (in each case, subject to the trading volume of the Company’s common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company’s common stock being listed on a national securities exchange, in which event the conversion price will be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company’s next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price will be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing. The Company may prepay the Notes upon 20 days’ written notice and payment of a 15% prepayment fee. Upon conversion of the Notes, the Company will also issue to the investors warrants (the “Warrants”) to purchase 50% of the number of shares of common stock issued upon conversion of the Notes. The Warrants will have a term of three years and an exercise price equal to 120% of the volume weighted average price of the common stock for the 20 days prior to the final closing date of the offering, subject to adjustment.

In July 2020, an exchangeable shareholder holding 179,540 exchangeable shares exchanged these for an equivalent number of common shares of the Company. Also in July 2020, the Company issued 83,500 common shares as compensation for services to be provided by a contractor.

On August 6, 2020, the Company announced that it received a 510(k) clearance from the FDA for its Bioflux Software II System, engineered to improve workflows and reduce estimated analysis time from 5 minutes to 30 seconds. Because ECG monitoring requires significant human oversight to review and interpret incoming patient data to discern actionable events for clinical intervention, highlighting the necessity of driving operational efficiency, this improvement in analysis time reduces operational costs and allows the company to improve customer service and provide improved response times to physicians and their at-risk patients.

On August 11, 2020, the Company entered into an agreement of understanding that establishes terms under which Biotricity will enter into a licensing agreement, with an exclusive right to acquire MD Matrix Inc. and its telemedicine platform, which includes capabilities for real-time streaming of medical devices. The terms of the agreement of understanding expire ninety days after its execution.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R19.htm IDEA: XBRL DOCUMENT v3.20.2

Summary of Significant Accounting Policies (Policies)
3 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Use of Estimates
Use of Estimates

The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of derivatives, convertible promissory notes, stock options, and assumptions used in the going concern assessment. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.

Earnings (Loss) Per Share
Earnings (Loss) Per Share

The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at June 30, 2020 and 2018.

Fair Value of Financial Instruments
Fair Value of Financial Instruments

ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities.

● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets.

● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value.

In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes, and accounts payable and accrued liabilities. The Company’s cash and derivative liabilities, which are carried at fair values, are classified as a Level 1 and Level 2, respectively. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.

Leases
Leases

On April 1, 2019, the Company adopted Accounting Standards Codification Topic 842, “Leases” (“ASC 842”) to replace existing lease accounting guidance. This pronouncement is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases will continue to be recognized in a manner similar to previous accounting guidance. The Company adopted ASC 842 utilizing the transition practical expedient added by the Financial Accounting Standards Board (“FASB”), which eliminates the requirement that entities apply the new lease standard to the comparative periods presented in the year of adoption.

The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the consolidated balance sheet.

Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in our consolidated statement of income. The Company determines the lease term by agreement with lessor. As our lease do not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion.

Government Loan
Government loan

For loans received from federal government that contains certain operating conditions and with terms over twelve month time, the Company records those loans as long term liabilities.

Convertible Notes Payable and Derivative Instruments
Convertible Notes Payable and Derivative Instruments

The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.

Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the new guidance effectively on April 1, 2020. The Company identified and updated existing internal controls and procedures to ensure compliance with the new guidance, but such modifications were not deemed to be material to the Company's overall system of internal control. While the adoption of this ASU did not have a material impact on the Company's consolidated financial statements, it required changes to the Company's process of estimating expected credit losses on trade receivables.

In July 2019, the FASB issued ASU 2019-07, Codification Updates to SEC Sections. This ASU amends various SEC paragraphs pursuant to the issuance of SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization. One of the changes in the ASU requires a presentation of changes in stockholders’ equity in the form of a reconciliation, either as a separate financial statement or in the notes to the financial statements, for the current and comparative year-to-date interim periods. The Company presented changes in stockholders' equity as separate financial statements for the current and comparative year-to-date interim periods beginning on April 1, 2019. The additional elements of the ASU did not have a material impact on the Company's consolidated financial statements.

In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. On June 16, 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis. That model replaces the probable, incurred loss model for those assets. Through the amendments in that Update, the Board added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. The amendments apply to all reporting entities within the scope of the affected accounting guidance. ASU 2019-11 is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements and related disclosures.

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impacts of the provisions of ASU 2019-12 on its financial condition, results of operations, and cash flows.

In March 2020, the FASB issued ASU No. 2030-20 Codification Improvements to Financial Instruments, An Amendment of the FASB Accounting Standards Codification: a)in ASU No. 2016-01, b) in Subtopic 820-10, c) for depository and lending institutions clarification in disclosure requirements, d) in Subtopic 470-50, e) in Subtopic 820-10, f) Interaction of Topic 842 and Topic 326, g) Interaction of the guidance in Topic 326 and Subtopic 860-20.The amendments in this Update represent changes to clarify or improve the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. For public business entities updates under the following paragraphs: a), b), d) and e) are effective upon issuance of this final update. The effective date for c) is for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company does not expect that the new guidance will significantly impact its consolidated financial statements.

The Company continues to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

X

- Definition
Convertible notes payable and derivative instruments [Policy Text Block]
+ References
No definition available.
+ Details

Name: BTCY_ConvertibleNotesPayableAndDerivativeInstrumentsPolicyTextBlock

Namespace Prefix: BTCY_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Government loan [Policy Text Block]
+ References
No definition available.
+ Details

Name: BTCY_GovernmentLoanPolicyTextBlock

Namespace Prefix: BTCY_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Operating leases [Policy Text Block]
+ References
No definition available.
+ Details

Name: BTCY_OperatingLeasesPolicyTextBlock

Namespace Prefix: BTCY_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R20.htm IDEA: XBRL DOCUMENT v3.20.2

Accounts Payable and Accrued Liabilities (Tables)
3 Months Ended

Jun. 30, 2020

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

As at
June 30, 2020
$ As at
March 31, 2020
$

Accounts payable 1,012,630 1,094,072

Accrued liabilities 715,842 427,617

1,728,472 1,521,689

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R21.htm IDEA: XBRL DOCUMENT v3.20.2

Derivative Liabilities (Tables)
3 Months Ended

Jun. 30, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Liabilities
The Company analyzed the compound features of variable conversion and redemption embedded in this instrument, for potential derivative accounting treatment on the basis of ASC 820 (Fair Value in Financial Instruments), ASC 815 (Accounting for Derivative Instruments and Hedging Activities), Emerging Issues Task Force (“EITF”) Issue No. 00–19 and EITF 07–05, and determined that the embedded derivatives should be bundled and valued as a single, compound embedded derivative, bifurcated from the underlying equity instrument, treated as a derivative liability, and measured at fair value.

Total

$

Derivative liabilities as at March 31, 2019 -

Derivative fair value at issuance 1,083,952

Change in fair value of derivatives 60,781

Derivative liabilities as at March 31, 2020 $ 1,144,733

Derivative fair value at issuance 41,749

Change in fair value of derivatives (204,142 )

Derivative liabilities as at June 30, 2020 $ 982,340

Schedule of Derivative Components Valuation Assumptions
The lattice methodology was used to value the derivative components, using the following assumptions:

Assumptions

Dividend yield 12 %

Risk-free rate for term 0.62% – 1.14 %

Volatility 117.4% – 198.3 %

Remaining terms (Years) 0.01 – 1.0

Stock price ($ per share) $0.650 – $1.367

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (k)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_ScheduleOfAssumptionsUsedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of derivative liabilities at fair value.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R22.htm IDEA: XBRL DOCUMENT v3.20.2

Stockholders' Deficiency (Tables)
3 Months Ended

Jun. 30, 2020

Schedule of Warrants Outstanding
Warrant issuances, exercises and expirations or cancellations during the three months ended June 30, 2020 and preceding periods resulted in warrants outstanding at the end of those respective periods as follows:

Broker
Warrants Consultant
Warrants Warrants Issued on
Conversion of
Convertible Notes Private
Placement
Warrants Total

As at March 31, 2018 384,152 669,972 * 2,734,530 1,163,722 4,952,376

Less: Exercised (62,838 ) - - - (62,838 )

Less: Expired/cancelled - (31,250 ) - - (31,250 )

Add: Issued - 65,000 - - 65,000

As at June 30, 2018 321,314 703,722 * 2,734,530 1,163,722 4,923,288

Less: Exercised - - - - -

Less: Expired/cancelled - - - -

Add: Issued - 393,333 - - 393,333

As at September 30 2018 321,314 1,097,055 * 2,734,530 1,163,722 5,316,621

Less: Exercised - - - - -

Less: Expired/cancelled - (126,250 )** - - (126,250 )

Add: Issued - 50,000 - - 50,000

As at December 31, 2018 321,314 1,020,805 * 2,734,530 1,163,722 5,240,371

Less: Exercised - - - - -

Less: Expired/cancelled - (184,916 )** - - (184,916 )

Add: Issued - 341,268 - - 341,268

As at March 31, 2019 321,314 1,177,157 * 2,734,530 1,163,722 5,396,723

Less: Exercised - - - - -

Less: Expired/cancelled - (5,000 ) - - (5,000 )

Add: Issued - 83,750 - - 83,750

As at June 30, 2019 321,314 1,255,907 * 2,734,530 1,163,722 5,475,473

Less: Exercised - - - - -

Less: Expired/cancelled - (10,000 ) - - (10,000 )

Add: Issued - 311,350 - - 311,350

As at September 30, 2019 321,314 1,557,257 * 2,734,530 1,163,722 5,776,823

Less: Exercised - - - - -

Less: Exercised - - - - -

Less: Expired/cancelled - (35,000 ) - - (35,000 )

Add: Issued - 568,000 - - 568,000

As at December 31, 2019 321,314 2,090,257 * 2,734,530 1,163,722 6,309,823

Less: Exercised - - - - -

Less: Expired/cancelled - (98,750 ) - - (98,750 )

Add: Issued - 58,330 - - 58,330

As at March 31, 2020 321,314 2,049,837 * 2,734,530 1,163,722 6,269,403

Less: Expired/cancelled - (65,000 ) (911,510 ) - (986,510 )

Add: Issued - 50,000 - - 50,000

As at June 30, 2020 321,314 2,034,837 * 1,823,020 1,163,722 5,332,893

Exercise Price $ 0.78-$3.00 $ 0.48-$7.59 2.00 3.00

Expiration Date March 2022 to July 2022 April 2020 to June 2023 March 2020 to November 2022 April 2020 to July 2020

*Consultant Warrants include warrants issued to directors and officers of the Company who were not members of the Company’s options plan at the time of issuance. As at June 30, 2020, Consultant Warrants include an aggregate of 638,806 warrants provided to an officer of the Company as compensation while he was not a member of any Company options plan.

Schedule of Fair Value of Option Granted Using Valuation Assumptions
The fair value of each option granted is estimated at the time of grant using multi-nomial lattice model using the following assumptions:

2019 2017-2018 2016-2017 2015-2016

Exercise price ($) 2.00 1.24-7.59 2.00 – 2.58 0.0001

Risk free interest rate (%) 2.27 to 2.54 1.98-2.81 0.45 - 1.47 0.04 - 1.07

Expected term (Years) 3 3 1 - 3 10

Expected volatility (%) 112.5 -141.10 97.8-145.99 101 – 105 94

Expected dividend yield (%) 0 0 0 0

Fair value of option ($) 0.28 0.6 0.88 0.74

Expected forfeiture (attrition) rate (%) 0.00 0.00 0.00 – 5.00 5.00 - 20.00

2015 Equity Incentive Plan [Member]

Schedule of Stock Option Activities
The following table summarizes the stock option activities of the Company:

Number of

options

Weighted

average exercise price ($)

Granted 3,591,000 0.0001

Exercised (3,390,503 ) 0.0001

Outstanding as of December 31, 2015 200,497 0.0001

Cancelled during 2016 (35,907 ) 0.0001

Outstanding as of March 31, 2018 164,590 0.0001

Exercised (164,590 ) 0.0001

Outstanding as of June 30, 2020 and March 31, 2019 -

2016 Equity Incentive Plan [Member]

Schedule of Stock Option Activities
The following table summarizes the stock option activities of the Company:

Number of

options

Weighted

average exercise price ($)

Granted 4,147,498 3.2306

Exercised - -

Outstanding as of June 30 and March 31, 2018 4,147,498 3.2306

Granted 270,521 1.8096

Exercised - -

Outstanding as of June 30, 2019 and March 31, 2019 4,418,019 3.1436

Granted 88,100 0.7763

Expired (112,509 ) 2.723

Outstanding as of March 31, 2020 4,393,610 3.1069

Granted 1,811,847 1.0513

Exercised - -

Outstanding as of June 30 and March 31, 2018 6,205,457 2.5070

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775
+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=BTCY_TwoThousandAndFifteenEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=BTCY_TwoThousandAndSixteenEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R23.htm IDEA: XBRL DOCUMENT v3.20.2

Related Party Transactions and Balances (Tables)
3 Months Ended

Jun. 30, 2020

Related Party Transactions [Abstract]

Schedule of Related Party Transactions
Other than those disclosed elsewhere in the financial statements, related party transactions are as follows:

Three Months
Ended

June 30, 2020

Three Months
Ended

June 30, 2019

$ $

Salary and allowance* 150,500 135,052

Stock based compensation** 236,044 308,755

Total 386,544 443,807

The above expenses were recorded under general and administrative expenses.

* Salary and allowance include salary, car allowance, vacation pay, bonus and other allowances paid or payable to key management of the Company.

** Stock based compensation represent the fair value of the options, warrants and equity incentive plan for directors and key management of the Company.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R24.htm IDEA: XBRL DOCUMENT v3.20.2

Lease (Tables)
3 Months Ended

Jun. 30, 2020

Leases [Abstract]

Schedule of Operating Leases Obligations

$

Operating lease right-of-use asset - initial recognition 413,236

Amortization (198,352 )

Balance at June 30, 2020 214,884

Operating lease obligation - initial recognition 413,236

Repayment and interest accretion (192,093 )

Balance at June 30, 2020 221,143

Current portion of operating lease obligation 221,143

Noncurrent portion of operating lease obligation -

Schedule of Contractual Undiscounted Cash Flows for Lease Obligation
The following table represents the contractual undiscounted cash flows for lease obligations as at June 30, 2020.

$

Less than one year 230,118

Beyond one year -

Total undiscounted lease obligations 230,118

X

- Definition
Schedule of Contractual Undiscounted Cashflows for Lease Obligation [Table text block]
+ References
No definition available.
+ Details

Name: BTCY_ScheduleOfContractualUndiscountedCashflowsForLeaseObligationTableTextblock

Namespace Prefix: BTCY_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 1,3)
-URI http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717

Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121555522&loc=d3e12069-110248

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121549808&loc=d3e36991-112694
+ Details

Name: us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R25.htm IDEA: XBRL DOCUMENT v3.20.2

Basis of Presentation, Measurement and Consolidation (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended

May 22, 2020

Jan. 09, 2020

Jan. 09, 2020

Dec. 19, 2019

Dec. 31, 2019

Oct. 31, 2019

Jun. 30, 2020

Jun. 30, 2019

Mar. 31, 2020

Accumulated deficit $ (49,758,760) $ (46,364,364)

Working capital deficit $ 2,696,943

Preferred stock, shares issued 1 1

Proceeds from preferred stock $ 100,000

COVID-19 [Member]

Funds raised $ 1,570,900

Series A Preferred Stock [Member]

Preferred stock, shares issued 215 7,830 7,830 7,830 8,045 8,045 7,830

Stock issued during the period, shares 6,000 6,000 6,100

Proceeds from preferred stock $ 6,000,000 $ 6,000,000 $ 6,100,000

Proceeds from convertible notes payable $ 100,000

Promissory Note and Short-Term Loans [Member]

Issuance value of debt, outstanding $ 3,094,820

Promissory Notes [Member]

Issuance value of debt, outstanding $ 916,301

Conversion of stock, shares 1,830 1,945 1,830

Proceeds from convertible notes payable $ 1,945,000 $ 1,830,000

X

- Definition
Working capital deficit.
+ References
No definition available.
+ Details

Name: BTCY_WorkingCapitalDeficit

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash received from principal payments made on loans related to operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585
+ Details

Name: us-gaap_ProceedsFromLoans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=BTCY_COVIDNineteenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=BTCY_PromissoryNoteAndShortTermLoansMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=BTCY_PromissoryNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R26.htm IDEA: XBRL DOCUMENT v3.20.2

Summary of Significant Accounting Policies (Details Narrative) - shares
3 Months Ended

Jun. 30, 2020

Jun. 30, 2018

Accounting Policies [Abstract]

Potentially dilutive shares outstanding

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 42 R27.htm IDEA: XBRL DOCUMENT v3.20.2

Accounts Payable and Accrued Liabilities (Details Narrative) - USD ($)

Jun. 30, 2020

Mar. 31, 2020

Payables and Accruals [Abstract]

Accounts payable $ 345,929 $ 379,881

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15(a))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(5))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878
+ Details

Name: us-gaap_AccountsPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R28.htm IDEA: XBRL DOCUMENT v3.20.2

Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)

Jun. 30, 2020

Mar. 31, 2020

Payables and Accruals [Abstract]

Accounts payable $ 1,012,630 $ 1,094,072

Accrued liabilities 715,842 427,617

Accounts payable and accrued liabilities $ 1,521,689 $ 1,521,689

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R29.htm IDEA: XBRL DOCUMENT v3.20.2

Convertible Promissory Notes and Short Term Loans (Details Narrative) - USD ($)
3 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Mar. 31, 2020

General and administrative expenses $ 3,205,233 $ 2,052,519

Promissory Notes [Member]

Debt face value $ 719,388

Debt instrument term 1 year 1 year

Debt interest rate 10.00%

Debt repayment $ 96,914

Converted preferred stock 100,000

Short term loan outstanding 1,152,001 $ 1,152,001

Promissory Notes [Member] | Interest Expense [Member]

General and administrative expenses $ 37,456 $ 30,052

Promissory Notes [Member] | Maximum [Member]

Debt interest rate 12.00%

Promissory Notes [Member]

Debt face value $ 916,301

X

- Definition
Converted preferred stock.
+ References
No definition available.
+ Details

Name: BTCY_ConvertedPreferredStock

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Short term loan outstanding.
+ References
No definition available.
+ Details

Name: BTCY_ShortTermLoanOutstanding

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=BTCY_PromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=BTCY_PromissoryNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R30.htm IDEA: XBRL DOCUMENT v3.20.2

Federally Guaranteed Loans (Details Narrative) - USD ($)
1 Months Ended

Apr. 30, 2020

May 31, 2020

Captioned Program Program [Member] | US Small Business Administration [Member]

Loan received $ 370,900

Interest rate 3.75%

Debt instrument term 30 years

Description debt instrument term The loan has a term of 30 years and an interest rate of 3.75%, without the requirement for payment in its first 12 months.

Payment Protection Program [Member]

Loan received $ 1,200,000

Description on loan The Note has a two-year term, bears interest at the rate of 1.0% per annum, and may be prepaid at any time without payment of any premium. No payments of principal or interest are due during the six-month period beginning on the date of the Note (the "Deferral Period").

Interest rate 1.00%

X

- Definition
Description debt instrument term.
+ References
No definition available.
+ Details

Name: BTCY_DescriptionDebtInstrumentTerm

Namespace Prefix: BTCY_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash received from principal payments made on loans related to operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585
+ Details

Name: us-gaap_ProceedsFromLoans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=BTCY_CaptionedProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=BTCY_USSmallBusinessAdministrationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=BTCY_PaymentProtectionProgramMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R31.htm IDEA: XBRL DOCUMENT v3.20.2

Derivative Liabilities (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended

May 22, 2020

Jan. 09, 2020

Jan. 09, 2020

Dec. 19, 2019

Dec. 31, 2019

Oct. 31, 2019

Jun. 30, 2020

Jun. 30, 2019

Mar. 31, 2020

Preferred stock, shares issued 1 1

Proceeds from preferred stock $ 100,000

Promissory Notes [Member]

Conversion of stock, shares 1,830 1,945 1,830

Proceeds from convertible notes payable $ 1,945,000 $ 1,830,000

Series A Preferred Stock [Member]

Preferred stock, shares issued 215 7,830 7,830 7,830 8,045 8,045 7,830

Proceeds from preferred stock $ 6,000,000 $ 6,000,000 $ 6,100,000

Stock issued during the period, shares 6,000 6,000 6,100

Proceeds from convertible notes payable $ 100,000

Preferred Stock [Member]

Preferred stock, shares issued 115

Proceeds from preferred stock $ 100,000

Stock issued during the period, shares 100

Accrued interest $ 15,000

X

- Definition
The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=BTCY_PromissoryNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R32.htm IDEA: XBRL DOCUMENT v3.20.2

Derivative Liabilities - Schedule of Derivative Liabilities (Details) - USD ($)
3 Months Ended 12 Months Ended

Jun. 30, 2020

Mar. 31, 2020

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative liabilities, beginning balance $ 1,144,733

Derivative fair value at issuance 41,749 1,083,952

Change in fair value of derivatives (204,142) 60,781

Derivative liabilities, ending balance $ 982,340 $ 1,144,733

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 48 R33.htm IDEA: XBRL DOCUMENT v3.20.2

Derivative Liabilities - Schedule of Derivative Components Valuation Assumptions (Details)
3 Months Ended

Jun. 30, 2020

$ / shares

Minimum [Member]

Stock price $ 0.650

Maximum [Member]

Stock price $ 1.367

Dividend Yield [Member]

Derivative liability, measurement input 12

Risk-Free Rate for Term [Member] | Minimum [Member]

Derivative liability, measurement input 0.62

Risk-Free Rate for Term [Member] | Maximum [Member]

Derivative liability, measurement input 1.14

Volatility [Member] | Minimum [Member]

Derivative liability, measurement input 1.174

Volatility [Member] | Maximum [Member]

Derivative liability, measurement input 1.983

Remaining Terms (Years) [Member] | Minimum [Member]

Derivative liability, remaining term (Years) 4 days

Remaining Terms (Years) [Member] | Maximum [Member]

Derivative liability, remaining term (Years) 1 year

X

- Definition
Derivative liability, remaining term (years).
+ References
No definition available.
+ Details

Name: BTCY_DerivativeLiabilityRemainingTerm

Namespace Prefix: BTCY_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Derivative stock price.
+ References
No definition available.
+ Details

Name: BTCY_DerivativeStockPrice

Namespace Prefix: BTCY_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Value of input used to measure derivative liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_DerivativeLiabilityMeasurementInput

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R34.htm IDEA: XBRL DOCUMENT v3.20.2

Stockholders' Deficiency (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended

Jan. 09, 2020

Jan. 09, 2020

Dec. 19, 2019

Feb. 02, 2016

Feb. 02, 2016

Mar. 31, 2020

Dec. 31, 2019

Dec. 19, 2019

Oct. 31, 2019

Jul. 31, 2019

May 31, 2019

Mar. 31, 2018

Jul. 31, 2016

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2018

Dec. 31, 2015

Dec. 31, 2020

Mar. 31, 2020

Mar. 31, 2019

Mar. 31, 2018

Mar. 31, 2017

Mar. 31, 2016

Dec. 31, 2015

May 22, 2020

Mar. 30, 2015

Common stock, shares authorized 125,000,000 125,000,000 125,000,000

Common stock, par value $ 0.001 $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000 10,000,000

Preferred stock, par value $ 0.001 $ 0.001 $ 0.001

Common stock, shares issued 32,593,769 33,384,769 32,593,769

Common stock, shares outstanding 32,593,769 33,384,769 32,593,769

Exchangeable shares outstanding 3,788,062 3,788,062 3,788,062

Preferred stock, shares issued 1 1 1

Number of common shares issued, value $ 14,003

General and administrative and research and development expenses $ 3,205,233 2,052,519

Accrued preferred stock dividends 257,927

Dividends paid 180,000

Issuance of shares for services, value 1,063,754 251,625

Research and development expenses $ 423,883 213,496

Stock price $ 0.588 $ 0.6 $ 0.76 $ 0.588 $ .28 $ 0.6 $ 0.88 $ 0.74

Number of options granted 1,811,847

Stock based compensation $ 232,519 $ 338,889

2015 Equity Incentive Plan [Member]

Number of common stock option exercise 164,590 3,390,503 164,590 164,590 3,390,503

Number of options authorized to issue 3,000,000

Number of options vested

Number of options non-vested 137,500 137,500 137,500

Options exercise price $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001

Number of options cancelled 35,907

Fair value of options $ 2,257,953

Vesting description Options were exercised by those employees who met the vesting conditions; 50% of the grants either vest immediately or at the time of U.S. Food and Drug Administration (FDA) filing date and 50% will vest upon Liquidity Trigger. Liquidity Trigger means the day on which the board of directors resolve in favour of i) the Company is able to raise a certain level of financing; ii) a reverse takeover transaction that results in the Company being a reporting issuer, and iii) initial public offering that results in the Company being a reporting issuer.

Number of options granted 3,591,000

Number of options granted, exercise price $ 0.0001

2016 Equity Incentive Plan [Member]

Number of common stock option exercise

Number of common stock compensation for services, value $ 1,600,515

Expected life 10 years

Stock price $ 0.974 0.974

Expected volatility 132.20%

Number of options authorized to issue 3,750,000 3,750,000

Options exercise price $ 3.1069 $ 3.2306 $ 2.5070 $ 3.1069 $ 3.2306 $ 3.1069 $ 3.1436 $ 3.2306 $ 3.2306

Plan description The maximum number of shares of stock that may be issued under the Plan shall be equal to 3,750,000 shares; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 15% of the Company's outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase.

Number of options granted 1,437,500 1,811,847 1,811,847 88,100

Number of options granted, exercise price $ 0.7763 $ 0.7763 $ 88,100 $ 1.8096

Weighted average remaining contractual life 10 years

Stock based compensation $ 232,519 $ 367,647 $ 2,408,713 $ 1,451,261

2016 Equity Incentive Plan One [Member]

Number of options granted 88,100

Stock based compensation $ 2,408,713

Intrinsic value of options $ 0 $ 0

Minimum [Member]

Expected life 1 year

Risk free rate 2.27% 1.98% 0.45% 0.04%

Minimum [Member] | 2016 Equity Incentive Plan [Member]

Risk free rate 0.46%

Weighted average remaining contractual life 2 years 9 months 3 days 2 years 9 months 3 days 2 years 9 months 3 days

Minimum [Member] | 2016 Equity Incentive Plan One [Member]

Weighted average remaining contractual life 2 years 9 months 3 days

Maximum [Member]

Expected life 3 years 3 years 3 years 10 years

Risk free rate 2.54% 2.81% 1.47% 1.07%

Maximum [Member] | 2016 Equity Incentive Plan [Member]

Risk free rate 0.75%

Weighted average remaining contractual life 9 years 6 months 3 days 9 years 6 months 3 days 9 years 6 months 3 days

Maximum [Member] | 2016 Equity Incentive Plan One [Member]

Weighted average remaining contractual life 9 years 6 months 3 days

Issuance of Common Shares [Member]

Number of common shares issued, shares 631,000 972,950

Number of common shares issued, value $ 666,129

Number of shares issued for services 791,000

General and administrative and research and development expenses $ 1,063,754 $ 835,619

Fair value of common share 791,000

Fair value of common share, value $ 1,063,754

Advisor [Member] | Issuance of Common Shares [Member]

Number of common shares issued, shares 25,000

Number of common shares issued, value $ 22,194

Promissory Notes [Member]

Conversion of stock, shares 1,830 1,945 1,830

Conversion of stock $ 1,830,000

Promissory Notes [Member]

Proceeds from issuance of warrants $ 92,416

Registered Offering [Member]

Number of common shares issued, shares 47,585 47,585

Proceeds from private offering $ 28,565 $ 28,565

Director of Company [Member]

Number of options granted 1,400,000

Another Director [Member]

Number of options granted 367,647

Various Consultants and Advisors [Member] | Issuance of Common Shares [Member]

Number of common shares issued, shares 178,750

Number of common shares issued, value $ 169,490

Investors [Member] | Common Stock [Member]

Number of common shares issued, shares 160,000 525,023

Consultants, Advisors and Other Service Providers [Member] | Common Stock [Member]

Number of shares issued for services 178,750

Issuance of shares for services, value $ 169,490

Research and development expenses $ 169,490

Officer [Member]

Consultant warrants shares 638,806

Officer [Member] | 2016 Equity Incentive Plan [Member]

Number of options granted 2,499,998

Number of options granted, exercise price $ 2.20

Options vesting period 3 years

Consultants and Advisors [Member]

Proceeds from warrants exercise $ 50,835

Number of warrants issued 62,838

Warrants exercise price $ 0.81

Advisor and Consultant [Member]

General and administrative and research and development expenses $ 184,637

Number of common stock compensation for services 50,000 1,021,430 849,601

Number of common stock compensation for services, value $ 45,113 $ 277,053 $ 467,411

Advisor and Consultant [Member] | Warrant [Member] | Minimum [Member]

Expected life 2 years 2 years

Risk free rate 0.259% 0.22% 2.13%

Stock price $ .970 $ .970 $ 0.48

Expected volatility 125.40% 114.30% 97.80%

Advisor and Consultant [Member] | Warrant [Member] | Maximum [Member]

Expected life 3 years 3 years 3 years

Risk free rate 0.692% 2.81%

Stock price $ 1.367 $ 1.367 $ 4.15

Expected volatility 131.90% 132.20% 141.10%

Two Employees [Member] | 2016 Equity Incentive Plan [Member]

Number of options granted 175,000

Number of options granted, exercise price $ 2.24

Options vesting period 1 year

One Employee [Member] | 2016 Equity Incentive Plan [Member]

Number of options granted 35,000

Number of options granted, exercise price $ 2.24

Options vesting period 2 years

Board of Director [Member] | 2016 Equity Incentive Plan [Member]

Weighted average remaining contractual life 3 years

Exchange Agreement [Member]

Percentage of common stock issued and outstanding 90.00%

Common stock exchange description 1.197 shares of its common stock in exchange for each common share

Number of common shares issued, shares 13,376,947

Exchange Agreement [Member] | 11% Secured Convertible Promissory Notes [Member]

Conversion description The outstanding 11% secured convertible promissory notes of the Company were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of Biotricity at a 25% discount to purchase price per share in Biotricity's next offering.

Discount percentage for purchase price per shares 25.00%

Exchange Agreement [Member] | Warrant [Member]

Common stock exchange description 1.197 shares of the common stock of Biotricity for each Warrant, with an inverse adjustment to the exercise price of the Warrants to reflect the exchange ratio of approximately 1.197:1

Exchange ratio 1.197:1

Exchange Agreement [Member] | Advisor Warrant [Member]

Common stock exchange description 1.197 shares of the common stock of Biotricity for each Advisor Warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1

Exchange ratio 1.197:1

Exchange Agreement [Member] | Options [Member]

Common stock exchange description 1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1

Exchange ratio 1.197:1

Exchange Agreement [Member] | Exchangeco [Member]

Common stock exchange description

Number of exchangeable shares issued

Pre-Exchange Agreement [Member] | 2015 Equity Incentive Plan [Member]

Number of common stock option exercise 2,832,500

Issuance of Employee Options [Member] | 2016 Equity Incentive Plan One [Member]

Expected life 6 years

Stock price $ 0.974 $ 0.974

Expected volatility 132.20%

Weighted average remaining contractual life 10 years

Stock based compensation $ 1,600,515

Issuance of Employee Options [Member] | Minimum [Member] | 2016 Equity Incentive Plan One [Member]

Risk free rate 0.46%

Stock price 0.970 $ 0.970

Expected volatility 125.40%

Number of options granted, exercise price $ 0.259

Issuance of Employee Options [Member] | Maximum [Member] | 2016 Equity Incentive Plan One [Member]

Risk free rate 0.75%

Stock price $ 1.367 $ 1.367

Expected volatility 131.90%

Number of options granted, exercise price $ 0.692

Series A Preferred Stock [Member]

Preferred stock, shares authorized 20,000 20,000 20,000

Preferred stock, par value $ 0.001 $ 0.001 $ 0.001

Preferred stock, shares issued 7,830 7,830 7,830 7,830 8,045 7,830 8,045 7,830 215

Number of common shares issued, shares 6,000 6,000 6,100

Series A Preferred Stock [Member] | Securities Purchase Agreement [Member]

Number of exchangeable shares issued 6,000

Proceeds from private offering $ 6,000,000

Preferred stock, conversion method on issuance, description The shares are convertible into common stock of the Company at a conversion price equal to the greater of $0.001 or a 15% discount to the 5-day volume weighted price at the time of conversion. The conversion rights commence 24 months after issuance, but conversion is limited to 5% of the aggregate purchase price of the holder on a monthly basis thereafter. Alternatively, the shares are convertible into common stock at a 15% discount to any qualified future common stock financing conducted by the Company. The Company may redeem the shares after 1 year for 110% of the purchase price plus accrued dividends. The preferred stock bears a dividend rate of 12% per annum

X

- Definition
Common stock exchange description.
+ References
No definition available.
+ Details

Name: BTCY_CommonStockExchangeDescription

Namespace Prefix: BTCY_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Consultant warrants shares.
+ References
No definition available.
+ Details

Name: BTCY_ConsultantWarrantsShares

Namespace Prefix: BTCY_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Discount percentage for purchase price per shares.
+ References
No definition available.
+ Details

Name: BTCY_DiscountPercentageForPurchasePricePerShares

Namespace Prefix: BTCY_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Exchange ratio.
+ References
No definition available.
+ Details

Name: BTCY_ExchangeRatio

Namespace Prefix: BTCY_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of common share
+ References
No definition available.
+ Details

Name: BTCY_FairValueOfCommonShare

Namespace Prefix: BTCY_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of common share, value.
+ References
No definition available.
+ Details

Name: BTCY_FairValueOfCommonShareValue

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of exchangeable shares issued.
+ References
No definition available.
+ Details

Name: BTCY_NumberOfExchangeableSharesIssued

Namespace Prefix: BTCY_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of common stock issued and outstanding.
+ References
No definition available.
+ Details

Name: BTCY_PercentageOfCommonStockIssuedAndOutstanding

Namespace Prefix: BTCY_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Preferred stock, conversion method on issuance, description
+ References
No definition available.
+ Details

Name: BTCY_PreferredStockConversionMethodOnIssuanceDescription

Namespace Prefix: BTCY_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.
+ References
No definition available.
+ Details

Name: us-gaap_CommonStockOtherSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586
+ Details

Name: us-gaap_ConversionOfStockAmountIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 405
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770
+ Details

Name: us-gaap_DividendsCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 405
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817
+ Details

Name: us-gaap_DividendsPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow associated with the amount received from entity's first offering of stock to the public.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Rate of weighted-average expected volatility for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares authorized for issuance under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=BTCY_TwoThousandAndFifteenEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=BTCY_TwoThousandAndSixteenEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=BTCY_TwoThousandAndSixteenEquityIncentivePlanOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementScenarioAxis=BTCY_IssuanceOfCommonSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=BTCY_AdvisorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=BTCY_PromissoryNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=BTCY_PromissoryNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=BTCY_RegisteredOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=BTCY_DirectorofCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=BTCY_AnotherDirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=BTCY_VariousConsultantsAndAdvisorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=BTCY_InvestorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=BTCY_ConsultantsAdvisorsAndOtherServiceProvidersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=srt_OfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=BTCY_ConsultantsAndAdvisorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=BTCY_AdvisorAndConsultantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=BTCY_TwoEmployeesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=BTCY_OneEmployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=BTCY_BoardOfDirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=BTCY_ExchangeAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=BTCY_ElevenPercentageSecuredConvertiblePromissoryNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=BTCY_AdvisorWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=BTCY_ExchangecoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=BTCY_PreExchangeAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=BTCY_IssueEmployeeOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=BTCY_SecuritiesPurchaseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R35.htm IDEA: XBRL DOCUMENT v3.20.2

Stockholders' Deficiency - Schedule of Warrants Outstanding (Details) - $ / shares
3 Months Ended

Jun. 30, 2020

Mar. 31, 2020

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Sep. 30, 2018

Jun. 30, 2018

Warrants outstanding, Beginning balance 6,269,403 6,309,823 5,776,823 5,475,473 5,396,723 5,240,371 5,316,621 4,923,288 4,952,376

Warrants outstanding, Exercised (986,510) (62,838)

Warrants outstanding, Expired/cancelled (95,750) (35,000) (5,000) (184,976) (126,250) (31,250)

Warrants outstanding, Issued 50,000 58,330 568,000 83,750 341,268 50,000 393,333 65,000

Warrants outstanding, Ending balance 5,332,893 6,269,403 6,309,823 5,776,823 5,475,473 5,396,723 5,240,371 5,316,621 4,923,288

Broker Warrants [Member]

Warrants outstanding, Beginning balance 321,314 321,314 321,314 321,314 321,314 321,314 321,314 321,314 384,152

Warrants outstanding, Exercised (62,838)

Warrants outstanding, Expired/cancelled

Warrants outstanding, Issued

Warrants outstanding, Ending balance 321,314 321,314 321,314 321,314 321,314 321,314 321,314 321,314 321,314

Broker Warrants [Member] | Minimum [Member]

Exercise Price $ 0.78

Expiration Date Mar. 31, 2022

Broker Warrants [Member] | Maximum [Member]

Exercise Price $ 3.00

Expiration Date Apr. 30, 2022

Consultant and Noteholder Warrants [Member]

Warrants outstanding, Beginning balance 2,049,837 ^[1] 2,090,257 ^[1] 1,557,257 ^[1] 1,255,907 ^[1] 1,177,157 ^[1] 1,020,805 1,097,055 ^[1] 703,722 ^[1] 669,972 ^[1]

Warrants outstanding, Exercised

Warrants outstanding, Expired/cancelled (98,750) (35,000) (10,000) (5,000) (184,916) ^[1] (126,250) ^[1] (31,250)

Warrants outstanding, Issued 58,330 568,000 311,350 83,750 341,268 50,000 393,333 65,000

Warrants outstanding, Ending balance 2,034,837 ^[1] 2,049,837 ^[1] 2,090,257 ^[1] 1,557,257 ^[1] 1,255,907 ^[1] 1,177,157 ^[1] 1,020,805 1,097,055 ^[1] 703,722 ^[1]

Consultant and Noteholder Warrants [Member] | Minimum [Member]

Exercise Price $ 0.48

Expiration Date Apr. 30, 2020

Consultant and Noteholder Warrants [Member] | Maximum [Member]

Exercise Price $ 7.59

Expiration Date Jun. 30, 2023

Warrants Issued on Conversion of Convertible Notes [Member]

Warrants outstanding, Beginning balance 2,734,530 2,734,530 2,734,530 2,734,530 2,734,530 2,734,530 (2,734,530) 2,734,530 2,734,530

Warrants outstanding, Exercised

Warrants outstanding, Expired/cancelled

Warrants outstanding, Issued

Warrants outstanding, Ending balance 1,823,020 2,734,530 2,734,530 2,734,530 2,734,530 2,734,530 2,734,530 (2,734,530) 2,734,530

Exercise Price $ 2.00

Warrants Issued on Conversion of Convertible Notes [Member] | Minimum [Member]

Expiration Date Mar. 31, 2020

Warrants Issued on Conversion of Convertible Notes [Member] | Maximum [Member]

Expiration Date Nov. 30, 2022

Private Placement Warrants [Member]

Warrants outstanding, Beginning balance 1,163,722 1,163,722 1,163,722 1,163,722 1,163,722 1,163,722 1,163,722 1,163,722 1,163,722

Warrants outstanding, Exercised

Warrants outstanding, Expired/cancelled

Warrants outstanding, Issued

Warrants outstanding, Ending balance 12,163,722 1,163,722 1,163,722 1,163,722 1,163,722 1,163,722 1,163,722 1,163,722 1,163,722

Exercise Price $ 3.00

Private Placement Warrants [Member] | Minimum [Member]

Expiration Date Apr. 30, 2020

Private Placement Warrants [Member] | Maximum [Member]

Expiration Date Jul. 31, 2020

[1] Consultant Warrants include warrants issued to directors and officers of the Company who were not members of the Company's options plan at the time of issuance. As at June 30, 2020, Consultant Warrants include an aggregate of 638,806 warrants provided to an officer of the Company as compensation while he was not a member of any Company options plan.

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of non-option equity instruments exercised by participants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares under non-option equity instrument agreements that were either cancelled or expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Net number of non-option equity instruments granted to participants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=BTCY_BrokerWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=BTCY_ConsultantWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=BTCY_WarrantsIssuedOnConversionOfConvertibleNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=BTCY_PrivatePlacementWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R36.htm IDEA: XBRL DOCUMENT v3.20.2

Stockholders' Deficiency - Schedule of Warrants Outstanding (Details) (Parenthetical)

Jun. 30, 2020

USD ($)

Consultant and Noteholder Warrants [Member] | Directors and Officers [Member]

Officer compensation $ 638,806

X

- Definition
Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(4))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227
+ Details

Name: us-gaap_OfficersCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=BTCY_ConsultantWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=BTCY_DirectorsandOfficersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R37.htm IDEA: XBRL DOCUMENT v3.20.2

Stockholders' Deficiency (Equity) - Schedule of Stock Option Activities (Details) - $ / shares
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended

Mar. 31, 2018

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2018

Dec. 31, 2015

Dec. 31, 2020

Mar. 31, 2020

Mar. 31, 2019

Mar. 31, 2018

Mar. 31, 2016

Dec. 31, 2015

Number of options outstanding, Granted 1,811,847

2015 Equity Incentive Plan [Member]

Number of options outstanding, Beginning balance 164,590 164,590

Number of options outstanding, Granted 3,591,000

Number of options outstanding, Exercised (164,590) (3,390,503) (164,590) (164,590) (3,390,503)

Number of options outstanding, Cancelled (35,907)

Number of options outstanding, Ending balance 164,590 200,497 164,590 200,497

Weighted average exercise price, Beginning balance $ 0.0001 $ 0.0001 $ 0.0001

Weighted average exercise price, Granted $ 0.0001

Weighted average exercise price, Exercised $ 0.0001 0.0001 0.0001

Weighted average exercise price, Cancelled $ 0.0001

Weighted average exercise price, Ending balance $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001

2016 Equity Incentive Plan [Member]

Number of options outstanding, Beginning balance 4,418,019 4,393,610 4,147,498 4,393,610 4,147,498 4,147,498

Number of options outstanding, Granted 1,437,500 1,811,847 1,811,847 88,100

Number of options outstanding, Expired (112,509)

Number of options outstanding, Exercised

Number of options outstanding, Cancelled

Number of options outstanding, Ending balance 4,147,498 6,229,866 6,205,457 4,147,498 4,418,019 4,393,610 4,147,498

Weighted average exercise price, Beginning balance $ 3.1069 $ 3.1436 $ 3.2306 $ 3.1436 $ 3.2306 $ 3.2306

Weighted average exercise price, Granted 0.7763 0.7763 $ 88,100 1.8096

Weighted average exercise price, Expired 2.723 2.723

Weighted average exercise price, Exercised

Weighted average exercise price, Ending balance $ 3.2306 $ 2.5070 $ 3.1069 $ 3.2306 $ 3.1069 $ 3.1436 $ 3.2306

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=BTCY_TwoThousandAndFifteenEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=BTCY_TwoThousandAndSixteenEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R38.htm IDEA: XBRL DOCUMENT v3.20.2

Stockholders' Deficiency (Equity) - Schedule of Fair Value of Option Granted Using Valuation Assumptions (Details) - $ / shares
12 Months Ended

Mar. 31, 2019

Mar. 31, 2018

Mar. 31, 2017

Mar. 31, 2016

Jun. 30, 2020

Mar. 31, 2020

Expected dividend yield 0.00% 0.00% 0.00% 0.00%

Fair value of option $ .28 $ 0.6 $ 0.88 $ 0.74 $ 0.76 $ 0.588

Expected forfeiture (attrition) rate 0.00% 0.00%

Maximum [Member]

Exercise price $ 2.00 $ 7.59 $ 2.58 $ .0001

Risk free interest rate 2.54% 2.81% 1.47% 1.07%

Expected term (Years) 3 years 3 years 3 years 10 years

Expected volatility 141.10% 145.99% 105.00% 94.00%

Expected forfeiture (attrition) rate 5.00% 20.00%

Minimum [Member]

Exercise price $ 1.24 $ 2.00

Risk free interest rate 2.27% 1.98% 0.45% 0.04%

Expected term (Years) 1 year

Expected volatility 112.50% 97.80% 101.00%

Expected forfeiture (attrition) rate 0.00% 5.00%

X

- Definition
Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.
+ References
No definition available.
+ Details

Name: BTCY_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate

Namespace Prefix: BTCY_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R39.htm IDEA: XBRL DOCUMENT v3.20.2

Related Party Transactions - Schedule of Related Party Transactions (Details) - USD ($)
3 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Related Party Transactions [Abstract]

Salary and allowance ^[1] $ 150,500 $ 135,052

Stock based compensation ^[2] 236,044 308,755

Total $ 386,544 $ 443,807

[1] Salary and allowance include salary, car allowance, vacation pay, bonus and other allowances paid or payable to key management of the Company.

[2] Stock based compensation represent the fair value of the options, warrants and equity incentive plan for directors and key management of the Company.

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.
+ References
No definition available.
+ Details

Name: us-gaap_SalariesWagesAndOfficersCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 55 R40.htm IDEA: XBRL DOCUMENT v3.20.2

Lease (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended

Jun. 30, 2020

Mar. 31, 2020

Apr. 02, 2019

Operating lease, weighted average rate 10.00%

General and Administrative Expense [Member]

Operating lease expense $ 55,299 $ 173,175

X

- Definition
Amount of operating lease expense. Excludes sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977
+ Details

Name: us-gaap_OperatingLeaseExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 R41.htm IDEA: XBRL DOCUMENT v3.20.2

Leases - Schedule of Operating Leases Obligations (Details) - USD ($)
3 Months Ended

Jun. 30, 2020

Mar. 31, 2020

Leases [Abstract]

Operating lease right-of-use asset - initial recognition $ 264,472

Amortization (198,352)

Balance at June 30, 2020 214,884

Operating lease obligation - initial recognition 413,236

Repayment and interest accretion (192,093)

Balance at June 30, 2020 221,143

Current portion of operating lease obligation 213,030 $ 213,030

Noncurrent portion of operating lease obligation $ 57,055

X

- Definition
Repayment and interest accretion.
+ References
No definition available.
+ Details

Name: BTCY_OperatingLeaseRepaymentAndInterestAccretion

Namespace Prefix: BTCY_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for right-of-use asset from operating lease.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 57 R42.htm IDEA: XBRL DOCUMENT v3.20.2

Operating Lease Right-Of-Use Assets and Lease Obligations - Schedule of Contractual Undiscounted Cash Flows for Lease Obligation (Details)

Jun. 30, 2020

USD ($)

Total undiscounted lease obligations $ 230,118

Less Than One Year [Member]

Total undiscounted lease obligations 230,118

Beyond One Year [Member]

Total undiscounted lease obligations

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LeaseContractualTermAxis=BTCY_LessThanOneYearMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LeaseContractualTermAxis=BTCY_BeyondOneYearMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 58 R43.htm IDEA: XBRL DOCUMENT v3.20.2

Subsequent Events (Details Narrative) - Subsequent Event [Member]

Jul. 31, 2020

USD ($)

shares

Number of exchangeable shares 179,540

Number of common shares issued, shares 83,500

Subscription Arrangement [Member] | Accredited Investors [Member]

Interest rate 12.00%

Convertible promissory notes Pricipal amount | $ $ 1,253,000

Conversion price 75.00%

Convertible promissory note, description The Notes will automatically convert into common stock (in each case, subject to the trading volume of the Company's common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company's common stock being listed on a national securities exchange, in which event the conversion price will be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company's next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price will be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing.

Convertible prepayment, description The Company may prepay the Notes upon 20 days' written notice and payment of a 15% prepayment fee.

Issue investors warrant, description Upon conversion of the Notes, the Company will also issue to the investors warrants (the "Warrants") to purchase 50% of the number of shares of common stock issued upon conversion of the Notes. The Warrants will have a term of three years and an exercise price equal to 120% of the volume weighted average price of the common stock for the 20 days prior to the final closing date of the offering, subject to adjustment.

X

- Definition
Conversion price.
+ References
No definition available.
+ Details

Name: BTCY_ConversionPrice

Namespace Prefix: BTCY_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Convertible promissory note, description.
+ References
No definition available.
+ Details

Name: BTCY_ConvertiblePrepaymentDescription

Namespace Prefix: BTCY_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Convertible promissory note, description.
+ References
No definition available.
+ Details

Name: BTCY_ConvertiblePromissoryNoteDescription

Namespace Prefix: BTCY_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Issue investors warrant, description
+ References
No definition available.
+ Details

Name: BTCY_IssueInvestorsWarrantDescription

Namespace Prefix: BTCY_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of exchangeable shares.
+ References
No definition available.
+ Details

Name: BTCY_NumberOfExchangeableShares

Namespace Prefix: BTCY_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TypeOfArrangementAxis=us-gaap_SubscriptionArrangementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_TitleOfIndividualAxis=BTCY_AccreditedInvestorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
M[WM0M2,:;>.%XFHCF-%):@L#?"PUIGFLEX/BO$77:>^K T^.C M^JU9/"SFB4@:\OSO+%;IPIDY**9[4N5JRP^_T69!5UHOXKDTO^A07SN!.T:5 M5+QH@F%<9*S^)Z]-(DX"?/],@-\$^!\"\.1,0- $!&:A-9E9UE>BR'(N^ $) M?36HZ0.3&Q,-J\F8?HP[)>!L!G%J^95'%3P5A0B+T3>F,O6&-JPN#YWF$9(I M$53.705WTS%NU"BO:V7_C'* OG.F4@FJ,8W?Q[M V:+Z1]2U;Q7\O6)C%'B? MD>_Y7@]/: ]?51_2Y-,B\)3N2,%[4N]76>]^?&PW82;AT>TN0O'%K*KENQJ"%D(E2)( M#A42TU?T!WWK8[,K>9Z'IX&'<6#!FK984ZM86[T/;V5OGNSAV!O]M%!<$HP!8N['4&Z TJ[09P2TLN5,82 MM%-$5?W&9U=\_&B7[\E.K!D/(=LP147]NM/I(D?47C*[X@4ROR/SAY#=9CE8 M8 B/,.&BUPLNZ-QQ-B)1!"]U 2)Q+6@C[,P9!T,(=P7)<[2N))R6\NP>N""F M1&7; [CS=SS(X+\55"2ZQ'X%!96BD!VIZX,W@\R.%W*7145B"[ MS$6@SMJQW9R/^Y(7!?0A.\6CY\^ IYL1]*-24D'' CGL:P0:Y2NCK!O9EV40 M3"?7,^]F[K[T4756CP=Z?6-DC>7?PG2_5=CE?EH]K#-Y;'?ICU3&7L\SV<7@ MS=-+Y9YTF;J 3?,M4<0KINJ&LYUM&_R5:6O=[O+ZZ^ [T?4O44[W$.J-K^%1 MB;KAK@>*EZ9G?>(*.F!SF,)'"A7Z CB_YUP=!_H&[6?/\G]02P,$% @ M!7X.4:D--"*B!@ <1D !@ !X;"]W;W)KV%4*AGW&49.>#K5*[T_$X"[8BYMF) MW(D$OEG+-.8*7M/-.-NE@J_R1G$TIA@[XYB'R6!REG]VFT[.Y%Y%82)N4Y3M MXYBGCQ]%)!_.!V3P],%=N-DJ_<%XF,6;I!;O%G*!ZRVC/2KBRE_*%?YJOS =:*1"0"I;O@\.L@9B**=$^@ MXY^RT\%Q3-VP_OS4^Z?<>7!FR3,QD]%?X4IMSP?> *W$FN\C=2 IDU&X MX@I>/O*()X% "]UQAD;HZ^("O7_WX6RL8%#==!R4 WPL!J = _R^3TX0PT-$ M,<6&YK/^YE]X"LV)J?D87#WZ2X_^TKP_UN7OU[N[R^M[-%TL+N\7/1VR8XP;JD(1'C@RT@,42*426?1DUW7Z3#'*29AS%.;T"KL0.YF%,(,\62&IMB*MS65F M4NNT9!#;MS!MJ#68,1>[EEFN>Y3K]LJ]EXI'D"[2%*83\2R#H#6)=-NC$VIA M%S=4&NPG4 ^L=._5K2'EV+7H6_74@E$\'>C M?M*.:9#O64T'#':.9;FTPX,J^Q/:'R@W]],KX]XK!5)#?'H^:<6QP1 J)\LB M3H?$BB>$O8I05_/IQ_G5_'Y^V1244=OQ1[Z\\M<&^2_? ^RCDRS * M52B>5M R+V"; \2FQ/'\YOR\;/CG]8M:E""<.LF=9?MGON0H4?\A;^U#:346V;+LRC!&/6E&LR!+64 M=.BM.$1>!!%Z8YQ5."+]//HD5K">4?2(-GN>\D0)'5^UC>B8U[#-&&*[V/=; MB_C_H?:\(L2'SK*'K^+DEHT/;9\7KF\8; MYA;B9[#ER4;D=44Q!))K!!UZWA [],5.R_CSS.'71B]SB=O$A5@=2--;?16I228S8Y52=EN7-/(=8I/F M8DKL0Z#T'B#0]N5P\CR7=MSG19F3:8.E^'+*[(V]$&X9\,D-Z_)#);Z ,[\COJ 5?4!ZZ\/6NA$T^N+ MM[E!6I=XYC,C,YQJ^\Z,K.(_Z^?_ BHS2#U35#%PD2>?;U]$O!3I]Q[ LMI- MYR^G-ZOHS7X-O6=E/_7I;EZ7CFOWX?J/$9!P-R'4WY%80QM\XL(2I,7]?O&B MY"Z_(E]*I62&\#W:PDYN7S1M^['O[),_@-02P,$% @ !7X. M47C_XCQ( P A T !@ !X;"]W;W)K 15!$ MU MEX#TOSQF.],480PI$0.V@4Q=63&>$JF& M?&V*#0<2Y4%I8MJ6Y9DIH9DQ'>?GYGPZ9EN9T SF'(EMFA+^]Q$2MI\8V'@[ M\4S7L=0GS.EX0]:P /E],^=J9%8N$4TA$Y1EB,-J8CS@^QGV=$"N^$%A+VK' M2*>R9.Q%#[Y&$\/21)! *+4%43\[F$&2:"?%\:-9#PQ @-%L"+;1#ZS_1B%H"'9P+L,L#N&^"4 4Z>:$&6I_6)2#(=<[9'7*N5FS[(YR:/5MG0 M3#_&A>3J*E5Q"D1('0F6T(A(-7@D"&0R1@D#4GR M 7U$[Y")1*S.BK$I%8=V,\/RGH_%/>TS]_RVS0;(L>Z0;=E62_BL._R)% YRKK-5LAR]W:$,XVI%D"VVI%5Y^[J7_([NI M-; L/#9W]0PNJ1J@3@7J7 =:/ !$MC)FG/Z#J VX\'1K*-@J/D?,/80-[&&% M/;P)FPJQ;4<>GI(G>!*E6/B%)%M%LW4;J7B3M4C1(O8K4ZR2= ML315ZU^?6O5ZU>HE58/2KRC]*RA[%:I_.E.VVUJI?90-ZJ"B#JZG/E^GP0F' MXSC!T/=&1\ M0ML=.75A@W=4\8ZNY[U0LJ.^T"W"3FAL'7J.=04VO(8QR=9 ME@GTS*'T;[#Y06!Y]E$./83-'&I]$U\_]9*A)7043.E9Q\D+]YCZ5(;]P'?/ M5#<^=#KH6P*G"?$"'Y6ZA$T"_GB!= O_=T4[QH4WA*_M4YR)5FEU:I2[* MFK"'YH1OZT[=:Q4^;4!VRT)U4=:$/C0K?%NWZJB\TSX46$/WF/=4Y0?..=Q# MQ\+=+>O&YEJZ7F(^5;4PF[4MLGX_49O(-4O!I)M\EWS MDDFU!\\/8_6:!%P+U/458_)MH#?BU8O7]#]02P,$% @ !7X.45C@YQ$O M!0 /Q$ !@ !X;"]W;W)K\8P?.]UWRG[P-2$"?&RRG-^UUD)L;]MMOER3#>8W=$MR^ MVGS+"$X*ITW61I;EMCWA^BWQ?D M)9E7S,F09E_21*SO6GX+)&2%=YF8T?='4A%R5+PES7CQ'[Q7ME8++'= 54.Z-RA<\'!KASL@FB)K* UP@+WNHR^ Z:L931U M4^2F\)9LTEQ-XUPP^6LJ_41O2/-$3@I)@+SC-$L3+.1@+N1%SI;@@*Y M"4, MJZQS@'-EN9$ELU9SN2?@B7(./BURO$M2Z?H97(/%? 0^_?&YVQ82H7I/>UFA M&91HT 4T-GBFN5AS$$I4R<_^;QX%^X'?;^]-L-,ULY%F659O]A,NI<3E&7$/*A2HC1O8DWQ$= MOC* <_)B&,".B\[P:IT(%S&V]%KM6QW3-P M33/HN1W8T8/S:G">L63"K]-P,@_GAOKPZU"^F2?)91]G10_C1"XFJ:H]M8P" M\K%5JP 'WR94R(MW!?S"+OBNRXC?H&HCRT&V?9:2IITRM'C#4/$1')LB\^JQQ M_D8D%;#"*0-[G.V(6HT2PM)]6?U9BE_3+!7IH0& I^>*FER1)5O\?)TR0_H- MMD>!@;:1[22,P5,TGX-!>!_-0C">#*/G$,3]KQ=*S6Y2LJ'C0:\Q@QI+9/F! MK+8+Q7;4+6@6KDH6!?[0MZ[9_9?267'X_X%^IGB40&C6P,.\:.DU9>W2'&@L MS7-PU$!H%L$GPOFM%$&R(HP5.T"Z_ %&Z3Z5^\/DT!>^OB\T"FE[Z&05JN ; M(?Q&^H\B"KU?:XM^',_&@T4$.S>L<,YSS#Y>$G^5L>#93D:>$V9?<:6HYU@J%"JS%$Z.)^ M"A[U&9H%6N9U.@L?I<"-7\++=1\TMIO74FH#.V@4CL8208B@[^FAHJ,N([,N M%U4A51G,'_NS\ H,^O/Q$/0G(S :/ZDZT2&O8GJG>*R;\V[56UD7LHN.VHS, MVOPE'#\\J@KNO\C=Q$,()HOG@600W=<%K;C,0;2(Y[&D(O<;6A9-Z;9=S_51 MT&"BL73LP.LX_AF9]LE1=$/86W%"YV!)=[DHCVWUT_HK0+\X^YX]'\#;87F6 M/X8I/RT\8_:6RJ-H1E8RI'7C25BL/*V7 T&WQ8'WE0IY?"YNUP1+O5<&\O<5 ME4M9-5 OJ+^9]/X#4$L#!!0 ( 5^#E$32A8Q80L $M4 8 >&PO M=V]R:W-H965T&ULM9QM;]LX$L>_BF R^EZOLZP)?FR*;7TU6S?-[N-\7B_7V2:M/Y2[;"O^\EA6F[01'ZNG>;VK MLG1U:+0IY@0A-M^D^79V?7GXW5UU?5GNFR+?9G=54.\WF[3ZXR8KRI>K&9Z] M_N+W_&G=M+^87U_NTJ?L/FN^[>XJ\6E^4EGEFVQ;Y^4VJ++'J]DG_/$6X[!M M<3#Y9YZ]U+V?@S:6A[+\WG[XLKJ:H=:EK,B63:N1BG^>LT56%*V4<.1_G>KL M]*5MP_[/K^I_/40OHGE(ZVQ1%O_*5\WZ:I;,@E7VF.Z+YO?RY6]9%U'4ZBW+ MHC[\/WCI;-$L6.[KIMQTC84'FWQ[_#?]T?5$KX'0L3<@70.B-P@'&M"N =4; ML($&8=?@T-7S8RB'?KA-F_3ZLBI?@JJU%FKM#X?./+06X>?;=N#OFTK\-1?M MFNM%N5V)8;+ M/-LN_PC>?=NF^U4N6KP/+H)O][?!N[^\OYPWPK%6?K[LG+@Y.D$&G*#!UW+; MK.O@LW!F96E_"[?'!!"8BQXY=0MY[98; BK^LM]^""CZ.2"(((M#"^?FF-OB M@9M_32O1'-N^78F&G@:9'O3" ;T[<2UE57485S&2P;^_9IN'K/H/(!V>I$-0 M^B8MTNTRLXWYL2$[-&SO/\_7HBN>^YUH6F#5XA:R4/R-3OY&+O[^'-3KM,IJ MF]]'@:CWG7%"-<<6II'N.F2AN,Y.KC/0]2]UO6]];Z_(H_>!N/$'NRI_%A=K ML"O2Y>&2M4U74+F%R\=Z)YI?S00]ZJQZSF;7 3 [XI/+\20N \.Q +]AO.O) MR?7$Q_7V&_*E?>* @DZ>'B-^NXX2,3]%S-\2,73)@,(C(G^[CA(Y1I*"R#GV ME[2JTI9\Y\8;UAP1]@1":MP]^F/GN'CA+I*/%U%)J8G6K_ M+DQP9+\/8XE3#//T-CO9.+JR5=_5!4LRXVH&>KTD'1?!)_O?[NS.@LJCIG:;Q=2HY:@QS#I3S-F6=;V M 0';>[@F08YADO]#W%_JXC@&9R;-V\'=C5,VY.C&@L&8UA2)]ZLX53L\Z".W$O M*FTUTP)6&N\DD30E,$V!HJ!K"54%%A,]MP955*LQM7.H M 8D$(H&!" TX-8:*,IH0O=,L9A%E1.^XF*5^A6K#["B6=(U$RD- 1 MR2CB5:="R7^GV.^CF!LSP30:O,HEJ:0$A]_":!2-W+2X#V'JY)3%(8D^ZE&"PT M9APFKCNI1#"%$3RJ%(.U/-R4-*8PC4>58K"6AYN2PQ3F\(A2#%;R<%(2E\+$ M!3+SKJ62G,0XIEHN8#.+PMY#M&,J:S-3\GQU>4FB,W2J)2'Z= J1%@@Q,W.; M91L+8DA?>+)8ZMF^&I%D; @SMBO FE)9"KTH3JC$ZQ?Y$OL!A3+C^<,=B M2-IY-S3E)?3"-Y6@X*40&W/W D?4HZ6&V\HY&D:.1=@();(28N1",)R0B&I%==!VMZN"N1&\'( M]:CK8,41TW\"(35JB>D(QO39N@YN[^&:Y&X$<]>]KH.%QHS#Q+B.>GN:8%R/ MJNM@+0\W)9+(<<'R?%T'*WDX*8D;P<0%;:481%UF#OH_-M--*!C4$"<_(J30%^2,^.U1V3%*1.:U1VKJJ:]D?IC!$ M841YK/66Q9+2).$.J3- MS-Q*2[!R&U#]Z&VHA8'DE60R''/ &&A$1G@!$+J-FL)H!@&T*@, M$-;R<%/R*X;Y-2H#A+4\W)1PBF$XC<@ 824/)R6M8N\]-[$)FS!B,1/)@'9C ML%C2D' 61OJC7INFGE^HD4B$Q3#"/BV7^\V^.+QX])OH[JK=JB2Z:]V^7R;N MS>_^+L;B??!E*^Z*F4M"%4L2Q4ZO@U@[T:3.11+%%.GYE,TPCD+.J-Z%YPW5 M,"3(XC_OU1!8VF,&]UX.F7S7#:PXXE8]@9 :M41F_"<\*X4UQ\0],8]CR>-X MTF>EL)K'>S^2I0G,4J^L$-;T<%KDDP)S"8W1//Q&3J!4:BLM'7K6V&[<;'@3(\D>A-8/2.RAMA+8\NE9A. M8$R/RAMA+0\W)883Q_TUY_-&6,G#24G=!*8ND/(DEH5$S@A%B3X?+89QW.8R M6LIC,]22*#6,WNN9,$;[2>/QC?3&)35,)*\2[YTSB?D<\2)DE(7B/[VG+*8T M0I2'7'_0ZF2JOMDIF<;=U__&)HBPM,?[J!)MW'TWJF."""N.>15U8K1QB3;N M_FC4.4&$-0F=W_\ZI @PFH>CDIHKDD"N287+S MO9,+BJ,8QP-/JGGO< ,8YZ-22&Y!,:'Q\*OCJ'_2@..C6HJ__(>S'QM:F:X? X2F+]P>#":DMC3#C2=\_=VG7US$F+B/0B\M[X M^MI4]1(AD5[IJUY64RS26Y;H[W$ZF6KA]$X90%[KD4Y)VZNVLG87BG"'W.J= M)H"\MK3")V585A(1HZ)B,#K?M"019F3PRNL="(#Q22Z$.[8%@=#ZX\?FC*W>$HQX>R:&PO=V]R M:W-H965T&ULK5A;: M;";>R[,,LJTN(%>2[3"<7&_IFBV8_K9]EG W MK*S$/&69XB)#DJUN!E-\=4=\HY!+?.?LH(ZND0EE*<1/*PW-X-@@&*VHKM$ MOXC#9U8&E .,1*+R_^A0R(Z] 8IV2HNT5 8$*<^*7_JK3,21 MBQ*Y!2@305 MNCRXI8+;5!AU*'BE@I=GI@@ES\,=U71R+<4!22,-ULQ%GLQ<&\+GF:G[0DMX MRT%/3V8BBZ&*+$9PI43"8ZKA9J'A!\JK%1(K-*-J@QZ@112Z^);17%FY)AUL7/8I,;Q2Z!_>Q1?^N7Q^3'@-#R$&5 M"/*6B%O2:_&/7?8)N?O5'*D$=V[R?1.-6975S>VY7 M6:>+S^CASR\_%NCAY-U[EQLO=>!UN MGF P)4(IM&0P@AB*^9Y#.\7*UA&%J5%NRHRC_>2CB_TQ'D.^]L>9M@@2)PA' M#JX$3]#Z%5J_-RG3^"]84$57:P%3*Q)9Q!.&LKL$:]>&<;FJV9:; 5 MY1+M:;++L<=,\CTU9(@23I<\X9K;P8'&9?<:6V-&(W ]@X MF&2QP03UM#IV:FIQ^H=0'J(Z6D39&E&E&%2&9O%Q?%=]#H^X#/?F=!I%8F?J M#DN;01:7";-2$VYG#J:0[S8+;Q<,?->QUQZ3&BGI[]9L#V-(R%-? IO)H]L-L+[XYMA>)EF83>,'F44FLSE@9/5S_,]B;BMICKD[!C ML..:AW _$565W])7@S$'3J-([EC\WCHJ39]DT7?#<7-N6>1<)W#''9,6U[2$ M_7=9U$8Y9K68;7$W:O6>Y>M_]AYM>LAOMI[5F*B+$8J%>*%*T8T!E-DE>TWE%# MRZDRNC:CP?[0"=OA_<^41FI*(\YY!;N0#$:-V4M>%OT( UUJ;D;/ M%B+G2L%P1YG0K!BB:B.D1IK)M#O^TO?)(@U'86L_8I'#9B<==DPB4A,HZ2?0 M:A)!#&8G'Z/E*UKQ#$)^?QJ1-EL"*#<,FB1@$W1)&#BD W]-JZ2?5N]7*Q9I M4Q#S.<+7&7Q"PY+*HE>DH?U4TKG9)A8J'?F!CYO8;90[=HG7 ;VF7-)/N2;U M/(LD@V\#=!&SXNK2T$%>D7@G30F BQ&P Q>VC^9;TJ;7CP$.,6FUD(6N/3+N M"**F8=)/P^:@X -\#*YYEAFT9JQU@VWS:>B%@1'Z+KV;%65MMICCZ>Z02RJE0PE9@TODT!FBR M.$TK;K38YN=+2Z&U2//+#:,P^(T O%$F(+EC7%0G6E._@%02P,$% @ M!7X.40P9O-"U P DP< !@ !X;"]W;W)K=7#%2@R )9RY:][7;7-F"G"38+)#;B;'LH>J"EL4B$XJ@D9<7] M]1U2LNL"35"@%XD?,V_>/ Z'TY;LLY.('EXJ;=PLD=[7G]+4Y1(KX094H^&= M'=E*>)[:,G6U15%$ITJGV7#X0UH)99+Y-*ZM[7Q*C=?*X-J":ZI*V,,2-;6S M9)0<%QY5*7U82.?36I2X0?^M7EN>I2>40E5HG"(#%G>S9#'ZM)P$^VCPB\+6 MG8TA9+(E>@Z3NV*6# ,AU)C[@"#XM\=KU#H ,8T_>LSD%#(XGH^/Z+D_Y5%5[.DH\)%+@3C?:/U'[!/I\/ 2\G[>(7VMYVF$#>.$]5[\P,*F6Z MOWCI=?@O#EGOD$7>7:#(\F?AQ7QJJ04;K!DM#&*JT9O)*1,.9>,M[RKV\_,' MX1N+0#M8U6A%4,I-4\_(83_->Y1EAY*]@C*&>S)>.K@Q!1;_]$^9T8E6=J2U MS-X$_-J8 8R'5Y -L^$;>.-3FN.(-WX%;V5+8=2?,;\KN.8D2:M"=(5A"EA; M=&A\M\!BW"HC3*Z$A@TO(E>A=_#;8NN\Y3KZ_0U&DQ.C260T^9_"OXTR&L## MXNG;XPVL;F&UOGEB$, Z+IJ2"QBRG$QCK(!J'LL5,ZBWAE#^R[GR.#BL@]^M'@].N-^ M;3B/<02=O,)F;6G/;IV^?*Y6$1^[,(%9..\MYJ)"$-!*TOKPGEJ#Q85KMDX5 MBIM3\#O3T$M+32FY"^W1.@0OGO$]\7@ 2_(RANQUB_"G1 4?,9J2VUMQH4(7 M)!YBR!UQZ^C$$HPB-)?^5N.%Y*&7P1BVC>-:-DM,IXW/@.+G&^*YGGE9/+\ZB:[1_FW?/ MU;VPI>+RU;ACU^'@QP$V.X)Z":>ZMAVM^2YB<IN0@ #X4 8 >&PO=V]R:W-H965T M&ULM5C; (1DVIN'Y,$6 4S?3G>?;N!L;=U7OU(JB*>R M,/[]8!5"]=-PZ+.5*J7?MY4R>+*PKI0!EVXY])53,F>ALAA.1J/C82FU&9R? M\;U[=WYFZU!HH^Z=\'592K>Y4(5=OQ^,!^V-![U;T&1S*W]2AZ-ST)DDP?[O5OL'CAVQS*57E[;XA\[#ZOW@9"!RM9!U M$1[L^A?5Q'-$^C);>/Y?K./9HX.!R&H?;-D(PX-2F_A7/C4X] 1.1M\1F#0" M$_8[&F(OKV20YV?.KH6CT]!&/SA4EH9SVE!29L'AJ89<.+^07GMA%^+>*:], MD(15*CXIZ6NG@'X0TN3BTAIO"YWSX[-A@&62'V:-E8MH9?(=*P?BDS5AY<6U MR57^7'X(CSNW)ZW;%Y,?*OQ;;?;%P2@5D]%D] -]!QT,!ZSOX#OZIEEF:Q.T M68I[Q)EIY<6_IG,?',KFWS\P<-@9.&0#A_]GG']L9;(O+J:SFYFX^R#N'ZYG MU[>?IY]O[FYAZ'HZ^_)P_0EWQ/3V*KF\NYW=?;RYXL?B\TJA/S);5M)L"(3: MR#K70>4BLTB9\?%7XYO*DX4VTF1:%L(C%@[ BY5\5&*NE!$@B$HZ"&G#BEV. MTPJU'59\W6!=.0TE50&TE\HH)XMB0\]5%:)L@&-?##LR(SM>O/[K7TXFD]&[ M+[/DY^GTGJ_&[]X(\!,$@G*Z%%OGM(F\Q00 ?$G?3&6UTX%23+>NG[*5-$L% M[,M2>V:;ULCL^K(SH VJH68N\2)80:20C$=[?V;E-S8B-P*8P/T9D6= _^B(%GR\*77"VL#CL)AIWZO->$Z MWVP12SK$=D-+T%!N"Q64V)DX,N)7MBZ@6 DB=P(?"?^M-I$].7,7V@:'Y@@; M0F7\]ATD8YGLK@*.I]\4FZ;"4.QK%UV?)D-#YMLZ/=\T+DL/?_ M5P6*DA3J"<7I?:ROY[65VZ(@3[45*,R>(;9R,A)L9" MH^H1!JG:!E99K[L:P2D,(J883&S'QWW29J#M##S1-O>M4MC<]BS&(J@TK M&0#GAJH/^8E>]*N';) ?SZIG'.OB,E9%5Y(+[3.@0V)[$$O NZU8%/BSVME" MG/1JI^W3T)1B;2+:8>L")T+C]GJ%2MKLV;6!-E_/D6 -#*B29WII] (XF!"S MDK6RK4[N!">-EY%LDFV*5*&Q Y"/^^*C!A4@C&AUYWSIPR,T:18(QBT)R24& M&%H:1TD%)8" :B@7T"%?"'ZI6"E\A!PAHO\@88IQH9T/*"2;@Q1CY)Y@I J' M5LXW]J-'['T5S[?2YBIMBY-:@-*O.#,DW3N:0.O2R9(T@#25([YMGD/#/ MA# 3K$6WR H"C\@Y2B9E97V'46V(B1K)HF.0D,9G_ZQ\T B<8_(^3[:-6EAP M!:)UMNPU5K0""=3ML\)/68_DJ5>7Y*"BT!;$FH3DJ\/3].W1"?V+*GAK)4.9 MK'1 #/&P,MDFH?.3]/CT.#T]/'CN;2'!S"N5]U*QC5EX2;S?H@B',(S9O!14 M0>035O"OV/D=]F,LM:G(:PZWWW# H=]OX]-4U)XS9[A+'7D9\5PH'IP\63=HYL8_KEFQA'K-65TS9_>Y;:R+A MP-5!/@'..48R]7 =VTJ75"B*02NZ_@&9V7JYHN)%89)+!;@F([X%VJBK9IS[>A$K*I!>7U>513&$'*XRW' M1]@[:0*@%S!\%XIH!AY@3H),Z!QI/$['HU$7>5SX1^5\4XNO^#"+XFHG)KR7\&X$7)0/C&W2CPE+BVU! M7J*9G.$J;*N3&DSGS?A6L \C65=U#<*7=[_>7.T18G&JTCTX=_1VE)["N4;[ M-AW)G^X;KSV>WR(,<2RXGL?OQ >5-Z\4/]<2 S4 0O&1,OUF]^;PHOXU[TF\ MLZ ,:,\2CS3%J=]!I0"YK&)M=U&DH([ :WW+L\'&LBBHU1O8>6+F"CV@)(ZY((+7W92RTI)*%!O<\^337&^Z*EG>:-X1M&I1YU,[&A*%ZURN- MRNX7;42@V;A125A3B$*,32AH6K--13QC,(1+X\VQU"[J<>QI+G*(M4KPB MX)U(;E^!*%M]P[1_\JI%#&9SO=CL,)/ 95_@W3_'LNO[PK#W38=V-OYR10L6=L3X>:>[VWT6D!T MM/_V:"!<_%H5+X*M^ O1W(9@2_ZYPCN@(%[)T"[;;?SFB03P/$DLUY,'HB3N5@L]@-;8G?S M1BWVB)(?\^OW5!5)46W9N;G ?DG<+;%8+%:=.E5DO[IV[3>_,:93-]NZ\;\< M;+IN]^+HR)<;L]5^[G:FP9.5:[>ZP\=V?>1WK=$5#]K61XOCXZ='6VV;@]>O M^+M/[>M7KN]JVYA/K?+]=JO;VS>F=M>_')P.M:U1K5K\/.8WN<7_K#FVF=_*UK)TKEO].&B^N7@ MF!0RM2D[DJ#QWY4Y-W5-@J#>'F09J2!N9_1^GO>.U8RU)[<^[J?]BJV_QR M\/Q 56:E^[K[[*[_TX3U/"%YI:L]_ZNNY=W'IP>J['WGMF$P--C:1O[7-\$. MV8#GQ_<,6(0!"]9;)F(M?]6=?OVJ==>JI;ZF^>D-:O/6=A2MCG5\V M1B&,=[K5'!YXV.&KTC4>*E5XIU(KV^BFM+HN?(MA"^U0TBFMY7G<.G;T:9-+-N*J4]4&!'$WM,JSNE5RO$ M*:L I5Q+T^LM6UJFRM07XQH1+4O#)-'Y0P-T!)CP]5W]*V#NN@3SO36E?-U1E@DPQX MY>HK^MYG/G&_?6Q3UGUE7A0 &].VT +?N*U1G;[)%]B:FG?M2M>][*FN@;E8 ME9D!_[*0.EE3=[AMM9[!_]M'!2;P0M<^4TY MT6MV1]'>LVZ\^+6C!4)<:=J&M?2>; HCE!T4@;8>P.GQ2E]7V$#L?ZM6F!+# MG<_\94ZNFG]1Z):,>P6 QGQB6]BPKF]9)?R#55;_!';*)BX-6ZLQ)71 -,Y( MP5LE4L*^0FNCVP8Z^[@"$4R?KC>VW,@@D55\:]PUH.AM'/+3[\[[1^H3EG"Y M(<$47>=NN]/-K=JP/K":$6=]ESQMP('BLH/JNJV\>N/PW]_^X_GBY-E+2*:_ M%L7YVG4%[>SI5H\/3X\.0YKPA9? MV0HF13@KF+#LZ^0700)2GBV##-[Q\'UEZQXKBD^2]6 VY*Y6#*@F1;\H?MC@2KY2V>03M:90-V$IP>BB+28=$K;6M-?@J$P9,MM&;_ MW+@:+NUI/%G[FO,RA2X<&Z"DFGZ[A":,$S**=/(%&(LG8])\9([!!^;J5UGL MU%I (NJ(7#N$";8%.QM71=-X4P(4&'<8ZL3CHR5X8)1;X'4-5X20[O;!:V$Y&/$BAAX:7=(2.3)9Q'AJNNL*%P;-=3WFV_07AT MWS35(!=R(-FU"!'L,$^MA1\O37=M3!-E@!ATEJ9B \GLF=$*RITC\R"YN/V- M&RRUL8B^MMP ?05Z$E=(_BY4X<9N[5^&I^N%L[BE-^T5A[IM@ V\2P6X\)TW M^^;NN]<;6M.$S[#G*Q_P$[OKR]8N.4A;8U2-]%ZS:P1!O*M;33F ,UU!ZHI! M,JDO@(\_/WWV\TOU.PE0)XR7)T#(/U+2I2JB@DV+/WM'X1TM3CO-Z4=*E?"] MY^T$2L-(@.CHJ=FNLJ..IUW\\+0TB8=%:]W>QYKN:+8_Z^E#LTYMCE _&-#W MNY") =N8KJL9Z1L7M>2)X22";*7%B)P=2113R6O;OKG-+ MI)(+:3_RCXL&>I*#D'VN&2:9-9K.@/PV.6\NIJ&%X#8:(*Z9.8[P'7IC\#-F MH9,10T_XO0@#4Z\51,5SML)A-7+.D6HK8+P?*X374 +BY7*_)3(,CJ4-FC@A''QPP0EA[,.^]233P9='II7R;Q%G'? F'_V MU9K>$,Y*-8YECK""6SG\[W>FI)FC_+O &7*:S#EP=4HQO2?[D7M0@,#@;-"B MW\&D8+^=M@E4<[9,FNR(:S>BNC18F+;GU&9P;3$CEK,S$H6E;MM;(SD/R>P6_#W56 MQ[P\%TA U> MAUHSK8KMT>8$?UK'P!6Q6+_A,D8*,,FJ)&Z& M@-PY;P-@.<*'[/&XJ"GN%#52Q42Q.WW+*H8OV][L\8$I3R;5>,102N6#8L9C M*V#++)'1G(R0$K!H6<,]X(7TF+)G3" D.:#Z+-O^^IZX6NKFV[ @$DR].7(+ M."67ZV-#VZX7A^2:%D'&!BA!H&R7H>T,B(HPY+2+D?)JZ/:AH9S4%?K'M;46"0\:PG?VCPJ$QP3?Y+[2J2%LHC -F&AE3"E^#& MIBEO Y2(5PNY6MYF.0FNYPU% &E5@G'!6*A$#MWJ4'(-Y=A"A+2TK4Z8M6B< MY]T S2&BE31K5Y$ \OOPS+>Q!0')#KM+MN;MEA?P-TH%:8U(7 LW=<# "; (4V4+(QCI)G:/8!H5=IFV@ZQ1,$O- MH\4M*6*#_N0WI [Y34I/<_41ZNC!RR78 UXFS:AMB*QHMG["_V8RLG#@[&L. M/J!EW[8I58J:^>/:-6M)!&&"4<=PY*-S]3F?,>[8YX]?4\A*HD74BD%]T4T@ MVFC]*!?ZAJL7*4-]5N^(MJSIY(WJTR,YGY]T&^@HX + 6@+*W35Y" D8[_PT MQ>.&T-XFDEWB*BE/3OI-\)GH)0@V:@]3F'P L5&HR"DL5GW+A"@058:FWV@K M&IZM=EC].^ZIZ<9GO0KR[Y5!G&%1Z_1^$1I8C8!3HIL)B$I*8@._Y3V@=<3M MOS8UE8_D@PH]:IIR5Y]RMC;KP,7R[M. M#S5FV2%\Y$)GEU\+L)AGAR=0V"QU4E2&8? M,_".5<$$Q$U$#VG'D79:9LN(TS,N/2OJH!?>S0:9(:;O3IW2-/=T#,<1Y$[S MT>\#-QLP%%95,>*J'.P;\E88@C9QF(VR+!7HK"4J]Z$'ST:3%AG/GHM#-M;< M#MH_+/F4EC2.P[ 1H:$FW)Z/B,.YA#+;I:E"!LS/,YCO2Q.#W(R7R[HR8SEY M,H]_J+5IR/'KH8*4\J6QPN>6%F%5TH[^\/0Q<< &V)OHW*LJ28\#5COBQ50 M[3 U7[-]G2R:AI7$!G]L/IJ;B/7,;@#+;0_=F'[<499/4DC+(I,MM4I%(%L% M%LD#&Y*JZYGX'75*N9<3%#E\?+S'%F.!,FQB;J8@/Y<-GQX>+X]G>@4KBR)P/!Q:[O]KL;(!= M<0G/0QUDD^J\U @P\^*,=8*D^G82.N7PB]&>?8C/1NYLJV2C#F4*'="DC.)[ MK&#"PI+%J)]1R&&K]*ZH*Q:;QGM-F4!K,J*6G]#DY,5V0]8+HTC)46G,Z*6-!,GI8< MJG.IN.FD$8;_28KDT\731WCV/FN"0>'QJS#2I,QYK*>I$%:C0GA6:$ZZ[).^ M7WH$"L-4E)I^KK\$O8 4>/"M2@<@Z+,UP MIM2YH:DLY=7*$)%129?0&>%#2O)X"JI]E \- 9T=T9-DMUI1.4/]Y+&.D4+O M7U4(19R?Z>+H;H=<7A@TC>A=U_(Y\-3AUD>H,XF,4/\)'A>J M^62"%?=('S#!;"BVM[V74]P6J9X&P^"=:U,GH+6&KRJ$ C3CDK-"C*8]0#T2 MO'!DP)^I055JW_GYA#-3^3W0+2;%@ 1,2D5[: "N8N?2;E.1'_KI3$:+\9"E M6=NFX0)TA4$ FM+PJ3*E#FI]3;=&0J-A2 Y)+4")&W7/%N-\6IB+H*3LHL<.4TY?7\JN]""S=T,T)W3:5YT-YSGB@J\3&9]R\-"? M:W5E\J[S7) ?^SIT0B>0_^?#XV>S8M3]_,I;RSI=OCU7EW)],7HVC=-8"?SS M"N!+G3EZBSI4ZU;O4-GO^M;WV1D-31A/5.A5R@6U^DRT[[.1QE'QPGA MR?&3T\5,_3J,O_ , M1 &OI3"6BV3F3E[NQ$W>"),#CL0PDN-,>UHL%2.@90UCAB("D\/.'9*)BSWT M&0/(T&^\9\%_CTO%$AY:@/^>4D6NU!U(''#/[?7Z15]="6(3HM?#Y8JXD7DT MJ_NBN?B!:.8H^P"<8?#]3J2=G.Q%VL66B$M0$SN9*-5LFC =CGC5G,X[F-L1 ML[N'WTWTKXL04Q1SB29-SL=>O'AY+_%[\>_QOEDAM0I5 *[J2TXIT_QEX%)[ M_(WZ3WN<[0&*)?2%7$0'ZE>$@QH?&R]+.CYBN.=Z5TZ,R$YK>O7FT!J M (;I9BKWI\3 LAMR6,#'"]G^%O^RO07GMH3NWG ^8Z\4/LR+'^9/663PL1 6 MPSM\XD#=9-+Q_@ /P00# M+&9%R%2W4=&SN?L&P O7=8?Z"9R1HL#&PP*HGZXT M,%"PX>D,.II@D,\UQ+Z UG29"*XI*Z'*HR=%0J$?\>]D^Y>C* M07#WL! Z]1BH9W9J"^VK\5S4=7MR#.(VK<+J$=8.EPT-)*PVW2E@9;),O[[S M*ADFA9=MAI>%!J>YGM)6S+]PL3[.0?"JD.2' \>LU(AM$T(/V;OOYPT^C-Q_ M2R'C6M-2.N'>%H>P]';SY(6%))>J+U%S#YE-/@UOYJ2HA%T)=^8@WDA5\),>&"7WXNE1> MJ[ 95URLR!QBDV%$%1L0<#@K5]A_!+XHE:J?[RG^1V+WSB(=WV*/394B M),.],I_S879]#AL2DN?]R7'$D%LDP&6$5LHT*#+%>-^WO9RM/E MEGMCS\DI;=K[4!R'JU5#MT'J?#^?^N'44?83M:UIU_Q#//[U1]/)K]72M^FW M?F?R$[?A=?FA((!R3:>/M5EAZ/'\V9,#N2(0/R ^^0=O2]=U;LM_;@P87$LO MX/G*(5N&#S1!^@7DZ_\#4$L#!!0 ( 5^#E&LH4#I]P( "L& 9 M>&PO=V]R:W-H965TXM%XDSG/?FS5 %*@L;](LB3]ZO,Q?N SQR/YL4:7"4[I;XY8U,N@M@)0H&%=0R, M7M]QC4(X(I+QSYDSZ%,ZX,OUA?UW7SO5LF,&UTK\Q4M;+8)I "7N62OLG3K^ M@>=ZQHZO4,+X)QR[V(PR%JVQJCZ#R:ZY[-[LZ=R'%X!I_ H@/0-2K[M+Y%5> M,\N6/--=QN\M7F=O.PN;D?Y%2B M!?\<](J:LZ(DC),TO!K%;C7+PGB2#BX*Q;-"F"3C<)JED*63\"J9#))PDD[# M;)(2;IPFX=5T!O\A9SXS'1SV!Q>Z'@P^,EU4,$HZ'W!9B+:DH&P<0BA;!*N @:F8QDJ)$K6/QRN#0@<$_0>#@9!Z"[T=095C5^'.R4I>'B MEQ5-<]0N@/;W2MF+X1+T_X?EOU!+ P04 " %?@Y11')6<1T$ "_" M&0 'AL+W=OY M^ 5(R)4@$4A[J9(0 ;VJJOIA;8_Q*O:N;W<-X=]W=NTX.?62GOH%]F7FF;=G M9SP]2/6@B K%'23254R0UNU\W6ED*5.J2S\ M* A._9)QT9]-W=F]FDUE;0HN\%Z!KLN2J>,E%O)PT0_[3P=KOLN-/?!GTXKM M<(/F]^I>T<[O4%)>HM!<"E"87?3GX@' MUB$L,#$6@='?'A=8%!:(W/C28O8[DU;QY?H)_1<7.\42,XT+6?S!4Y-?]"=] M2#%C=6'6\O )VWC&%B^1A7:_<&ADQT$?DEH;6;;*Y$')1?//'ML\O%"8O*80 MM0J1\[LQY+Q<,L-F4R4/H*PTH=F%"]5IDW-?+Z,W@3\K18#& 8>1$$4O($W['(P='C#5_"6&!M8D%:T,,X&(',H.3L_#<&TXF\/Z6J22'8=@@P8\_3*(P_!E. MSL-3;QB$'P:P)>QG/&CP=BA0L:*PYO8(#(SE%"&'/QV1*;?UR-$>%[1$;4 Q MYT<&,9H#HH P>.N?AZ F\]WW@)V$0>$$00$;9=J9> M5JW)^X'IIR@)@**DYIVA4K2A[I(\#."])2.<>8Z4,/GP?831MC'T7!$+:@S_ MXDOHA>.(G M?9TPG0IRY98*&@,M+3A[CGA4UA&.WIL0D19TZ,Q0RZ=/[IZH+ M2:U=\3VS,P.(6C&Q-^,);WA R;13J9%<>.9]>P,M#UDL]RV@2^SPS!N-3QWD"94G&$<=^?^+ M,4XI"N@E$PUUA6XD%L?!M_J<_V*HE*AV;G1:*A%AF_G2G7;3>=X,I6?Q9K13 M_7=<:"@P(]5@<#;N@VK&9;,QLG(C*I:&!IY;YO2%@&ULK5;;;MM&$'W75RS4I$@ 19)EY]+$-B#;2II"<04K:='' M%3F4MB%WZ=VE9?U]SPPOEHPD*- ^R";WK7HU!ZTJE<*O+19#Q^-2JTL?WS4UE;^/-3 M5\7<6%IX%:JBT'YW0;G;GO6/^NW"C5EO(B^,SD]+O:8EQ2_EPN-MU*&DIB ; MC+/*4W;6GQZ]O3CA\W+@#T/;L/>LV).5^.+BG/ M&0@T;AO,?F>2+^X_M^COQ7?XLM*!+EW^ITGCYJS_IJ]2RG25QQNW_94:?UXR M7N+R('_5MCX[>=U7216B*YK+8% 86__7]TT<]BZ\&7_GPJ2Y,!'>M2%A>:6C M/C_U;JL\GP8:/XBK/Z>4O(ZSW?J0Z6]MI$H57.G;3@= M1>#SJ5'28%W46)/O8!VK3\[&35 SFU)Z>'\$7AVY24ON8O)#P-\J.U3'XX&: MC"?C'^ ==\X>"][Q?W3V /RD S\1\)/_)9(_QGHU5.]G5[.;Z7S^E_KP97HS MO?X\FUVI^>_3ZZ6:)1 Q0VI2U>4VNY060FA,%+UY/CU>/#+>-S+O"ODR)?A2U4]6UY,GZL*"?=R)=$EKP.N]&[M=3%4G[&<,[.- M#DHK$"V4RY!7M2/ML613_)1!Q#R%V ,RR8'AZY=/!ZB'N$$W$71/MY7QA*80 M%1J2*O5.G@VNQZ RXT-41Q-5B YKTZV?A=Z!$^&*0 FC%ALM3N=QIW3$4IX/ MU:(!7G@7F_ZQJ/WIXKM8+-KP]B3PB/$G@-<1OC N>I.8N!=@,8FP)%!&Z,'# M)T=#<(5!B22S>L"69';Y>P@PF*$Q)U^_10W1TZOHTB0<\+J]!_>P4^\IB)5H4!"<&5%%KIH%P'*J"&0H;Y MA0L@=8@+K-9UY6FMO?C%_:^FR2&KB>H2KXG$^9#OY\?VZ[XHL;4M\_V\%JZJ MQ=BFL>[+79('BB>LNN_B"X@Y2=*<8^9K%?A(0HP;K4;8*?UW/9PO)Y^/VG0L0%-*L/5 M,3Y]?>7KB;)^B:Z4*6[E(F9">=Q@""?/!["?.62E>6$#W5A__@]02P,$% M @ !7X.4<^:%8-=!0 Y0L !D !X;"]W;W)K&ULI5;;;N-&#'W75Q!NMD@ K2W)=FSG8L")$ZP7>T.2IBB*/HPE.AI$FO'. MC.+U?GW)D>PXS2;=HB^V+N3A(7E(SLE*GJST*84CF[-7<MN+5Y<"7O(Y%P4!$XVN#V=J& M9,?=ZPWZI<^=Z^%UF+C]M#5N0X4)4A;O2JW?8Y--GO%07UO_"JK8] M)..TLDZ7C3,Q**6J_\6WI@X[#L/H!8>D<4@\[SJ09SD53HQ/C%Z!86M"XPN? MJO2_-QXBD8^"*X,?)!B+@OI)-J3CB-LMNBD#;:-?C=?\]T9FR MSE2D+&=!J S>878GU1U,6"$^?YA*FQ;:5@;AS\FO^[ MW*_B\*@>V:5(\;1%LVC1/&!K/&C#].)J=CNYF=U>P(?9Y&SV878SN[B&SPJF MF&(Y1P/QB&L:CWSJ[X6J:!9A5-D#C=P"[>N--/ (MR5)3 DH[8N=RX2 7&9-\D+JRQ1KFB.IE M.E+!Y]1I+@P7I9^0N-;"BVX8;H;V0CE"C6 MW[Q"&Q%\\R9@3H7A8+GUU6*M9YC,A',F-V@QMZ,DL MJ0#*25'0#M[.%*5/P1P/LZ-/E&-S\+5&WMV260>3ZW,8)A'L7PIIX%84%7*4 M2ZF$2AEP9S\UC)C:7'. MVRH^ULB28G559#07,*?&%"Q83_ "6$N%Z0:X7BN2)\^ M(!FC*=:LZDQ(%;UXB0_KE'GEN[>!&.U$$ M>\'TN2=/):,Z&EY2,G3C9LF]W;5^!&-+GE;J.-("BH;=<-1/@O- P"@?#^.=)D-+V*$34ZTX6^6\.*W"K+2M)-8&[N3L>\,A0+/@PJ MZ^>-#!:ZH$,>WPE*IIYD>Q1,'F^"*0U$AM3DM40289S F^!*VONW"X,(AN3A MAXNE#%'[,'D#CDZ$0D7Z X6Q M!P07Q3MH47#M='I/"XVSW]^#)2UYO^T.8(]"]Z.M\5[<[AX.X$??_\[.T8L' MW!\P+?A-49_"MD^W9]A)?71[-*\/P"0:V@\6"ER0:]0>]%M@ZD-E?>/TTA_D MYMK1L=!?YG0.1\,&]'ZA:2[(?_PU02P,$% @ !7X.48@6WYK1 M& 1%( !D !X;"]W;W)K&ULW5SK<]M([YX$! M"-*T=C=)I5RV07 PTZ_I_G5/@Z\>R^ISO>6\85]V>5%_?[%MFOW+Z^MZM>6[ MI)Z5>U[ -^NRVB4-?*PVU_6^XDE*#^WR:\]QPNM=DA47KU_1O4_5ZU=EV^19 MP3]5K&YWNZ1Z>L/S\O'["_="W?@EVVP;O'']^M4^V?![WOQY_ZF"3]=ZEC3; M\:+.RH)5?/W]Q:W[\LT$A\TK]7L[XEWX&69U/QMF?\U2YOM]Q>+"Y;R==+F MS2_EXY^XY"? ^59E7M._[%&,]8(+MFKKIMS)AX&"75:(_Y,O4@[& POGR .> M?, CNL5"1.6[I$E>OZK*1U;A:)@-+XA5>AJ(RPI4RGU3P;<9/->\OF_*U>=M MF:>\JO^-O>/K;)7Q8O7TZKJ!V7',]4K.]$;,Y!V9R6<_E46SK=E=D?*T__PU M4*5)\Q1I;[R3$_[0%C/F.S;S',\Y,9^O6?5I/O_(?'?_:+/FB?WG[;)N*K"& M_SHQYUS/.:^,7KQ8S=__KQ[7_\Z>./ M[^Y^N?_7?UEX;G3#WMV]__#VP]W/;__&D@F[;9MM667_Y"FKD1QV6[.D82 ^ MKL5GLV;+V=MRMT^*)Y;! /V0U91PHVXY<[W =AP'_[*KGY)JM66^*YYGM+1[ M8XZ9L'J; *FL7+-5N=O!'A/K7UTZ,\=QV3ZIV$.2MWS"DB)EKG-L=DO/[HQ- M#O)8\ZK2_!W./V.W8PQ7G#WB/[YO^XNY'86Q7-DZX,OW["#V<3XI45KW)WAB6YZG M;"FF$]:-\U5\55:IS1ZW&9 .Z^("OU;@I#B0@1X6OT^*%7";-5OZNN'5KE;$ MT%AVNZDX![_>S-ARPNXD9]UMM-^L )&B0,'#UJLJ6P*1L,+/90-FRI)E^2A'-WP)IA2'47R#PC'L77"YWU?EEPQ<.8>)W9D;1X:NLZ8> MZ+O08F<0_1A/@&LU0LDX^XFGV0H$K$2&?.J;-$RZ!Q!;B7-N>,$K^(XD _8" M\Q1E \*MLQ2X)UK>)D62)NP*E\4)]VVU+VNN!?FA #I GLD7=KMJV)48C]N M5 J1%-L#D7@PDZ(0CN>*\YOM,#N35I-SH[33(=+F;NHW!/P M /\*PH ':]ZCA#C1I%P];CEZ"O; 83_!=JQ86XCK"7M,:LT6;D#87; 00QK7 M;46/)0+EP&.KLD!M5(FX(:0%OK)1JNAV=-TBR42F3>(:TP&(M2AW2"3?B-JWX/H=X15M6S%&+?0\&D0'I%?";I'^'+4]#0 RX./_"JU4&7^VK;*7= MU.%<.!Z<%:(W^9S4*O&%SXW0^M(]H8['I*H20<@9^D"1"^I1XB>]&SGX")S_XHS(@,WG9&\IRQ3F[9DRGZVY.4$]3/E?5S< M2?J0U4#F_TNQ#YA[OOAOY41__6UJN,$0WHM]IBI<]P6K.: $\"NPF8'")D,/ M!A/MP,>5$#\A!/&!VT=P\555&'S";, +N0&M&M0F8(LU+,16>5D#-:"O$N^C M/8 >L\;0%-V5%+(K?!*6K3%NK+)JU>Z0HQ70:3RH5 ,/@G: -*%#4@/YO_7$ MN'6$[ZR Q\\W ["TA'G!"Y9F]:IL!\8M] LDRH #++S)R@;N0OHA(7S-"OX% M'3*@,0*1'R#4D&0'J-,>@WX62F:%P_-<>OFUL9F U4(FO5I/%1=VV22?.8 G MV!-@;K4,&A1=P %#2I(*<(4.&;,0M$C8.B+49O]4BUDJ^%:\J4J168,Q"F- MBR/36)%LR!>L(&Q4O-+!0*A)B;6)VEW(/ZX.KV($?![8*6 M\ #;E'6Q#1W(IBKK&FUPQ7E*LUR&769$$#>:$+I7.D6.#/NUR%R_:J#&)A F M";%;"!N' MH&T@@%R'0*PS]S!U:-0X-IFCRQAS)O=YC'8)T#$@@Q9R)4UF0[ M:;IJ3<& 04.%SPF(S='0O3G;B8)!LD9"E,ILM@1H8SP(B4:>P78'V0)!0)]@ MUDHVP,.&Y-O?>@.8@YJ@E; &>5MC3NH0AM.LP<$ZZG(( \L=PGSP6 ]#",/R=3U7I!7 M2XJBW7&+>'&"0-LDQ0G?LC*MD:-=IL/MBGN=7950PI+6R^ K??N M#)_18]8ZD"TY@!W9!-+M!9$=>Q$%PUV2N"' M%O@XZI+FD1TL NM(T:(M< \D8#^;# (YREH%G1Y$D$F5$AS8:(T@ -E7"7^5 M 'I)^X[+6]A!&)PCL0'UEC:/II1>/HX\.PZ<8^47E 16(#8%E;HP72^7>;9) M1.:AJUC&C&ZTL*.C,V+AZR&IB%W,F=J\(02&"TE\5RM@QP!\M#EY";9.,EEW M$KX[#"$_C.FQ2S>,[7D,Q@'K[?E*>16PN\N%']@AF!I*&@F\L4 A&25< MZ=EF18=V22!"RJ#G)%S^D$-[SVE,(L5&$S6L('CLY5$X?Z22T.T):&J& 8& MGJ73K)C*0-Z7R;,V65Z77<6*=?X?^ BP+NGYI^HY:"&449?HW^I>2EP6? K> M88H%+PVY1>E1.1*QL#4"QT1D,"C5,.>M6/]>"$W7S1* G2@7\$0&#)N! ]*) M=)=;2-M0Z4-J:423$1#.RG1V"O4T6X!*,M1:0LB] J6I"',L&QEK6V,>?J * M-Q0>6@H'0A%2149D;EC^)1-8,:%R=5_Q_0!H*-[JXDD(@XUUQE1^;&WM+&@+ M"BOK;VNAJ^&N%&*USA$5<$!NJ#\M/4GWHUA0WTN%[6$TL)W0!Q5ZSG-0YSN<,==B8:8C7,N,I1-5'6Q*2[LDK"0#,R=.0CK=6L)X"CH: M0IS\M> B#D*.12L"@BJ,"+$?2+CNL!RI7)S%7'J>[<9S8AD@G P4F2$@']K M7- %5."LS#.TD;0+"O5H5$B.JNFXP_\JUWV39LJD+<.D>X"^;Q&URCT.C5RH M_40H(9#X&W1_&EC((H8"%+9&$^*B"58^;.NJEX:#DB! )9LJ MV<,>L45:/CG;DI &A4;.,B7K#S E=KXI67^(*;'S3S/OQ>RTV?_AH#,0&%-CY&>8O,U.V/,\ ML%W7UQ)! [7.,]!OC9C,Q#%G6(SU7(M!-6IC20;F O\4&YR72O5@-T%,VG9F M8>SU+0?E4*D$B2S'$?MPYH?121OR@ME[%.Y/ M<]X[1Y,'01"B*7B5-3?(TI2G6[4$2YBX8-LVXX"%"P!%QY+'OF&='_MP.(/:XMHNIB>>QN1T''K85 M6#_RNG[)[K3&KD+/7O@+-F%3^J,_ZY$@6IY>2YG"$S &5O< 6HEG]"?K-DU? M*NJG+!3@>ZHOK8.F)Z0?XJ3OSEGD"$J/TN_YMK=8'- _57].T"N^[U/GQ[[M M^SY])Z\E??=\WXAC!B"A1R-$]1A#:'"$R@!&A7;HN<^B\LKU0B'([[X3@M4W M!K1+QSK5EY)R?3[264='.3CIA7.< M#OQQ)03AHC-Y<7W$YCN./-BMS@F.0MMWXC,Y&J$[%NFEI%M]&M*] ,2_.,D>Y@N.OXIPD(ET*L8E!^X@D:@,!0?SG0F_P&'Z8PX=H%L3,PSMXV[K389R] MP[ GI 3K$P"61RSPX18P3B[HHOM J(>%93V>[O\,R3A9QN@S8BZ'?3<6@;-B ME;>IT7@C"YOP9 H"7S6Z4+!> W.5[DA0"!C[\0@:8=O@CL@8CM$%:%5.WN=8 MC>J?U?;J)9 #\IDIV@?EGQ#?P$!(.QXDF6-5-;!)"L'Q]1]T([Y90Z0EU,Z MC]PEDC_J>X$'U(,F6S.VGH@*^Q3;\U.KEP? K@V8[/S^ ,P6!)H^H3@^%FJK M"'\5V%WS"S798%/B.Z42V_JH]('*N=OM\_*)8\,!(>./HFD-)[;EH9LL]S=& MKS4]*C,87Y_Y2VX0_6=25=3P!Q!PF6?UEL0(610=.0QZ7@#V8]%*EFLH>Z]>U.N=+DH3%ENJ35): C68^Y$=@#Q5 MWV3W92.2H6$#UB4X!L>5ZFJ4\"D+@V'JZ0)?"5#M,**9!EL9++/GI]\[--R% M_1-979BBD^YS&KS"^*6+LFAK0R"6&X(+CQV*:P@*L*9)J:+VV!/=OS4BDQ' MKSBO.+[.0YUC<@W=WWGD*.K$L:\XUJ*BYT;F=5F>X[DA'82/"5]F,C2U.&>C M5X9@!]7R!)-Z7H@FB[J/(*$^$/]+Z^=6.0])O_57V;W"D@?(XS<'77E7EQ/K MWY%*VJ"!/*-QR$XL([$!3 _Q/W!\B'_RVX]FSD:T#.%# /\X]CR.U"-O=6B5 M@L06=JW/$S,/\C2EI4,ZU33I2?#5V%DI?CPR(LKK&X!AND=([D:>-:KMG&6['7 K' \6SOJ X<^S^QE[7Y8B@KRKV@V[ M-00)>KAZ_^YVPM99CAZ:BNDX$M>D/4]KM"!9]F,&(3G%H/PK.-,--F(=W (^ M$M%+RK#_#+L9R73PQK),*D1(!F0"G95H,Z#J=?)05E@MR2:#CADF8F@IFEFP M2"=+WCF>;N"$NCGKAF7P>'*Z#@DH1+=/;;QKAZ8O,"8) M Z&'(J@#1;9"1 (4:W* M394MVX9W;97E8[.5M;YR#=YAJ>N?!PU^)(F:\\]"&*MM!K9FB5@H9=;CDXK: MR(8V"N3!\,>J3HLZP_>^FJ[QDLZ(L FYT>UV&KTHV'FL6>'TR4GIB2V"3@)E&E6M+21.6P( +?8]YNC#5@BI@B^ M9,ODB"N@EV!VNZS!%].0EJ[!DD;?Z/S$9MOR$3>X+?8<$B E+*A92C])+?!K M2PS!5\]PD26'R;GV4*;W[ J]Y$'!-K=84VFV^"YDD:%+P;THK4+PB=:+3E.( M9)< !FQWK- @1C9_XY4X9D:*L3FT:WA0:*HGT:71^DM5)J-QX<9(U;;2WQ]; MF:F5K:^O;';>] 0*R5 )T%:^3D21>N1M)IWH5>8[=-(7);EMP7ZO.-INJ=M0 MF8L$TNL9NB>64F2A(R#*=<3QASCD.!0\O9J MP\X/V38PF"B3_T@.5$-U6(E MW:9\F)(;"&P@5Q+'\!X)-G\2?NZIEP.-]:()4$>.2LO%4+(2,#$$5-- +/)*BB-PNGVF!*+A=\4TKCDML\1&C M&AV8IBJP?J$$$VR4TSEBOYF.@ C\A^UZV2K;DU$A]8(FT+!%ON4Q$PR!6 ,TTJL^ MV&2GA.!&XE1E3 +/X'.NSD3='H?LZQQ:ISET^QQ^+/@8A^*M,I,_60H^ASWK M&]CSOI4]3<&0,:_/V!G]U51!,7L4L$=$%$3,?%EJ6PE"$OXXS(N[$H#9%T7' MR.0\O5D4HMCB62!T4)_;!-XGTHL@"?+<_R42K:_VJ7=-DA(1$73IE1A%H^8\ MP!,G=^S]J[O[CY\$>J;0*"+E.5V4WY*.]MH(WJC$&#FAE7OUR7Y3D5F?U,UN M>NOTW^R%$#HEW2(0FQDEU+&&)1WR#I,,G550HII EIN*=W_71A-2!AY<+;^1 MC4Y=WX[\T8/.C=F'W=J*:K\CVGQ=%/V+<92NUAHB&O3Z*A>O9=C9)@\$_#(Q M*^BL$;:$W0V.,K=^MZUL+VG,ZJ(%^)IA.G=F X>:^TB[SSR471M1,-KN,^SR ML08=&M3;0UW(:/3JS5G1)DFJ-;VK,%- ''6)N882-P[+RP(S>!+-X,6-A)KM MJ:8 #K?:4"<3;*#0 4_@!O3&)[K@Z>%6.]):TW_75I<\#W;%>1UW??^T6-CN M_YP''>O.MLR+ZQ#F:=YWB>W=:E@8>]<.'O/.I26E'$ MHVHT,.L, [>(RJM6=ZVJ//#@M*E(!\KUP\@.NZ7$;")159,PE9(!^IF<_M.0 RZAB8N7._6TCZ$W#04>A;\HR=7;DN%H!C-D&W MX/E?*?E#WC"WL;$H=/%TVW7"6"_0;2!WY@2N_UO$%=J>$P"RB8"JP(E^0]=F M'T4==698!D< =N0E=G)E7%0@NX(?'9A>]54B?T[)NO3Q9'H13[[5^3V[?7. M\:D<(7_11/FXK#:Z.0T+],A68P$*=(OVB/90^\B57=?4"Y_ BE!., MG\-<\6+JS18N8I, +-"=S>GX:T[73H1;0'@DP@I7?T,G.(',U8?<;HK_.MT0 M ZS@2K!I9C"G.W=A"[ XFBW@.IC%,3SD=K]8Y@0LGG>3Z/>:GS+\R2:"M^&; ;+GY?$?8VA!'\ MZ84U/(H(\4(4?M6'IMS3[P0NRZ8I=W2YY0GL&AP WZ_+LE$?< ']PY&O_QM0 M2P,$% @ !7X.40L5?-*2 P MP< !D !X;"]W;W)K&ULK57?C^(V$'[/7S%*3WU8120$V.6V@!38K7K5W1X"VJJJ^F"2 M@5CKV#G;69;_OF,'4NYTBU2I+XGMF6_FFQ\>3PY*/YL2T<)K):29AJ6U]7T< MF[S$BIF>JE&29*=TQ2QM]3XVM496>% EXC1);N.*<1G.)OYLJ6<3U5C!)2XU MF*:JF#[.4:C#-.R'YX,5WY?6'<2S25D,^Q< M.N#E^FS]9Q\[Q;)E!A=*_,$+6T[#<0@%[E@C[$H=?L%3/"-G+U?"^"\<6MUA M$D+>&*NJ$Y@85%RV?_9ZRL,%8/P6(#T!4L^[=>19/C#+9A.M#J"=-EES"Q^J M1Q,Y+EU1UE:3E!/.SE8HF,4"EDS;(VPTDX;Y?!E@LH Y$TSF:":Q)6<.$NM7@KXWLP2")($W2Y(J]01?Y MP-L;_/?(_\JVQFK:_7W%S[#S,_1^AO]_AJ\;?M^#U>/';//X ,MLM?D3-JOL M:9TM-A\^/ZTA>WJ >?8Q>UH\KF%3(BQ453-Y_/&'<=J_^\F O61RX+:D.^:9 M!C4QY4B'J!%RIC4G^G2A@6Z1=%=!0*ZJ"G7.:6E15VTH7((E1[EJM$%0.[_[ MUNVV,12',3WX3&)-.LS!%"$*;G)!BR) 8?!0.OP;M@30721Q\@<\9< MM6Z@/TJB49) ?S"*DE$:K*W*G_U\*%QR:&8:YIC:;A T=(\T[%&B9B+P= H: M"-QUJIML':X'-_ ]TI3+7#0%@O'"R)4VZ*01O+#<4Z9TDG"K9-.65?DZ=8J& MY)Q.M=-C6X%@%3SCD::2I#'N2O--[8D0,7HC010@O2;&H0@2[!C7Q$0T70.I MVEU+XI>%4\<4PI1[? M^R?#N*Z6MIVKW6GW*F7M,/Y7O7W2/C&]Y]2, G<$37IWHQ!T^TRT&ZMJ/YJW MRM*@]\N27E;43H'D.Z7L>>,<=&_U[!]02P,$% @ !7X.499#J9*?! M:@H !D !X;"]W;W)K&ULE5;;;N,V$'W75Q!N M6K2 ;Y+LC;.U#=C9](9L$R2;[D/1!UH:6<12I):D['B_OC.4K#A.XJ(OMDC. MG)DYX&_!&SMP3>C2%9:?Z'% M[^FL,R2'0$+B"('CWP8N04H"0C>^-IB=UB0I'G[OT7_QL6,L*V[A4LO/(G7Y MK#/IL!0R7DEWI[>_01//F/ 2+:W_9=M:=HS"266=+AIE]* 0JO[GCPT/!PJ3 MX1L*4:,0>;]K0][+#]SQ^=3H+3,DC6CTX4/UVNB<4)24>V?P5*">FU\#AC0= M.(2BC4'2J"UKM>@-M9A]U,KEEEVI%-+G^@-TH?4CVONQC$X"_E&I/HN'718- MH^$)O+B-*_9X\:FX+/M[L;+.8.K_.8$Y:C%''G/T!N9-"88[H=;,HS-?P;V; MK/> BX6UX"SC*FU.;U92K#F5GGV-WY.FJ!7?VY(G,.M@KUDP&^C,PV&?75\M M[J_8IQS8I2Y*KG8LYY9I!4RWWDEOOS0"VTS(78"MRW26B02\>SS%.A)$"SG7 M?P;&4UTZ2-GB_I)-1A'[X;M)%(8_UR'9H+*$[U"AT*G(!$H:<$;;$GQW8<46 ME>3U)W=)WJM*QLO2:)[D; 5KH10A8#LNT#_)0DIX>-%G#UA'!I&%;>6[WM#> MLU2D@=(.[5G''3"!9"=T9FISO-"5:A)@(-%K);ZA>YP9GR6=]2HDA5.6&'RM MN&1.>P.>7^78ALL*62;[#,82S+SBDR@\6M( PZ+'<-6 T9A)$ MA\<24D' ** 5G1N.L\S/H@2;AR0MV^8"F=F"\8YLA*XLBHH4%6M^,;NRKF6, M+#@P6I/1!/I*E#45=03ZJ18954.#B,'B4&XBKY7Z[',.BA4H4)E]LE^ /$M- MD J;$/F0'A'&ZGJA5 F5&*!-I&:E#78>G1C*)'?'Q4 T;_T\A;3'-UC7:^C5 MLL@TL8)E$@Z_[P=GP!RQGX(EEUPEWCT<3M .)Q:%H^YD,GIA^8F?_[!X!PU!/D,"B:.BQ@L* M*=I[$76'%_%)+Z*P&X[BX+(RAJ!*B@)U,:?'D^# L;W6GUHE_TNQYY-R+$!% MKO!_BU5Z-AYWHXL+JJ^ JL/E!FA.^&L"Z)HXBH""/PO/XVYX/O9525H[X*:1 M_L@-MD8<'HAC%^MQ M]OV(8R&HU$$])]SF+$/5@[YYUDT8^'%JJ"JOP1(R5WXT^Z B/ _#2;"$G49W MV_U>\$E35SRS^])0H\Y>N\<&!_=_ 6;M7SDT'A&L?@JTN^U#:E&_'Y[$ZU<8 MDHY#FF9.AJK#_OFX4[?4?N%TZ5\3*^WP;>(_]7C/P_ U(L&S5L;/DYJH.4U37]2H MA1_;!@WO;*S3@GCJJM0W#D4905JE>9:]3[60)EG,XMJ-6\QL2TH:O''@6ZV% M>UFBLMT\F22[A5M9U106TL6L$17>(7UK;AS/TH&EE!J-E]: P\T\.9N<+H]" M? SX+K'S>V,(E:RM?0B3RW*>9$$0*BPH, C^>$5*A6(6,;CEC,94@;@_GC' M_C'6SK6LA<>553]D2?4\.4F@Q(UH%=W:[C-NZSD.?(55/OY"U\<>YPD4K2>K MMV!6H*7I_\7SM@][@)/L#4"^!>11=Y\HJCP7)!8S9SMP(9K9PB"6&M$L3IIP M*'?D>%A >C'CJ&U'@/&&G>71/F"PFDS&LOE[? M7UY_NKA>75[M?%6.^1/R4/ MP,O*R(TLA*$1=+4L:H@Q[%Q/W"K6'\($ 9$#F<2NCAB:N/QL>6VJI=12-\X M^R2C4_FA8(LS6\WH-6+P;F$YUV\LWTFS56:\5;(4Q%HVT@ANE%# >0GC68WA M7Z>0[MUSC:Z*;O;,UAKJK_RP.CP89[U/_H;WK\V5WUA+NTE(,#RCBS]02P,$% @ !7X.41%4 M(C?>!P CA( !D !X;"]W;W)K&ULI5A;<]LV M%G[GK\"HVQUG1M7-5N,DMF=LQ^FF,VFS==,^[.P#1((2&A!@ 5"R_OU^YP"4 M95MQ,K,/EDD".)?O?.="GFV<_QQ62D5QUQ@;S@>K&-O7XW$H5ZJ18>1:9;%2 M.]_(B%N_'(?6*UGQH<:,9Y/)C^-&:CNX..-G'_W%F>NBT59]]")T32/]]DH9 MMSD?3 ?]@]_TT MGS?\H=4F[%T+\F3AW&>Z>5^=#R9DD#*JC"1!XM]:72MC2!#,^#O+'.Q4TL'] MZU[Z._8=OBQD4-?._*FKN#H?G Y$I6K9F?B;V_Q+97_F)*]T)O"OV*2]LU<# M478ANB8?A@6-MNF_O,LX[!TXG7SAP"P?F+'=21%;^59&>7'FW49XV@UI=,&N M\FD8IRT%Y39ZK&JWW2*HOSMEH[A9XS>U;@SYT=B>/)4,PFL\DS\HYW/AZSO.-O]5'\ MYW(1H@_/O3S2^_BYL_\'LK?E\I M<>V:5MKM/[\[G4U?O@D(O46N-*1L)8-0:VDZ&555A'LK5'*R:T5TXK);@D5B M>D)P3E\-1834"D?XHG2(F0VJHJO@C*:52M3:2EMJ:42(>-"PO(WR2N@0.E4- M1=OYT$DH@PH(*CQT:Y]WNEI,'Q]/T(/F342IP#$960EOL(X&EUVW*_J57 MO1\ZKE -2FS4D3>O%?+,!UCE65R01F7']E;A%4!:*Q_U NLMC ,:SF^%=5$% M<40X4*!FDS>_T!.^GKYY 1DL2BYAQ)*@;[T&O"V\EHWKX#%D_V,ZG,V/AY/) M9,219Q$PUABQ4-*33_ -H921I7D2A'/3V?>B55YLL:D@N/D(8.T0+F<5+XB: MH&3D$5HC2N,"H5]E(;3BZAJ1L,L#ZA\XGL!=21B3,&D: R,RL_#(AOG$NI9 M\LJ92ODA;U5P'(J#OA--*AML&O$*E%-#R7(E2O2-(1'R+S2C7DNO/[N1[7V<\ _L7R@Z M(*D1Z*9KF#;SR81(P[ZQLBRW@%\]\Y XE-^J[.(3SS5B4FFX"5?0UTO%2P=@ M>#%$27%)("AEM&+ 7%EVGBPYTB\.>5 <\,#H0 &CO!16$E6H , \KZ,&RNJN M7$F[!&9P8+/2\(IKPF.S4J1[DGZ9(\5CCHBOP\]^W MH%0\AU)"@ZH(Y_5!7(Z5)%]!2\$^@]58^0) M/-EA,=KO@ZAKS-(6_^(N*1ETQ(OBE!$6&^B,RE)M)@M1& L<:K*!4DSA?1+$ MSVJ%-/]$-)IZ4+W50CZON=#;Y6MG]MI1ZDDK%UQO2@\HIJ[\PSU#,1N*]S=,!#P)L?JH; MDAC&V*76PQV(:N+TY:OA_&1R8.-]T>$))2BVFF0B23%E$4GNX]*[MPO/'CE& MXI*)\<"X_2DE1^_T>(C:_4B4Y(J/5Z[ 99&-",JO 6T@]Q<\>*PU)FVQV*9. MR9.L\R/QJ^W'O1\/3$=PQJ+2E.R@C(6.@LH]&@)B*.;3R1%RL#2@ S7B^XGA MW=M+-D.#1E?:U::[$[>NCANJ%._?B]LMBGDS%,HN,=_Q_ 5#=4-V*GXIJS'K M)8IAL2->A:@;'ELQSIIMT/ -KWI)YYS:6Q>3O\<3*B"84D'H*U7*#H&YN?Z) M9@<-GXDR>?0,F"F65M?HRC0<=YB4A>/, $U)E%=K>DLD,WB60O8#! NX24H+ MO"G&(*"DW94.I?+IM1'MB7B2YVK"HL0$3^T_2:+GV#04*^@RI*]OH18 AT!% M'ARIO%YS2T"AS4VO4#4,AN)R2['2H<>-BQ(H]!"?!%_8EP "A)CSUS#..?TX MY'N!2"^3:D>G5!(3E_I-%*#0TJ3 ^C@"[0KZ\2Y@DQ)(U\B+^(/7X7./6MCG MWO30:"[V1W-$_7X@)V30_Q"H"/D).,R H A UWBS#5RP0MJ4^QQX&%%N"%BN M;"P]]12)Z:*DKP8T*?5*AGGJYQ)AN@#2%[XGABR90.+#6_%!0NP="DLY2D2) MI-TH&I'0C)!\1D;Z%#+,AH _IJM@8RE;N= FS2]$$?1J\P-'#:^:2C9Y&&!) M"%NE.*='!97IY& N(\\@H^Y:,M3"$GC.M536['FD^L7SG;.C0R^UX[UO!&#! MDK^$4+'!ZT?Z7+![NOO8M'NHFN MY2\."Q=!.;Y<*0E': /6:X<.E6](P>X3U,7_ %!+ P04 " %?@Y1_;Q5 MLU44 Z/ &0 'AL+W=OO0'FK]DRJ9%F2%C>W7F]ZW1%2_:U6>KQ>+IV4[;YN3U*_[N8_OZE>N[VC;F8ZM\ MO]OI]NZ-J=W-#R?+D_C%)WNU[>B+L]>O]OK*7)KN\_YCBT]GB4IE=Z;QUC6J M-9L?3BZ6+]\L%[2 W_C=FAN?_:UH*VOGOM"'#]4/)PN2R-2F[(B$QG_7YJVI M:Z($.?X(1$\23UJ8_QVIO^?-8S-K[=VX7%D."G6WD?WT;%)$M>+YX8,$J+%BQW,*( MI?Q1=_KUJ];=J);>!C7Z@[?*JR&<;<@JEUV+IQ;KNM>78@WE-NK27C5V8TO= M=.JB+%W?=+:Y4A]=;4MKO/HN_O7HU5D'UD3@K QLW@B;U0-LSM7/KNFV7KUK M*E.-UY]!Y"3W*LK]9G64X'_WS5R=+V9JM5@MCM [3WHX9WKG#]";VO#_7*Q] MU\)O_O<(@\>)P6-F\/@!!I^](26_\YV%+QD_I<-OHZ!^VQJ%4-SK5K.'XV&' MKTK7>&RAPCN5VMA&-Z75=>$[?(%XZKRR#;U$(6V[.SAV+LP59W2F\V"#46 4*YEMCK'6G5 M0[0"[YM.EM96KVUM.QM(T9+*^K)VOF]YDQ"/;$'<'UHGG&B7<>-IKRK;:Z!? M3(@$,:]-TP'JF_)#89]T*>]::VKYNH"J8\4>.WJ:_K>9T'SL'YL M4]9]95X6R!>F;2$%OG$[HSI]FV^P-35;[5K7O=A4U\B;V)69(8&5;:]K>7-X M _NH(-RUIO3F9Z2Z:P.AUS5YA]M9[QT"O'$0; 8O<.47Y42NV3U!>\^R\>:O M'&T0Y$K3-BRE]Z13**'L( BD]M1MY=4;A__^\S^>KY;/ MO@=E^FNU^/[]Q>4;_G/Y_:,\VP_KWL(DY-CL9''9Q>7;M.HWM[>E6CU=G"X7 M0<'PMVM;P;[(+0KV+/LZ.6F@@!)JRT"#W2]\7]FZQX[BDV1*V%!YTL%'DXN6(Z8%D0;4O.N=L38;6^PS-(1[ML '="!$)0I!UH]%K;6E/0(-WA MR0Y2<[!L78WX\K2>M'W#=9[R"*(,&5(U_6X-23AIR2J2R1> 0)Z42?Q('8-# MSM6/LMFIO0"4U#&-[A&S, LL&W=%;+PID:$X"7+>E?"+FN"%D6Z!US7B D2Z MNZ-LS2VKD/+-P+:^"XRO3=B5LIQJ;:N,9'M+Z:BSI_$]#O66U(1_&E<)5M^56HR@CS&UIQ/EN MV/G6Y+>E@6TK]G4M]:*CZ-IK6U%, 4DUGBJ$3JSOU'?DG;>V$Y*/4N+&QDN[ M!VHA33@/%%!=P\\0;ZXG;-)^ ?$858G50!=T0-FUB%PX'K/6T@:L37=C3!-I M #QUEEBQ@H1[IK2"\,5(/2C [M!P@Z:V%DFA+;>H4)(1$YY*82APZM;N[)^& MV?6"Z]S:F_::,Y!MD++82@4@_[TW^^;^NS=;VM.$SW! *A_2.JSKR]:N.7>T MQJ@:$*AFUPB$V*H[3762T4!!XHI",JHOD;9?/'WVXGOU$Q%02T[C2R3NWQ,P MH6:I@DZ+/WI'62=JG"S-)5HZLO"]9W.B>$!)J!S14S.KLJ..V:Z^F2TQ\=!H MK=N'D.4]R0ZYGA_C.F4<@<=0H._W :V@FH!=5W,!:ER4DAG#21C@H!0XK@CD M0F35 9.G>@Y+#L"38/:-V.^^XMB.K50%8@*B'MF'"B8D-X8_(R1^F3$T!-^+Z:!J=<*:E=R1,=A-7+.D6@; ME!X_$I#9N!M27.0&B<5(>"]'])2VM@^1+B"%Q4Z%/]77#*4E PVX.6Y^8%!R M..M@IYY\,LARC*\2OD7D.^28?_;5%;TAN)[Z0,O090.WD?M?QTH;V;GF=*UKTN,I3T"*H0.T60G6>^#26]Y* M%=#+H%GJ]TQ4B-\B.D_)[Q7\/O2B'?(A=J64$QP@N"F^C'TZY8 M'VW>!$W+&" L-NNWW.I)DRI5E3:+QB:#?S1;'BL19@,DL8.0O3S5]:I7QMU@3H&;1%"7KZ0 ME!G[PM@33G:!HVY..K?GCZ'HT'T)@]A\9=T>O94Z/G@T5%?KDK"@]=PPUK0R M&H*^N.IM12%)9K.>/+'!HS(5"HH<&@(2M= O(H5N:4DE2 T!9)KR+B0QB2>! M=>N[K!K"Z;VAV".I2F ]F FMV:G;G$J5H^I>")&6',I)JR$2YQ4_%(602Y2, MPS<1>O+[B(EW<4 $R@Y^1;IF1Y,7\#=Z)QE<24815.R0[?^$3U+6I#37F &! ML K,M250^X *)^PK5E'PY]K^&4=5K#G+YMW3S))!%,VT*LM3M HJ+T(/.S4Q M4 <3@\E)08QQ4UM&!L:',1D7(!D64B9DI,M3NOV^%IZ-N2E$\PF+AJ0;3,SY M1!ID3UKQ(#(,H^XH*JE85C*[&JO&^@ >R",8P 4KDSE(&P7CXSQ:W)IR19"? M_(;$(;])A7&N?H4X>O!R23,A4R?)*%91C\W.3_C?3%86#MW"%0<8+?;IU\\I9*7$(VI%H;[H)G+I:/]H5/J& M^R;IRWW6:8FT+-R4\'Y@I*;X9&\6<:@L-%"00JU&JN4&1L:(X3FR,@H>V3_5 MF"RTQM N"I#0 B.IGJLYI_5^%XR2F#K4S7O[ZZ)SXIV0O:09_"F&.R32^1+P M6JZ0,_B@@U"5\3S5@,>8O4 >'HIT(5\A(-W73"PEF@FIMZ9PD"A@3!CE"*N[\,1@8@$'$A9CZD4.0X]HLD7 M29,OCBKB;78<0G;SZF,&?G\62=%JX91CS M&<\'*CH**KR;#31#^KO/.B$:'KP93CF@.]TT?+W&L0)#]UL5HX:"\^*6 AN* M(&<;N!$@H2D*2]FX[#")E29S3.:>DP-PT3RS.SSU^YBV-$Y9P1!AZBD-&-]7 M" =LRNS6I@I@(3^8XZ9,)DT4#KQ=EI7!W?+)//ZAKDQ# 5H/;;[TF(T5Z+NV MR$ E6?2;V<<:"P5L">B.>N:FFO TE$5?;% 3M/@/K/K9&<[["0>#L4)L;F- M99&!("I8VT,V1FKWA.4C09*RR&A+0UE1/:H"X.:%#5'5]4S\CL;9/' +@IP^ M7AP Z]A%#D;,U13HYY1#5W%4WXUK3O,U$Y0%S/S1Z]IN[@:W%?P5Q9U-N$DQ ME2+>JL?/%J>KQ>S@,"ZU$PP=!L!_N-OL7(E=<0W/0\MHD^B\U9A@YL4%RP1* M]=UDBI=37"Z,[$-\KG;/K%*X.W1T=+B7BJ_OL8,)#4O!IZ%3(;<&9,!(H\LX MV3^8G 4$F&':_'0OQWFV&P!"6$5"CHX/XG6%E#.+3$@Y%\F=(-*8HP:LNZ0+ M'TPLHR5.J5?QO@(=X^PH_Q"R39@N DQIM^260 62QTKDL]8O5 #^/L*SG[-)*A0Z?A5&G*0YCZ,1FFFHT4QC5F@&+QPS MOE][!#'1AKRI\I+KH]^G*+]7V-.F4E7BD$ HV9:%W+G*U,,X8LBRV82#9P^A M0.1'14BS0574/Y3D-73:'7?@]]""[QX5J1>GV58 MF^%@LG/#R81TRAM#@% E6<)XC0_@*2(IZ ^K4)CMZ.PN#%%VFPUUIG0H,98Q M=D.'=X)"/RZ75LC[>$S0\-$0(__1)2JY)31(&JM+71/'WW:7YC7A4(9! M?3%>LC97MFEXEK#!(B3"TO"-"2IM-,6MY(8>( M,F%NJ%@(K$PC2Q8^5.2N=>%&%?10FHJQ,SENPR>>!+4 5Q,\.Y0*V^L[\=M= M-F'U1;C_T(W1"?E!2\X81E]!XK])ZT1W+_R=1W,NY[%C*>?J'UM;A_E4F(*) MMUK/>:2R%7/<:E0E/?"B5%)VT6,'EM/W!+.[W1#-*3L=BLZ*\QQQP=>I M69AR\#!J;75E\J.+N61^V'48:D]D_A>GBV>S8C3(_LRF99DNW[U5EW+5-WHV MK=/8"?SS&LF7AJST%@T;KUJ]WT+TOO5]=M!'#..Q'+U*M:!6GPB6?C(R RQ^ M<7-U?GZZ7#PY7\W4C\/E"Q&&?>F2YQU13 F;7YP/"U?G74E&9LR M>CWB*L1TANP?PW<111!%BBF(NP:1)?NS%J^\?!'XO_S7<-RNDEZ(.Q55] MR25E&K\,6.H O]$H\0"S'8%8 E_(172 ?D4X<_-Q,+26\V# @Y[O$M]C[]+Q M%]%I77^U#: &R3!= >!7NGU*BW(1W5331VJ9CQ]'.T,$ M%Y/(9;6Z=P@5$@4JF0D7M ,(#%'+*N>"G6 -HV8.HN"GHQG@]\D$NRO^E;X[-CX:C!U>'!H ^%+SCKP;1A MN/1.SC(<(A9QR)Q&0LFX--9X]G@Q&TD2[K=P1T6LXG+-EP92&HUI.^E:3IQW M3H9E"+-.SIEWZ-^*^PZ6^\KJK_K*-,I=+>>HXW2/<7#OW'U#P@OWXH?^"9B1 MHL#&>A:"U03-=\M_6R7W=R]X(ODZ)_>\2N%*[V MT'4=.5>5V>KHWDIP][ 1.L :H&=V _IJS$OF@H^60"X38NP>82]PV7#@ N[ M3==#6)BLTE_=>Y44D\++-L/+ H,3KZ=DBOEOW*R/:Q"\*A3YX>PX:S7BV(2R MA]CNZW6#SY4/WU*HN-:T5$YX]L8A)Q>J^0%/N_FVPOHNI28QPI KX@^69+3* ML\3<*G!..F?;]^L:FU[WGLY0_5"PI!/U11K^P?@TT^"CAM25D NAKWS$AF0! M'\D)<,H^?.P^I?WZ@^1^1 M/3A6=OP+C3A4*4(Q/&CSN1YF=S!AD% \'RZ.(Y2;LXRW<:2EEY1ELH15Q#$O M),AJU7B^E^T\W5-Z,/:<'+@GVX?F.-S/&Z8-TN=/GW">93_GW)GVBG^TRC^S M:CKY96?Z-OTP]D)^#CJ\+K^J1:*\HE/+YQJ);A S%(/Q=^_7]02P,$% @ !7X.48O$GRL^ @ M[@0 !D !X;"]W;W)K&ULC51-CYLP$+WG5UB< M6@D%,"1D5P0IV;9JJZX4;?IQJ'HP, G6&IO:INS^^]J&L*FTB7K!,_:\]V:& ML;->R$=5 VCTU#"NUEZM=7L;!*JLH2%J+EK@YN0@9$.T<>4Q4*T$4CE0PP(< MALN@(91[>>;V=C+/1*<9Y;"32'5-0^3S%ICHUU[DG38>Z+'6=B/(LY8<80_Z M6[N3Q@LFEHHVP!45'$DXK+U-=+M-;+P+^$ZA5VA>4K!5/NB_HA=A%[J.R4%LT(-ADTE \K>1K[< 98A1< > 1@E_<@ MY+)\1S3),REZ)&VT8;.&*]6A37*4VY^RU]*<4H/3^:8L1<>U0COR3 H&B/ * MF4W9086^4%)01C4%A=Y\M"ZUJA][R"ZE]\ M8-*=7*:J,^T5!_2_+7^MT]=5-J8$C=QW-JFTHTKDAQ'VEW%H MK9O$#U,\.ZFRLQ^=1@M_E6"4X-1?1NDL\E.\\I,4&]P"1_YR=?-:0X*S&6Q M'MU-4\@E,8SCM#M=YLTPPR_APTMP3^21=.EZE51DJ:JJGY8[#%>9>WU[:[AZ*_O[)H8GYK0M%_POLP\ M^\PK,]M*]:PS1 /?26X?G%V,H[@2>.6]U:@[5D)>6SW=PF M\TY@":' V%@$1I\-7J(0%HAH?-UC=IHGK6)[_8)^XVPG6U9,XZ44O_'$9//. MM ,)IJP2YEYN/^/>'D<4,6\R4W(*RTH1F%\Y4ITWD>&&#\F 4W7+2,XLK5'S#K&?@ M9\Y67'##44/WD:T$ZMYL8.@1*SJ(]X 7-6#T!N 0OLC"9!JNBP23[_4'1*YA M&+TPO(B. OY4%7T8!CY$010*41G\>83%J6(PNCK"?(4)A19X03A&*B0OO*#2]8$5O M5L!Z/CCQ< S=Y0'<$OA/$2:G@3^9AN\G09EV0D^$HY$_&0[?06<4^I/1V;NX=*-@1,@1]([SH>Z& M37QLI5S<\/.]2KN&00*I%#0_V!T[4#WW M6KR]*ZKH!"E+=QRIBL((/GCW7#]_3!4B*,IOUQUL+4+0/XT^P+Y.(>R'(Q)^ MDD3893N$X:0_:@F<3?M#"X=VSG&<"(6B_#LRI7L$%X0MM,![,#)^AE)9Z[LG M4"+-01E3V(,3>GH<-,(G87]X.GDUW(/6O[KM4&YVT>!:7?T'WYPVX]&RG@H. MXO5L15E/#4Z#P)14@_Z$ JKJ>:7>&%FZ&6$E#4T<;IG1B(?*"M!]*JFI[S?V M@69H7/P-4$L#!!0 ( 5^#E&&8OX"O@< )H6 9 >&PO=V]R:W-H M965TQU31%@8-@F:0X,\\,9\@9GF^DNM-+ MS@WY7E>-OA@MC5F=3:=ZMN1UH2=RQ1OX,I>J+@QTU6*J5XH7I26JJRD+@F1: M%Z(979[;L1MU>2[7IA(-OU%$K^NZ4 _7O)*;BQ$==0.?Q6)I<&!Z>;XJ%OP+ M-S^M;A3TICV74M2\T4(V1/'YQ>B*GEUG.-].^%GPC=YI$]3D5LH[['PH+T8! M N(5GQGD4,#?/7_#JPH9 8S?6YZC7B02[K8[[N^M[J#+;:'Y&UE]$Z597HRR M$2GYO%A7YK/<_)VW^L3(;R8K;=]DX^8F^8C,UMK(NB4&!+5HW'_QO;7##D$6 M'"%@+0&SN)T@B_)M88K+#U&UF&\9H,,_[%N)B0,?,("%@SP"WN=0\LO.J8S>':YKCB1<_*M M4*IHC":?UD:;HBE%LSBD\C#'E@L16J^+9L:U3_AWKF9"":7DY;6T*%# 'I+,X:&GZGG=5EF<=^C%)8C\( CO%-5L%=BR.^!GU0QJ1 M-'!(C^)GH<^R[ G^QSTEG7-%OE;<%P'G/I/D+/ MSX+CR%D4@'^\%#DX84Z3'>3=P+[5(_"5)'-6=^U#;IWO *=I"@Z>'C=YGD K M?!EPYZ*M'[>=/<@9"(J=L5WS@!OOXF5Q[.?!<;Q1BK\7XJ7!+N"NMV]D"EA: MR&W[@&L_ 1['*8 _#CQ-$S][EJ'_*Y7"1VL0'EZ$.,FV+N_:1WQ^JQ&#: T& M-$K\,,B?J=$!W'EF_:+%W?7V<6>PL;2P;?. M\.QLP,Y DCA<<@,MODH"(> M)9U!3W)8_)@ZC( P<9UG;B:/#\8=A(#*(:1H/-Q8'L=C" =('GJ=.?$0FW'R MB@23-!N_"B<@##L1=-))G!.&(SCLO>N/P:&;5NN3;PUY8:WE 68+!9T8JEWC( M.61TD-L1>^QS.,[K5=$\D,U2D@U7G#32D-K"V)_SES]EC*8_P/#*Y2FKJFBZ M3,) 9H[SNXQG0JZTM[\H_L'LH<..S!8+Q1=H26"5A!D< ,E6IY62]P)3(- * M)K>J[&L".XJ]9D(*V,^K0R>G9: M^;X0BOQ<5&O;^V0ED;^A6J#.3QI3,OSJ7.D*;%@[,(=2ST&I6+2=Z54QXQ-M %IWI#] )\X@.F$?H-YGH>_('%-F 1J!^H8H]*:3/R,/ MEJ+GP'PX/"9Y-F:3C&)3/ $'!?J<"[.&F#Z!-5("J4ZW M]D"3[;PZ6#%V[&L,:X+_ Z$0]Z$0#X8"+BYY]_L:+?0!=H?&5ADWN'_\^M$& MXV\#4I)>2O+L@+-U;!=H5UC5@/[\8#P-,AV(I][!#5;&[36&^!=4>.C_V@)P M:^45/8"]W>K,^W'=[47M_N-]LS<'L(+%/5?%@O>EXS8@O&[K"/TXI_8X;"-@ MITZ"$@'2B3@(R6GW]=-N"6BQ[&?]#]Y:?)R+\UZ*=G_PTL'F?[!O10* M_B@%IX+R;L+"(/$>9:['U_OI2F=/>75"6 K.SBCLWEF0/UM$ZS\'7"KR(PIY M.^;G$QJ%6T%9YE,;<%!?A%Z;T8(;4P;!EA,\:;"\&XX(<./(QS(^H9A+TB#) M>P&0ID(>G,&!!"=13,/_Q5R0@ =0OD%- 6=2D![>S:<[]X4U5PM[*XIIU+HQ M[NJP'^TO7J_-VNKNU!?$+ 4E4Q>= "C:"@T&YFU#7,7)E;Q]OI3&RMLTE M+TJN< )\GTMIN@X*Z*^C+_\-4$L#!!0 ( 5^#E&%<@&R.0, /\& 9 M >&PO=V]R:W-H965TXSTT[I M1U,A6GBNA32SH+*VN8DB4U18,W.A&I0DV2A=,TM7O8U,HY&5'E2+*(GCRZAF M7 ;SJ7^[U_.I:JW@$N\UF+:NF=XM4*AN%HR#P\,#WU;6/43S:<.VN$3[K;G7 M=(L&*R6O41JN)&CX3O'SKPX@XMDK=2CNWPJ9T'L"*' PCH+ MC/Z>\ Z%<(:(QN^]S6!PZ8 OSP?K'WSL%,N:&;Q3X@')GKU#"^%_H>MWL.H"B-5;5>S QJ+GL_]GS/@\O )/X""#9 Q+/NW?D M6;YCELVG6G6@G399PTDP:YO-E M@,D2%DPP6:"!-RNV%FC>3B-+7ATV*O8>%KV'Y(B'%+XH:2L#[V6)Y;_XB-@. ME),#Y45RTN#G5EY &H>0Q$E\PEXZI"#U]M+_3\'/V[6QFFZ_3OC)!C^9]Y,= M\;.D@2I;@: V<-SG:PD^;?>KK5"#K9BD'V402FX*08<24!CL2(K G1!'&RZI MGIP),)8(T'19$])P]6P:S\;^TP2$908V2M#XFIO1JM*(AXI2)7"HQ%'1^'IT M!F>C);62WOFN8LZ8ZZMS&.=QF,/1S5D*A:MH]ACDFY^>0 MI)=AG&5D=1)>Y?EHI2S%D4XNPYQ>LRP-)_$5K"HBO%9/"/CLT-2[G4N QD)I M:D!HJ0TU;%&B9F+DZ90T6-P5VFV( 7$ MB-&1!%& M)6-0_E",ZZ)B6CQ8$0UOJ(A=$Q3A6U/"G^WG&I.(1'21=_0P%.Y M-741IN=)O;:=$0OEE*->NM7KR'.K;3]?AI>A^U^VR^UO^K]I^$+TUM. MS2AP0]#XXBH/0/?KMK]8U?@5MU:6%J8_5O2%0NT42+Y1RAXNSL'PS9O_ 5!+ M P04 " %?@Y1'XUN: P# !.!P &0 'AL+W=OU:]&,[##LH-A,+ ME25/DIMFOWZ4[+CIVF3;Q99$O<='BJ)&*ZD>= Y@R%/!A1[[N3'E:1#H-(>" MZIXL0:!E(55!#4[5,M"E IHY4,&#. R/@X(RX4]&;NU:34:R,IP)N%9$5T5! MU7H*7*[&?N1O%F[8,C=V(9B,2KJ$6S#WY;7"6="R9*P H9D41,%B[)]%I].! MW>\V?&6PTEMC8B.92_E@)Y^RL1]:0< A-9:!XN\19L"Y)4(9/QM.OW5I@=OC M#?NYBQUCF5,-,\F_LM@##< <@;@"QTUT[_B2-L#$\27[ M3D^]E<&X4U\&,/9[_E M[#O._@[.6[P:6<6!R 6Y*D%1P\22-)ZNYIPMJ2TY_58Z]S,?>,]\W!V-LF75 ME8MNA1.J-=[3+F&"&48YWHI4+NT8Z[L?)9TX.?;."JD,^^44D,/H9-A)!C$Y M\J:44Y$BAR&88VAS3.*HWQD.^Z\\RS:0OWB\@9*N\:(:0D6&.PTHT#A)4P4; M%7$G/$GVJHBC3M1/O%FEE*4J;12(Q13+W<(VJ"]2I/\%[.XI@T%;!H-_+H,9 MW@);7A7FZ%YD3*>RPD1D9$9U3LZQ]VF"+;0NDJT:>:M$]GJU7?I4ES2%L8]M M6(-Z!']REP/2 M=^!=@+;,%%.-EC5016*T1]'0F\):8BFTZUWO3AK,S N_KQTU[=K5]+,[J'OF\O7YI+JE:,G3'88'0L/<.$Z[J[EU/C"Q=QYQ+ M@_W7#7-\\$#9#6A?2&DV$^N@?4(GOP%02P,$% @ !7X.4=O"E;IO! MDA$ !D !X;"]W;W)K&ULK5A1;Z,X$/XK%KJ' M7:DM& B$*HG4)DVWU76WVMSN/ISNP8%)@PJ8LTVR_?=G$TI"( [:VRA*,,PW M\\UX/&,SVE+VRM< OU,DXR/C;40^;5I\G -*>%7-(=,/EE1EA(AA^S%Y#D# M$I6@-#%MR_+,E,29,1F5]Y[99$0+D<09/#/$BS0E[.T6$KH=&]AXO_$U?ED+ M=<.!*22)TB1Y_%LI-6J;"GAX_:Y]7CHOG5D2#E.: M_(@CL1X;0P-%L")%(K[2[2>H'!HH?2%->/F+MI6L9:"PX(*F%5@R2.-L]T]^ M5H$X &#G!,"N /8QP#T!<"J TQ?@5@"W+V!0 09] 5X%\/H"_ K@]P4,*\"P M+R"H $%? +;>9\XJ,V@WY66^S(@@DQ&C6\24O-2G+LJD*_$R3>),K8^%8/)I M+'%BH"<@O& @%X) )(O0E&:<)G%4/D8?9B!(G'#T MF3!&5()_1)?HVV*&/OSQ<60*R4MI-\.*P^V.@WV"PQ-Y0[9]@6S+MCK04SWZ MD617R I.PF?_#WZGA\\@O$*XA..@ S[O 7?P2?B]'OXE%%KXIS.^%])WQSKI M^T-O>*?UQW/3SM[)'ULW91;7J6S7J6R7^MP3^F["L$B+A B(5(6,PUATA62G MQ"N5J.ZQF5RZ@3\8^IXDL3FDWR7I.9XKO[5D@ZE3,W6T3'_(EA%G+R@D>2Q( MHF/KM#C87N %KM/-P*T9N%H&'V24.T-]/D"Z!_:/1Z=9')^# 2 M\\Y9>_3;$1GX5G 0DH;986UVJ#6[ !;+;+E!^SQ:J$GIXUI0VPA^;XK>!JT$ MM/&@.??3MHP_=(X29-9'Z*Z/T+PM-+3<(TZ?^@@]GC'7"#&V]MW?TD]D.6N[ MD**H8*HJB36@7$XPC=YCWME5K18AK[74[GI)S;ND\*DLTN<= ML>UPJZ?@O$OPJ"8UG=LW.ZSO=DWG0IIM@(EXF0#*J)#+)"=O1(XZ=V/MQJ;E MM&]K6-_7)*=4YA)E;^BS)%'N'!=KRL3E7\!2]"]3(O"^C6%]'WN0F4NR M$-"&) 6H?6P$2W&!Y$F0"VE>YG/GQL1M1<"Q G=HGPK!OF7ALSWK, 3]W-UW M$*QO(;_JKM=R-\">8YWHSWC??;"^_4S+M"O/RI)+HTYW;N3]]A:A73.[I(+C M>GA_3E?3HWUCP_K.]NO+:EYI]HYXMXK"?9>@I-Y>@.;!N4Z]K9 [YI=8+J$$ M5A)I7?G2>[9[ ; ;")J71[TE%?+H6%ZN@43 E(!\OJ+2B6J@3H_U:YC)?U!+ M P04 " %?@Y1U"*U+T," !S!0 &0 'AL+W=O0()FC0I;*K:2&T' J2A:A7P@'APDTMBS;&# M[2S;?[^SDX8RM142+XE_W/?=?7>^6W1*WYL*T<)C+:19!I6US3P,359ASV_P MG6-GCM;@E.R5NG>;S_DRB%Q *#"SCH'1[P$W*(0CHC!^#YS!Z-(!C]<']H]> M.VG9,X,;)7[PW%;+X#J ' O6"GNGND\XZ'GG^#(EC/]"U]M>Q0%DK;&J'L 4 M0/0QZ. ,1S&A /@/@E8'8&D R Q OM(_.R;IAEZ4*K#K2S)C:W\+GQ M:%+#I:OBSFJZY82SZ:ZO'J@"=KR4O. 9DQ966:9::;DL8:L$SS@:>'6#EG%A MX"O3FKGLOX:W8"JFT2Q"2\$XRC ;'*][Q_$9QPG<*FDK Q]DCOG?^)!$C$KB M@Y)U?)'P2RLGD$1O(([BZ$0\FW^&3Z\OA).,B4T\7W*&[U0&?Z[VQFIZN;\N M.)B-#F;>P>R,@ZVR2/Q,B"?(N6A=089J +6KL4SFY/U492X2N[DQ-PW+O=\:=>G;VH!/8/\ QM-Q;ZQJ?)?LE:6>\\N*IB)J9T#WA:)\#QOG8)RS MZ3-02P,$% @ !7X.436X$1T+ @ =P0 !D !X;"]W;W)K&ULC511;YLP$/XK%MI#*VTQ@;1)*H*4)IJVJ9NB1MT>ICT8 MN 2KQF:V">V_W]D0EH>DVPOX[/N^[^[C3-(J_6Q* $M>*B'-(BBMK>\H-7D) M%3,C58/$DYW2%;,8ZCTUM096>% E:!2&M[1B7 9IXO:Y:J0U9,->62: ,%D0W-0-%.2!LXP+;CD8]_I1A=TOS1R1.+P/8G"*#P#7[T- M_\HTPL?GX!0=&&R(!ALBSQ=?X.N[-W_;9]CJSV5FK,9)^_6&1#Q(Q%YB\B^G MZT[KG&<=PZUGTKH"Z1=85?M)R93%N?/+$O\,H%T"GN^4LL? #=_PKTG_ %!+ P04 M " %?@Y1H@)>^T\" %!@ &0 'AL+W=O^K[,-%$SW9 4E MGJRD*IA!4ZU]72E@N0,5PJ=!T/<+QDLO';F]N4I'LC:"ES!71-=%P=3S#0BY M'7NAM]NXX^N-L1M^.JK8&A9@[JNY0LOO6')>0*FY+(F"U=B;A-?3Q/H[AQ\< MMGIO36PF2RD?K/$U'WN!%00",F,9&/X>80I"6"*4\:?E]+J0%KB_WK%_=KEC M+DNF82K%3YZ;S=@;>B2'%:N%N9/;+]#FXP1F4FCW)=O6-_!(5FLCBQ:,"@I> M-G_VU-9A#Q#&1P"T!=!S 5$+B%RBC3*7UHP9EHZ4W!)EO9'-+EQM'!JSX:7M MXL(H/.6(,^DDRV1=&DWF[)DM!1!6Y@0W50TYN>5LR04W'#3Y1!9X@_(:7>2* MG V[F(%A7.A+)+A?S,C%A\N1;U"X#>]GK'H+[6*ZN9K2K&75\T1&^-F?]DC03FOR:++51>"U_OQ,BZD)$+D1\ MJBU5$^M0S1J&OF.PC_4Q#8.0]B-,\7&_.(?\KN)@0#N_?R3&G<3XE$37;?'2 M[4,J&Y)D+_H@3(8Q?27RK5M,!_UP<%ACTFE,_JN,KF/L/.')V[(E-.P/KUXI M/^W72/?W'JD=D'@KU[S41, *D4%O@$2J&3J-863EWNU2&IP";KG!.0W*.N#Y M2DJS,^PHZ"9_^A=02P,$% @ !7X.4<5N?3J0 P )PP !D !X;"]W M;W)K&ULM5=AC]HX$/TKH^A.:J7KQDY(@!4@=:&] M]M2M5MWKW8>J'PP9(-K$YFP'=J7[\3=.L@&6;):K5#Z G?@]OQG;S\-HI_2= M62-:N,\S:<;>VMK-I>^;Q1IS82[4!B6]62J="TM=O?+-1J-(2E">^0%CL9^+ M5'J34?GL1D]&JK!9*O%&@RGR7.B'*\S4;NQQ[_'!EW2UMNZ!/QEMQ IOT7[= MW&CJ^0U+DN8H3:HD:%R.O;?\L\ PAH0G@OHU8!>F9DJE#(/,V'%9*35#K0;36RN42:S1%/XJ73K?FLUO4T) M9R=3);>H;3K/$&ZTRE-CE'Z S\JB 2$3N%TK;>%/U#E\4D(:>#5#*]+,P&>A MM7"K]AK>P-?;&;SZY?7(MR3*4?N+6L!5)2!X1D (UTK:M8%W,L'D&.]3,$U$ MP6-$5T$GX1^%O("0_08!"UB+GNG9<#YL@<^ZX=="$YRWS7X43=BL3UCR]9[A M^QTE:I&52R$2V@"IL576 >_I\!LT;3FO2..2U!W][20,6!2$XXWJ7J?JDYWT[1KS.>KO'1F)&NZHDWN&UZF !=EDO4FEIDM8N[-@45572@@#/W:9? V=YY6:>(REG=+H*,G!7H5C:6 MSGDJ5ZTVRDYU\(CN=WY\IF?UP+ACX+'B@[N"_]BQAG_AX^..>E?9TCE'G@?[ MF8.?88,UZY$/]GM1_,0%VX8Q\L%G\K7W;MYMWEWYNA;W:5[D9Z5I;[N\VW?/ M.]LOD/#@AYJJA*;*8$6W!V2X)$IVT:?4Z:HJ MK3I6; , )() 9 >&PO=V]R:W-H965TX>EV8RC M?K1_\4FN"\\OXLFH$FM\0/^EFEO:Q:V67"K43AH-%E?CZ+;_9MI/&! DODK< MN(,UL"L+8[[SYGT^CA)FA"4N/:L0]'C$*98E:R(>/QJE46N3@8?KO?:WP7ER M9B$<3DWYC\Q],8Z&$>2X$G7I/YG-W]@X=,7ZEJ9TX3]L=K*#FPB6M?-&-6!B MH*3>/<53$X@#P#!Y 9 V@/2U@*P!9,'1';/@UDQX,1E9LP'+TJ2-%R$V 4W> M2,UI?/"63B7A_.0MYFA%66[A72VLT!XQAP]&: >G,_1"E@X^"FL%1_L,+N#+ MPPQ._SH;Q9ZLLXYXV5BZVUE*7[!T6]D>9,DYI$F:'(%/N^'W8@M9_Q@Z)I=; MO]/6[S2HNWQ!W5147$;D[-R:M16J??Y[CVJ!]AO\1[["@Z+@P%WM".\H.KDP[OKUH:5YUZ9KCP(#4%MJ8>X8%(J6-L MNK5D"6Q16-=!Z+HE=/T;0FYI9:@1Z@JO(]>M\7.!4'*2"^% !"5@5K#G#$+G M]",[!PD) ASBFP,FRM#/_H#DR'O]R!/LVKY*5+<-/:O7EU MLNF/LW3,>K<2SN]'BLX^OQMSP8D-B3Z'18B34[VUU)K/J:PL$3>$/9[9T]Y%J@Q!4I2NC&16!W'P"[ MC3=5F*$+XVDBAV5!'TUH68#.5X:"T6QX++>?89/_ 5!+ P04 " %?@Y1 M3FQZ!]P# !5$ &0 'AL+W=O) PFP J0%EGU1VUL5]>Y#=1],,H"U29S:!KK__FR3#0DD M(=MK^0!Q,L_,,R^>B1GN&7\6&P")?L11(D;61LKTVK9%L(&8B"N60J*>K!B/ MB51+OK9%RH&$!A1'MNLXOAT3FECCH;GWQ,=#MI413>")([&-8\)?)A"Q_AF@ MUQ;0SP#]MH!!!ABT!6#G-7..J:!#RDV]S(@DXR%G>\2UO-*G+TS1&;PJ$YKH M_;&07#VE"B?',^!T1W2-HH^4+&E$)06!WLU $AH)])EP;AZ_1W^BKXL9>O?' M^Z$ME66-MX/,RN1@Q:VQ\HF$-?]@%S'=2K0TV;T(TFND#.HA<_^'_RV&3Z# MX IA \>#"OB\!;R#:^%WS?"_ MD(O[_@^U;YWG%J?7]H#:^T_G@I[?R5_*EU M6]5I7JQN7JRNT=>MT?>D>B=P#B%2.R-X_H#$AG!5K52(+815T3GH\XP^/2IV M8SRT=T4/FB1*)#LYRA#HU4]1J]% M2@(86E>(E\#_;=#MY;J]1MU3 MENR FU'+5N6<5G4)[SQ5_^!<4W2900H M,7%+R0M1JZH.XI]7@.)\5@)W%7**=E&NQ+R7,^\U,E^H&: (WJ#C_EKH7+1) M=3^WT?^U6W?2/\N1BT_R.#V7Z9U5Q*R-T&T;H?FY4-\YK:W[-D*/%\R50CS( M0SSXI8UG-C@K)]^IZ#RW+>7F%7(GG:SD%W:.[RA. M4E6X+&QH&;-,L7?"_<3!5E+S*BEM& M@(_S$5\:D&]M!9G"4K\N]((RC^-@PQ!6KX1KF@@4P4KAG*N> MHLX/9]C#0K+4G%:63*K3C[G&PO=V]R:W-H965TW"3V\;"L3O;:=F_ MG^VDH?0C3'M);.>>DW.NKZ_3#1O*O(0*RRN^ J:_ M++BHL-)3L73E2@ N+*BB;N!YL5MAPIPLM6N/(DMYK2AA\"B0K*L*BS^W0/EF MY/C.=N&)+$ME%MPL7>$ES$ ]KQZ%GKD=2T$J8))PA@0L1L[8OYDD)MX&?">P MD3MC9)S,.7\QD_MBY'A&$%#(E6' ^K6&"5!JB+2,WRVGT_W2 '?'6_8OUKOV M,L<2)IS^((4J1\[0004L<$W5$]_<0>MG8/AR3J5]HDT;ZSDHKZ7B50O6"BK" MFC=^;?.P ] \QP%!"PCV ?$)0-@"0FNT469M3;'"62KX!@D3K=G,P.;&HK4; MPLPNSI307XG&J6P*@JRQ227Z1O"<4*((2'2)9KI>BIH"X@MT(NAL"@H3*L]U M^/-LBLX^G:>NTJ(,M9NW FX; <$) 2%ZX$R5$GUF!11'$-^O!_T$+@Z&UU* M@FU*;H->QJ\UNT*A=X$"+_".">J'/V"AX?XQ^#LY8;=#H>4+/]ZA>R:5J/49 M4A)A5J [*):$+='8G(5F3Z9$YI3+6@#Z.9[K<'U.?O6HB#H5D541?:R"OI7 M!9J#5L",B#FFF.5PK (:ZMA2F[:RSGP_BI(P3-WU;F)[)9A^=B-7.(>1HQN6 M!+$&)T,]W@:=M\&_>EM@(M :TQH05HA(69_RU% .=CQ%?A)=[SDZC/*]87@] M"+JX=XKC3G'G6U8@EO82D2CG-5--X^Q6 MNWMJ;-NS^Q;>7'+ZK.OREXC"0D.]JT3G3#071S-1?&5[[YPKW&ULM5==;]HP%/TK5]$>5JDCS$]]QSKIV3F\%*JGN] M0#3P$'.AA]["F.3$]_5T@3'5#9F@L'=F4L74V*F:^SI12*,L*.9^& 0=/Z9, M>*-!=NU:C08R-9P)O%:@TSBFZO$,N5P-/>(]71BS^<*X"_YHD- YWJ#YF5PK M._-+E(C%*#23 A3.AMXI.3D+ Q>0K;AEN-)K8W!2)E+>N\G7:.@%CA%RG!H' M0>W?$L^1?PM0+TRIPM<'S^A7V;BK9@)U7@N^2\6F<70ZWD0X8RFW(SE MZ@L6@MH.;RJYSGYA5:P-/)BFVLBX"+8,8B;R?_I0%&(M(&QM"0B+@##CG2?* M6%Y00T<#)5>@W&J+Y@:9U"S:DF/"[4JSTIYJNZF)&VKX>(&&,JZ/!KZQ_%P6 M?UIP.WYJ MM]2!K'D6.;@2NQ]M$E9YPW>K1/BB$J1!6ELJ4=D0J?>A6\DM'\=CWV-0V1.I M]Z=#Q.?(_>?BN]O45_9%ZOUKB_HW;'UE:Z3>UPY1W]F@OM]K;E%?N1ZIM[TQ MNJZ+B7EV^.V;]PZITD?['H3*$\D^IJA*-L8]B@69C?6HAV]!1!_KWM&D,DSR MBF/N4*'=#TM8.6:XCV/N7J%7X D\VM!-3/VU1C!&-<_:70U3F0J3]X3EU;*E M/LT;R6IYWH]?435GMI_C.+.A0:-K'T65M[CYQ,@D:RLGTM@F-1LN[&X)J=&W5997;P[NZWK]Z]%1E=R355S-BC7)X3>W1;F*:_BQO#NJ MUB6)EXQIE1W9EN4?K>(T/WC[FGUV4;Y]76SJ+,W)18FJS6H5ET_O2%8\OCG M!]T'7]*[^YI^D7JPO2OCI:"MEF:Y(7J5%CDIR^^;@&/]Z?(P# MA[(PFJN4/%;"_Q$UYJ8HOM(?/BW?'%A4)Y*1I*9"8OCG@;PG649E@2;_M&(/ MMJU21O'_G?139CZ8[T;?9Z!\U496%Y).XCM^^+HM'5%)ZD$?_P^(ZXX=(G.8T M"5W6)?PV!;[Z[65=)%_OBVQ)RNI'=$)NTR0E>?*$?CHA=9QF%?HTN#Q!/_WP\^NC&MJF$HZ2MIUW33OV1#N_Q_D,6=$ALBW;DK"_?Q[[B9K] MA"0SA!D[CB3L']3LI^0&6K<9NR]A/WT>^TC%F8C[NLZZZ>YS;7YNR!A/TO]]L5K!.J>B2>X0 M5?=Q22H4;^K[HDS_ERQEL;@1Z#&!= 7W\!;;GL7^O#YZ$*>O,>7VN$I;+F#M2;O8IA\LS&BXCJKF.JF>.OS7'WWUJI56UD8^3 M/^I5Q_8B)_"C@4D20L<)W1'AW$!BS[!@:UBPNV'%IJ[J.%^F^9W,NL#4.@FA MW#H#B3WKPJUUH=*Z#]^2^SB_(_%-1@R-"\>J!&%H^?; -D.ZN9ZN9UFTM2S: M*WY,^V0TGND#D[0444J:>V+1[HZMN79CM/OX(N64.QA2N?AB8F >6V U<7!<9*4T*%H MW7<KX73>0GS MQ(O5F?<3.%:<)X2Z7.MKMT6)*E(^I FIICWN',N2I>\$GCLQ.Z M\Z2*U5GURU[.YXVTOU;K."%O#M:T"BD?R,%;)-MR>0%!?7-Y M7K?5>7UL;E[DOTR:?&9+LCPDU.$R],5PVVNFHX;\WIIMYT.E,+ M,A_%LU80M@=+V>&*]XLIX?RE5%N\E* K4]6O30G_-B#LNP OOFQU\37V[836 MD5DV,9O'Y90#T7 B7]J\FK+51<=IG+8[*8(JLJW/5DXO6=+JW9L*M+QRL-65 MPQ7,9U@^0P5:)66ZGLC6?VND=%/JD91D.Z^6Z.8)0="&&496ZZQX(E"?/]X7 M:$5J^)RP\$G;3@I8PC,!_T*>]8KV!?TU*V%@FJ;P0\F(4;I:D64:UR1[0E#H MQXV<.EVQ#ES,+F?HM"B6K*8^*3=WZ%A8]4&V_>GTY/AG=)MFS&20PRAIFX]I MEC5M;-9 ^$<*A<&2E@;S,KV[(^5L_!'8$8/-5(-E#/KD8%P*!3W]X*:(RR75 M:9F6)*F+LJ*KS2*#"B/-T6W\4&R8^Z4_,_+W4"S%^1.D-<3V-R##E3$-33%* M2%G'P)/1)0)EN4US\%4PX%\H!?88!#^0$FCK^"LIX+\(K(7"J[DI4]]#)T'3 MFPRZ,LU[K=T0V@U4P+HHV4BPM%H>LEY)J73HO#J%%?1Z8NY2Z7VS)EHT7X>EB@%>/MKIZG%3C4)]7OK2RC0.;PXM-1UUL MTK.3_8M:A]=GCFE]MFM1JQ9LGF_^?"E!BY<2=/4"@OK#P4M3Q[0T[0V'N 8S MW!GYV+;4VXOS+CG#DHRXH/WQ;0RB$M)"EM_*FU?S80D\D+BM5C_$B MT%$7@9J-C):[OZD0!8/=H7E+%DV2];7C]8FCKD^V7?509#!Z&4QGJ99J*=BQ M9[;U2M5?O%1QU*7*O@NR#X[DN"/PQL=7IP:$?=UYC>.852?Z@K\5U O,S@Q; MPU..,SFA[5C#32P9H3WSA-JQV>8P;?E/TY;GIA(7$X2N,Y!X9=KTM0%A?RAY M]G?4V9]E,G6M^D$C8@ZERBK^EJXV*Y1OO;H[4;IM0RT MN+IO\REP0,D(OR;_;*!"@CG@'(*_'H+#MM+^!8Y6T,WQ92.N?J&6UYN2[GO7 MM,WX$0K-JE4&IF2Q@GB1P ]/K(A[A.*YV-2(UF6WFY)5TEV=1O,!;;NY1(?B M-=4VS@ZAGDM*$L,\@:SQ>YQOXO()8:H@B:&\I3&8)9.\ #T+*/A!XQQUT1G= MEL6*Z4J@6&3WM%FE?8BJ@GT\LEQB,*V#=LE0FO* MC[VCP%&/THX8?L:Z-'MBE2KM"X&=2$X:XX9U _9O>T08WJYKF2F@+R/<=B/W ME&V/I%#ZU^BQV&00XU,:Y G3 P8!ZFS6B T_%=,:IBGJ'5]/.GM6T;#/%D1Q=NI(=I',9X6"CNPV^ MAH1_JLW8I>8+17]@+M]:^T\(6$:[IKO?OZYKR5/5C?!($_/*]\;) >YTCH'#_PAS/M4B;/M<( #\\T M)(38];#M3]WJXNL55[W>4*RESW-BLIYVA2MDZN7(+@%P[H[/I/N3H:\$7W6X MZO7"#N,]=\J7Q"29!FE=I8K(S^M$=[XR.[L6I2/I*\B6% MJUY2G,&,I66L]7]@+/&9XZ9SPOO9UII-OM&B."A4=>WU?(H5OO MLL!P^6*2%B\AJ=^;/ 5YZA2TFT\99B6/9R5/G96>-YASC?0].DZXLJQ.96?M M,MND.WAF\M2921>?%QI^1U:;-5%Q;\[KO3G_TG :E)(>SY>>.E_J\XE&@#WS MAG&Z[3D=7XBE^43#AV>N-'_]I>6SAGS]+N/5@*?.YD,7?GX^X=G?>V;V_Z@1 M &NX83;NW]7G6=579]5GYA.-]*@-0;X^G[R8I,5+2.KW)B\4?'6>W\VG#/.) MSXL#_WL6!W.-]#TZCB=B7YV(Q9O&[3N+RV9GT*2#>,+U39>!\AOTS8^R];<_ M7A/Z#AZ=LBPD=%%@1][$BLCG&=2?J^C^V)"YZ^\,['],BJ MITKO(%3:E>.#J$!Q9\#G2=!7YX;O\1RA;;*W_2&[R+Z0$(:.YT^]1O!YGO+5 M>:I_B4D2M01_'CY4-:@:,) MD?99,23@,3[8]6J&:0P))"]6O,FA"7C8#W:]G6 6&LX#R2:@C:.IP>'1/%!' M\XNR6$'C1?F$/A>UX0#P(!ZH@_C[(J=',/3.17?MNT8(/X=C$^MW, +!U[XAY:L_P"4Q]10'5/[X[0NTP=Z;-K=290I'(Z/ MC>S0\X<*:\GZ"O-0'*I#\4E[^;.-^.S_822U_RNXF5$ MR.-IJ(ZGQSD[*T9;>TV,Y/$T?+FSD?-P' $'YTM]+7@,#-4Q\"HNTV)3P3CF M]#"<74VFA5J;Z*L7R_0ACXJA:8&[XT1>A.,2%P=A,+4*"'DH#4T?HNVX"@@E M=:P?N=&41L*S<74X_9336]V# >H&A1UXF8P)#Z[A=PJNYZ'D$H(O@7F0T'E0 MIMD3!V\1#Z^1.KP*GGW(W9KZ^#F;W9?-F@E=-+=>GM>C$0^BD6D]N],R;AZ- MJUF5CT<\Z$;JH+OWJ^-Y)+M;.^WD$0_ D3H [_.8>-[*--:&!^Q(';"A;(&. M,,H"$8^_D;8&;;US6Y4I)E,T?K'C.Q2K8<(V'G,C=)!)Z^4U M5(2%O%_4@J3')0,X#!$/PSBBRFL%93L"S(6E#I']PG@[/13/,!:=2''V>U;H M3.$:6+:@C6E1NM5D&LI$(\S\2MW\Q20M.DF]Z&&'SL34P9: E6&I _7U<&PF MI\JB$S7$%.A G9H_DZ M HB&I0[7W585]5 ARAKYJ !W8:GC]W?8_)QW;?9W M'%S?F4(RL 2@"VO7XEK]I$:6A;HV>K6:I*23T8$38G>X#;20489NY$_[@8 A M8>U:N^_[B.B\:ZH'5.+AX>6]N8S.#@++&][RDPKT Q=/VBV 5ECJA*;Q?\CP M[:P5/]KA ABV!$P*2YU_=%<,YCH!]N1Y_V(OU@'RDI#[-&!0VC/DP,?F[ :X8=U;DU[F%/J9.R#BI'P_X#FD6!'$)T7\Y%QSE(*>Y4 M8A,AJ3285&8OULYU8K#MS=SAD[7.; TK=F>.E'6A8XV"6:A\)X=%."P-'M9^ MX<3\OA(6\;$T %FZ<'*N$S!]?6B^/^MB+]9!)PB5APYIRR 2J258,S^2!I2Y MAG.7HE.C@^0BTZ!'A-KFF2A>$D@M/'/\8)B]S>@66 9[YMOT$V?-V,!<@L;8V[ML4?1"1]N4DRAM FH5E@#:V6^3Z&3I+WK MCP5@*ZQ!MJ(7O3K7>4'/$;"F\,Y@4RK/D4!#.2K'$1*F!AOJF8[C[N8X0@[3 M !;MXCB:/*+/K0* $=8@&+WK<&Y&1W\OX#Y"&M#@#SWS49U.O$$](@#88 V" M38=DC([OH"AAFQQ&W2'$80TXS05X*HBE'3%')[0X5:,GG^H:B2ABC3)Y M"; U6(-;(V)7\\?.ZH?^ISJAD%VC0'CYG=;5H#-RWA;=V6#OVZ=OL VL$\+^ MSF@YAH>"IYWD/@H>1=.>1.L44&.P!C9&X8DP?3%^A2Y)LJ$W49H;0'5*'Z;O ML.Z[ ;:WC;0.H)9$H1[$E_W4HJJU*!$L6G.+DN#VD$ )TUK$M^B0K*E"( M82+$[&D^!/15VD!$M%]J1#]ME40_,4 N\)MB15"2ELEF18VBS_H%QDY=8 1O M3@C[,!'O;OTL?#1A>IH#.Y\S#;T(\72+WJ5%#3F0AO6X1C&RO5=HF58)0VN@ MMFQ*\*LN4U(-&X'4 L[[8X5R\JW>WM]1(0E@ =@':Y!]3CI-UCP*TLD]I=7$ MO%,W8GO:X"1@0A&BP?38T\%TSX/W M<["!K?L[VD#0]W X :0#:U Z#!Q.(\%$'Z'0TKY^\$#C864KD'.X,L,&835 MY!V,4XW.B)+^HA_AY0/U8P-_ &@"-O5%-_^XD]^Y;A8X]"5>. M!2P.K,&H$"\<;K?IAL'T19YR8@'N FOP+O1'U1H!OGY718# P!H("]V91LNN M0_34TPTT%/*4!BC"[*QBKA.C1_7$ L $UB!,//-)KDZ\ 8@ %O HL 8R8A>$ MHDZ6,9(M]L0O[U$G!],I^5T /+ 68$U* [:P\^Y3H(.&P8+*!!8@XZ@G:0- M^Q!/=S1' ^D,IZ@&B$EVBV&@E!#^-6 *SSF3F'?"^WUE>U-? MGR,@,V -4('Q'/@>H -8 #W &M0#@SF@D:##L\"^D 9\$U0]Q5=HV6:'[UJZ M@89"3M" '9C. HT8Z:'Z0"DA]!M#(^PS"UKA_5G@1S@2_TSUG) 6-" (EZ1, MH=0^1OP['8U?Q&!?_!8VW7O8?;YR%DN0#6S)-\X:TLWU= ,#A42A@4K8[3MG M.VFZ;YTUI)OKZ0:&"1E&@Y:P\Y=]OL,RR(31 _'W9F0G9F0?S=FTN9FTOXC([,G:S\!: )KD";V/LU[WTGN/2P8S:L3,[+?I&23,*!8 MP*[ &O *;1B#%,Y.!M.:TEUT)RN['6@+D!;8&--BIYV-3U@":>%/!R@!T@)K M,"UV?HO^"4O0+'S5-]-A = ":Q$M!F%%./9;$4@*2PKFWD$;'&JVL3[IFJ,' MJUW**?L'BNS\<+@E+YY.LB-#0;UF,W0+HM]\\U,#]PZ,Y( M2;U?Z' M<10#76!,*U@:K]*Z^1(,#DP?WX$-=]0E!L>.[>];S'V0$#EMRE#KZTTY.#_9?KL4^U:N#2L# MV==X;0>PZ;QN-"EN/[@=3/N>>JS7,/^N (SY]WH-#V*S347/T]E7&F^_PKAI M9?@-QS<,X"O>DK&"GLK%]BMVHAOG^68E"SI'U3TA]4E&ULM9QM;Z-($L=?[WT*9)VT=]),3#?/5A)I$H_'PQ"& MQ;K;%ZM]0>QVC :#%W R(]V'/\#8;:#<;MB>U6HW)O_^]4,5N*JZP^U;DG[+ M-H3DTO=M%&=WHTV>[R;C<;;_62?I-LB+C^G+.-NE)%A5C;;1 M&,NR/MX&83RZOZVN>>G];;+/HS F7BIE^^TV2'\\D"AYNQNAT?&"'[YL\O+" M^/YV%[R0!D^CW<)5O[D;F2%J1=;"/+P1/ UPWP*T&2+G00*D;*.T&ZH4&:MU Y>U!JQMHO#WH M=0.=MP>C;F#P]F#6#4S>'JRZ@<7; Y*/EI-Y^T G8[>M?;F7H[D1M[W1T>"( MV^+H:'+$;7-T-#KBMCHZFAUQVQT=#8^X+8^.ID?-E/8:'PQCPA3$HTE,2YYM,^ABOR*K9?ES,YS0I M?)S4 V8"[7U$RGR.PG+6 ;&,V4W?PK2HCFZV'S&;CXERV-S9 '-Y^SF"[([ M#AYL;G//'6SN<,\=;.[RS]T$FGO\:^_QS-QE^I)QN#J7BJ1=X)Z]/J->_ MDQ[(2QC'Y0WP'$1!O"20QQ_ 6@4NPXW7>QWKEBHKM^/7+(,Y<$,<6Q'$%<3Q!'!^PJXY-Q80=3#LYF#;(P79A M2E;C9?FXB"+8T9A@_HE--L,D"F:++=DY,I>.33E>EJ(5=6U\.+M #,4HI_6M\T79G><,R& M98V398TACX%#W,P(&PS@:[3X=K3:84-7!X87,T 'A1=SH%\HO+ !'11>.- \ M@/#"!710>.%!/""\\+NZ=GC1,*=Y,J?)-.=#FGPC*2_LF(,:T3 MVOI9,:;5=7",%*2V?(5/-N.3S?ED-I_,X9.Y?#*/3^8#,E-%&H9]!,DTE99% M!Y=L8H\O?5&@F2C07!3(%@5R1(%<42!/%,BO0;S1+#HK#Z&?%<^RR7U\6Q!H M)@IDBP(YHD"N*) G"N0+ #5]%E.?Q4+#:C:NCZ,* LU$@6Q1($<4R!4%\D2! M? &@IJ/2\B(:4E^\GB6@;G4,C/PX=3-.W9Q39W/J'$Z=RZGS.'7^=5W3H+2Z MB-CEQ4MY@O0_Z2F,P^U^RY,Z(%IL0NQJTS&VE+PTO. J!P!"9W.5;XQ+<0&M M7"!VZ:** ()JMWH:Y'#7;,)QI^$?O_R"98Q9ZT&S;L1.NUGK'WSG7G^:%B)V M7LBQ_@> ?NYJ%]:>9HR(G3+RK#V;\&&75ALEU]<>T^P'L[.?QR3.]E'Q%,NE MXDDFN4E.#ON*O=)F3"-3/"0RY4J<:_+Y_8]EU3(5H_F@>+PRA#_0GU 8 .(M M&6LM_,=!^!F 1YIF=/"?!N'G$!YKFB6W$\'X6T(CPP#M4?_91#>@? REDU9 M:WVG@$++D+66\.N@<7@ WI 5 ^,F_;=!=!^@Z[IE&2WZHB^]>2O2@!L/";B9 MA0\VL4?,+0HT$P6:BP+9HD".*) K"N2) OD"0$VGI\$['A2\\U1&V.0^SM\- M9-];9G>O#])!FWV0#G6W5FQ(!^SF@3A3M5!K.^_IRE+#3T$7Q .[@%\'X3U1 M5O+!U;^\>XAINH&'G&:X7.A@X_KX77?S'-ICA&30)B.@4Q!2VG:T 1VTBPCA MH&U$:'C /B*$@S82 1UC)Q'3) \/.E)PM4J NYO66%94(,IE]W\IRH7P0!#] M<1!^!N*!(/K3(/P!O"0T'TET%X!\)#0?33(+P+X:$@V@.%0!#] MVZ!Q^ >"J(7?>G-&Y'6/#"[8M$CP^U7\,&TP('9!8[K!8<:T"KXJ!<*/IB6 M.O"U4L?5HL,50K/H(+/6@Y9",+N0T=,D_#4@A=8]%';=X[I):D##),:-9L$F M46@%1&&G;QPFN4(X'I@]F$1AK0=-!A7.9/ 0ATC%Z HKO9*T^NN89%U_RL/G MB%0&XZH+*6=G=G_>H=UNH(8-1=7:@)$^ MA[!I71KR*L(/\+*)/:)>4:"9*-!<%,@6!7)$@5Q1($\4R!< :CH]S0"4GW:H MF$WNX_R"0#-1H+DHD"T*Y(@"N:) GBB0+P#4='X:=2MB#TFS<7T\7A!H)@HT M%P6R18$<42!7%,@3!?(%@)H>3Y,\Y><<'E>ZIY^1B94JUVJ&KUWAA?"54SCG M%=J\0H=7Z/(*/4 (Q[D^![)I6II%*W_WP(#2/3!PX6"R0K-DA?.,>?^4K%\A M0Z59LWHM:[Z:NUXA-,^/L,H)*LVH5U&(WD1<43<$OBO-KAU-> MX8Q7..<5VKQ"AU?H\@H]7J'/(6P:EZ8UZK"TYG(N/V43^_R5K:@L1!3(%@5R M1(%<42!/%,@7 &KZ*LU"U"%9"$\*/F63^_BLJ#Q"%,@6!7)$@5Q1($\4R!< M:OHLS2/4(7G$QH<\A;)J6II[JM;/JUQ+>&L!Q M0EZCV:7&S@TYTI-^B:U&4TCM;V_*7B'P[Y-K-(O4V#D@YX+P)[ :314U=JK( MLR!L@KV/.#-]K4PLFU?.7MPRY S*PY569P<03BL:QLMHOR+2V^G"H9J0)]*J M"!>7>9)FU7&%9+TN;HKB0[*6\@V1'I/M+HA_2&^;1'HC*9'B))>VE2W:FE^+ M"[MR43-I5SP?I2"O?IN'V^I];66/Y5/S1OJ0E;^S]S$YO1'MG<0:=0E[>4G) M2^DO!4I7S'>FK-/9[-+D-5P=YA/$QTFTYQ!DTK+XD<39P?9OFS BTJ9E%GVMH_S^J_O3I=/;^/\4+V3L'7] M 4T6"+J.)X^0?HHG'Z'K,SSY!%V?X\EGZ+J-)U^@ZPZ>/$'773SY"EWW\.0W MZ+J/)POH^@=-G2PT%9JQIAU?6#JF:WIXW>E3D+Z$A4$BLB[65[XQBCLB/;Q! M]/ A3W;5"P:?DSQ/MM6/&Q*L2%H*BM^ODR0_?B@[.+W']?[_4$L#!!0 ( M 5^#E&2OPM3'@( "<$ 9 >&PO=V]R:W-H965T&R4=O.H)MI?QK$K:FR$.S=[U+Q3&=L( MXM!N8[>W*,H :E2<)LDT;H3449Z%M97-,].2DAI7%ES;-,(^7:$RAWDTCEX6 M;N6V)K\0Y]E>;'&-=+=?68[B@:64#6HGC0:+U3SZ-+Z\FOC\D/!#XL$=S<$[ MV1BS\\'7<(%*>2*6\;OGC(8C/?!X_L+^.7AG+QOA<&'4 MO2RIGD>S"$JL1*OHUAR^8._GPO,51KGPA4.?FT10M(Y,TX-902-U-XK'O@Y' M@'1\ I#V@#3H[@X**I>"1)Y9 ]K;H"R50BF@GMAK=#DX*8E1T*74F]AM$024KDS&*V$ M14TUDBR$.LMB8FG^@+CH95QU,M(3,KZU^APFR3M(DS2Y6R]A].8?EIB-#>[2 MP5T::#^,5/9-!S^15/3TG%*;A5^6$;\S_%:MCF086_ZP>\NED-DNF6?QP?'I\=._^ M"5T+NY7:@<**@674!F'UIA8X@;*TQK?LEH?0+O5X8KU >^NX9_ M0_X'4$L#!!0 ( 5^#E'T8,V=[04 +DD 9 >&PO=V]R:W-H965T ME7R387]9@.)(0:IJ*K$?)J/9M'CV MD,VFZ99$88(?,I!OX]C/WJ]PE+Y>CN!H_^!K^+PF[($RFV[\9_R(R=^;AXS> M*17+,HQQDH=I C*\NAQ]AA=WR&2 0N*?$+_F!]> N?*4IM_9C;N\'*G,(ASA M@# *GWZ\X#F.(L9$[?A1DHXJG0QX>+UG7Q3.4V>>_!S/T^A;N"3KRY$U DN\ M\K<1^9J^WN+2(8/Q!6F4%W_!:RFKCD"PS4D:EV!J01PFNT__K0S$ 8#R\ &H M!"!9@%8"M#9 /P'02X N"S!*@"%KDED"S#; / &8E(")K$E6";!D 78)L&4! M4-UG3I6&5,D^RO9)R#[=L,BWLEM8Q:J\]HD_FV;I*\B8/.5C%\72+O!T,88) MVX6/)*/?AA1'9H\D#;ZOTVB)L_QW<(U781#B)'@''YP?VY"\_P$^@4>Z]9?; M"(-T!0IY\->FV$*?V18*28AS\.$:$S^,+L+?]-A/Q(0*#0Y58;0/D-72,AX M[V=CH,&/ *G0X@5$#/>V"86K#(Y4#OQ:&@YM#MR1A_.,7XCAUSBH?#=XR9"& M/X*;S$\(?[_O>(V"E_44+S-H06CIDZGRPC%(KPS2A08Q MO\"NQ@$W"7#"N@'P$/D)^/<>,V/_$[AM5%J,/FY?X>@E[22HY@#S B#4 MP+JTBWSC!_AR1-NP'&#0#O(T^$(]C'"?$U U;K?*QVUL#J7,[U3428U:) M,?^?];@PC^S1#!NJZ@F#)I5!DSX&.6\X"\*I)R=Q**&T&SJJ!9?8(V9ULJBKA!^V)Q;**6GR@K=F61W2N-Q:=@MU_9 M4KMK<2Q&YR[=GK0VH=#8,S;A0#R>G'=WG=XU<@/5NME5A=GY5@QE> G\%YS1 M(1/@IGE;"2E^2=85WL!;4.05="L.EIW=%!<4O7Z:FP_);D M\AFH&SLH[NRZ,]!9A$L-$FF0%+P5VWS.QAN(R),U_4Y"L)FINCF&XNZ8C2:_ MWH/#NM>#O9H]N:)_W/?I.K2*T>XP7-<\06 MT9,0;(:Z[F)AKS;V=$F^@L=-(M2UB:&VO)SS!%L389D)24%'[-,YF_-8HV7! MM@?> /J:Z:G[9=BK87;>-F'&38\C)CXG1IS&&T)DJ'8[2OTU-J-4]_"P7Q,O M?(,/U"H[0Q&Y0Q%Y Q U?P&M^W8D[MM[S'ES,?49"1F*R!V*R!N J)F0NO=& MXMZ[]YA;\G>^JN8<01,AVS+-5K7G"JJ&;K2KO:SJ6YX@[Y7O\@1Y+VA/0G4S M(?78@7J.'5)-#N*,']H8JF:[R3DAJ&MF.]A<0:2I9CO8DHRN+*,G(=@,=CWY MH)Z3C^#G[)*Z-8]-)J;6#K&DX$TI:(J;#I?'!\>6:A_%3>C\+U25>G)#?2>W MD_W)O*2V#W\S&D_0452[Q)JFUZ,,$H\R_<9^,?DYKY:!B+P!B)J1K(U45/0O4N(\K!:8$89\_% M&9@4D#0N+M?87^*,"=#O5VE*]C=,075::?83 M4$L#!!0 ( 5^#E&2UWQ4;@0 -X3 9 >&PO=V]R:W-H965TDN33%SWUE)N MKEQ71&M(B7#8!C)U9\EX2J0ZY2M7;#B06$-IXOJ>-W130K/>=**O/?+IA.4R MH1D\=V[P5?W."P ;?&=PDX<':/"E1?&7HN3W^+KGE>,"!*(9"%!U-\69I D MA9(:QX]*M%<_LP"/C]_5[[3SRID7(F#&DC]I+-?7O5$/Q; D>2*?V.XK5 X- M"KV()4+_HEUEZ_50E O)T@I6(TAI5OZ3MRH01P >G@'\"O!/@> ,T*^ ?E<@ MJ("@*S"H@$%78%@!PZY 6 %Z]MTRNGIJYD22Z82S'>*%M5(K#O3\:EK-",V* M5'R67-VEBI/39\FBUS5+8N#B9S2')8TH9-$>72Q^Y%3N+]&OZ%GE?YPG@-@2 MW1'*T7>2Y/KLCXW.IWM.,@DQ^B9HMM)WB;Y^(U2&:Q.!+N8@"4U$(?@%N4BL M"0-*E$JDV*ZI3%D,=I32&)3EMB%/,?S?C+-Y>>P^>>PQ8>Q M1M2".FJ!54>_D]OW=Y+I%\X4,KO*%^3XIOR=E1CV-%:YBGZ^P'2%^#_6"3#6C)LB1/P MB I &TXC8T1*?G@T/7YS F?A?ZYV&+WZ/: M[Y%5Z8F*5[3D (BJ%4\M8/)L2MB%E ^!,27:L!$V%B@[AIT@-!:H-LP[Q1I1 M&]=1&W=[JU3(4G3Q%Q N+DTQL\OTT;X@35'[+#C_++BP@]@SD8W@8>_0HGG= MPK=EB6JL$M66&?LFNPH.L(/-9:B5'#CCL3'MVDAO<&YI;"''04OQPT<=+OX_ M:OJ\1?:\9W;.;ROKV#]XYML+.\VZ%G9\:,%P6P_64MIGE4"C)F/'/UG&YY69 M>0EH#N[0Z6![D_*!^MNBY#N^L23.6CCLC$?F5\'.>4XP,*=+&^>=+A3-V!U: M&]RQMVFIPO,6':Q+FVU(A\8$VSN3KI7-KH*Q6DW/5#8[.0Z=D;GA;WNDA]O> MXD,KA=MZJ4_6)[OLV8^2%LY0UTK'W*-=AA3X2F\@"12Q/)/EUW9]M=ZDNM%; M,R?7;_'5HMQJ.LB4.U_J>W)%,X$26"I)U?2K3.3E9E)Y(ME&[V6\,"E9J@_7 M0&+@A8&ZOV1,OI\4#ZBW]*;_ E!+ P04 " %?@Y1UJ\&,4@# !["0 M&0 'AL+W=ON #Q,?W,1MK3EVL)UU^_><[VG6<' MJ>[UGE(#CP47>N[MC2FGOJ^S/2V(OI0E%3BSE:H@!H=JY^M249([4,'], B& M?D&8\!8S9[M6BYFL#&>"7BO055$0];2D7![FWL [&F[8;F^LP5_,2K*C:VJ^ ME=<*1WX;)6<%%9I) 8INY][58+J:6'_G\)W1@S[Y!JMD(^6]'7S.YUY@"5%. M,V,C$/Q[H"GEW 9"&K^:F%Z[I 6>?A^C?W3:4 ; A;L! M40.(S@'Q*X"X <0N,[44EX<5,60Q4_( RGIC-/OADNG0*)\)N^UKHW"6(LKSB%.06>AS?KJ@AC.MW"/FV7L';-^]F MOD%R=@D_:XBD-9'P%2(1?)7"[#5\$#G-G^-]%-4J"X_*TK WX)=*7$(47$ 8 MA$$'G]5?PP>3'CI1F^C(Q8O^/=%W5QMM%(Y^]JP3M^O$;IWXE776A./U!2)R M(!PO-1$9[5"_[(]R-_C9M84U:.A MJ \+ 9)D 28WH?3S':X1>@7MF[/E"6M MLJ1?F9'9O;OD.62RP,*GB4U@E[K^2'=AI[H:E)S0#J-A$,=GZEZZ1<%XE"3= MZH:MNF$OIUMI".]B-7R1S&@\3%ZP>ND6Q]$X&'6S&GEGAG%+<_P?!V/9#^HZ MD\!$QJN<@G:3%Y 1]6?V AY(YG872H*3&RDJ[0)(LZB$(4CPS1#Q=]ERR29N%R7\UM;:=?^D:WID]Q1?!H,-^-9JFHP[[&ULE57);MLP$/V5@= ""9!:JY,FL 4X M<;JA:8,$:0]%#[0UEHA(I$K2EOOW'5*R:J2V@%XL+O/>O%DXGC12/>L"T<"V M*H6>>H4Q]97OZV6!%=,C6:.@FY54%3.T5;FO:X4L@5Y7%5._K[&4S=0+O=W! \\+8P_\=%*S'!_1/-7WBG9^SY+Q M"H7F4H#"U=2;A5?SL;5W!M\X-GIO#3:2A93/=O,QFWJ!%80E+HUE8/39X V6 MI24B&;\Z3J]W:8'[ZQW[.Q<[Q;)@&F]D^9UGIIAZ;SW(<,76I7F0S0?LXG$" ME[+4[A>:UC9)/%BNM9%5!R8%%1?MEVV[/.P!B.E$R0:4M28VNW#)=&@*GPM;]D>CZ)83SJ2?D9(&)W,T MC)<:OC"EF*W$*;R!I\DT1'2&.ZD,(6&6Y%A=@!_ M,XP/HP$"GR+LPXQV85Y'@XR?UF($<7 &41 %AP0-P^^8(GAX%#X?AL]J@@>1 MA8>7 ]'$?=%BQY<TCG,&P:C('@] M(##I!2:#1.]1D(X2F,A@EE';!&'%^/>K)7I[SV["E7NQI>&I5P+ MT[[ _K2?D#,W&/R_YNUXI0;+N= 4P(J@P>B")*AV9+4;(VOWB!?2T$APRX*F M/"IK0/6U;U-; M:>U @'B9-@T^(#ZXR;6UYMC!=MK!K^?L9%FW)1$(OK2VX^>YY^[L.\\.4MWJ M'8 A=SD7>N[MC"G.?%^G.\BI/I4%"/RRD2JG!J=JZ^M" (N96[M4BYDL#6<"+A7199Y3]7,)7![F7NC=+URQ[<[8!7\Q*^@6KL'<%)<* M9W[#DK$GJU"!W [OC XZ*,QL:ZLI;RUDW?9W NL(N"0&DM! M\6\/*^#<,J&.'S6IU]BTP./Q/?L;YSPZLZ8:5I)_99G9S;V)1S+8T)*;*WEX M"[5#0\N72J[=+SE4>\>!1])2&YG78%20,U']T[LZ$$< Y&D'1#4@>@I(.@!Q M#8B=HY4RY]8%-70Q4_) E-V-;';@8N/0Z T3-HW71N%7ACBS^ 8 TT&Y!H/ M2%9R(')#/A>@J&%B2^K/G]><;:F-NR8O+\!0QO4)@FZN+\C+%RPO>E."5Q\(I$012TZ%GU MPS]2A?"P#?Y(3MR$-79\<7]8OYVOM5%X5+_W<"8-9^(XDP[.AZQPRTZ4/:$# MN1F4.*%:XYT?$":8893C#4OEUHZE:,M.96GD+-F;OE]$HR091S-_WZ)PV"@< M]BH\SZ4R[!?MLEJAAT=6!^%T$@\[S(X:LZ->LTO*J4@Q!H;@,8"^8[ IB@,DPX%8?!0[8)>#:M2*1N, MPAY4S X6.]F9N]:R%K0D8,Z&J5EU-C"Q&ULM5113]LP$/XKIV@/3!HD36F'4!J) M%J%M K6B=-,T[<%-+HV%8V>VT\*_Y^R$K-J@VAYX27R^N\_?=_9=LE/ZWI2( M%AXJ(V=\SB=!Y BAP,PZ!$:_+*D^F\AQZ2YE:35Y.>79=%ZC9I;+#5PCB0-_*\?SXGA%QH4Q: TP MF7?>^5KP#7/E-' ,2WHA>2,05 $S):VF$C=,P$KFW&2JD19SF#%3PA7=O0%Z M0G_AP-$E6L:%>9^$EO0X5F'6<9^VW.-7N']IY D,HP\01W&T6E["T;L_4$*J M1E^2N"])[&%/7X&]4Y9$-/LBA&>M?JM_B6R+.O:HKA>V:3R,!H.S)-R^P&;8 MLQD>9'.-QL!=R23,)<)W9!I^W&"U1OWS@-;3'OWT3;2VJ*-_U#KJV8P.LIGB MHZ*W]C]"QSWT^$V$'D1U$_/8I#"2W3#O19UT^Z&Z0VG+A)8 M$')T\I$JH]L)TAI6U;YKU\K2#/#+DH8N:A= _D(I^VRX0="/\?0)4$L#!!0 M ( 5^#E&#](GGX00 )4- 9 >&PO=V]R:W-H965T0X.R54A5$83@*4BZSUG3BUV[-=*(+IV0&MX;9(DVY M65^ TJNS5K^U6?@J%XFCA6 ZR?D"[L#=Y[<&WX(:)98I9%;JC!F8G[7.^Y\N M^B$I>(D_)*SLUC,C4V9:/]#+=7S6"HD1*!".(#C^6\(E*$5(R..Q FW59Y+B M]O,&_3=O/!HSXQ8NM?HN8Y>?H3)H2'A"*^M_V:J4'8U: M3!36Z;121@:IS,K__*ERQ);"27A (:H4(L^[/,BSO.*.3R=&KY@A:42C!V^J MUT9R,J.HW#F#NQ+UW/2NF%EX+"!S[-J+8G\N#'!\!O"F+%])S!DTAXM@ ^4\#VX9=<2[BAAZ,47D[[X]/A<3@) MEGMH#&H:@W?2$#I-,?M* DQ:6T#<;> S>,7G9# ,#] YKND<-]*AZ DCX3"L.0P;.5QG#M!FQS"I8)_E MS>K]J!>&'QIXC&H>HT:@2XW6&2 MG4W[*#8C?TN W7AGKZ1"1Q?8XK#-"*[4&JO%'\MDYG1=.DZ+!]:6&0,N$B:P M!V,!%;,?V-@9BCD$=(;',ENPI59%"E1WM'JITYQGZX]V%VH&),JIG,^5QVP08[Y&-AXN"HF?!5%05]R6P,).4RP>S&PT J]' 7Z+M,1S M4&/<[W19D>L2$+A1$ML$&J&%*'R_:,O.V]R5M%2G=*NQC%,<,&6)F)%.HF)1'O =^T7A'R6E7&8(9W' F&0S'CX8>/"RJ$K?[OAD1Q5\;:N-"NA M'8;DP"9(GHY?&&WI0"T 8DO["YQ8''D:W8+!IE#[O__LGU(B1VC?TO=ZI*W-\_H+ M["JURM,K(UT6%6JYB@;(&6U+[H-?2!T[H/G/Z#/@ Y7].] M\68+: ;]]AQ0G&76%;"WO>P,/@LP@2AQ/K(5.L%!1LV'7,8QY!4/\A)G?0S' M,SH?Q;\#>DW%;B5!%W5O>W4[VJD$J MJ\NY85,\KQCAT$;KK>_5:ZM#HGEAL M88,.P3M>LGDNJ@61K0O&Y6@XH90 . M<.PQBM_FK))D@GT!(X$EEI:R!H"ML;]9'RXL.G@"(Z3=5$Q=2_TH_'^:S>LF M0X6@ZD9"?6:#H>=S,+BX],GV!JRZ8/E"S<+F5FF8(YA#GMC MG%],^0U0OCB=^[E[IAU>\F,"2 ^W.-WJQ>:)2OO\2F?P-02P,$% M @ !7X.454JIJUM @ 2 X T !X;"]S='EL97,N>&ULU5=;;YLP%/XK MEC--K3052)JD60%IJU1ITC95:A[V5CE@P)(OS)B,]-?/Q@1(6K*H#VOR$I^+ MSW<^'P[.P2_4AN+'#&,%*D9Y$M"=CE6QQ ;W8-@86[$S$.X-/% MQ]^E4+(DI4D)BI!C-"--8^-(1)42*!T4^N$GK$4S];M6X/#"!>RSFTS MV-]5LWW/L=4,04)I2W ,K2'T*_7FVOC"!1IYN>PBZ@ M7G22E9 QEFT:#VY-H4]Q8NA(DF9F52)WC%,IP;00$Y0*CFH.VXA&T+ 1IO31 M7 :_DAWL*ND]N?JY\5;4A!K1PEC%X/?1+'8?]OI-N" G:Z&^EOHXO-9-M^$' MB1-2U7J5M 2&T+UA=)3G=/.%DI0S; ]_=,+01]LXD E)GG4VTRJ1-F )P1I+ M1:*^Y8]$^1)7:MM.53+,>7R&G/]OG5/,L42T3UKW_BE7^-8?20$3;8T.P6BP^0"X99K>]9!:GO@%;G)M;7FV,5V.LI?SSEI-0?HB1TPD;?\$W @WW<[S?95EBQ$%*X MW21I?TM(6"V4J,4OJ";).&%VK1\^:R-^:>6XG)=&2SE)TF['-S!.E'\USSWD M'5_8ML7QQ2U'D$ER-L8!E\)8U_9HQ^?(N 7LW&TU3G\4TH&9<@>?C&XV0JW\ M,'@5H^ RVC@+D4)4UTV-2C7Q=& ](#*KL7&)DSQ&B;)H0OC MJF(7RF&0V*7JAL*^_DKQU)=5=]4.<8,8FG.!.\QEU8+'@_R@507*0L7PE]52 M5,A1L?=<4I G@X) MF0>09P3D65S(:^X: TPOV6V$]V,R Q:YMC^?L"W"+ MQ'4 ^8J ?!47/H]\O6>]03HK5K8:W&T%ZCORTBAYBD:2*KYB-4 M>*-(N6.?&FYPML%'4?/>?9-2FDDC>V8*1FRY+R=P=GE;UPCHT5%^22,+9NYT M>;_6$J-HG[ IX&$"5+D+^2BUI)'=URA7D00AA*(FEDB^"MZ[ ^Q6G\XX]&^2.-+)!YL[#PH_&EZ\46/WM@E#/2 M(:71JUY2RAKID-KH86:4-K+(VOAWMF-/[SRS?19B4MK((FOC6-K;@X:8Y"-* M9'>0V:\_Z91$LL@2:;/?/^>84D<661UDR=H/'J6.++(ZZ/P3/IADE%2RR%*A M\T\/D]),%EDS-&818E+2R2)+AZRN^_]-2CI99.D-2$F)9U\D >6/69_88Q<&1OHR64_[2$F9:$\ MLH6.8G;Q##$I"^6Q+41A]B>=LE >V4+')_WB1R-Z"8FR4![[88?"[$>3LE > MV4)$>>FG/<2D+)1'MM"^O-QG:_NA7"XM0_WB\;*3]@VXW"*JY)W?^> 0 "!H !H !X;"]?/M8 M4,!!*=*@/96U:WG\%]8GRYY]A5.9#G45]XZ-N$_$^OM]K .G_7Z M^QRJ],=@]U.WQ[@/(16]5=GN0IH7[G)Z;$=W.TB_FUSTEIMYT2XW4KC<00I! MFC_((,CR!WD(\OF#AA TS!\T@J!1_J Q!(WS!TT@:)(_: I!T_Q!,D 9!P1) M+U@3:"W(M1!X+0BV$(@M2+80F"V(MA"H+BOJK01Z*^JM!'HKZJT$>BOJK01Z M*^JM!'H;ZFT$>AOJ;01Z&^IM!'K;R\<2 KT-]38"O0WU-@*]#?4V KT-]38" MO0WU-@*]#?4V KT]ZNT)]/:HMR?0VZ/>GD!OCWK[=^H=T_44XJ/GOL;[OY/J MU%T;'K>_+>^;+X_*#6<'/WX6OU!+ P04 " %?@Y1J,J'V:L! !!&@ M$P %M#;VYT96YT7U1Y<&5S72YX;6S-F6 M0U_ 338D(HDMVU!X^SKA1VI%HR(J=2ZQ$N_.C+W2=\GT;6?(#;9UU;A95'AO M'AAS:4&U-Z&SZ[4S2RR5+EH\+@O;+UFD3*F*E/EPS[;--DWE]'!(0Z=78TK2N.&H2!B M9QW:G9\-#GVO&[*VS&BP4-:_J#I4L6W%G-]5Y.)^B3,9=9Z7*64Z7=>A)7;& MDLI<0>3K*MZ+#ON=?;AAVC_YU?Z=3)]AJ%Q8;5R8F*7+[8XC:;M')@B1]67_ M$4^.0?KJ\U$[[8RR7WJ'Z_W0=M7-P[%NN?Z.O\[XI']A#@&20X+D2$!RW(#D MF(#DN 7)<0>2XQXD!Q^C!$$A*D=!*D=A*D>!*D>A*D?!*D?A*D&PO=&AE;64O M=&AE;64Q+GAM;%!+ 0(4 Q0 ( 5^#E$WB[.;I0, (- 8 M " @0\( !X;"]W;W)K&PO=V]R:W-H M965T&UL4$L! A0#% @ !7X.47C_XCQ( P A T !@ M ("!PA( 'AL+W=O&PO=V]R:W-H965T&UL M4$L! A0#% @ !7X.49PE3$C>!0 WQ0 !@ ("!/"< M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ !7X. M4<#!M845% #3D !@ ("!*CH 'AL+W=O&UL4$L! A0#% M @ !7X.441R5G$=! OP@ !D ("!HU$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ !7X.48@6WYK1 M& 1%( !D ("!(F$ 'AL+W=O@ >&PO=V]R:W-H965T&UL4$L! A0#% @ !7X.4&PO=V]R M:W-H965T&UL M4$L! A0#% @ !7X.48O$GRL^ @ [@0 !D ("!*:( M 'AL+W=OI >&PO=V]R:W-H965T&UL4$L! A0#% @ M!7X.485R ;(Y P _P8 !D ("!0K$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ !7X.4=0BM2]# @ M&PO=V]R:W-H965T&UL4$L! A0#% @ !7X.4<5N?3J0 P )PP !D M ("!W<, 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ !7X.47&PO=V]R:W-H965T&UL4$L! A0#% @ !7X. M47UOZ8C."@ TU4 !D ("!!^X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ !7X.49+7?%1N! WA, M !D ("!A0$! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ !7X.434/KB4> P / D !D M ("!3@P! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ !7X.454JIJUM @ 2 X T ( !2A6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% M @ !7X.4>Y)W?^> 0 "!H !H ( !WQX! 'AL+U]R96QS M+W=O XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 295 298 1 true 60 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://biotricity.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://biotricity.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://biotricity.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://biotricity.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficiency (Unaudited) Sheet http://biotricity.com/role/StatementsOfStockholdersDeficiency Condensed Consolidated Statements of Stockholders' Deficiency (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://biotricity.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Nature of Operations Sheet http://biotricity.com/role/NatureOfOperations Nature of Operations Notes 7 false false R8.htm 00000008 - Disclosure - Basis of Presentation, Measurement and Consolidation Sheet http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidation Basis of Presentation, Measurement and Consolidation Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://biotricity.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://biotricity.com/role/AccountsPayableAndAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 10 false false R11.htm 00000011 - Disclosure - Convertible Promissory Notes and Short Term Loans Notes http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoans Convertible Promissory Notes and Short Term Loans Notes 11 false false R12.htm 00000012 - Disclosure - Federally Guaranteed Loans Sheet http://biotricity.com/role/FederallyGuaranteedLoans Federally Guaranteed Loans Notes 12 false false R13.htm 00000013 - Disclosure - Derivative Liabilities Sheet http://biotricity.com/role/DerivativeLiabilities Derivative Liabilities Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders' Deficiency Sheet http://biotricity.com/role/StockholdersDeficiency Stockholders' Deficiency Notes 14 false false R15.htm 00000015 - Disclosure - Related Party Transactions and Balances Sheet http://biotricity.com/role/RelatedPartyTransactionsAndBalances Related Party Transactions and Balances Notes 15 false false R16.htm 00000016 - Disclosure - Lease Sheet http://biotricity.com/role/Lease Lease Notes 16 false false R17.htm 00000017 - Disclosure - Contingencies Sheet http://biotricity.com/role/Contingencies Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Subsequent Events Sheet http://biotricity.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://biotricity.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://biotricity.com/role/AccountsPayableAndAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://biotricity.com/role/AccountsPayableAndAccruedLiabilities 20 false false R21.htm 00000021 - Disclosure - Derivative Liabilities (Tables) Sheet http://biotricity.com/role/DerivativeLiabilitiesTables Derivative Liabilities (Tables) Tables http://biotricity.com/role/DerivativeLiabilities 21 false false R22.htm 00000022 - Disclosure - Stockholders' Deficiency (Tables) Sheet http://biotricity.com/role/StockholdersDeficiencyTables Stockholders' Deficiency (Tables) Tables http://biotricity.com/role/StockholdersDeficiency 22 false false R23.htm 00000023 - Disclosure - Related Party Transactions and Balances (Tables) Sheet http://biotricity.com/role/RelatedPartyTransactionsAndBalancesTables Related Party Transactions and Balances (Tables) Tables http://biotricity.com/role/RelatedPartyTransactionsAndBalances 23 false false R24.htm 00000024 - Disclosure - Lease (Tables) Sheet http://biotricity.com/role/LeaseTables Lease (Tables) Tables http://biotricity.com/role/Lease 24 false false R25.htm 00000025 - Disclosure - Basis of Presentation, Measurement and Consolidation (Details Narrative) Sheet http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidationDetailsNarrative Basis of Presentation, Measurement and Consolidation (Details Narrative) Details http://biotricity.com/role/BasisOfPresentationMeasurementAndConsolidation 25 false false R26.htm 00000026 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://biotricity.com/role/SummaryOfSignificantAccountingPoliciesPolicies 26 false false R27.htm 00000027 - Disclosure - Accounts Payable and Accrued Liabilities (Details Narrative) Sheet http://biotricity.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative Accounts Payable and Accrued Liabilities (Details Narrative) Details http://biotricity.com/role/AccountsPayableAndAccruedLiabilitiesTables 27 false false R28.htm 00000028 - Disclosure - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) Sheet http://biotricity.com/role/AccountsPayableAndAccruedLiabilities-ScheduleOfAccountsPayableAndAccruedLiabilitiesDetails Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) Details 28 false false R29.htm 00000029 - Disclosure - Convertible Promissory Notes and Short Term Loans (Details Narrative) Notes http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoansDetailsNarrative Convertible Promissory Notes and Short Term Loans (Details Narrative) Details http://biotricity.com/role/ConvertiblePromissoryNotesAndShortTermLoans 29 false false R30.htm 00000030 - Disclosure - Federally Guaranteed Loans (Details Narrative) Sheet http://biotricity.com/role/FederallyGuaranteedLoansDetailsNarrative Federally Guaranteed Loans (Details Narrative) Details http://biotricity.com/role/FederallyGuaranteedLoans 30 false false R31.htm 00000031 - Disclosure - Derivative Liabilities (Details Narrative) Sheet http://biotricity.com/role/DerivativeLiabilitiesDetailsNarrative Derivative Liabilities (Details Narrative) Details http://biotricity.com/role/DerivativeLiabilitiesTables 31 false false R32.htm 00000032 - Disclosure - Derivative Liabilities - Schedule of Derivative Liabilities (Details) Sheet http://biotricity.com/role/DerivativeLiabilities-ScheduleOfDerivativeLiabilitiesDetails Derivative Liabilities - Schedule of Derivative Liabilities (Details) Details 32 false false R33.htm 00000033 - Disclosure - Derivative Liabilities - Schedule of Derivative Components Valuation Assumptions (Details) Sheet http://biotricity.com/role/DerivativeLiabilities-ScheduleOfDerivativeComponentsValuationAssumptionsDetails Derivative Liabilities - Schedule of Derivative Components Valuation Assumptions (Details) Details 33 false false R34.htm 00000034 - Disclosure - Stockholders' Deficiency (Details Narrative) Sheet http://biotricity.com/role/StockholdersDeficiencyDetailsNarrative Stockholders' Deficiency (Details Narrative) Details http://biotricity.com/role/StockholdersDeficiencyTables 34 false false R35.htm 00000035 - Disclosure - Stockholders' Deficiency - Schedule of Warrants Outstanding (Details) Sheet http://biotricity.com/role/StockholdersDeficiency-ScheduleOfWarrantsOutstandingDetails Stockholders' Deficiency - Schedule of Warrants Outstanding (Details) Details 35 false false R36.htm 00000036 - Disclosure - Stockholders' Deficiency - Schedule of Warrants Outstanding (Details) (Parenthetical) Sheet http://biotricity.com/role/StockholdersDeficiency-ScheduleOfWarrantsOutstandingDetailsParenthetical Stockholders' Deficiency - Schedule of Warrants Outstanding (Details) (Parenthetical) Details 36 false false R37.htm 00000037 - Disclosure - Stockholders' Deficiency (Equity) - Schedule of Stock Option Activities (Details) Sheet http://biotricity.com/role/StockholdersDeficiencyEquity-ScheduleOfStockOptionActivitiesDetails Stockholders' Deficiency (Equity) - Schedule of Stock Option Activities (Details) Details http://biotricity.com/role/StockholdersDeficiencyTables 37 false false R38.htm 00000038 - Disclosure - Stockholders' Deficiency (Equity) - Schedule of Fair Value of Option Granted Using Valuation Assumptions (Details) Sheet http://biotricity.com/role/StockholdersDeficiencyEquity-ScheduleOfFairValueOfOptionGrantedUsingValuationAssumptionsDetails Stockholders' Deficiency (Equity) - Schedule of Fair Value of Option Granted Using Valuation Assumptions (Details) Details http://biotricity.com/role/StockholdersDeficiencyTables 38 false false R39.htm 00000039 - Disclosure - Related Party Transactions - Schedule of Related Party Transactions (Details) Sheet http://biotricity.com/role/RelatedPartyTransactions-ScheduleOfRelatedPartyTransactionsDetails Related Party Transactions - Schedule of Related Party Transactions (Details) Details 39 false false R40.htm 00000040 - Disclosure - Lease (Details Narrative) Sheet http://biotricity.com/role/LeaseDetailsNarrative Lease (Details Narrative) Details http://biotricity.com/role/LeaseTables 40 false false R41.htm 00000041 - Disclosure - Leases - Schedule of Operating Leases Obligations (Details) Sheet http://biotricity.com/role/Leases-ScheduleOfOperatingLeasesObligationsDetails Leases - Schedule of Operating Leases Obligations (Details) Details 41 false false R42.htm 00000042 - Disclosure - Operating Lease Right-Of-Use Assets and Lease Obligations - Schedule of Contractual Undiscounted Cash Flows for Lease Obligation (Details) Sheet http://biotricity.com/role/OperatingLeaseRight-of-useAssetsAndLeaseObligations-ScheduleOfContractualUndiscountedCashFlowsForLeaseObligationDetails Operating Lease Right-Of-Use Assets and Lease Obligations - Schedule of Contractual Undiscounted Cash Flows for Lease Obligation (Details) Details 42 false false R43.htm 00000043 - Disclosure - Subsequent Events (Details Narrative) Sheet http://biotricity.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://biotricity.com/role/SubsequentEvents 43 false false All Reports Book All Reports btcy-20200630.xml btcy-20200630.xsd btcy-20200630_cal.xml btcy-20200630_def.xml btcy-20200630_lab.xml btcy-20200630_pre.xml http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 true true ZIP 64 0001493152-20-015819-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-20-015819-xbrl.zip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end

1.	I have reviewed this Quarterly Report on Form 10-Q of Biotricity Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	/s/ John Ayanoglou
	John Ayanoglou
	(Principal Financial Officer)

	(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 14, 2020
Cover [Abstract]
Entity Registrant Name	BIOTRICITY INC.
Entity Central Index Key	0001630113
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		33,647,809
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Mar. 31, 2020
CURRENT ASSETS
Cash	$ 64,875	$ 949,848
Accounts receivable, net	663,687	486,187
Inventory	236,106	85,720
Deposits and other receivables	159,402	137,074
Total current assets	1,124,070	1,658,829
NON-CURRENT ASSETS
Deposits		33,000
Long-term accounts receivable	50,148	48,115
Operating lease right-of-use assets [Note 10]	214,884	264,472
TOTAL ASSETS	1,389,102	2,004,416
CURRENT LIABILITIES
Accounts payable and accrued liabilities [Note 4]	1,521,689	1,521,689
Convertible promissory notes and short term loans [Note 5]	1,871,389	2,068,302
Operating lease obligations, current [Note 10]	213,030	213,030
Total current liabilities	3,821,003	3,803,021
NON CURRENT LIABILITIES
Federally guaranteed loans [Note 6]	1,570,990
Derivative liabilities [Note 7]	982,350	1,144,733
Operating lease obligations, long term [Note 10]		57,055
TOTAL LIABILITIES	6,374,244	5,004,809
STOCKHOLDERS' DEFICIENCY
Preferred stock value	1	1
Common stock, $0.001 par value, 125,000,000 authorized as at June 30 and March 31, 2020, respectively. Issued and outstanding common shares: 33,384,769 and 32,593,769 as at June 30 and March 31, 2020, respectively, and exchangeable shares of 3,788,062 as at June 30 and March 31, 2020 [Note 8]	37,173	36,382
Shares to be issued (25,000 and 178,750 shares of common stock as at June 30 and March 31, 2020, respectively) [Note 8]	22,194	169,490
Additional paid-in-capital	45,676,541	44,015,397
Accumulated other comprehensive loss	(961,518)	(857,307)
Accumulated deficit	(49,758,760)	(46,364,364)
TOTAL STOCKHOLDERS' DEFICIENCY	(4,985,151)	(3,000,393)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$ 1,389,102	2,004,416
Series A Preferred Stock [Member]
STOCKHOLDERS' DEFICIENCY
Preferred stock value		$ 8

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Mar. 31, 2020
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	33,384,769	32,593,769
Common stock, shares outstanding	33,384,769	32,593,769
Common stock, exchangeable shares outstanding	3,788,062	3,788,062
Common stock, shares to be issued	25,000	178,750
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued	8,045	7,830
Preferred stock, shares outstanding	8,045	7,830

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
REVENUE	$ 451,898	$ 327,000
Cost of revenue	191,462	150,586
Gross Profit	260,436	176,414
EXPENSES
General and administrative expenses [Notes 7, 8 and 9]	3,205,233	2,052,519
Research and development expenses	423,883	213,496
TOTAL OPERATING EXPENSES	3,629,116	2,266,015
Other income [Note 3]	(7,359)
Change in fair value of derivative liabilities [Note 7]	(204,142)
NET LOSS BEFORE INCOME TAXES	(3,157,179)	(2,089,601)
Income taxes
NET LOSS	(3,157,179)	(2,089,601)
Less: Preferred Stock Dividends [Note 8]	237,215
NET LOSS ATTRIBUTED TO COMMON STOCKHOLDERS	(3,394,394)	(2,089,601)
Translation adjustment	(105,001)	(22,586)
COMPREHENSIVE LOSS	$ (3,499,395)	$ (2,112,187)
LOSS PER SHARE, BASIC AND DILUTED	$ (0.900)	$ (0.060)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	36,768,299	35,397,458

Condensed Consolidated Statements of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020
Preferred Stock [Member]
Balance	$ 9	$ 1	$ 1
Balance, shares	7,831	1	1
Issuance of shares for private placement
Issuance of shares for private placement, shares
Issuance of shares for services
Issuance of shares for services, shares
Issuance of warrants for services
Issuance of preferred stock
Issuance of preferred stock, shares	215
Derivative liabilities adjustment
Stock based compensation - ESOP
Issuance cost
Translation adjustment
Net loss before dividends
Preferred stock dividends
Net loss for the Period
Balance	$ 9	$ 1	$ 9
Balance, shares	8,046	1	7,831
Common Stock and Exchangeable Common Shares [Member]
Balance	$ 36,382	$ 35,362	$ 35,362
Balance, shares	36,381,831	35,361,656	35,361,656
Issuance of shares for private placement		$ 23
Issuance of shares for private placement, shares		22,585
Issuance of shares for services	$ 791	$ 31
Issuance of shares for services, shares	791,000	30,835
Issuance of warrants for services
Issuance of preferred stock
Issuance of preferred stock, shares
Derivative liabilities adjustment
Stock based compensation - ESOP
Issuance cost
Translation adjustment
Net loss before dividends
Preferred stock dividends
Net loss for the Period
Balance	$ 37,173	$ 35,415	$ 36,382
Balance, shares	37,172,831	35,415,060	36,381,831
Shares to be Issued [Member]
Balance	$ 169,490	$ 91,498	$ 91,498
Balance, shares	178,750	62,085	62,085
Issuance of shares for private placement
Issuance of shares for private placement, shares
Issuance of shares for services	$ (147,296)	$ 217,878
Issuance of shares for services, shares	(153,750)	350,415
Issuance of warrants for services
Issuance of preferred stock
Issuance of preferred stock, shares
Derivative liabilities adjustment
Stock based compensation - ESOP
Issuance cost
Translation adjustment
Net loss before dividends
Preferred stock dividends
Net loss for the Period
Balance	$ 22,194	$ 309,375	$ 169,490
Balance, shares	25,000	412,500	178,750
Additional Paid in Capital [Member]
Balance	$ 44,045,397	$ 33,889,916	$ 33,889,916
Issuance of shares for private placement		13,980
Issuance of shares for services	1,210,259	350,415
Issuance of warrants for services	45,113	19,955
Issuance of preferred stock	215,000
Derivative liabilities adjustment	(41,749)
Stock based compensation - ESOP	232,519	338,889
Issuance cost
Translation adjustment
Net loss before dividends
Preferred stock dividends
Net loss for the Period
Balance	45,676,539	34,296,458	44,045,397
Accumulated Other Comprehensive (Loss) Income [Member]
Balance	(857,307)	(754,963)	(754,963)
Issuance of shares for private placement
Issuance of shares for services
Issuance of warrants for services
Issuance of preferred stock
Derivative liabilities adjustment
Stock based compensation - ESOP
Issuance cost
Translation adjustment	(105,001)	(22,586)
Net loss before dividends
Preferred stock dividends
Net loss for the Period
Balance	(962,308)	(777,549)	(857,307)
Accumulated Deficit [Member]
Balance	(46,364,364)	(35,039,495)	(35,039,495)
Issuance of shares for private placement
Issuance of shares for services
Issuance of warrants for services
Issuance of preferred stock
Derivative liabilities adjustment
Stock based compensation - ESOP
Issuance cost
Translation adjustment
Net loss before dividends	(3,157,179)
Preferred stock dividends	(237,215)
Net loss for the Period		(2,089,601)
Balance	(49,758,758)	(37,129,096)	(46,364,364)
Balance	(3,000,393)	(1,777,681)	(1,777,681)
Issuance of shares for private placement		14,003
Issuance of shares for services	1,063,754	251,625
Issuance of warrants for services	45,113	19,955
Issuance of preferred stock	215,000
Derivative liabilities adjustment	(41,749)
Stock based compensation - ESOP	232,519	338,889
Issuance cost
Translation adjustment	(105,001)	(22,586)
Net loss before dividends	(3,157,179)
Preferred stock dividends	237,215
Net loss for the Period	(3,394,394)	(2,089,601)
Balance	$ (4,985,151)	$ (3,265,396)	$ (3,000,393)

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2020
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals and valuation of derivatives, convertible promissory notes, stock options, and assumptions used in the going concern assessment. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as at June 30, 2020 and 2018.
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC 820 defines fair value, establishes a framework for measuring fair value and expands required disclosure about fair value measurements of assets and liabilities. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: ● Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities. ● Level 2 – Valuation based on quoted market prices for similar assets and liabilities in active markets. ● Level 3 – Valuation based on unobservable inputs that are supported by little or no market activity, therefore requiring management’s best estimate of what market participants would use as fair value. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments or interest rates that are comparable to market rates. These financial instruments include cash, accounts receivable, deposits and other receivables, convertible promissory notes, and accounts payable and accrued liabilities. The Company’s cash and derivative liabilities, which are carried at fair values, are classified as a Level 1 and Level 2, respectively. The Company’s bank accounts are maintained with financial institutions of reputable credit, therefore, bear minimal credit risk.
Leases	Leases On April 1, 2019, the Company adopted Accounting Standards Codification Topic 842, “Leases” (“ASC 842”) to replace existing lease accounting guidance. This pronouncement is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases will continue to be recognized in a manner similar to previous accounting guidance. The Company adopted ASC 842 utilizing the transition practical expedient added by the Financial Accounting Standards Board (“FASB”), which eliminates the requirement that entities apply the new lease standard to the comparative periods presented in the year of adoption. The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the consolidated balance sheet. Right-of-use (“ROU”) asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in our consolidated statement of income. The Company determines the lease term by agreement with lessor. As our lease do not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Refer to Note 10 for further discussion.
Government Loan	Government loan For loans received from federal government that contains certain operating conditions and with terms over twelve month time, the Company records those loans as long term liabilities.
Convertible Notes Payable and Derivative Instruments	Convertible Notes Payable and Derivative Instruments The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of April 1, 2017. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments.” This pronouncement, along with subsequent ASUs issued to clarify provisions of ASU 2016-13, changes the impairment model for most financial assets and will require the use of an “expected loss” model for instruments measured at amortized cost. Under this model, entities will be required to estimate the lifetime expected credit loss on such instruments and record an allowance to offset the amortized cost basis of the financial asset, resulting in a net presentation of the amount expected to be collected on the financial asset. In developing the estimate for lifetime expected credit loss, entities must incorporate historical experience, current conditions, and reasonable and supportable forecasts. This pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the new guidance effectively on April 1, 2020. The Company identified and updated existing internal controls and procedures to ensure compliance with the new guidance, but such modifications were not deemed to be material to the Company's overall system of internal control. While the adoption of this ASU did not have a material impact on the Company's consolidated financial statements, it required changes to the Company's process of estimating expected credit losses on trade receivables. In July 2019, the FASB issued ASU 2019-07, Codification Updates to SEC Sections. This ASU amends various SEC paragraphs pursuant to the issuance of SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization. One of the changes in the ASU requires a presentation of changes in stockholders’ equity in the form of a reconciliation, either as a separate financial statement or in the notes to the financial statements, for the current and comparative year-to-date interim periods. The Company presented changes in stockholders' equity as separate financial statements for the current and comparative year-to-date interim periods beginning on April 1, 2019. The additional elements of the ASU did not have a material impact on the Company's consolidated financial statements. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. On June 16, 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost basis. That model replaces the probable, incurred loss model for those assets. Through the amendments in that Update, the Board added Topic 326, Financial Instruments—Credit Losses, and made several consequential amendments to the Codification. The amendments apply to all reporting entities within the scope of the affected accounting guidance. ASU 2019-11 is effective for fiscal years beginning after December 15, 2022. The Company is currently evaluating the impact that this guidance will have on its consolidated financial statements and related disclosures. In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. The Company is currently evaluating the impacts of the provisions of ASU 2019-12 on its financial condition, results of operations, and cash flows. In March 2020, the FASB issued ASU No. 2030-20 Codification Improvements to Financial Instruments, An Amendment of the FASB Accounting Standards Codification: a)in ASU No. 2016-01, b) in Subtopic 820-10, c) for depository and lending institutions clarification in disclosure requirements, d) in Subtopic 470-50, e) in Subtopic 820-10, f) Interaction of Topic 842 and Topic 326, g) Interaction of the guidance in Topic 326 and Subtopic 860-20.The amendments in this Update represent changes to clarify or improve the Codification. The amendments make the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. For public business entities updates under the following paragraphs: a), b), d) and e) are effective upon issuance of this final update. The effective date for c) is for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company does not expect that the new guidance will significantly impact its consolidated financial statements. The Company continues to evaluate the impact of the new accounting pronouncement, including enhanced disclosure requirements, on our business processes, controls and systems.

Basis of Presentation, Measurement and Consolidation (Details Narrative) - USD ($)					1 Months Ended		3 Months Ended		12 Months Ended
	May 22, 2020	Jan. 09, 2020	Jan. 09, 2020	Dec. 19, 2019	Dec. 31, 2019	Oct. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020
Accumulated deficit							$ (49,758,760)		$ (46,364,364)
Working capital deficit							$ 2,696,943
Preferred stock, shares issued							1		1
Proceeds from preferred stock							$ 100,000
COVID-19 [Member]
Funds raised									$ 1,570,900
Series A Preferred Stock [Member]
Preferred stock, shares issued	215	7,830	7,830	7,830	8,045		8,045		7,830
Stock issued during the period, shares			6,000	6,000	6,100
Proceeds from preferred stock			$ 6,000,000	$ 6,000,000	$ 6,100,000
Proceeds from convertible notes payable	$ 100,000
Promissory Note and Short-Term Loans [Member]
Issuance value of debt, outstanding									$ 3,094,820
Promissory Notes [Member]
Issuance value of debt, outstanding									$ 916,301
Conversion of stock, shares		1,830			1,945	1,830
Proceeds from convertible notes payable					$ 1,945,000	$ 1,830,000

Summary of Significant Accounting Policies (Details Narrative) - shares	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2018
Accounting Policies [Abstract]
Potentially dilutive shares outstanding

Accounts Payable and Accrued Liabilities (Details Narrative) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
Payables and Accruals [Abstract]
Accounts payable	$ 345,929	$ 379,881

Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
Payables and Accruals [Abstract]
Accounts payable	$ 1,012,630	$ 1,094,072
Accrued liabilities	715,842	427,617
Accounts payable and accrued liabilities	$ 1,521,689	$ 1,521,689

Federally Guaranteed Loans (Details Narrative) - USD ($)		1 Months Ended
	Apr. 30, 2020	May 31, 2020
Captioned Program Program [Member] \| US Small Business Administration [Member]
Loan received	$ 370,900
Interest rate	3.75%
Debt instrument term	30 years
Description debt instrument term	The loan has a term of 30 years and an interest rate of 3.75%, without the requirement for payment in its first 12 months.
Payment Protection Program [Member]
Loan received		$ 1,200,000
Description on loan		The Note has a two-year term, bears interest at the rate of 1.0% per annum, and may be prepaid at any time without payment of any premium. No payments of principal or interest are due during the six-month period beginning on the date of the Note (the "Deferral Period").
Interest rate		1.00%

Derivative Liabilities (Details Narrative) - USD ($)					1 Months Ended		3 Months Ended
Derivative Liabilities (Details Narrative) - USD ($)	May 22, 2020	Jan. 09, 2020	Jan. 09, 2020	Dec. 19, 2019	Dec. 31, 2019	Oct. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020
Preferred stock, shares issued							1		1
Proceeds from preferred stock							$ 100,000
Promissory Notes [Member]
Conversion of stock, shares		1,830			1,945	1,830
Proceeds from convertible notes payable					$ 1,945,000	$ 1,830,000
Series A Preferred Stock [Member]
Preferred stock, shares issued	215	7,830	7,830	7,830	8,045		8,045		7,830
Proceeds from preferred stock			$ 6,000,000	$ 6,000,000	$ 6,100,000
Stock issued during the period, shares			6,000	6,000	6,100
Proceeds from convertible notes payable	$ 100,000
Preferred Stock [Member]
Preferred stock, shares issued	115
Proceeds from preferred stock	$ 100,000
Stock issued during the period, shares	100
Accrued interest	$ 15,000

Derivative Liabilities - Schedule of Derivative Liabilities (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liabilities, beginning balance	$ 1,144,733
Derivative fair value at issuance	41,749	1,083,952
Change in fair value of derivatives	(204,142)	60,781
Derivative liabilities, ending balance	$ 982,340	$ 1,144,733

Derivative Liabilities - Schedule of Derivative Components Valuation Assumptions (Details)	3 Months Ended
	Jun. 30, 2020 $ / shares
Minimum [Member]
Stock price	$ 0.650
Maximum [Member]
Stock price	$ 1.367
Dividend Yield [Member]
Derivative liability, measurement input	12
Risk-Free Rate for Term [Member] \| Minimum [Member]
Derivative liability, measurement input	0.62
Risk-Free Rate for Term [Member] \| Maximum [Member]
Derivative liability, measurement input	1.14
Volatility [Member] \| Minimum [Member]
Derivative liability, measurement input	1.174
Volatility [Member] \| Maximum [Member]
Derivative liability, measurement input	1.983
Remaining Terms (Years) [Member] \| Minimum [Member]
Derivative liability, remaining term (Years)	4 days
Remaining Terms (Years) [Member] \| Maximum [Member]
Derivative liability, remaining term (Years)	1 year

Stockholders' Deficiency (Details Narrative) - USD ($)						1 Months Ended								3 Months Ended			9 Months Ended	12 Months Ended
Stockholders' Deficiency (Details Narrative) - USD ($)	Jan. 09, 2020	Jan. 09, 2020	Dec. 19, 2019	Feb. 02, 2016	Feb. 02, 2016	Mar. 31, 2020	Dec. 31, 2019	Dec. 19, 2019	Oct. 31, 2019	Jul. 31, 2019	May 31, 2019	Mar. 31, 2018	Jul. 31, 2016	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2015	Dec. 31, 2020	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2015	May 22, 2020	Mar. 30, 2015
Common stock, shares authorized						125,000,000								125,000,000					125,000,000
Common stock, par value						$ 0.001								$ 0.001					$ 0.001
Preferred stock, shares authorized						10,000,000								10,000,000					10,000,000
Preferred stock, par value						$ 0.001								$ 0.001					$ 0.001
Common stock, shares issued						32,593,769								33,384,769					32,593,769
Common stock, shares outstanding						32,593,769								33,384,769					32,593,769
Exchangeable shares outstanding						3,788,062								3,788,062					3,788,062
Preferred stock, shares issued						1								1					1
Number of common shares issued, value															$ 14,003
General and administrative and research and development expenses														$ 3,205,233	2,052,519
Accrued preferred stock dividends														257,927
Dividends paid														180,000
Issuance of shares for services, value														1,063,754	251,625
Research and development expenses														$ 423,883	213,496
Stock price						$ 0.588						$ 0.6		$ 0.76					$ 0.588	$ .28	$ 0.6	$ 0.88	$ 0.74
Number of options granted														1,811,847
Stock based compensation														$ 232,519	$ 338,889
2015 Equity Incentive Plan [Member]
Number of common stock option exercise														164,590			3,390,503			164,590	164,590			3,390,503
Number of options authorized to issue																										3,000,000
Number of options vested
Number of options non-vested												137,500									137,500	137,500
Options exercise price												$ 0.0001					$ 0.0001				$ 0.0001	$ 0.0001		$ 0.0001
Number of options cancelled																					35,907
Fair value of options																								$ 2,257,953
Vesting description																								Options were exercised by those employees who met the vesting conditions; 50% of the grants either vest immediately or at the time of U.S. Food and Drug Administration (FDA) filing date and 50% will vest upon Liquidity Trigger. Liquidity Trigger means the day on which the board of directors resolve in favour of i) the Company is able to raise a certain level of financing; ii) a reverse takeover transaction that results in the Company being a reporting issuer, and iii) initial public offering that results in the Company being a reporting issuer.
Number of options granted																	3,591,000
Number of options granted, exercise price																	$ 0.0001
2016 Equity Incentive Plan [Member]
Number of common stock option exercise
Number of common stock compensation for services, value						$ 1,600,515
Expected life						10 years
Stock price						$ 0.974													0.974
Expected volatility						132.20%
Number of options authorized to issue				3,750,000	3,750,000
Options exercise price						$ 3.1069						$ 3.2306		$ 2.5070	$ 3.1069	$ 3.2306			$ 3.1069	$ 3.1436	$ 3.2306	$ 3.2306
Plan description				The maximum number of shares of stock that may be issued under the Plan shall be equal to 3,750,000 shares; provided that the maximum number of shares of stock that may be issued under the Plan pursuant to awards shall automatically and without any further Company or shareholder approval, increase on January 1 of each year for not more than 10 years from the effective date, so the number of shares that may be issued is an amount no greater than 15% of the Company's outstanding shares of stock and shares of stock underlying any outstanding exchangeable shares as of such January 1; provided further that no such increase shall be effective if it would violate any applicable law or stock exchange rule or regulation, or result in adverse tax consequences to the Company or any participant that would not otherwise result but for the increase.
Number of options granted												1,437,500		1,811,847	1,811,847					88,100
Number of options granted, exercise price														$ 0.7763	$ 0.7763			$ 88,100		$ 1.8096
Weighted average remaining contractual life						10 years
Stock based compensation														$ 232,519	$ 367,647			$ 2,408,713		$ 1,451,261
2016 Equity Incentive Plan One [Member]
Number of options granted																			88,100
Stock based compensation																			$ 2,408,713
Intrinsic value of options						$ 0													$ 0
Minimum [Member]
Expected life																						1 year
Risk free rate																				2.27%	1.98%	0.45%	0.04%
Minimum [Member] \| 2016 Equity Incentive Plan [Member]
Risk free rate						0.46%
Weighted average remaining contractual life												2 years 9 months 3 days						2 years 9 months 3 days		2 years 9 months 3 days
Minimum [Member] \| 2016 Equity Incentive Plan One [Member]
Weighted average remaining contractual life																			2 years 9 months 3 days
Maximum [Member]
Expected life																				3 years	3 years	3 years	10 years
Risk free rate																				2.54%	2.81%	1.47%	1.07%
Maximum [Member] \| 2016 Equity Incentive Plan [Member]
Risk free rate						0.75%
Weighted average remaining contractual life												9 years 6 months 3 days						9 years 6 months 3 days		9 years 6 months 3 days
Maximum [Member] \| 2016 Equity Incentive Plan One [Member]
Weighted average remaining contractual life																			9 years 6 months 3 days
Issuance of Common Shares [Member]
Number of common shares issued, shares														631,000						972,950
Number of common shares issued, value																				$ 666,129
Number of shares issued for services														791,000
General and administrative and research and development expenses														$ 1,063,754						$ 835,619
Fair value of common share														791,000
Fair value of common share, value														$ 1,063,754
Advisor [Member] \| Issuance of Common Shares [Member]
Number of common shares issued, shares														25,000
Number of common shares issued, value														$ 22,194
Promissory Notes [Member]
Conversion of stock, shares	1,830						1,945		1,830
Conversion of stock	$ 1,830,000
Promissory Notes [Member]
Proceeds from issuance of warrants															$ 92,416
Registered Offering [Member]
Number of common shares issued, shares										47,585	47,585
Proceeds from private offering										$ 28,565	$ 28,565
Director of Company [Member]
Number of options granted														1,400,000
Another Director [Member]
Number of options granted														367,647
Various Consultants and Advisors [Member] \| Issuance of Common Shares [Member]
Number of common shares issued, shares																				178,750
Number of common shares issued, value																				$ 169,490
Investors [Member] \| Common Stock [Member]
Number of common shares issued, shares														160,000					525,023
Consultants, Advisors and Other Service Providers [Member] \| Common Stock [Member]
Number of shares issued for services																			178,750
Issuance of shares for services, value																			$ 169,490
Research and development expenses																			$ 169,490
Officer [Member]
Consultant warrants shares														638,806
Officer [Member] \| 2016 Equity Incentive Plan [Member]
Number of options granted													2,499,998
Number of options granted, exercise price													$ 2.20
Options vesting period													3 years
Consultants and Advisors [Member]
Proceeds from warrants exercise																				$ 50,835
Number of warrants issued																				62,838
Warrants exercise price																				$ 0.81
Advisor and Consultant [Member]
General and administrative and research and development expenses																			$ 184,637
Number of common stock compensation for services														50,000					1,021,430	849,601
Number of common stock compensation for services, value														$ 45,113					$ 277,053	$ 467,411
Advisor and Consultant [Member] \| Warrant [Member] \| Minimum [Member]
Expected life																			2 years	2 years
Risk free rate														0.259%					0.22%	2.13%
Stock price						$ .970													$ .970	$ 0.48
Expected volatility														125.40%					114.30%	97.80%
Advisor and Consultant [Member] \| Warrant [Member] \| Maximum [Member]
Expected life														3 years					3 years	3 years
Risk free rate														0.692%						2.81%
Stock price						$ 1.367													$ 1.367	$ 4.15
Expected volatility														131.90%					132.20%	141.10%
Two Employees [Member] \| 2016 Equity Incentive Plan [Member]
Number of options granted													175,000
Number of options granted, exercise price													$ 2.24
Options vesting period													1 year
One Employee [Member] \| 2016 Equity Incentive Plan [Member]
Number of options granted													35,000
Number of options granted, exercise price													$ 2.24
Options vesting period													2 years
Board of Director [Member] \| 2016 Equity Incentive Plan [Member]
Weighted average remaining contractual life						3 years
Exchange Agreement [Member]
Percentage of common stock issued and outstanding					90.00%
Common stock exchange description					1.197 shares of its common stock in exchange for each common share
Number of common shares issued, shares					13,376,947
Exchange Agreement [Member] \| 11% Secured Convertible Promissory Notes [Member]
Conversion description					The outstanding 11% secured convertible promissory notes of the Company were adjusted, in accordance with the adjustment provisions thereof, as and from closing, so as to permit the holders to convert (and in some circumstances permit the Company to force the conversion of) the convertible promissory notes into shares of the common stock of Biotricity at a 25% discount to purchase price per share in Biotricity's next offering.
Discount percentage for purchase price per shares					25.00%
Exchange Agreement [Member] \| Warrant [Member]
Common stock exchange description					1.197 shares of the common stock of Biotricity for each Warrant, with an inverse adjustment to the exercise price of the Warrants to reflect the exchange ratio of approximately 1.197:1
Exchange ratio					1.197:1
Exchange Agreement [Member] \| Advisor Warrant [Member]
Common stock exchange description					1.197 shares of the common stock of Biotricity for each Advisor Warrant, with an inverse adjustment to the exercise price of the Advisor Warrants to reflect the exchange ratio of approximately 1.197:1
Exchange ratio					1.197:1
Exchange Agreement [Member] \| Options [Member]
Common stock exchange description					1.197 economically equivalent replacement options with an inverse adjustment to the exercise price of the replacement option to reflect the exchange ratio of approximately 1.197:1
Exchange ratio					1.197:1
Exchange Agreement [Member] \| Exchangeco [Member]
Common stock exchange description
Number of exchangeable shares issued
Pre-Exchange Agreement [Member] \| 2015 Equity Incentive Plan [Member]
Number of common stock option exercise																								2,832,500
Issuance of Employee Options [Member] \| 2016 Equity Incentive Plan One [Member]
Expected life																			6 years
Stock price						$ 0.974													$ 0.974
Expected volatility																			132.20%
Weighted average remaining contractual life																			10 years
Stock based compensation																			$ 1,600,515
Issuance of Employee Options [Member] \| Minimum [Member] \| 2016 Equity Incentive Plan One [Member]
Risk free rate																			0.46%
Stock price						0.970													$ 0.970
Expected volatility																			125.40%
Number of options granted, exercise price																			$ 0.259
Issuance of Employee Options [Member] \| Maximum [Member] \| 2016 Equity Incentive Plan One [Member]
Risk free rate																			0.75%
Stock price						$ 1.367													$ 1.367
Expected volatility																			131.90%
Number of options granted, exercise price																			$ 0.692
Series A Preferred Stock [Member]
Preferred stock, shares authorized						20,000								20,000					20,000
Preferred stock, par value						$ 0.001								$ 0.001					$ 0.001
Preferred stock, shares issued	7,830	7,830	7,830			7,830	8,045	7,830						8,045					7,830						215
Number of common shares issued, shares		6,000	6,000				6,100
Series A Preferred Stock [Member] \| Securities Purchase Agreement [Member]
Number of exchangeable shares issued								6,000
Proceeds from private offering								$ 6,000,000
Preferred stock, conversion method on issuance, description								The shares are convertible into common stock of the Company at a conversion price equal to the greater of $0.001 or a 15% discount to the 5-day volume weighted price at the time of conversion. The conversion rights commence 24 months after issuance, but conversion is limited to 5% of the aggregate purchase price of the holder on a monthly basis thereafter. Alternatively, the shares are convertible into common stock at a 15% discount to any qualified future common stock financing conducted by the Company. The Company may redeem the shares after 1 year for 110% of the purchase price plus accrued dividends. The preferred stock bears a dividend rate of 12% per annum

Stockholders' Deficiency - Schedule of Warrants Outstanding (Details) (Parenthetical)	Jun. 30, 2020 USD ($)
Consultant and Noteholder Warrants [Member] \| Directors and Officers [Member]
Officer compensation	$ 638,806

Lease (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
Lease (Details Narrative) - USD ($)	Jun. 30, 2020	Mar. 31, 2020	Apr. 02, 2019
Operating lease, weighted average rate			10.00%
General and Administrative Expense [Member]
Operating lease expense	$ 55,299	$ 173,175

Leases - Schedule of Operating Leases Obligations (Details) - USD ($)	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2020
Leases [Abstract]
Operating lease right-of-use asset - initial recognition	$ 264,472
Amortization	(198,352)
Balance at June 30, 2020	214,884
Operating lease obligation - initial recognition	413,236
Repayment and interest accretion	(192,093)
Balance at June 30, 2020	221,143
Current portion of operating lease obligation	213,030	$ 213,030
Noncurrent portion of operating lease obligation		$ 57,055

Operating Lease Right-Of-Use Assets and Lease Obligations - Schedule of Contractual Undiscounted Cash Flows for Lease Obligation (Details)	Jun. 30, 2020 USD ($)
Total undiscounted lease obligations	$ 230,118
Less Than One Year [Member]
Total undiscounted lease obligations	230,118
Beyond One Year [Member]
Total undiscounted lease obligations

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Jul. 31, 2020 USD ($) shares
Number of exchangeable shares	179,540
Number of common shares issued, shares	83,500
Subscription Arrangement [Member] \| Accredited Investors [Member]
Interest rate	12.00%
Convertible promissory notes Pricipal amount \| $	$ 1,253,000
Conversion price	75.00%
Convertible promissory note, description	The Notes will automatically convert into common stock (in each case, subject to the trading volume of the Company's common stock being a minimum of $500,000 for each trading day in the 20 consecutive trading days immediately preceding the conversion date), upon the earlier to occur of (i) the Company's common stock being listed on a national securities exchange, in which event the conversion price will be equal to 75% of the volume weighted average price of the common stock for the 20 trading days prior to the conversion date, or (ii) upon the closing of the Company's next equity round of financing for gross proceeds of greater than $5,000,000, in which event the conversion price will be equal to 75% of the price per share of the common stock (or of the conversion price in the event of the sale of securities convertible into common stock) sold in such financing.
Convertible prepayment, description	The Company may prepay the Notes upon 20 days' written notice and payment of a 15% prepayment fee.
Issue investors warrant, description	Upon conversion of the Notes, the Company will also issue to the investors warrants (the "Warrants") to purchase 50% of the number of shares of common stock issued upon conversion of the Notes. The Warrants will have a term of three years and an exercise price equal to 120% of the volume weighted average price of the common stock for the 20 days prior to the final closing date of the offering, subject to adjustment.